

# Phase III Study Comparing Cisplatin Plus Gemcitabine Versus Gemcitabine Plus Carboplatin in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer

Journal of Clinical Oncology

26, 3543-3551

DOI: [10.1200/jco.2007.15.0375](https://doi.org/10.1200/jco.2007.15.0375)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Individualizing Chemotherapy for Non-small Cell Lung Cancer (NSCLC) in the Adjuvant and Advanced Setting: Current Status and Future Directions. <i>Current Treatment Options in Oncology</i> , 2008, 9, 300-312.	1.3	5
4	Will FLEX Allow Us Flexibility in the Therapy of Advanced Non-Small-Cell Lung Cancer? Insights from the 2008 American Society of Clinical Oncology Meeting. <i>Clinical Lung Cancer</i> , 2008, 9, 249-251.	1.1	6
5	Adjuvant Chemotherapy for Resected Non-Small Cell Lung Cancer. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2008, 20, 198-203.	0.4	10
6	Chemotherapy for Advanced Stage Non-Small Cell Lung Cancer. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2008, 20, 210-216.	0.4	20
7	Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study. <i>Lancet Oncology</i> , The, 2008, 9, 1135-1142.	5.1	78
8	Personalized Medicine in Advanced Non-Small-Cell Lung Cancer: Reality or Wishful Thinking?. <i>Journal of Clinical Oncology</i> , 2008, 26, 5651-5651.	0.8	1
9	First-Line Chemotherapy for Non-Small-Cell Lung Cancer: Is There a Superior Regimen Based on Histology?. <i>Journal of Clinical Oncology</i> , 2008, 26, 3485-3486.	0.8	54
10	Efficacy and Toxicity of Pemetrexed as a Third-line Treatment for Non-small Cell Lung Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2008, 39, 27-32.	0.6	40
12	Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients. <i>PLoS ONE</i> , 2008, 3, e3695.	1.1	121
13	Tailoring treatment of nonsmall cell lung cancer by tissue type: role of pemetrexed. <i>Pharmacogenomics and Personalized Medicine</i> , 2009, 2, 21.	0.4	0
14	Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer. <i>Therapeutics and Clinical Risk Management</i> , 2009, 5, 781.	0.9	7
15	Efficacy of Pemetrexed in Relapsed Non-Small Cell Lung Cancer and Thymidylate Synthase Expression. <i>Tuberculosis and Respiratory Diseases</i> , 2009, 67, 191.	0.7	6
16	Hormone Replacement Therapy and Outcomes for Women with Non-Small-Cell Lung Cancer: Can An Association be Confirmed?. <i>Current Oncology</i> , 2009, 16, 21-25.	0.9	31
17	Non-Cross Resistant Sequential Single Agent Chemotherapy in First-Line Advanced Non-Small Cell Lung Cancer Patients: Results of a Phase II Study. <i>Journal of Oncology</i> , 2009, 2009, 1-6.	0.6	3
18	Gemcitabine for the treatment of advanced nonsmall cell lung cancer. <i>OncoTargets and Therapy</i> , 2009, 2, 209.	1.0	15
19	Lung Cancer. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2009, 106, 809-18; quiz 819-20.	0.6	61
20	Is there a role for maintenance therapy in non-small-cell lung cancer? An emerging issue. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 1455-1465.	1.1	2
21	Efficacy and Safety of Axitinib in Patients With Advanced Non-Small-Cell Lung Cancer: Results From a Phase II Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 3836-3841.	0.8	176

#	ARTICLE	IF	CITATIONS
22	Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 4787-4792.	0.8	176
23	Randomized Double-Blind Placebo-Controlled Trial of Thalidomide in Combination With Gemcitabine and Carboplatin in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5248-5254.	0.8	65
24	Integration of Molecular Profiling into the Lung Cancer Clinic. <i>Clinical Cancer Research</i> , 2009, 15, 5317-5322.	3.2	82
25	Review Article: A Reevaluation of the Clinical Significance of Histological Subtyping of Non-Small-Cell Lung Carcinoma: Diagnostic Algorithms in the Era of Personalized Treatments. <i>International Journal of Surgical Pathology</i> , 2009, 17, 206-218.	0.4	84
26	Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed Plus Carboplatin Compared With Gemcitabine Plus Carboplatin As First-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 3217-3224.	0.8	266
28	Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2009, 20, 1249-1256.	0.6	61
29	Non-small-cell lung cancer: should histology guide chemotherapy treatment?. <i>Annals of Oncology</i> , 2009, 20, 1608-1609.	0.6	2
30	Current Treatments for Advanced Stage Non-Small Cell Lung Cancer. <i>Proceedings of the American Thoracic Society</i> , 2009, 6, 233-241.	3.5	130
31	Pemetrexed for the treatment of non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 1195-1209.	1.1	11
32	Potential Treatment Options After First-Line Chemotherapy for Advanced NSCLC: Maintenance Treatment or Early Second-Line?. <i>Oncologist</i> , 2009, 14, 137-147.	1.9	48
33	Approval Summary: Pemetrexed in the Initial Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2009, 14, 930-935.	1.9	63
34	Review: Angiogenesis inhibitors in the treatment of non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2009, 1, 95-107.	1.4	10
35	Morphology and a Limited Number of Immunohistochemical Markers May Efficiently Subtype Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, e141-e142.	0.8	41
36	Evolution of Therapy Decision-Making Process for Advanced Non-Small Cell Lung Cancer. <i>Oncology</i> , 2009, 77, 97-102.	0.9	1
37	Chemotherapy of Advanced Non-Small Cell Lung Cancer. <i>Frontiers of Radiation Therapy and Oncology</i> , 2010, 42, 157-163.	1.4	17
38	Cost-Effectiveness of Pemetrexed Plus Cisplatin as First-Line Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1404-1414.	0.5	34
39	Molecular Analysis-Based Treatment Strategies for the Management of Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2009, 4, S1029-S1039.	0.5	41
40	Update in Lung Cancer 2008. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 860-868.	2.5	41

#	ARTICLE	IF	CITATIONS
41	Review: Adjuvant therapy for resected non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2009, 1, 109-118.	1.4	11
42	The Role of Histology with Common First-line Regimens for Advanced Non-small Cell Lung Cancer: A Brief Report of the Retrospective Analysis of a Three-arm Randomized Trial. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1568-1571.	0.5	44
43	Revisiting Stage IIIB and IV Non-small Cell Lung Cancer. <i>Chest</i> , 2009, 136, 701-709.	0.4	105
45	Bisphosphonate Use in Patients with Lung Cancer and Bone Metastases: Recommendations of a European Expert Panel. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1280-1288.	0.5	57
46	Angiogenesis Inhibitors and Vascular Disrupting Agents in Non-Small Cell Lung Cancer. <i>Current Medicinal Chemistry</i> , 2009, 16, 3919-3930.	1.2	12
47	New avenues for second-line treatment of metastatic non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 115-124.	1.1	9
48	The Drug Targeting and Delivery Approach Applied to Pt-Antitumour Complexes. A Coordination Point of View. <i>Current Medicinal Chemistry</i> , 2009, 16, 4544-4580.	1.2	71
49	Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial. <i>Annals of Oncology</i> , 2009, 20, 850-856.	0.6	16
50	First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtype. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 425-435.	1.1	25
51	Expression of IL-32 in Human Lung Cancer Is Related to the Histotype and Metastatic Phenotype. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 769-779.	2.5	90
52	Phase II Study of the Anti-Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2516-2522.	0.8	251
53	<i>EML4-ALK</i> : Honing In on a New Target in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 4232-4235.	0.8	313
54	Duration of Chemotherapy for Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Trials. <i>Journal of Clinical Oncology</i> , 2009, 27, 3277-3283.	0.8	193
55	Re-Evaluating Duration of Therapy in Advanced Non-Small-Cell Lung Cancer: Is It Really Duration or Is It More About Timing and Exposure?. <i>Journal of Clinical Oncology</i> , 2009, 27, 3268-3270.	0.8	9
56	Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung. <i>Clinical Cancer Research</i> , 2009, 15, 7547-7552.	3.2	68
57	Reply to Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer. <i>Annals of Oncology</i> , 2009, 20, 967.	0.6	1
58	Phase II Study of Pemetrexed and Carboplatin Plus Bevacizumab With Maintenance Pemetrexed and Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 3284-3289.	0.8	168
59	Phase I and Pharmacokinetic Study of Pemetrexed plus Cisplatin in Chemonaive Patients with Locally Advanced or Metastatic Malignant Pleural Mesothelioma or Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 382-389.	3.2	16

#	ARTICLE	IF	CITATIONS
60	PROCLAIM: A Phase III Study of Pemetrexed, Cisplatin, and Radiation Therapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiation Therapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Locally Advanced Stage III Nonâ€“Small-Cell Lung Cancer of Other than Predominantly Squamous Cell Histology. <i>Clinical Lung Cancer</i> , 2009, 10, 193-198.	1.1	50
61	Highlights from: The 2009 Annual Meeting of the American Society of Clinical Oncology Orlando, FL May 29-June 2, 2009. <i>Clinical Lung Cancer</i> , 2009, 10, 217-222.	1.1	0
63	Evolving Treatment Algorithms for Advanced Nonâ€“Small-Cell Lung Cancer: 2009 Looking Toward 2012. <i>Clinical Lung Cancer</i> , 2009, 10, 392-394.	1.1	22
64	Lung Cancer Outcomes in Women. <i>Seminars in Oncology</i> , 2009, 36, 532-541.	0.8	15
65	A technique to improve diagnostic information from fineâ€“needle aspirations. <i>Cancer Cytopathology</i> , 2009, 117, 120-127.	1.4	7
66	Toxicity and Response of Pemetrexed Plus Carboplatin or Cisplatin with Concurrent Chest Radiation Therapy (CRT) for Patients with Locally Advanced Nonâ€“small-cell Lung Cancer (LANSCLC): A Phase I Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, S110.	0.4	2
67	SEOM guidelines for the management of non-small-cell lung cancer (NSCLC). <i>Clinical and Translational Oncology</i> , 2009, 11, 284-289.	1.2	14
68	Clinical-molecular factors predicting response and survival for tyrosine-kinase inhibitors. <i>Clinical and Translational Oncology</i> , 2009, 11, 428-436.	1.2	4
69	Dramatic complete response in patient with lung adenocarcinoma. <i>Clinical and Translational Oncology</i> , 2009, 11, 851-853.	1.2	1
70	Therapeutic uses of topotecan for thoracic malignancies. <i>Oncology Reviews</i> , 2009, 3, 125-131.	0.8	0
71	NSCLC in the Elderlyâ€“The Legacy of Therapeutic Neglect. <i>Current Treatment Options in Oncology</i> , 2009, 10, 180-194.	1.3	9
73	Non-small cell lung cancer â€“ ASCO 2009. <i>Memo - Magazine of European Medical Oncology</i> , 2009, 2, 202-205.	0.3	0
74	Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 233-241.	1.1	18
75	Fixed-dose rate infusion of gemcitabine and weekly cisplatin in elderly or poor performance status patients with unresectable non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 385-390.	1.1	3
76	Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 917-924.	1.1	5
77	Reinforcement learning design for cancer clinical trials. <i>Statistics in Medicine</i> , 2009, 28, 3294-3315.	0.8	179
78	Pulmonary adenocarcinomas: classification and reporting. <i>Histopathology</i> , 2009, 54, 12-27.	1.6	108
79	Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. <i>Modern Pathology</i> , 2009, 22, 709-717.	2.9	91

#	ARTICLE	IF	CITATIONS
80	A novel five-antibody immunohistochemical test for subclassification of lung carcinoma. <i>Modern Pathology</i> , 2009, 22, 1032-1043.	2.9	87
81	Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs. <i>Oncogene</i> , 2009, 28, S4-S13.	2.6	62
82	Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2009, 101, 225-231.	2.9	46
83	Molecular Biomarkers in Non-small Cell Lung Cancer "pointing the way to better outcomes from treatment. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2009, 5, 213-214.	0.7	0
84	Targeted Therapy for Advanced Non-small Cell Lung Cancers: Historical Perspective, Current Practices, and Future Development. <i>Current Problems in Cancer</i> , 2009, 33, 73-111.	1.0	17
85	Pharmacogenomics in non-small-cell lung cancer chemotherapy. <i>Advanced Drug Delivery Reviews</i> , 2009, 61, 408-417.	6.6	30
86	American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-small Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 6251-6266.	0.8	732
87	VEGF kinase inhibitors: how do they cause hypertension?. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2009, 297, R1-R5.	0.9	66
88	Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non-small Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5080-5087.	0.8	208
89	Pemetrexed in first-line treatment of non-small cell lung cancer. <i>Cancer Treatment Reviews</i> , 2009, 35, 364-373.	3.4	26
90	Positioning pemetrexed in the treatment of ovarian cancer. <i>European Journal of Cancer</i> , 2009, 45, 1330-1332.	1.3	2
91	Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: A risk-benefit analysis of a large phase III study. <i>European Journal of Cancer</i> , 2009, 45, 2298-2303.	1.3	47
92	Palliative chemotherapy: Do we need yet another end-point?. <i>European Journal of Cancer</i> , 2009, 45, 2234-2235.	1.3	2
93	Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: A review of practice in British Columbia. <i>Lung Cancer</i> , 2009, 64, 308-313.	0.9	41
94	Adult onset Still's disease after first cycle of pemetrexed and gemcitabine for non-small cell lung cancer. <i>Lung Cancer</i> , 2009, 64, 124-126.	0.9	9
95	Adenocarcinoma has an excellent outcome with pemetrexed treatment in Korean patients: A prospective, multicenter trial. <i>Lung Cancer</i> , 2009, 66, 338-343.	0.9	16
96	Major and prolonged response to pemetrexed in two cases of lung adenocarcinoma with bronchioloalveolar carcinoma features. <i>Lung Cancer</i> , 2009, 65, 385-387.	0.9	11
97	Typhlitis during second-line chemotherapy with pemetrexed in non-small cell lung cancer (NSCLC): A case report. <i>Lung Cancer</i> , 2009, 65, 251-253.	0.9	9

#	ARTICLE	IF	CITATIONS
98	Activity of pemetrexed against brain metastases in a patient with adenocarcinoma of the lung. Lung Cancer, 2009, 65, 383-384.	0.9	15
99	Pemetrexed in the treatment of advanced non-squamous lung cancer. Lung Cancer, 2009, 66, 141-149.	0.9	52
100	Clinical overview on Lipoplatin <sup>®</sup> : a successful liposomal formulation of cisplatin. Expert Opinion on Investigational Drugs, 2009, 18, 1197-1218.	1.9	226
101	Pemetrexed. Drugs, 2009, 69, 2279-2302.	4.9	31
102	A Multicenter, Single-Arm Phase II Study of Pemetrexed Plus Doxorubicin Administered Every 21 Days in Patients With Advanced Breast Cancer. Clinical Breast Cancer, 2009, 9, 155-160.	1.1	2
103	Individualizing Therapy for Non-Small-Cell Lung Cancer: A Paradigm Shift from Empiric to Integrated Decision-Making. Clinical Lung Cancer, 2009, 10, 148-150.	1.1	23
104	Advanced Non-Small-Cell Lung Cancer in the Elderly. Clinical Lung Cancer, 2009, 10, 158-167.	1.1	10
105	Treatment Rationale and Study Design for the PointBreak Study: A Randomized, Open-label Phase III Study of Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer. Clinical Lung Cancer, 2009, 10, 252-256.	1.1	65
106	Cancer Treatments: Can We Find Treasures at the Bottom of the Sea?. Clinical Lung Cancer, 2009, 10, 295-300.	1.1	23
107	Pemetrexed-Induced Pneumonitis: A Case Report. Clinical Lung Cancer, 2009, 10, 364-366.	1.1	14
108	Updated Clinical Information on Multitargeted Antifolates in Lung Cancer. Clinical Lung Cancer, 2009, 10, S35-S40.	1.1	26
109	Novel Targeted Agents for Lung Cancer. Clinical Lung Cancer, 2009, 10, S41-S46.	1.1	11
111	Prise en charge des cancers bronchiques non À petites cellules au stade métastatique : Évolution du traitement de première ligne. Revue Des Maladies Respiratoires Actualites, 2009, 1, 401-414.	0.0	0
112	Chemotherapy for lung cancer: the state of the art in 2009. Expert Review of Anticancer Therapy, 2009, 9, 1365-1378.	1.1	44
113	Therapeutics by Cytotoxic Metabolite Accumulation: Pemetrexed Causes ZMP Accumulation, AMPK Activation, and Mammalian Target of Rapamycin Inhibition. Cancer Research, 2009, 69, 5467-5474.	0.4	136
114	Analisi di costo-efficacia di pemetrexed pi <sup>1</sup> cisplatino versus gemcitabina pi <sup>1</sup> cisplatino nel trattamento di prima linea in pazienti con NSCLC non squamoso in stadio avanzato. Giornale Italiano Di Health Technology Assessment, 2009, 2, 73-80.	0.1	1
115	Analisi di costo-efficacia nel trattamento di prima linea con i regimi chemioterapici pemetrexed pi <sup>1</sup> cisplatino, gemcitabina pi <sup>1</sup> cisplatino e bevacizumab pi <sup>1</sup> gemcitabina pi <sup>1</sup> cisplatino in pazienti con NSCLC localmente avanzato o metastatizzato in Italia. Giornale Italiano Di Health Technology Assessment, 2009, 2, 99-109.	0.1	1
116	The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies. Oncologist, 2009, 14, 253-263.	1.9	669

#	ARTICLE	IF	CITATIONS
117	Novel therapies in metastatic head and neck squamous cell carcinoma. <i>Community Oncology</i> , 2009, 6, 310-316.	0.2	2
118	Phase II Study of Preoperative Gefitinib in Clinical Stage I Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 6229-6236.	0.8	93
119	First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009. <i>Lancet Oncology</i> , The, 2009, 10, 1102-1110.	5.1	28
120	Pemetrexed approved for the first-line treatment of non-small-cell lung cancer: summary of the NICE appraisal. <i>Lancet Oncology</i> , The, 2009, 10, 1031-1032.	5.1	5
121	Reclassifying bronchial-pulmonary carcinoma: Differentiating histological type in biopsies by immunohistochemistry. <i>Revista Portuguesa De Pneumologia</i> , 2009, 15, 1101-1119.	0.7	9
122	Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. <i>Lancet</i> , The, 2009, 374, 1432-1440.	6.3	1,062
123	Gefitinib in the treatment of advanced non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 401-412.	1.1	25
125	Chimiothérapie péri-opératoire des cancers bronchiques non à petites cellules. <i>Revue Des Maladies Respiratoires Actualites</i> , 2009, 1, 365-375.	0.0	0
127	Chemotherapy in the Older Patient with Operable Non-Small Cell Lung Cancer: Neoadjuvant and Adjuvant Regimens. <i>Thoracic Surgery Clinics</i> , 2009, 19, 377-389.	0.4	4
128	Cas clinique n°4 proposé par l'Équipe de Lyon. <i>Revue De Pneumologie Clinique</i> , 2009, 65, 19-22.	0.0	0
131	Traitement histo-guidé des cancers bronchiques non à petites cellules : pour. <i>Revue De Pneumologie Clinique</i> , 2009, 65, S16-S18.	0.0	0
134	Le cetuximab en 1re ligne de traitement dans les CBNPC. <i>Revue De Pneumologie Clinique</i> , 2009, 65, H19-H21.	0.0	0
135	Histology-based treatment: a new scenario in the management of advanced nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , 2009, 21, 97-98.	1.1	3
136	Treatment of Advanced Lung Cancer. <i>Clinical Pulmonary Medicine</i> , 2009, 16, 157-171.	0.3	2
137	Nonsmall cell lung cancer in never smokers. <i>Current Opinion in Oncology</i> , 2009, 21, 99-104.	1.1	69
138	Population Pharmacokinetic/Pharmacodynamic Analyses of Pemetrexed and Neutropenia: Effect of Vitamin Supplementation and Differences between Japanese and Western Patients. <i>Clinical Cancer Research</i> , 2009, 15, 346-354.	3.2	11
139	Results of cutting-edge surgery in stage IIIA-N2 nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , 2009, 21, 105-109.	1.1	10
140	Beyond anti-epidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier. <i>Current Opinion in Oncology</i> , 2009, 21, 116-123.	1.1	14



#	ARTICLE	IF	CITATIONS
141	Non-small-cell lung cancer: targeted therapies. <i>Therapy: Open Access in Clinical Medicine</i> , 2009, 6, 95-98.	0.2	0
142	Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy. <i>Journal of Thoracic Oncology</i> , 2009, 4, 326-332.	0.5	99
144	Treatment Paradigms for Advanced Stage Non-small Cell Lung Cancer in the Era of Multiple Lines of Therapy. <i>Journal of Thoracic Oncology</i> , 2009, 4, 243-250.	0.5	53
145	Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1202-1211.	0.5	75
146	A Phase I Study of TS-1 Plus Carboplatin in Patients with Advanced Non-Small-Cell Lung Cancer. <i>Journal of Chemotherapy</i> , 2009, 21, 80-85.	0.7	2
147	Docetaxel and Oxaliplatin as First-Line Therapy for Advanced Non-Small Cell Lung Cancer: A Phase II Trial. <i>Journal of Chemotherapy</i> , 2009, 21, 439-444.	0.7	6
148	Histologic Considerations for Individualized Systemic Therapy Approaches for the Management of Non-small Cell Lung Cancer. <i>Chest</i> , 2009, 136, 1112-1118.	0.4	39
149	Improving Survival for Stage IV Non-small Cell Lung Cancer: A Surveillance, Epidemiology, and End Results Survey from 1990 to 2005. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1524-1529.	0.5	80
150	A Phase II Study of Weekly Docetaxel-Cisplatin As First-Line Treatment for Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1144-1147.	0.5	5
151	The International Association for the Study of Lung Cancer Staging Project: Prognostic Factors and Pathologic TNM Stage in Surgically Managed Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2009, 4, 792-801.	0.5	387
152	Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1537-1543.	0.5	60
153	Intermittent Erlotinib in Combination with Pemetrexed: Phase I Schedules Designed to Achieve Pharmacodynamic Separation. <i>Journal of Thoracic Oncology</i> , 2009, 4, 862-868.	0.5	47
154	Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1148-1155.	0.5	26
155	Survival Prognostication in Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2009, 4, 785-786.	0.5	2
156	Current Approach to Treatment of Non-small Cell Lung Cancer in Developing Countries—Time for a Rethink?. <i>Journal of Thoracic Oncology</i> , 2009, 4, 143-144.	0.5	7
157	Efficacy Differences of Pemetrexed by Histology in Pretreated Patients with Stage IIIB/IV Non-small Cell Lung Cancer: Review of Results from an Open-Label Randomized Phase II Study. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1530-1536.	0.5	29
158	Brief Report of Biweekly Pemetrexed and Gemcitabine in Elderly Patients with Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1170-1173.	0.5	1
159	Treatment Outcomes of Different Prognostic Groups of Patients on Cancer and Leukemia Group B Trial 39801: Induction Chemotherapy Followed by Chemoradiotherapy Compared with Chemoradiotherapy Alone for Unresectable Stage III Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1117-1125.	0.5	40

#	ARTICLE	IF	CITATIONS
160	Asian Ethnicity Is a Favorable Prognostic Factor for Overall Survival in Non-small Cell Lung Cancer (NSCLC) and Is Independent of Smoking Status. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1083-1093.	0.5	113
162	Recent Developments of Targeted Therapies in the Treatment of Non-Small Cell Lung Cancer. <i>Current Drug Discovery Technologies</i> , 2009, 6, 91-102.	0.6	29
163	Adjuvant cisplatin-based chemotherapy for resected NSCLC: one size fits all?. <i>Anti-Cancer Drugs</i> , 2010, 21, 799-804.	0.7	10
164	Intercalation of Erlotinib and Pemetrexed in the Treatment of Non-Small Cell Lung Cancer. <i>Current Drug Targets</i> , 2010, 11, 85-94.	1.0	11
165	Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung Cancer: Results of an Exploratory Subgroup Analysis of a Phase III Trial. <i>Journal of Thoracic Oncology</i> , 2010, 5, 688-695.	0.5	45
166	The Role of Pemetrexed in Lung Adenocarcinoma, Mixed Subtype with Bronchioloalveolar Carcinoma Features. <i>Current Drug Targets</i> , 2010, 11, 74-77.	1.0	8
167	The Role of Pemetrexed in Second-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer. <i>Current Drug Targets</i> , 2010, 11, 58-60.	1.0	5
168	Role of Pemetrexed and Platinums Combination in Patients with Non- Small Cell Lung Cancer. <i>Current Drug Targets</i> , 2010, 11, 29-36.	1.0	5
169	The Role of Chemotherapy and Radiation in the Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC). <i>Current Drug Targets</i> , 2010, 11, 67-73.	1.0	32
170	Predictive Markers for Haematological Toxicity of Pemetrexed. <i>Current Drug Targets</i> , 2010, 11, 48-57.	1.0	9
171	The Role of Pemetrexed Combined with Gemcitabine for Non-Small-Cell Lung Cancer. <i>Current Drug Targets</i> , 2010, 11, 61-66.	1.0	5
172	Pemetrexed with or without Matuzumab as Second-Line Treatment for Patients with Stage IIIB/IV Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1977-1985.	0.5	50
173	A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1630-1636.	0.5	147
174	Feasibility study of dose-dense biweekly administered pemetrexed in patients with non-small cell lung cancer. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2010, 3, 34-38.	0.6	2
175	Survival Benefit of Neoadjuvant Chemotherapy in Non-small Cell Lung Cancer: An Updated Meta-Analysis of 13 Randomized Control Trials. <i>Journal of Thoracic Oncology</i> , 2010, 5, 510-516.	0.5	191
176	First-Line Systemic Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer: A Systematic Review. <i>Journal of Thoracic Oncology</i> , 2010, 5, 260-274.	0.5	229
177	A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma. <i>Anti-Cancer Drugs</i> , 2010, 21, 777-784.	0.7	17
178	Advances in the diagnosis of lung cancer: contribution of molecular biology to bronchoscopic diagnosis. <i>Current Opinion in Pulmonary Medicine</i> , 2010, 16, 315-320.	1.2	11

#	ARTICLE	IF	CITATIONS
179	Initial evaluation of the nonsmall cell lung cancer patient: diagnosis and staging. <i>Current Opinion in Pulmonary Medicine</i> , 2010, 16, 307-314.	1.2	29
180	Angiogenesis in Non-small Cell Lung Cancer. <i>Journal of Thoracic Imaging</i> , 2010, 25, 142-150.	0.8	23
181	The Role of Pemetrexed in Advanced Non Small-Cell Lung Cancer: Special Focus on Pharmacology and Mechanism of Action. <i>Current Drug Targets</i> , 2010, 11, 37-47.	1.0	45
182	Features of Potentially Predictive Biomarkers of Chemotherapeutic Efficacy in Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 484-490.	0.5	23
183	Refining the Diagnosis and EGFR Status of Non-small Cell Lung Carcinoma in Biopsy and Cytologic Material, Using a Panel of Mucin Staining, TTF-1, Cytokeratin 5/6, and P63, and EGFR Mutation Analysis. <i>Journal of Thoracic Oncology</i> , 2010, 5, 436-441.	0.5	196
184	A Phase II First-Line Study of Gemcitabine, Carboplatin, and Bevacizumab in Advanced Stage Nonsquamous Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1821-1825.	0.5	13
185	Japanese Ethnicity Compared with Caucasian Ethnicity and Never-Smoking Status Are Independent Favorable Prognostic Factors for Overall Survival in Non-small Cell Lung Cancer: A Collaborative Epidemiologic Study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry Databases. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1001-1010.	0.5	125
186	Genetic Determinants of Pemetrexed Responsiveness and Nonresponsiveness in Non-small Cell Lung Cancer Cells. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1143-1151.	0.5	44
187	Non-Small Cell Lung Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 740-801.	2.3	606
188	1. Pemetrexed (Alimta®). <i>The Journal of the Japanese Society of Internal Medicine</i> , 2010, 99, 1597-1604.	0.0	0
190	Safety and Resource Utilization by Non-small Cell Lung Cancer Histology: Results from the Randomized Phase III Study of Pemetrexed Plus Cisplatin versus Gemcitabine Plus Cisplatin in Chemona-ve Patients with Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1602-1608.	0.5	9
191	Novel Taxanes/Epothilones. <i>Journal of Thoracic Oncology</i> , 2010, 5, S490-S491.	0.5	1
192	A Multi-Institution Phase I/II Trial of Triweekly Regimen with S-1 Plus Cisplatin in Patients with Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 702-706.	0.5	21
193	Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1424-1429.	0.5	28
194	Verification of the Newly Proposed T Category (Seventh Edition of the Tumor, Node, and Metastasis) Tj ETQq0 0 0 rgBT /Overlock 10 Tf . Reference to Tumor Size. <i>Journal of Thoracic Oncology</i> , 2010, 5, 45-48.	0.5	16
195	Randomized, Double-Blinded, Multicenter, Phase II Study of Pemetrexed, Carboplatin, and Bevacizumab with Enzastaurin or Placebo in Chemona-ve Patients with Stage IIIB/IV Non-small Cell Lung Cancer: Hoosier Oncology Group LUN06-116. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1815-1820.	0.5	22
196	Phase II, Double-Blinded, Randomized Study of Enzastaurin Plus Pemetrexed as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 369-375.	0.5	38
197	Prognostic Impact of Node Involvement Pattern in pN1 Non-small Cell Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1576-1582.	0.5	10

#	ARTICLE	IF	CITATIONS
198	Randomized, Phase II Trial of Pemetrexed and Carboplatin with or without Enzastaurin versus Docetaxel and Carboplatin as First-Line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1963-1969.	0.5	36
199	Pathologic Diagnosis of Advanced Lung Cancer Based on Small Biopsies and Cytology: A Paradigm Shift. <i>Journal of Thoracic Oncology</i> , 2010, 5, 411-414.	0.5	172
200	Sorafenib in Patients with Advanced Non-small Cell Lung Cancer that Harbor K-Ras Mutations: A Brief Report. <i>Journal of Thoracic Oncology</i> , 2010, 5, 719-720.	0.5	37
201	Subtyping of Undifferentiated Non-small Cell Carcinomas in Bronchial Biopsy Specimens. <i>Journal of Thoracic Oncology</i> , 2010, 5, 442-447.	0.5	214
202	Maintenance Therapy in Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 723-734.	0.5	17
203	A Comparison Study of Clinicopathologic Characteristics of Southern California Asian American Non-small Cell Lung Cancer (NSCLC) Patients by Smoking Status. <i>Journal of Thoracic Oncology</i> , 2010, 5, 158-168.	0.5	12
204	Phase II Study of Biweekly Pemetrexed and Gemcitabine in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 841-845.	0.5	7
205	Proteomic Profiling Identifies Pathways Dysregulated in Non-small Cell Lung Cancer and an Inverse Association of AMPK and Adhesion Pathways with Recurrence. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1894-1904.	0.5	57
206	Time Trends of Surgical Outcome in Patients with Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 825-829.	0.5	37
207	Differences of Gene Expression in Non-small Cell Lung Cancer: Are Histology, Tumor Site, and Methodology Relevant?. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1310-1311.	0.5	1
208	Serum Concentrations of Erlotinib at a Dose of 25 mg Daily. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1311-1312.	0.5	8
209	Biomarkers with Predictive and Prognostic Function in Non-Small Cell Lung Cancer: Ready for Prime Time?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 822-832.	2.3	36
210	Toxicity and Response of Pemetrexed Plus Carboplatin or Cisplatin with Concurrent Chest Radiation Therapy for Patients with Locally Advanced Non-small Cell Lung Cancer: A Phase I Trial. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1391-1396.	0.5	8
211	Histone Deacetylase Inhibitors in Malignant Pleural Mesothelioma: Preclinical Rationale and Clinical Trials. <i>Journal of Thoracic Oncology</i> , 2010, 5, 275-279.	0.5	60
212	Lung Adenocarcinoma: Lessons in Translation from Bench to Bedside. <i>Mount Sinai Journal of Medicine</i> , 2010, 77, 597-605.	1.9	36
213	Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 547-558.	1.1	18
214	A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 861-868.	1.1	10
215	Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 611-617.	0.8	30

#	ARTICLE	IF	CITATIONS
217	The similar survival benefits of stable disease and partial response to pemetrexed in previously treated non-small cell carcinoma patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 547-552.	1.2	5
218	Phase II study of carboplatin and gemcitabine as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: a report from the Central Japan Lung Study Group, CJLSG 0503 trial. <i>International Journal of Clinical Oncology</i> , 2010, 15, 583-587.	1.0	18
219	Short-term outcomes of cetuximab combined with standard chemotherapy as non-first line setting for patients with non-small cell lung cancer: a report of 6 cases. <i>Chinese-German Journal of Clinical Oncology</i> , 2010, 9, 502-506.	0.1	2
220	Impact of biomarkers on non-small cell lung cancer treatment. <i>Targeted Oncology</i> , 2010, 5, 5-17.	1.7	17
221	Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial. <i>Targeted Oncology</i> , 2010, 5, 231-235.	1.7	14
222	Personalized medicine in lung adenocarcinoma: no longer a hope or a passing fashion, but a new reality. <i>Targeted Oncology</i> , 2010, 5, 229-230.	1.7	0
223	Biomarkers in bronchopulmonary cancer. <i>Clinical and Translational Oncology</i> , 2010, 12, 92-99.	1.2	3
224	Circulating endothelial and endothelial progenitor cells in non-small-cell lung cancer. <i>Clinical and Translational Oncology</i> , 2010, 12, 521-525.	1.2	11
225	Smoking habits in elderly lung cancer patients: still no changes in epidemiology? A single-center experience. <i>Clinical and Translational Oncology</i> , 2010, 12, 686-691.	1.2	4
226	SEOM clinical guidelines for the treatment of non-small-cell lung cancer: an updated edition. <i>Clinical and Translational Oncology</i> , 2010, 12, 735-741.	1.2	13
227	UFT and S-1 for treatment of primary lung cancer. <i>General Thoracic and Cardiovascular Surgery</i> , 2010, 58, 3-13.	0.4	18
228	Biomarkers for Therapies Directed at Angiogenesis. <i>Current Colorectal Cancer Reports</i> , 2010, 6, 133-143.	1.0	4
229	Molecular Testing in Lung Cancer: The Time Is Now. <i>Current Oncology Reports</i> , 2010, 12, 335-348.	1.8	22
230	Cancer of Unknown Primary Site. <i>Seminars in Oncology</i> , 2010, 37, 71-79.	0.8	36
231	Phase I/II and Pharmacokinetic Study of Intravenous Vinflunine in Combination With Cisplatin for the Treatment of Chemonaive Patients With Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2010, 11, 105-113.	1.1	19
232	The Emerging Role of Biomarkers in Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2010, 11, 149-159.	1.1	20
233	Extended-Duration Therapy in Advanced Non-Small-Cell Lung Cancer: Promise and Pitfalls. <i>Clinical Lung Cancer</i> , 2010, 11, 383-390.	1.1	1
234	Analysis of 5-Fluorouracil-Related Enzymes in Pulmonary Neuroendocrine Carcinoma: Differences in Biological Properties Compared to Epithelial Carcinoma. <i>Clinical Lung Cancer</i> , 2010, 11, 412-422.	1.1	6

#	ARTICLE	IF	CITATIONS
235	Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population. <i>BMC Cancer</i> , 2010, 10, 26.	1.1	24
236	In vitro study on the schedule-dependency of the interaction between pemetrexed, gemcitabine and irradiation in non-small cell lung cancer and head and neck cancer cells. <i>BMC Cancer</i> , 2010, 10, 441.	1.1	13
238	Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer. <i>Cancer</i> , 2010, 116, 670-675.	2.0	111
239	Implications of key trials in advanced nonsmall cell lung cancer. <i>Cancer</i> , 2010, 116, 1155-1164.	2.0	17
240	Phase 2 trial of pemetrexed disodium and carboplatin in previously untreated extensive-stage small cell lung cancer, N0423. <i>Cancer</i> , 2010, 116, 2382-2389.	2.0	3
241	Identification of <i>GOS2</i> as a gene frequently methylated in squamous lung cancer by combination of <i>in silico</i> and experimental approaches. <i>International Journal of Cancer</i> , 2010, 126, 1895-1902.	2.3	48
242	Thymidylate synthase expression in high-grade neuroendocrine and non-small cell lung cancer histotypes—is it ready for primetime?. <i>Journal of Surgical Oncology</i> , 2010, 102, 10-10.	0.8	1
243	The expression of stem cell-related indicators as a prognostic factor in human lung adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2010, 102, 856-862.	0.8	18
244	Surgical Management of Non-small Cell Lung Cancer with Mediastinal Lymphadenopathy. <i>Clinical Oncology</i> , 2010, 22, 325-333.	0.6	8
245	Ligand-based virtual screening and ADME-tox guided approach to identify triazolo-quinoxalines as folate cycle inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 7773-7785.	1.4	20
246	Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 75, 173-234.	2.0	165
247	Genetic polymorphisms in the endothelial nitric oxide synthase gene correlate with overall survival in advanced non-small-cell lung cancer patients treated with platinum-based doublet chemotherapy. <i>BMC Medical Genetics</i> , 2010, 11, 167.	2.1	31
248	Significance of thymidylate synthase for resistance to pemetrexed in lung cancer. <i>Cancer Science</i> , 2010, 101, 161-166.	1.7	113
249	ABCC11/MRP8 confers pemetrexed resistance in lung cancer. <i>Cancer Science</i> , 2010, 101, 2404-2410.	1.7	46
250	AAVrh.10-mediated genetic delivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumors. <i>Gene Therapy</i> , 2010, 17, 1042-1051.	2.3	46
251	Anti-angiogenesis drugs in lung cancer. <i>Respirology</i> , 2010, 15, 387-392.	1.3	7
252	Targeted therapies in metastatic non-small cell lung cancer (NSCLC): the rational approach. <i>Current Oncology</i> , 2010, 17, 13-23.	0.9	64
253	Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC). <i>Drug Design, Development and Therapy</i> , 2010, 4, 81.	2.0	42

#	ARTICLE	IF	CITATIONS
254	Astragalus-containing Chinese herbal combinations for advanced non-small-cell lung cancer: a meta-analysis of 65 clinical trials enrolling 4751 patients. <i>Lung Cancer: Targets and Therapy</i> , 2010, 1, 85.	1.3	5
255	Maintenance therapy for metastatic non-small-cell lung cancer &ndash; the role of pemetrexed. <i>Lung Cancer: Targets and Therapy</i> , 2010, 1, 1.	1.3	0
256	Refining the treatment of advanced nonsmall cell lung cancer. <i>Lung Cancer: Targets and Therapy</i> , 2010, 1, 9.	1.3	1
257	Gene Expression-Based Classification of Non-Small Cell Lung Carcinomas and Survival Prediction. <i>PLoS ONE</i> , 2010, 5, e10312.	1.1	656
258	The Use of P63 Immunohistochemistry for the Identification of Squamous Cell Carcinoma of the Lung. <i>PLoS ONE</i> , 2010, 5, e12209.	1.1	51
259	Treatment results including more than third-line chemotherapy for patients with advanced non-small cell lung cancer. <i>Oncology Letters</i> , 2010, 1, 51-55.	0.8	4
260	Modulation of the Ribonucleotide Reductase-Antimetabolite Drug Interaction in Cancer Cell Lines. <i>Journal of Nucleic Acids</i> , 2010, 2010, 1-10.	0.8	16
261	Cancer chemotherapy: targeting folic acid synthesis. <i>Cancer Management and Research</i> , 2010, , 293.	0.9	11
262	Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer. <i>Cancer Management and Research</i> , 2010, 2, 143.	0.9	19
263	Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC). <i>Current Drug Targets</i> , 2010, 11, 12-28.	1.0	15
264	Pemetrexed: Potential Role in the Adjuvant Chemotherapy of Non-Small Cell Lung Cancer. <i>Current Drug Targets</i> , 2010, 11, 78-84.	1.0	4
265	The role of maintenance pemetrexed in the treatment of non-small-cell lung cancer. <i>Lung Cancer: Targets and Therapy</i> , 2010, 1, 101.	1.3	1
266	Shifting the paradigm for maintenance therapy in advanced non-small-cell lung cancer. <i>Lung Cancer: Targets and Therapy</i> , 2010, 1, 53.	1.3	0
267	The Role of Pemetrexed Combined with Targeted Agents for Non-Small Cell Lung Cancer. <i>Current Drug Targets</i> , 2010, 11, 2-11.	1.0	6
268	Pemetrexed versus Gefitinib versus Erlotinib in Previously Treated Patients with Non-Small Cell Lung Cancer. <i>Korean Journal of Internal Medicine</i> , 2010, 25, 294.	0.7	25
269	Treatment of Non-Small Cell Lung Cancer: Focus on Pemetrexed Disodium. <i>Clinical Medicine Insights Therapeutics</i> , 2010, 2, CMT.S5262.	0.4	0
270	The Role of Pemetrexed in the Pharmacotherapy of Malignant Pleural Mesothelioma. <i>Clinical Medicine Insights Therapeutics</i> , 2010, 2, CMT.S1166.	0.4	0
271	Overall survival with cisplatin&ndash;gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). <i>Annals of Oncology</i> , 2010, 21, 1804-1809.	0.6	585

#	ARTICLE	IF	CITATIONS
272	Lung cancer: multidisciplinary approach for management: Cell and Molecular Biology Assembly contribution to the celebration of 20 years of the ERS. <i>European Respiratory Journal</i> , 2010, 35, 717-720.	3.1	10
273	Consequences of targeted treatments for second-line therapy. <i>Annals of Oncology</i> , 2010, 21, vii234-vii240.	0.6	4
274	Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. <i>Health Technology Assessment</i> , 2010, 14, 47-53.	1.3	30
275	Surgery With or Without Preoperative Paclitaxel and Carboplatin in Early-Stage Non-Small-Cell Lung Cancer: Southwest Oncology Group Trial S9900, an Intergroup, Randomized, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 1843-1849.	0.8	206
276	Development of Central Nervous System Metastases in Patients with Advanced Non-Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib. <i>Clinical Cancer Research</i> , 2010, 16, 5873-5882.	3.2	209
277	The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer. <i>Future Oncology</i> , 2010, 6, 1827-1832.	1.1	19
278	A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 2450-2457.	3.2	215
279	Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 1835-1842.	0.8	421
280	Maintenance Therapy for Advanced Non-small Cell Lung Cancer: Current Status, Controversies, and Emerging Consensus. <i>Clinical Cancer Research</i> , 2010, 16, 2496-2504.	3.2	28
281	Approval Summary: Pemetrexed Maintenance Therapy of Advanced/Metastatic Nonsquamous, Non-Small Cell Lung Cancer (NSCLC). <i>Oncologist</i> , 2010, 15, 1352-1358.	1.9	52
282	ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial. <i>Annals of Oncology</i> , 2010, 21, 1817-1824.	0.6	62
283	New Strategies in Kidney Cancer: Therapeutic Advances through Understanding the Molecular Basis of Response and Resistance. <i>Clinical Cancer Research</i> , 2010, 16, 1348-1354.	3.2	80
284	Biweekly Vinorelbine and Gemcitabine as Second-Line Treatment and Beyond in Non-Small Cell Lung Cancer. <i>Chemotherapy</i> , 2010, 56, 353-358.	0.8	5
285	Update on nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2010, 19, 173-185.	3.0	20
286	Phase III Trial Comparing Vinflunine With Docetaxel in Second-Line Advanced Non-Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy. <i>Journal of Clinical Oncology</i> , 2010, 28, 2167-2173.	0.8	70
287	Pemetrexed Plus Bevacizumab for Second-Line Therapy of Non-Small-Cell Lung Cancer: The Importance of Patient Selection. <i>Journal of Clinical Oncology</i> , 2010, 28, e131-e131.	0.8	2
288	Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 3138-3145.	0.8	351
289	Pemetrexed Pathway-Associated Germline Polymorphisms: A Useful Tool for Treatment Individualization?. <i>Journal of Clinical Oncology</i> , 2010, 28, e482-e483.	0.8	4



#	ARTICLE	IF	CITATIONS
290	What is the role of maintenance therapy in the treatment of non-small cell lung cancer?. Therapeutic Advances in Medical Oncology, 2010, 2, 229-235.	1.4	3
291	Does Type of Tumor Histology Impact Survival among Patients with Stage IIIB/IV Non-Small Cell Lung Cancer Treated with First-Line Doublet Chemotherapy?. Chemotherapy Research and Practice, 2010, 2010, 1-8.	1.6	7
292	A Cost-Effectiveness Analysis of Docetaxel versus Pemetrexed in Second-Line Chemotherapy for Stage IIIB or IV Non-Small Cell Lung Cancer in China. Chemotherapy, 2010, 56, 472-477.	0.8	6
293	Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial. Annals of Oncology, 2010, 21, 2227-2232.	0.6	102
294	Current and emerging therapies for patients with advanced non-small-cell lung cancer. American Journal of Health-System Pharmacy, 2010, 67, S9-S14.	0.5	13
295	Future Scenarios for the Treatment of Advanced Non-Small Cell Lung Cancer: Focus on Taxane-Containing Regimens. Oncologist, 2010, 15, 1102-1112.	1.9	64
296	Clinical Management of Lung Cancer. , 2010, , 437-445.		0
297	If Histology Matters. Journal of Clinical Oncology, 2010, 28, 1810-1812.	0.8	15
298	Pemetrexed Indirectly Activates the Metabolic Kinase AMPK in Human Carcinomas. Cancer Research, 2010, 70, 10299-10309.	0.4	81
299	Gene Profiling of Clinical Routine Biopsies and Prediction of Survival in Non-Small Cell Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 181-188.	2.5	44
300	How to integrate current knowledge in selecting patients for first line in NSCLC?. Annals of Oncology, 2010, 21, vii230-vii233.	0.6	5
301	Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2010, 21, v116-v119.	0.6	273
302	Targeting Angiogenesis with Multitargeted Tyrosine Kinase Inhibitors in the Treatment of Non-Small Cell Lung Cancer. Oncologist, 2010, 15, 436-446.	1.9	54
303	Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer. Expert Opinion on Pharmacotherapy, 2010, 11, 1683-1693.	0.9	10
304	Personalized medicine for non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2010, 10, 1601-1611.	1.1	15
305	The Evolving Role of Histology in the Management of Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2010, 28, 5311-5320.	0.8	247
306	Phase III Trial Comparing Oral S-1 Plus Carboplatin With Paclitaxel Plus Carboplatin in Chemotherapy-Naïve Patients With Advanced Non-Small-Cell Lung Cancer: Results of a West Japan Oncology Group Study. Journal of Clinical Oncology, 2010, 28, 5240-5246.	0.8	161
307	Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non-Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099. Journal of Clinical Oncology, 2010, 28, 911-917.	0.8	419

#	ARTICLE	IF	CITATIONS
308	MicroRNA Expression Differentiates Histology and Predicts Survival of Lung Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 430-441.	3.2	316
309	Strategies for Prolonged Therapy in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 5116-5123.	0.8	64
310	Optimizing Collection of Adverse Event Data in Cancer Clinical Trials Supporting Supplemental Indications. <i>Journal of Clinical Oncology</i> , 2010, 28, 5046-5053.	0.8	18
311	Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2010, 21, 556-561.	0.6	49
312	Lung Cancer Working Group Report. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, i7-i12.	0.6	17
313	Pemetrexed Safety and Pharmacokinetics in Patients with Third-Space Fluid. <i>Clinical Cancer Research</i> , 2010, 16, 2872-2880.	3.2	21
314	Introduction. <i>American Journal of Health-System Pharmacy</i> , 2010, 67, S1-S2.	0.5	0
315	Prognostic Significance of OCT4 Expression in Adenocarcinoma of the Lung. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 961-966.	0.6	61
316	Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer. <i>Pharmacogenomics Journal</i> , 2010, 10, 180-190.	0.9	22
317	Thymidylate Synthase But Not Excision Repair Cross-Complementation Group 1 Tumor Expression Predicts Outcome in Patients With Malignant Pleural Mesothelioma Treated With Pemetrexed-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , 2010, 28, 1534-1539.	0.8	155
318	Histology Matters: Individualizing Treatment in Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2010, 15, 3-5.	1.9	31
319	Can a decisional algorithm be used in first-line treatment of advanced nonsmall cell lung cancer?. <i>Current Opinion in Oncology</i> , 2010, 22, 77-78.	1.1	1
320	Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1416-1423.	0.5	153
323	Clinical outcomes in non-small-cell lung cancer in relation to expression of predictive and prognostic biomarkers. <i>Future Oncology</i> , 2010, 6, 741-767.	1.1	24
324	The Emerging Role of Histology in the Choice of First-Line Treatment of Advanced Non-Small Cell Lung Cancer: Implication in the Clinical Decision-Making. <i>Current Medicinal Chemistry</i> , 2010, 17, 1030-1038.	1.2	24
325	Pemetrexed in heavily pretreated non-small-cell lung cancer patients: case report and review of the literature. <i>Future Oncology</i> , 2010, 6, 1937-1940.	1.1	1
326	Maintenance and Consolidation Therapy in Patients with Unresectable Stage III/IV Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2010, 15, 1034-1042.	1.9	20
327	Cisplatin plus Gemcitabine for Biliary Tract Cancer. <i>New England Journal of Medicine</i> , 2010, 363, 192-193.	13.9	10

#	ARTICLE	IF	CITATIONS
328	Accelerated second-line or maintenance chemotherapy versus treatment at disease progression in NSCLC. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 549-557.	1.1	1
329	Advances in Diagnostic Bronchoscopy. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 589-597.	2.5	62
330	Novel Agents in the Management of Lung Cancer. <i>Current Medicinal Chemistry</i> , 2010, 17, 4291-4325.	1.2	21
331	Prospects for molecular staging of non-small-cell lung cancer from genomic alterations. <i>Expert Review of Respiratory Medicine</i> , 2010, 4, 499-508.	1.0	8
332	Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2363-2389.	0.9	19
335	Aspects médico-économiques de la pneumologie. <i>Revue Des Maladies Respiratoires Actualites</i> , 2010, 2, 205-222.	0.0	0
336	Oncologie thoracique. <i>Revue Des Maladies Respiratoires Actualites</i> , 2010, 2, 167-177.	0.0	1
337	New strategies for targeting the therapy of NSCLC: the role of ERCC1 and TS. <i>Advances in Medical Sciences</i> , 2010, 55, 22-25.	0.9	10
340	Pattern of care for advanced non-small cell lung cancer in the era of histology-based treatment: A survey of the Italian Association of Thoracic Oncology (AIOT). <i>Lung Cancer</i> , 2010, 67, 339-342.	0.9	4
341	Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2010, 68, 94-98.	0.9	11
342	Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer. <i>Lung Cancer</i> , 2010, 68, 264-268.	0.9	107
343	The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2010, 68, 427-432.	0.9	7
344	Phase I/II study of docetaxel and S-1, an oral fluorinated pyrimidine, for untreated advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2010, 68, 409-414.	0.9	9
345	Methodological aspects of lung cancer clinical trials in the era of targeted agents. <i>Lung Cancer</i> , 2010, 67, 127-135.	0.9	30
346	First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: A quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale. <i>Lung Cancer</i> , 2010, 69, 218-224.	0.9	17
347	Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. <i>Lung Cancer</i> , 2010, 68, 319-331.	0.9	60
348	Second-line weekly paclitaxel in resistant or relapsed non-small cell lung cancer treated with docetaxel and carboplatin: A multi-center phase II study. <i>Lung Cancer</i> , 2010, 69, 319-322.	0.9	7
349	Pemetrexed and cisplatin with concurrent radiotherapy for locally advanced non-small cell and limited disease small cell lung cancer: Results from 2 phase I studies. <i>Lung Cancer</i> , 2010, 69, 302-306.	0.9	16

#	ARTICLE	IF	CITATIONS
350	The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2010, 69, 323-329.	0.9	60
351	A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2010, 70, 71-76.	0.9	16
352	Histology classification is not a predictor of clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine or gemcitabine combinations. <i>Lung Cancer</i> , 2010, 70, 200-204.	0.9	5
353	Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2010, 70, 168-173.	0.9	12
354	A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2010, 70, 340-346.	0.9	15
355	Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study). <i>Lung Cancer</i> , 2010, 70, 301-307.	0.9	40
356	Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2010, 70, 233-246.	0.9	15
357	Targeted therapy in non-small-cell lung cancer—“is it becoming a reality?”. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 401-414.	12.5	231
358	Pemetrexed in advanced non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1387-1402.	0.9	40
359	Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer. <i>BMC Cancer</i> , 2010, 10, 85.	1.1	28
360	Management of Patients with Advanced Non-Small Cell Lung Cancer. <i>Drugs</i> , 2010, 70, 167-179.	4.9	18
361	Response to Pemetrexed Chemotherapy in Lung Adenocarcinoma-Bronchioloalveolar Carcinoma Insensitive to Erlotinib. <i>Clinical Lung Cancer</i> , 2010, 11, 57-60.	1.1	8
362	Comparison of Patient Outcomes According to Histology Among Pemetrexed-Treated Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer in Two Phase II Trials. <i>Clinical Lung Cancer</i> , 2010, 11, 126-131.	1.1	20
363	Carboplatin/Pemetrexed/Bevacizumab in the Treatment of Patients With Advanced Non-Small-Cell Lung Cancer: A Single-Institution Experience. <i>Clinical Lung Cancer</i> , 2010, 11, 192-197.	1.1	13
364	Second-line Treatment for Non-Small-Cell Lung Cancer: One Size Does Not Fit All. <i>Clinical Lung Cancer</i> , 2010, 11, 320-327.	1.1	11
365	Treatment Rationale and Study Design for a Randomized Trial of Pemetrexed/Carboplatin Followed by Maintenance Pemetrexed Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients With Advanced Non-Small-Cell Lung Cancer of Nonsquamous Histology. <i>Clinical Lung Cancer</i> , 2010, 11, 352-357.	1.1	15
366	Study of use of pemetrexed in non-small cell lung cancer. <i>Farmacia Hospitalaria (English Edition)</i> , 2010, 34, 194-203.	0.0	0
367	Randomized Phase III Trial of Platinum-Doublet Chemotherapy Followed by Gefitinib Compared With Continued Platinum-Doublet Chemotherapy in Japanese Patients With Advanced Non-Small-Cell Lung Cancer: Results of a West Japan Thoracic Oncology Group Trial (WJTOG0203). <i>Journal of Clinical Oncology</i> , 2010, 28, 753-760.	0.8	174

#	ARTICLE	IF	CITATIONS
368	Phase I/II Study of Inhaled Doxorubicin Combined with Platinum-Based Therapy for Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 2466-2473.	3.2	98
369	Membrane Topological Analysis of the Proton-Coupled Folate Transporter (PCFT-SLC46A1) by the Substituted Cysteine Accessibility Method. <i>Biochemistry</i> , 2010, 49, 2925-2931.	1.2	46
370	Survival comparison between glioblastoma multiforme and other incurable cancers. <i>Journal of Clinical Neuroscience</i> , 2010, 17, 417-421.	0.8	145
371	The role of the percutaneous biopsy in the evolving diagnosis and treatment of lung cancer. <i>Clinical Radiology</i> , 2010, 65, 951-952.	0.5	7
372	Parameters for individualizing systemic therapy in non-small cell lung cancer. <i>Drug Resistance Updates</i> , 2010, 13, 196-204.	6.5	15
373	ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial. <i>European Journal of Cancer</i> , 2010, 46, 1554-1562.	1.3	23
374	Gefitinib for the treatment of non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1343-1357.	0.9	20
375	Editorial: Comparative efficacy and cost associated with new agents in the treatment of non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2010, 69, S1-S3.	0.9	2
376	Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer. <i>Lung Cancer</i> , 2010, 69, S4-S10.	0.9	17
377	Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy. <i>Lung Cancer</i> , 2010, 69, S11-S17.	0.9	26
378	Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany. <i>Lung Cancer</i> , 2010, 69, S18-S23.	0.9	10
379	Results of surgical resection for patients with large cell carcinoma of the lung. <i>International Journal of Surgery</i> , 2010, 8, 391-394.	1.1	11
380	Pemetrexed for Heavily Pretreated Patients With Advanced Non-small Cell Lung Cancer. <i>Journal of the Formosan Medical Association</i> , 2010, 109, 338-344.	0.8	8
381	Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. <i>Lancet Oncology</i> , The, 2010, 11, 521-529.	5.1	1,158
382	The Classification of Lung Carcinoma: Time to Change the Morphology-Based Approach?. <i>International Journal of Surgical Pathology</i> , 2010, 18, 161-172.	0.4	23
383	The role of pemetrexed as maintenance treatment in advanced NSCLC: a Phase III randomized trial. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 321-324.	0.9	5
384	Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients. <i>Journal of Experimental and Clinical Cancer Research</i> , 2010, 29, 38.	3.5	16
385	Comparison of the epidermal growth factor receptor protein expression between primary non-small cell lung cancer and paired lymph node metastases: implications for targeted nuclide radiotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2010, 29, 7.	3.5	13

#	ARTICLE	IF	CITATIONS
386	Biological markers in lung cancer: A clinician's perspective. <i>Cancer Biomarkers</i> , 2010, 6, 123-135.	0.8	46
387	Advances in chemotherapy in advanced non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2997-3007.	0.9	30
388	Valutazioni di farmacoeconomia che danno risultati opposti. <i>Giornale Italiano Di Health Technology Assessment</i> , 2010, 3, 89-90.	0.1	0
389	Generalized or personalized treatment for stage IIIA-N2 non-small-cell lung cancer?. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1605-1609.	0.9	4
390	Synthesis and Antitumor Activity of a Novel Series of 6-Substituted Pyrrolo[2,3- <i>d</i> ]pyrimidine Thienoyl Antifolate Inhibitors of Purine Biosynthesis with Selectivity for High Affinity Folate Receptors and the Proton-Coupled Folate Transporter over the Reduced Folate Carrier for Cellular Entry. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 1306-1318.	2.9	63
391	Role of DNA Repair Gene Polymorphisms in the Efficiency of Platinum-Based Adjuvant Chemotherapy for Non-Small Cell Lung Cancer. <i>Molecular Diagnosis and Therapy</i> , 2011, 15, 159-166.	1.6	22
392	Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 3307-3315.	0.8	379
393	Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 1067-1074.	0.8	268
394	The BATTLE Trial: Personalizing Therapy for Lung Cancer. <i>Cancer Discovery</i> , 2011, 1, 44-53.	7.7	778
395	Diagnostic Workup of Lung Cancer. <i>Surgical Oncology Clinics of North America</i> , 2011, 20, 667-679.	0.6	9
397	A Decade of Advances in Treatment for Advanced Non-Small Cell Lung Cancer. <i>Clinics in Chest Medicine</i> , 2011, 32, 839-851.	0.8	58
399	La radio-chimiothérapie exclusive des cancers bronchiques non À petites cellules. <i>Revue Des Maladies Respiratoires Actualites</i> , 2011, 3, 353-359.	0.0	0
400	Current Management of Small Cell Lung Cancer. <i>Clinics in Chest Medicine</i> , 2011, 32, 853-863.	0.8	34
402	Pemetrexed in advanced non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 311-317.	1.0	14
403	Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 1223-1231.	1.4	28
404	Cancer: Beyond Speciation. <i>Advances in Cancer Research</i> , 2011, 112, 283-350.	1.9	60
405	Pathology of Lung Cancer. <i>Clinics in Chest Medicine</i> , 2011, 32, 669-692.	0.8	436
406	Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003. <i>Value in Health</i> , 2011, 14, 41-52.	0.1	99

#	ARTICLE	IF	CITATIONS
407	A Trial-Based Assessment of the Cost-Utility of Bevacizumab and Chemotherapy versus Chemotherapy Alone for Advanced Non-Small Cell Lung Cancer. <i>Value in Health</i> , 2011, 14, 836-845.	0.1	88
408	Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. <i>Lung Cancer</i> , 2011, 71, 191-198.	0.9	45
409	A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients. <i>Lung Cancer</i> , 2011, 71, 151-155.	0.9	12
410	Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): Preliminary results of a phase II study. <i>Lung Cancer</i> , 2011, 72, 327-332.	0.9	27
411	Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany. <i>Lung Cancer</i> , 2011, 71, 244.	0.9	1
412	Diverging prognostic impacts of hypoxic markers according to NSCLC histology. <i>Lung Cancer</i> , 2011, 72, 294-302.	0.9	40
413	Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group. <i>Lung Cancer</i> , 2011, 73, 338-344.	0.9	4
414	Phase II study of S-1 monotherapy in platinum-refractory, advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2011, 74, 85-8.	0.9	19
415	Phase I study of concurrent chemoradiation with pemetrexed and cisplatin followed by consolidation pemetrexed for patients with unresectable stage III non-small cell lung cancer. <i>Lung Cancer</i> , 2011, 74, 69-74.	0.9	19
416	Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: The association with treatment efficacy of pemetrexed. <i>Lung Cancer</i> , 2011, 74, 132-138.	0.9	103
417	Impact of histology on survival of resected non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy: Subgroup analysis of the adjuvant vinorelbine (NVB) cisplatin (CDDP) versus observation in the ANITA trial. <i>Lung Cancer</i> , 2011, 74, 30-34.	0.9	24
418	The search for improved systemic therapy of non-small cell lung cancerâ€”What are today's options?. <i>Lung Cancer</i> , 2011, 72, 265-270.	0.9	19
419	Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines. <i>Lung Cancer</i> , 2011, 73, 1-10.	0.9	28
420	Medical treatment choices for patients affected by advanced NSCLC in routine clinical practice: Results from the Italian observational â€œSUNâ€”(Survey on the lUng cancer maNagement) study. <i>Lung Cancer</i> , 2011, 74, 462-468.	0.9	14
422	Predictive markers in the adjuvant therapy of non-small cell lung cancer. <i>Lung Cancer</i> , 2011, 74, 355-363.	0.9	22
423	Tumours. , 2011, , 531-705.		0
424	Thymidylate synthase inhibitors for non-small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 1343-1356.	1.9	28
425	Role of Genotyping in Non-Small Cell Lung Cancer Treatment. <i>Drugs</i> , 2011, 71, 2231-2246.	4.9	23

#	ARTICLE	IF	CITATIONS
426	Case 21-2011. New England Journal of Medicine, 2011, 365, 158-167.	13.9	10
427	Maintenance therapy in NSCLC: why? To whom? Which agent?. Journal of Experimental and Clinical Cancer Research, 2011, 30, 50.	3.5	24
428	The BATTLE to Personalize Lung Cancer Prevention through Reverse Migration. Cancer Prevention Research, 2011, 4, 962-972.	0.7	47
430	Prognostic, therapeutic and diagnostic potential of microRNAs in non-small cell lung cancer. Clinical Chemistry and Laboratory Medicine, 2011, 49, 1591-603.	1.4	49
431	Induction Chemotherapy. , 2011, , .		5
433	The Changing Pathology of Lung Cancer. Surgical Oncology Clinics of North America, 2011, 20, 637-653.	0.6	10
434	Bronchial washing levels of vascular endothelial growth factor receptor-2 (VEGFR2) correlate with overall survival in NSCLC patients. Cancer Letters, 2011, 304, 144-153.	3.2	13
435	Establishment of pemetrexed-resistant non-small cell lung cancer cell lines. Cancer Letters, 2011, 309, 228-235.	3.2	43
436	A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: An Alpeâ€“Adria Thoracic Oncology Multidisciplinary group trial (ATOM) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50		
437	Under usage of zoledronic acid in non-small cell lung cancer patients with metastatic bone disease â€“ a short communication. European Journal of Cancer, 2011, 47, 1603-1605.	1.3	12
439	2010 Consensus on Lung Cancer, new clinical recommendations and current status of biomarker assessment â€“ First-line therapy. European Journal of Cancer, 2011, 47, S248-S257.	1.3	5
440	Second-line treatment options in advanced non-small cell lung cancer. European Journal of Cancer, 2011, 47, S258-S271.	1.3	2
441	67 INVITED Stage III-N2 Non-Small Cell Lung Cancer â€“ Choice of Chemotherapy Schemes. European Journal of Cancer, 2011, 47, S18-S19.	1.3	0
442	New driver mutations in non-small-cell lung cancer. Lancet Oncology, The, 2011, 12, 175-180.	5.1	1,038
443	A retrospective study of pemetrexed combined with oxaliplatin as secondâ€“line treatment for advanced nonâ€“smallâ€“cell lung cancer: Comparable toxicity, better outcome. Thoracic Cancer, 2011, 2, 201-206.	0.8	0
444	Therapeutic advances in non-small cell lung cancer: Highlights from the annual clinical cancer conferences. Community Oncology, 2011, 8, 5-16.	0.2	0
445	Molecular tumor classification using a 92-gene assay in the differential diagnosis of squamous cell lung cancer. Community Oncology, 2011, 8, 123-131.	0.2	0
446	Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations. Lung Cancer, 2011, 72, 333-339.	0.9	45



#	ARTICLE	IF	CITATIONS
447	First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging. <i>Annals of Oncology</i> , 2011, 22, 559-566.	0.6	70
448	First-line Systemic Therapy for Metastatic Non-small-cell Lung Cancer – A Review. <i>Journal of Experimental and Clinical Medicine</i> , 2011, 3, 116-120.	0.2	7
449	Personalized Therapy for Non-Small Cell Lung Cancer: Hype or Clinical Reality?. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2011, 23, 30-35.	0.4	2
450	Kinase-driven pathways of EGFR in lung carcinomas: perspectives on targeting therapy. <i>Frontiers in Bioscience - Landmark</i> , 2011, 16, 1714.	3.0	8
451	Radiotherapy and Third Generation Concurrent Chemotherapy Agents. <i>Medical Radiology</i> , 2011, , 291-312.	0.0	0
452	Drugs, Genomic Response Signatures, and Customized Cancer Therapy. , 0, , 301-319.		0
453	Systemic Therapy for Lung Cancer for the Radiation Oncologist. <i>Medical Radiology</i> , 2011, , 247-266.	0.0	0
454	Pathology of Lung Cancer. <i>Medical Radiology</i> , 2011, , 53-62.	0.0	0
455	Smoking and Prognostic Factors in an Observational Setting in Patients with Advanced Non-Small Cell Lung Carcinoma. <i>Journal of Cancer</i> , 2011, 2, 52-61.	1.2	14
456	Emerging treatment options in the management of non-small cell lung cancer. <i>Lung Cancer: Targets and Therapy</i> , 2011, 2, 11.	1.3	3
458	Afatinib treatment in advanced non-small cell lung cancer. <i>Lung Cancer: Targets and Therapy</i> , 2011, 2, 47.	1.3	3
459	A multi-institutional phase II study of combination chemotherapy with S-1 plus cisplatin in patients with advanced non-small cell lung cancer. <i>Oncology Letters</i> , 2011, 2, 465-470.	0.8	3
460	Adjuvant Chemotherapy for Early Stage Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2011, 1, 45.	1.3	5
461	Novel Cytotoxic Agents in Combination with Radiation in the Management of Locally Advanced Non-Small Cell Lung Cancer: Focus on Pemetrexed and Nab-Paclitaxel [Abraxane]. <i>Medical Radiology</i> , 2011, , 765-771.	0.0	2
462	Dramatic Response to Pemetrexed in a Patient with Pneumonic-Type Mucinous Bronchioloalveolar Carcinoma. <i>Journal of Thoracic Oncology</i> , 2011, 6, 397-398.	0.5	5
464	Role of Survival Post-Progression in Phase III Trials of Systemic Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Systemic Review. <i>PLoS ONE</i> , 2011, 6, e26646.	1.1	66
465	Duodenal perforation in a patient with non-small cell lung cancer receiving Pemetrexed-Cisplatin combination. <i>Journal of Surgical Case Reports</i> , 2011, 2011, 1-4.	0.2	0
466	You Just Can't Call it Lung Cancer Anymore. <i>Journal of Thoracic Oncology</i> , 2011, 6, 239-240.	0.5	5

#	ARTICLE	IF	CITATIONS
468	Maintenance Therapy in Advanced Non-small Cell Lung Cancer: Current Status and Future Implications. <i>Journal of Thoracic Oncology</i> , 2011, 6, 174-182.	0.5	35
469	Phase II Trial of S-1 as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 790-795.	0.5	16
470	Actual and Predicted Survival Time of Patients With Spinal Metastases of Lung Cancer. <i>Spine</i> , 2011, 36, 983-989.	1.0	64
471	Primary Squamous Cell Carcinoma of Lung in a 7-year-old Boy. <i>Journal of Pediatric Hematology/Oncology</i> , 2011, 33, e307-e309.	0.3	3
472	Synchronous double primary lung cancers with different response to pemetrexed. <i>Anti-Cancer Drugs</i> , 2011, 22, 473-476.	0.7	0
473	Chemoradiation therapy in nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , 2011, 23, 140-149.	1.1	28
474	Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer. <i>Current Opinion in Oncology</i> , 2011, 23, 150-157.	1.1	5
475	Predicting Response to Chemotherapy With Early-Stage Lung Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2011, 17, 49-56.	1.0	10
476	Novel Therapies for Non-Small Cell Lung Cancer. <i>Journal of Thoracic Imaging</i> , 2011, 26, 175-185.	0.8	12
477	Factors Driving the Choice of the Best Second-Line Treatment of Advanced NSCLC. <i>Reviews on Recent Clinical Trials</i> , 2011, 6, 44-51.	0.4	17
478	Computed Tomography-Guided Interstitial High-Dose-Rate Brachytherapy in the Local Treatment of Primary and Secondary Intrathoracic Malignancies. <i>Journal of Thoracic Oncology</i> , 2011, 6, 545-552.	0.5	26
479	Molecular Predictors of Response to Chemotherapy in Non-Small Cell Lung Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2011, 17, 104-113.	1.0	27
480	Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma. <i>Oncology Reports</i> , 2011, 25, 921-8.	1.2	73
481	New discoveries in lung cancer biology: paving the road of personalized medicine. <i>Therapy: Open Access in Clinical Medicine</i> , 2011, 8, 1-4.	0.2	0
482	What's new in non-small cell lung cancer for pathologists the importance of accurate subtyping, EGFR mutations and ALK rearrangements. <i>Pathology</i> , 2011, 43, 103-115.	0.3	54
483	Utility of 10 Immunohistochemical Markers Including Novel Markers (Desmocollin-3, Glypican 3,) Tj ETQq1 1 0.784314 rgBT /Overlock 1 Adenocarcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1190-1199.	0.5	81
484	Maintenance Therapy With Continuous or Switch Strategy in Advanced Non-small Cell Lung Cancer. <i>Chest</i> , 2011, 140, 117-126.	0.4	67
485	Differential Effect of Polymorphisms of CMPK1 and RRM1 on Survival in Advanced Non-small Cell Lung Cancer Patients Treated with Gemcitabine or Taxane/Cisplatinum. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1320-1329.	0.5	28

#	ARTICLE	IF	CITATIONS
486	An Open-Label, Multicenter, Three-Stage, Phase II Study of S-1 in Combination with Cisplatin as First-Line Therapy for Patients with Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1400-1406.	0.5	15
487	A Phase III Randomized Trial of Gemcitabine+Oxaliplatin versus Carboplatin+Paclitaxel as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 358-364.	0.5	21
488	Optimizing Pemetrexed-Gemcitabine Combination in Patients with Advanced Non-small Cell Lung Cancer: A Pharmacogenetic Approach. <i>Journal of Thoracic Oncology</i> , 2011, 6, 768-773.	0.5	14
489	A Randomized Phase 3 Trial Comparing Pemetrexed/Carboplatin and Docetaxel/Carboplatin as First-Line Treatment for Advanced, Nonsquamous Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1907-1914.	0.5	82
490	Anticancer treatment for advanced non-small cell lung cancer. <i>Breathe</i> , 2011, 8, 124-133.	0.6	2
491	Phase I and Pharmacokinetic Study of IV Vinflunine in Combination with Gemcitabine for Treatment of Advanced Non-small Cell Lung Cancer in Chemo-naïve Patients. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1247-1253.	0.5	10
492	Chemotherapy with or without low-dose interleukin-2 in advanced non-small cell lung cancer: results from a phase III randomized multicentric trial. <i>International Journal of Oncology</i> , 2011, 39, 1011-7.	1.4	25
493	Emerging treatments for small-cell lung cancer: Phase II and III trials. <i>Clinical Investigation</i> , 2011, 1, 255-263.	0.0	0
494	Anaplastic Lymphoma Kinase Translocation: A Predictive Biomarker of Pemetrexed in Patients with Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1474-1480.	0.5	148
495	Successful Treatment with Pemetrexed in a Patient with Mucinous Bronchioloalveolar Carcinoma: Long-Term Response Duration with Mild Toxicity. <i>Journal of Thoracic Oncology</i> , 2011, 6, 641-642.	0.5	7
496	A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1379-1391.	0.5	89
497	Accuracy of Fine Needle Aspiration Cytology in the Pathological Typing of Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 489-493.	0.5	92
498	Bortezomib for Patients with Advanced-Stage Bronchioloalveolar Carcinoma: A California Cancer Consortium Phase II Study (NCI 7003). <i>Journal of Thoracic Oncology</i> , 2011, 6, 1741-1745.	0.5	10
499	Everolimus in Combination with Pemetrexed in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with Chemotherapy: A Phase I Study Using a Novel, Adaptive Bayesian Dose-Escalation Model. <i>Journal of Thoracic Oncology</i> , 2011, 6, 2120-2129.	0.5	32
500	Immunohistochemistry by Means of Widely Agreed-Upon Markers (Cytokeratins 5/6 and 7, p63, Thyroid) Tj ETQq0 0 0 rgBT /Overlock 10 Parallels the Corresponding Profiling and Eventual Diagnoses on Surgical Specimens. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1039-1049.	0.5	60
503	Differential efficacy of docetaxel according to non-small cell lung cancer histology and the therapeutic effect of epidermal growth factor receptor tyrosine kinase inhibitors. <i>Oncology Letters</i> , 2011, 2, 1059-1064.	0.8	1
504	Significance of Thymidylate Synthase and Thyroid Transcription Factor 1 Expression in Patients with Nonsquamous Non-small Cell Lung Cancer Treated with Pemetrexed-Based Chemotherapy. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1392-1399.	0.5	108
505	Comparison of Nedaplatin and Irinotecan for Patients with Squamous and Nonsquamous Cell Carcinoma of the Lung: Meta-Analysis of Four Trials. <i>Journal of Thoracic Oncology</i> , 2011, 6, 128-131.	0.5	8

#	ARTICLE	IF	CITATIONS
506	A Systematic Review of the Interobserver Variability for Histology in the Differentiation between Squamous and Nonsquamous Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 55-63.	0.5	31
507	Phase II Study of Pemetrexed and Cisplatin, with Chest Radiotherapy Followed by Docetaxel in Patients with Stage III Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 927-933.	0.5	46
508	Histology as a treatment effect modifier in advanced non-small cell lung cancer: A systematic review of the evidence. <i>Respirology</i> , 2011, 16, 1210-1220.	1.3	26
509	Efficacy of gefitinib for non-adenocarcinoma non-small cell lung cancer patients harboring epidermal growth factor receptor mutations: A pooled analysis of published reports. <i>Cancer Science</i> , 2011, 102, 1032-1037.	1.7	128
510	Randomized phase 2 sequencing and pharmacokinetic study of gemcitabine and oxaliplatin in advanced non-small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011, 7, 376-384.	0.7	1
511	Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer. <i>British Journal of Cancer</i> , 2011, 104, 1594-1601.	2.9	153
512	An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011, 7, 13-21.	0.7	6
513	Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011, 7, 22-33.	0.7	21
514	Comparative effectiveness of bevacizumab plus cisplatin-based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non-squamous non-small cell lung cancer patients applying real-life outcomes. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011, 7, 34-40.	0.7	9
515	Classification of Lung Cancer. <i>Seminars in Roentgenology</i> , 2011, 46, 178-186.	0.2	42
516	Personalized Treatment of Lung Cancer. <i>Seminars in Oncology</i> , 2011, 38, 274-283.	0.8	35
517	Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancer. <i>BMC Cancer</i> , 2011, 11, 93.	1.1	16
518	Lung cancer: New biological insights and recent therapeutic advances. <i>Ca-A Cancer Journal for Clinicians</i> , 2011, 61, 91-112.	157.7	413
519	Biomarkers, Prediction, and Prognosis in Non-Small-Cell Lung Cancer: A Platform for Personalized Treatment. <i>Clinical Lung Cancer</i> , 2011, 12, 360-368.	1.1	28
520	Randomized Phase IIIb Trial Evaluating the Continuation of Bevacizumab Beyond Disease Progression in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer after First-Line Treatment with Bevacizumab Plus Platinum-Based Chemotherapy: Treatment Rationale and Protocol Dynamics of the AvaALL (MO22097) Trial. <i>Clinical Lung Cancer</i> , 2011, 12, 407-411.	1.1	43
521	Induction Pemetrexed and Cisplatin Followed by Maintenance Pemetrexed Versus Carboplatin Plus Paclitaxel Plus Bevacizumab Followed by Maintenance Bevacizumab: A Quality of Life-Oriented Randomized Phase III Study in Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer (FRACLE). <i>Clinical Lung Cancer</i> , 2011, 12, 402-406.	1.1	11
522	Costs and Ethical Issues Related to First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer: Considerations From a Public Healthcare System Perspective. <i>Clinical Lung Cancer</i> , 2011, 12, 335-340.	1.1	2
523	Monoclonal antibodies against EGFR in non-small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 80, 1-9.	2.0	42

#	ARTICLE	IF	CITATIONS
524	Milestones in the use of chemotherapy for the management of non-small cell lung cancer (NSCLC). <i>Critical Reviews in Oncology/Hematology</i> , 2011, 81, 49-57.	2.0	24
525	Sustained activation of ERK and Cdk2/cyclin-A signaling pathway by pemetrexed leading to S-phase arrest and apoptosis in human non-small cell lung cancer A549 cells. <i>European Journal of Pharmacology</i> , 2011, 663, 17-26.	1.7	53
526	NSCLC: novel targeted therapies offer hope for the future. <i>Future Prescriber</i> , 2011, 12, 6-9.	0.1	0
527	Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive. <i>Expert Review of Respiratory Medicine</i> , 2011, 5, 413-424.	1.0	24
528	Individualised treatment in non-small cell lung cancer: precise tissue diagnosis for all?. <i>Thorax</i> , 2011, 66, 273-275.	2.7	7
529	Pemetrexed monotherapy and pemetrexed plus platinum combination therapy as non-first-line treatments for advanced non-small cell lung cancer. <i>Clinical Oncology and Cancer Research</i> , 2011, 8, 235-241.	0.1	0
532	Non-small cell lung cancer in never smokers as a representative "non-smoking-associated lung cancer": epidemiology and clinical features. <i>International Journal of Clinical Oncology</i> , 2011, 16, 287-293.	1.0	91
533	Clinical observation of pemetrexed on advanced non-small-cell lung cancer. <i>Chinese-German Journal of Clinical Oncology</i> , 2011, 10, 140-143.	0.1	3
536	A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 751-764.	1.1	67
537	Phase II study of S-1, a novel oral fluoropyrimidine, and biweekly administration of docetaxel for previously treated advanced non-small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 791-797.	1.1	8
538	A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 415-422.	1.1	1
539	Drug therapy of cancer. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 437-447.	0.8	23
540	High response of second-line chemotherapy with pemetrexed or gemcitabine combined with carboplatin in patients with non-small-cell lung cancer experiencing progression following 6 months after concluding platinum-based chemotherapy. <i>Medical Oncology</i> , 2011, 28, 300-306.	1.2	11
541	Short-term outcomes of cetuximab combined with standard chemotherapy as first line setting for Chinese patients with non-small cell lung cancer: a report of 12 cases. <i>Medical Oncology</i> , 2011, 28, 570-576.	1.2	5
542	Monoclonal antibodies for medical oncology: a few critical perspectives. <i>Clinical and Translational Oncology</i> , 2011, 13, 84-87.	1.2	5
543	Treatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panel. <i>Clinical and Translational Oncology</i> , 2011, 13, 460-471.	1.2	28
544	Maintenance therapy for patients with advanced non-small cell lung cancer: Who to treat and how to treat?. <i>Memo - Magazine of European Medical Oncology</i> , 2011, 4, 19-22.	0.3	2
545	Maintenance therapy for NSCLC: Consensus and controversy. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2011, 23, 254-258.	0.7	6

#	ARTICLE	IF	CITATIONS
546	How Affordable are Targeted Therapies in Non-Small Cell Lung Cancer?. Current Treatment Options in Oncology, 2011, 12, 1-11.	1.3	12
547	Phase i study of 'dose-dense' pemetrexed plus carboplatin/radiotherapy for locally advanced non-small cell lung carcinoma. Radiation Oncology, 2011, 6, 17.	1.2	8
548	Subgroup identification based on differential effect searchâ€”A recursive partitioning method for establishing response to treatment in patient subpopulations. Statistics in Medicine, 2011, 30, 2601-2621.	0.8	218
549	A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer. Cancer, 2011, 117, 795-801.	2.0	11
550	Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fineâ€”needle aspiration cytology. Cancer, 2011, 117, 3416-3423.	2.0	124
551	Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancer. Cancer, 2011, 117, 3069-3080.	2.0	18
552	Phase I Trial of Radiation With Concurrent and Consolidation Pemetrexed and Cisplatin in Patients With Unresectable Stage IIIA/B Nonâ€”Small-Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1395-1401.	0.4	31
553	Rationale for Treatment and Study Design of TAILOR: A Randomized Phase III Trial of Second-line Erlotinib Versus Docetaxel in the Treatment of Patients Affected by Advanced Nonâ€”Small-Cell Lung Cancer With the Absence of Epidermal Growth Factor Receptor Mutations. Clinical Lung Cancer, 2011, 12, 138-141.	1.1	15
554	Genomic and Cellular Pathology of Lung Cancer. Current Respiratory Medicine Reviews, 2011, 7, 313-322.	0.1	1
555	An Overview: Current Systemic Therapies for Advanced Non-Small Cell Lung Cancer. Current Respiratory Medicine Reviews, 2011, 7, 354-363.	0.1	0
556	Sorafenib Enhances Pemetrexed Cytotoxicity through an Autophagy-Dependent Mechanism in Cancer Cells. Cancer Research, 2011, 71, 4955-4967.	0.4	89
557	Treatment of Advanced Lung Cancer in the Elderly. Hospital Practice (1995), 2011, 39, 107-115.	0.5	11
558	Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer. Annals of Oncology, 2011, 22, 2482-2488.	0.6	12
559	Case 31-2011. New England Journal of Medicine, 2011, 365, 1426-1435.	13.9	6
560	Pathological Diagnosis and Classification of Lung Cancer in Small Biopsies and Cytology: Strategic Management of Tissue for Molecular Testing. Seminars in Respiratory and Critical Care Medicine, 2011, 32, 022-031.	0.8	140
562	Chemotherapy for Non-Small-Cell Lung Carcinoma: From a Blanket Approach to Individual Therapy. Seminars in Respiratory and Critical Care Medicine, 2011, 32, 078-093.	0.8	14
563	Targeted Therapies and other Agents as First-Line Maintenance and Beyond: Particular Benefit in Pulmonary Adenocarcinoma Patients. Current Medicinal Chemistry, 2011, 18, 1640-1650.	1.2	2
565	An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer. Current Medical Research and Opinion, 2011, 27, 2193-2201.	0.9	3

#	ARTICLE	IF	CITATIONS
566	Pemetrexed versus docetaxel single agent chemotherapy in chemotherapy-naïve elderly patients with advanced non-small cell lung cancer. , 2011, , .		1
567	Phase I/II Study of Pemetrexed With or Without ABT-751 in Advanced or Metastatic Non-“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 1075-1082.	0.8	49
568	Randomized Phase II Study of Two Schedules of Carboplatin and Gemcitabine for Stage IIIB and IV Advanced Non-Small Cell Lung Cancer (JACCRO LC-01 Study). <i>Chemotherapy</i> , 2011, 57, 357-362.	0.8	11
569	Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients. <i>Cancer Biology and Therapy</i> , 2011, 12, 112-118.	1.5	37
570	Subclassification of Non-small Cell Lung Carcinomas Lacking Morphologic Differentiation on Biopsy Specimens. <i>American Journal of Surgical Pathology</i> , 2011, 35, 15-25.	2.1	278
571	The importance of ultrasound in staging and gaining a pathological diagnosis in patients with lung cancer—a two year single centre experience. <i>Thorax</i> , 2011, 66, 414-417.	2.7	27
572	New Strategies in Non-“Small Cell Lung Cancer: Improving Outcomes in Chemoradiotherapy for Locally Advanced Disease. <i>Clinical Cancer Research</i> , 2011, 17, 4192-4199.	3.2	17
573	Customizing systemic therapy in patients with advanced non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2011, 3, 207-218.	1.4	11
574	Maintenance therapy in advanced non-small cell lung cancer: evolution, tolerability and outcomes. <i>Therapeutic Advances in Medical Oncology</i> , 2011, 3, 139-157.	1.4	22
575	Lung cancer in never smokers. <i>Future Oncology</i> , 2011, 7, 1195-1211.	1.1	39
576	Genotype-driven therapies for non-small cell lung cancer: focus on <i>EGFR</i> , <i>KRAS</i> and <i>ALK</i> gene abnormalities. <i>Therapeutic Advances in Medical Oncology</i> , 2011, 3, 113-125.	1.4	96
577	Impact of New Chemotherapeutic and Targeted Agents on Survival in Stage IV Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2011, 16, 1307-1315.	1.9	27
578	Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives. <i>European Respiratory Review</i> , 2011, 20, 045-52.	3.0	20
579	Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 1140-1145.	0.8	112
580	Efficacy and Safety of <i>Rhus verniciflua</i> Stokes Extracts in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer. <i>Research in Complementary Medicine</i> , 2011, 18, 2-2.	2.2	26
581	Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1587-1597.	1.1	15
582	Emerging antiangiogenic therapies for non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1607-1618.	1.1	14
583	Emerging Concepts in the Pathology and Molecular Biology of Advanced Non-“Small Cell Lung Cancer. <i>American Journal of Clinical Pathology</i> , 2011, 136, 228-238.	0.4	43

#	ARTICLE	IF	CITATIONS
584	2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 3825-3831.	0.8	259
585	Low-Dose Weekly Docetaxel Is as Tolerable as Pemetrexed in Previously Treated Advanced Non-Small-Cell Lung Cancer. <i>Chemotherapy</i> , 2011, 57, 147-155.	0.8	14
586	Gemcitabine: Efficacy in the Treatment of Advanced Stage Nonsquamous Non-Small Cell Lung Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2011, 5, CMO.S6252.	0.6	28
587	Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy. <i>Annals of Oncology</i> , 2011, 22, 1507-1519.	0.6	117
588	International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2011, 6, 244-285.	0.5	4,127
589	BRIDGE: An Open-Label Phase II Trial Evaluating the Safety of Bevacizumab + Carboplatin/Paclitaxel as First-Line Treatment for Patients with Advanced, Previously Untreated, Squamous Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 109-114.	0.5	58
590	Long-Term Survival in a Smoking Caucasian Male Patient Treated with Gefitinib for Spinal Cord Compression Secondary to Lung Cancer. <i>Onkologie</i> , 2011, 34, 326-328.	1.1	4
591	Multicenter Phase II Trial of Motexafin Gadolinium and Pemetrexed for Second-Line Treatment in Patients with Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 786-789.	0.5	16
592	Bevacizumab in the Treatment of Advanced, Non-Squamous Non-Small Cell Lung Cancer: An Evidence-Based Approach. <i>Oncology</i> , 2011, 80, 350-358.	0.9	12
593	Long-Term Administration of Second-Line Chemotherapy with S-1 and Gemcitabine for Platinum-Resistant Non-small Cell Lung Cancer: A Phase II Study. <i>Journal of Thoracic Oncology</i> , 2011, 6, 156-160.	0.5	10
594	Treatment-by-Histology Interaction Analyses in Three Phase III Trials Show Superiority of Pemetrexed in Nonsquamous Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 64-70.	0.5	236
595	Role of Radiotherapy for Local Control of Asymptomatic Adrenal Metastasis From Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 249-253.	0.6	66
596	Suitability of Thoracic Cytology for New Therapeutic Paradigms in Non-small Cell Lung Carcinoma: High Accuracy of Tumor Subtyping and Feasibility of EGFR and KRAS Molecular Testing. <i>Journal of Thoracic Oncology</i> , 2011, 6, 451-458.	0.5	230
597	Randomized Phase II Study of Pemetrexed, Carboplatin, and Thoracic Radiation With or Without Cetuximab in Patients With Locally Advanced Unresectable Non-Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 30407. <i>Journal of Clinical Oncology</i> , 2011, 29, 3120-3125.	0.8	186
598	Oncogenic Targets, Magnitude of Benefit, and Market Pricing of Antineoplastic Drugs. <i>Journal of Clinical Oncology</i> , 2011, 29, 2543-2549.	0.8	64
599	Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01). <i>Annals of Oncology</i> , 2011, 22, 2466-2470.	0.6	210
600	Potential role of soluble VEGFR-1 in antiangiogenesis therapy for cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 541-549.	1.1	27
601	Paradigm shifts in lung cancer as defined in the new IASLC/ATS/ERS lung adenocarcinoma classification. <i>European Respiratory Journal</i> , 2011, 38, 239-243.	3.1	54



#	ARTICLE	IF	CITATIONS
602	Afatinib (BIBW 2992) development in non-small-cell lung cancer. <i>Future Oncology</i> , 2011, 7, 817-825.	1.1	66
603	Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. <i>Annals of Oncology</i> , 2011, 22, 2616-2624.	0.6	326
604	Evaluation of adjunct immunohistochemistry on reporting patterns of non-small cell lung carcinoma diagnosed histologically in a regional pathology centre. <i>Journal of Clinical Pathology</i> , 2011, 64, 1136-1138.	1.0	8
605	Experience of first- and subsequent-line systemic therapy in the treatment of non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2011, 3, 163-170.	1.4	13
606	Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population. <i>Annals of Oncology</i> , 2011, 22, 1791-1797.	0.6	36
607	An Evidence-Based Approach to the Use of Predictive Biomarkers in the Treatment of Non- Small Cell Lung Cancer (NSCLC). <i>Cancers</i> , 2011, 3, 3506-3524.	1.7	6
608	Longitudinal Perceptions of Prognosis and Goals of Therapy in Patients With Metastatic Non-Small-Cell Lung Cancer: Results of a Randomized Study of Early Palliative Care. <i>Journal of Clinical Oncology</i> , 2011, 29, 2319-2326.	0.8	603
609	Class III $\beta$ -Tubulin in Advanced NSCLC of Adenocarcinoma Subtype Predicts Superior Outcome in a Randomized Trial. <i>Clinical Cancer Research</i> , 2011, 17, 5205-5214.	3.2	41
610	A P425R mutation of the proton-coupled folate transporter causing hereditary folate malabsorption produces a highly selective alteration in folate binding. <i>American Journal of Physiology - Cell Physiology</i> , 2012, 302, C1405-C1412.	2.1	31
611	Making a Difference with Teamwork. <i>Current Oncology</i> , 2012, 19, 5-6.	0.9	6
612	Optimizing patient outcome: Of equal importance in the palliative setting. <i>Indian Journal of Cancer</i> , 2012, 49, 255.	0.2	2
613	The Importance of a Satisfactory Biopsy for the Diagnosis of Lung Cancer in the Era of Personalized Treatment. <i>Current Oncology</i> , 2012, 19, 16-23.	0.9	42
614	Third CECOG consensus on the systemic treatment of non-small-cell lung cancer. <i>Annals of Oncology</i> , 2012, 23, 1223-1229.	0.6	26
615	Treatment Paradigms for Patients with Metastatic Non-Small-Cell Lung Cancer: First-, Second-, and Third-Line. <i>Current Oncology</i> , 2012, 19, 52-58.	0.9	114
616	Molecular Imaging in Therapeutic Efficacy Assessment of Targeted Therapy for Nonsmall Cell Lung Cancer. <i>Journal of Biomedicine and Biotechnology</i> , 2012, 2012, 1-10.	3.0	2
618	MicroRNA Profiling in Lung Cancer Reveals New Molecular Markers for Diagnosis. <i>Acta Cytologica</i> , 2012, 56, 645-654.	0.7	53
619	The Role of Molecular Pathology in Non-Small-Cell Lung Carcinoma—Now and in the Future. <i>Current Oncology</i> , 2012, 19, 24-32.	0.9	25
620	Personalized Choice of Maintenance Therapies in Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2012, 19, 64-72.	0.9	2

#	ARTICLE	IF	CITATIONS
621	Precision Medicine for Lung Cancer: Role of the Surgical Pathologist. <i>Archives of Pathology and Laboratory Medicine</i> , 2012, 136, 1186-1189.	1.2	8
622	Applications of microRNAs in the diagnosis and prognosis of lung cancer. <i>Expert Opinion on Medical Diagnostics</i> , 2012, 6, 197-207.	1.6	33
623	Survival Following Surgery with or without Adjuvant Chemotherapy for Stage IIIA Non-Small Cell Lung Cancer: An East Asian Population-Based Study. <i>Oncologist</i> , 2012, 17, 1294-1302.	1.9	13
624	Ancillary Testing in Lung Cancer Diagnosis. <i>Pulmonary Medicine</i> , 2012, 2012, 1-8.	0.5	14
625	EGFR Tyrosine Kinase Mutation Testing in the Treatment of Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2012, 19, 67-74.	0.9	15
626	Non-Small-Cell Lung Carcinoma Subtyping on Cytology without the Use of Immunohistochemistry â€“ Can We Meet the Challenge?. <i>Acta Cytologica</i> , 2012, 56, 413-418.	0.7	6
627	Maintenance treatment with chemotherapy and immunotherapy in non-small cell lung cancer: a case report. <i>Frontiers in Oncology</i> , 2012, 2, 152.	1.3	5
628	Interobserver agreement in determining non-small cell lung cancer subtype in specimens acquired by EBUS-TBNA. <i>European Respiratory Journal</i> , 2012, 40, 699-705.	3.1	33
629	Mechanisms of Resistance to Crizotinib in Patients with <i>ALK</i> Gene Rearranged Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 1472-1482.	3.2	1,018
630	New Strategies in Squamous Cell Carcinoma of the Lung: Identification of Tumor Drivers to Personalize Therapy. <i>Clinical Cancer Research</i> , 2012, 18, 3002-3007.	3.2	32
631	Phase I Study of Pemetrexed, Cisplatin, and Concurrent Radiotherapy in Patients With Locally Advanced Non-small Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 115-119.	0.6	18
632	IASLC/ATS/ERS International Multidisciplinary Classification of Lung Adenocarcinoma. <i>Journal of Thoracic Imaging</i> , 2012, 27, 340-353.	0.8	69
633	Immunohistochemical study of Napsin A and thyroid transcription factor-1 in non-small-cell lung carcinoma. <i>Egyptian Journal of Pathology</i> , 2012, 32, 47-51.	0.0	0
634	Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2012, 23, vii56-vii64.	0.6	647
635	Tissue-Sparing Application of the Newly Proposed IASLC/ATS/ERS Classification of Adenocarcinoma of the Lung Shows Practical Diagnostic and Prognostic Impact. <i>American Journal of Clinical Pathology</i> , 2012, 137, 946-956.	0.4	52
636	Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models. <i>Clinical Cancer Research</i> , 2012, 18, 6771-6783.	3.2	156
637	Patterns of Care for Non-Small-Cell Lung Cancer at an Academic Institution Affiliated With a National Cancer Institute-Designated Cancer Center. <i>Journal of Oncology Practice</i> , 2012, 8, 57-62.	2.5	4
638	Novel Approaches of Chemoradiotherapy in Unresectable Stage IIIA and Stage IIIB Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2012, 17, 682-693.	1.9	35

#	ARTICLE	IF	CITATIONS
639	Statistical Issues and Recommendations for Noninferiority Trials in Oncology: A Systematic Review. <i>Clinical Cancer Research</i> , 2012, 18, 1837-1847.	3.2	45
640	Role of Pemetrexed in Advanced Non-Small-Cell Lung Cancer: Meta-Analysis of Randomized Controlled Trials, with Histology Subgroup Analysis. <i>Current Oncology</i> , 2012, 19, 9-15.	0.9	38
641	Should we abandon standard forceps biopsy to diagnose an endobronchial lesion?. <i>European Respiratory Journal</i> , 2012, 39, 513-514.	3.1	0
642	Worldwide Overview of the Current Status of Lung Cancer Diagnosis and Treatment. <i>Archives of Pathology and Laboratory Medicine</i> , 2012, 136, 1478-1481.	1.2	58
643	Bevacizumab in Non Small Cell Lung Cancer: Development, Current Status and Issues. <i>Current Medicinal Chemistry</i> , 2012, 19, 961-971.	1.2	19
644	Suitability of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Specimens for Subtyping and Genotyping of Non-Small Cell Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 1316-1322.	2.5	227
647	Molecular and Clinical Analysis of Predictive Biomarkers in Non-Small-Cell Lung Cancer. <i>Current Medicinal Chemistry</i> , 2012, 19, 3689-3700.	1.2	11
648	Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancer. <i>Future Oncology</i> , 2012, 8, 1239-1251.	1.1	23
649	Targeted Therapies for Advanced Non-Small Cell Lung Cancer. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2012, 15, 641-655.	0.6	2
650	Management of advanced lung cancer in resource-constrained settings: a perspective from India. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1479-1495.	1.1	37
651	Maintenance therapy for advanced non-small-cell lung cancer: ready for clinical practice?. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 529-539.	1.1	6
652	A Phase II Randomized Study of Cisplatin-Pemetrexed plus either Enzastaurin or Placebo in Chemonaive Patients with Advanced Non-Small Cell Lung Cancer. <i>Oncology</i> , 2012, 82, 25-29.	0.9	12
653	Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage III-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST). <i>British Journal of Cancer</i> , 2012, 106, 658-665.	2.9	18
654	Phase I/II trial of a biweekly combination of S-1 plus docetaxel in patients with previously treated non-small cell lung cancer (KRSC-0601). <i>British Journal of Cancer</i> , 2012, 107, 1474-1480.	2.9	7
655	A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2012, 107, 604-611.	2.9	16
656	EC145: a novel targeted agent for adenocarcinoma of the lung. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 755-761.	1.9	33
657	Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. <i>Annals of Oncology</i> , 2012, 23, 388-394.	0.6	87
658	Methodology for Comparative Effectiveness Research: Potential and Limitations. <i>Journal of Clinical Oncology</i> , 2012, 30, 4185-4187.	0.8	39

#	ARTICLE	IF	CITATIONS
659	Inhibition of dUTPase Induces Synthetic Lethality with Thymidylate Synthase—Targeted Therapies in Non—Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 616-628.	1.9	44
660	Hypertension as a Predictive Factor for Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib after Progression on Cytokines. <i>Kidney and Blood Pressure Research</i> , 2012, 35, 18-25.	0.9	39
661	Interstitial Pneumonitis after Treatment with Pemetrexed: A Rare Event?. <i>Chemotherapy</i> , 2012, 58, 84-88.	0.8	22
662	Therapeutic advances in non-small cell lung cancer. <i>Thorax</i> , 2012, 67, 1097-1101.	2.7	22
663	The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival. <i>Annals of Oncology</i> , 2012, 23, 78-85.	0.6	57
664	The Evolving Role of Maintenance Therapy Using Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) in the Management of Advanced Non-Small-Cell Lung Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2012, 6, CMO.S5127.	0.6	4
665	Safety and Efficacy of Pemetrexed in Maintenance Therapy of Non-Small Cell Lung Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2012, 6, CMO.S6248.	0.6	6
666	A Call for the Aggressive Treatment of Oligometastatic and Oligo-Recurrent Non-Small Cell Lung Cancer. <i>Pulmonary Medicine</i> , 2012, 2012, 1-7.	0.5	23
667	ERCC1 and BRAC1 mRNA Expression Levels in the Primary Tumor Could Predict the Effectiveness of the Second-Line Cisplatin-Based Chemotherapy in Pretreated Patients with Metastatic Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 663-671.	0.5	58
669	Toxic Epidermal Necrolysis after Pemetrexed and Cisplatin for Non-Small Cell Lung Cancer in a Patient with Sharp Syndrome. <i>Onkologie</i> , 2012, 35, 783-786.	1.1	11
670	Lung Cancer and Other Pulmonary Neoplasms. , 2012, , 1264-1272.		4
671	Expression Profiling-Based Subtyping Identifies Novel Non-small Cell Lung Cancer Subgroups and Implicates Putative Resistance to Pemetrexed Therapy. <i>Journal of Thoracic Oncology</i> , 2012, 7, 105-114.	0.5	39
672	FGFR1 Amplification in Squamous Cell Carcinoma of The Lung. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1775-1780.	0.5	197
673	Exhaled Breath Analysis with a Colorimetric Sensor Array for the Identification and Characterization of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 137-142.	0.5	201
674	Subclassification of Non-Small Cell Lung Cancer by Cytologic Sampling: A Logical Approach with Selective Use of Immunocytochemistry. <i>Acta Cytologica</i> , 2012, 56, 419-424.	0.7	15
675	Toxic Epidermal Necrolysis Related to Cisplatin and Pemetrexed for Metastatic Non-Small Cell Lung Cancer. <i>Onkologie</i> , 2012, 35, 600-603.	1.1	13
676	Gene expression-based diagnostics for molecular cancer classification of difficult to diagnose tumors. <i>Expert Opinion on Medical Diagnostics</i> , 2012, 6, 407-419.	1.6	6
677	First-Line Systemic Therapy Practice Patterns and Concordance With NCCN Guidelines for Patients Diagnosed With Metastatic NSCLC Treated at NCCN Institutions. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 847-856.	2.3	25

#	ARTICLE	IF	CITATIONS
678	Maintenance erlotinib improves clinical outcomes of unresectable advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials. <i>Experimental and Therapeutic Medicine</i> , 2012, 4, 849-858.	0.8	5
679	Ask the Experts: Lung cancer management: leaving behind the "one-fits-all"™ concept for a personalized approach. <i>Clinical Practice (London, England)</i> , 2012, 9, 367-372.	0.1	0
680	Personalized medicine for lung cancer. <i>Lung Cancer Management</i> , 2012, 1, 83-86.	1.5	2
681	Choroidal Metastasis as a Presenting Manifestation of Lung Cancer. <i>Medicine (United States)</i> , 2012, 91, 179-194.	0.4	51
682	Making the Most of Pathological Specimens: Molecular Diagnosis in Formalin-Fixed, Paraffin Embedded Tissue. <i>Current Drug Targets</i> , 2012, 13, 1475-1487.	1.0	35
684	Skin Metastases in Non-small Cell Lung Cancer. <i>American Journal of the Medical Sciences</i> , 2012, 344, 59-62.	0.4	7
685	Non Small-Cell Lung Cancer in a 15-Year-Old Nonsmoker. <i>Journal of Thoracic Oncology</i> , 2012, 7, e12-e13.	0.5	1
686	Detection of Circulating Lung Cancer Cells with Strong Thymidylate Synthase Reactivity in the Peripheral Blood of a Patient with Pulmonary Adenocarcinoma Treated with Pemetrexed. <i>Journal of Thoracic Oncology</i> , 2012, 7, 766-767.	0.5	7
687	Thymidylate Synthase Protein Expression by IHC and Gene Copy Number by SISH Correlate and Show Great Variability in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 982-992.	0.5	15
688	Demographic profile of lung cancer patients at the Universitas Academic Hospital Bronchoscopy Unit in Bloemfontein. <i>The Southern African Journal of Epidemiology &amp; Infection: Official Journal of the Sexually Transmitted Diseases, Infectious Diseases and Epidemiological Societies of Southern Africa</i> , 2012, 27, 130-132.	0.2	0
689	Personalized medicine in the treatment of advanced nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , 2012, 24, 115-116.	1.1	0
690	Chemotherapy Effectiveness After First-Line Gefitinib Treatment for Advanced Lepidic Predominant Adenocarcinoma (Formerly Advanced Bronchioloalveolar Carcinoma): Exploratory Analysis of the IFCT-0401 Trial. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1423-1431.	0.5	9
691	A 66-Year-Old Woman With Newly Diagnosed Oligometastatic Non-Small Cell Lung Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 297-301.	2.3	1
692	S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type. <i>Oncology Letters</i> , 2012, 3, 405-410.	0.8	5
693	Increasing Age and Carcinoma Not Otherwise Specified: A 20-Year Population Study of 40,118 Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2012, 7, 57-63.	0.5	9
694	Stage III Non-Small-Cell Lung Cancer: Population-Based Patterns of Treatment in British Columbia, Canada. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1155-1163.	0.5	32
695	High Expression of Folate Receptor Alpha in Lung Cancer Correlates with Adenocarcinoma Histology and Mutation. <i>Journal of Thoracic Oncology</i> , 2012, 7, 833-840.	0.5	123
696	Non-Small Cell Lung Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 1236-1271.	2.3	312

#	ARTICLE	IF	CITATIONS
698	A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 196-202.	0.5	28
699	Clinical Outcomes with Perioperative Chemotherapy in Sarcomatoid Carcinomas of the Lung. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1400-1405.	0.5	42
700	Randomized Phase 2b Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non-small-Cell Lung Cancer (NSCLC) After Failure of Prior Platinum-Based Therapy. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1041-1048.	0.5	25
701	Correlation between thymidylate synthase gene polymorphisms and efficacy of pemetrexed in advanced non-small cell lung cancer. <i>Experimental and Therapeutic Medicine</i> , 2012, 4, 1010-1016.	0.8	12
702	Primary treatment of advanced non-small-cell lung cancer: role of monoclonal antibodies. <i>Lung Cancer Management</i> , 2012, 1, 219-225.	1.5	0
703	Pathologic Complete Response to Preoperative Chemotherapy Predicts Cure in Early-Stage Non-small-Cell Lung Cancer: Combined Analysis of Two IFCT Randomized Trials. <i>Journal of Thoracic Oncology</i> , 2012, 7, 841-849.	0.5	104
704	Nitric oxide (NO) enhances pemetrexed cytotoxicity via NO-cGMP signaling in lung adenocarcinoma cells in vitro and in vivo. <i>International Journal of Oncology</i> , 2012, 41, 24-30.	1.4	11
705	Phase I/II Trial of Custirsen (OGX-011), an Inhibitor of Clusterin, in Combination with a Gemcitabine and Platinum Regimen in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 579-586.	0.5	74
706	Genetic Changes in Squamous Cell Lung Cancer: A Review. <i>Journal of Thoracic Oncology</i> , 2012, 7, 924-933.	0.5	131
707	Safety, Resource Use, and Quality of Life in Paramount: A Phase III Study of Maintenance Pemetrexed Versus Placebo after Induction Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1713-1721.	0.5	49
708	The Introduction of Systematic Genomic Testing for Patients with Non-small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1767-1774.	0.5	96
709	The surgeon's role in molecular biology. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012, 144, S18-S22.	0.4	10
710	Maintenance therapy for advanced non-small-cell lung cancer: switch versus continuation. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 685-697.	0.9	3
711	Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies. <i>Histopathology</i> , 2012, 61, 1017-1025.	1.6	102
712	Clinical Trial Design in the Age of Molecular Profiling. <i>Methods in Molecular Biology</i> , 2012, 823, 19-34.	0.4	2
713	Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. <i>Lancet Oncology</i> , The, 2012, 13, e418-e426.	5.1	178
714	Pemetrexed Versus Pemetrexed and Carboplatin As Second-Line Chemotherapy in Advanced Non-small-Cell Lung Cancer: Results of the GOIRC 02-2006 Randomized Phase II Study and Pooled Analysis With the NVALT7 Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 4501-4507.	0.8	47
716	EGF receptor-targeted therapy in non-small-cell lung cancer: role of germline polymorphisms in outcome and toxicity. <i>Future Oncology</i> , 2012, 8, 1015-1029.	1.1	21

#	ARTICLE	IF	CITATIONS
717	Utility of small biopsies for diagnosis of lung nodules: doing more with less. <i>Modern Pathology</i> , 2012, 25, S43-S57.	2.9	29
718	Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. <i>Lancet Oncology</i> , The, 2012, 13, 247-255.	5.1	549
719	Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. <i>Lancet Oncology</i> , The, 2012, 13, 528-538.	5.1	904
720	Proteins involved in DNA damage response pathways and survival of stage I non-small-cell lung cancer patients. <i>Annals of Oncology</i> , 2012, 23, 2088-2093.	0.6	25
721	Correlation of immunohistochemical staining p63 and TTF-1 with EGFR and K-ras mutational spectrum and diagnostic reproducibility in non small cell lung carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012, 461, 629-638.	1.4	32
722	miRNAs expression profiling to distinguish lung squamous-cell carcinoma from adenocarcinoma subtypes. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 1641-1650.	1.2	64
723	Pemetrexed versus docetaxel in second line non-small-cell lung cancer: Results and subsets analyses of a multi-center, randomized, exploratory trial in Chinese patients. <i>Pulmonary Pharmacology and Therapeutics</i> , 2012, 25, 364-370.	1.1	9
724	Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives. <i>Revista Da Associação Médica Brasileira</i> , 2012, 58, 263-268.	0.3	6
725	Lung Cancer. <i>Radiologic Clinics of North America</i> , 2012, 50, 951-960.	0.9	3
726	Low-dose radiotherapy as a chemo-potentiator of a chemotherapy regimen with pemetrexed for recurrent non-small-cell lung cancer: A prospective phase II study. <i>Radiotherapy and Oncology</i> , 2012, 105, 161-166.	0.3	19
727	Antibioprophylaxie et facteurs de croissance mÃ©dullaire dans la prise en charge du cancer bronchique. <i>Revue Des Maladies Respiratoires Actualites</i> , 2012, 4, 530-536.	0.0	0
728	Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives. <i>Revista Da Associação Médica Brasileira (English Edition)</i> , 2012, 58, 263-268.	0.1	0
729	Introduction from the Guest Editor. <i>Journal of Infection and Public Health</i> , 2012, 5, S2-S3.	1.9	0
730	Vandetanib for the treatment of lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1211-1221.	1.9	6
731	Disparities in subgroup populations enrolled in lung cancer trials. <i>Expert Review of Respiratory Medicine</i> , 2012, 6, 163-172.	1.0	0
732	Two MicroRNA Panels to Discriminate Three Subtypes of Lung Carcinoma in Bronchial Brushing Specimens. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 1160-1167.	2.5	45
733	Exhaled breath volatile organic compound biomarkers in lung cancer. <i>Journal of Breath Research</i> , 2012, 6, 027106.	1.5	52
734	Second-line therapy for non-small cell lung cancer in clinical practice: final results and treatment pathways from the SELECTION observational study. <i>Current Medical Research and Opinion</i> , 2012, 28, 1253-1262.	0.9	9

#	ARTICLE	IF	CITATIONS
735	Sorafenib in non-small cell lung cancer. Expert Opinion on Investigational Drugs, 2012, 21, 1417-1426.	1.9	25
736	Current and emerging medical treatments for non-small cell lung cancer: A primer for pulmonologists. Respiratory Medicine, 2012, 106, 473-492.	1.3	8
737	Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Final Results of a Phase III Trial. Journal of Clinical Oncology, 2012, 30, 2055-2062.	0.8	676
738	Why RECIST Works and Why It Should Stay? Counterpoint. Cancer Research, 2012, 72, 5151-5157.	0.4	28
739	Problems involved in the clinical trials for non-small cell lung carcinoma. Cancer Treatment Reviews, 2012, 38, 194-202.	3.4	6
740	Systemic Issues in Small Cell Lung Cancer. Current Problems in Cancer, 2012, 36, 131-155.	1.0	4
741	A phase II trial of second-line pemetrexed in adults with advanced/metastatic osteosarcoma. European Journal of Cancer, 2012, 48, 564-570.	1.3	30
742	ALK translocation and crizotinib in non-small cell lung cancer: An evolving paradigm in oncology drug development. European Journal of Cancer, 2012, 48, 961-973.	1.3	84
743	Crizotinib in the treatment of non-small-cell lung cancer. Expert Opinion on Pharmacotherapy, 2012, 13, 1195-1201.	0.9	73
744	Single agent maintenance therapy for advanced stage non-small cell lung cancer: A meta-analysis. Lung Cancer, 2012, 77, 331-338.	0.9	51
745	The Antifolates. Hematology/Oncology Clinics of North America, 2012, 26, 629-648.	0.9	196
746	Expression of Bim, Noxa, and Puma in non-small cell lung cancer. BMC Cancer, 2012, 12, 286.	1.1	12
747	Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study. BMC Cancer, 2012, 12, 296.	1.1	11
748	Treatment of Lung Cancer. Radiologic Clinics of North America, 2012, 50, 961-974.	0.9	90
749	Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?. Pharmacogenomics, 2012, 13, 1073-1086.	0.6	29
750	Cost Effectiveness of Treatment with New Agents in Advanced Non-Small-Cell Lung Cancer. Pharmacoeconomics, 2012, 30, 17-34.	1.7	32
751	Pemetrexed Therapy in Elderly Patients With Good Performance Status: Analysis of Two Phase III Trials of Patients With Nonsquamous Non-Small-Cell Lung Cancer. Clinical Lung Cancer, 2012, 13, 340-346.	1.1	33
752	Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non-Small-Cell Lung Cancer. Clinical Lung Cancer, 2012, 13, 391-395.	1.1	128



#	ARTICLE	IF	CITATIONS
753	Recurrent non-small-cell lung cancer in elderly patients: a case-based review of current clinical practice. <i>Community Oncology</i> , 2012, 9, 165-170.	0.2	0
754	EGFR inhibition and other targeted therapies in NSCLC. <i>Community Oncology</i> , 2012, 9, S30-S34.	0.2	0
755	Multitargeted anti-angiogenic agents and NSCLC: Clinical update and future directions. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 84, 47-58.	2.0	37
756	Squamous-cell carcinoma of the lungs: Is it really so different?. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 84, 327-339.	2.0	17
757	Targeted (and chemotherapeutic) agents as maintenance treatment in patients with metastatic non-small-cell lung cancer: Current status and future challenges. <i>Cancer Treatment Reviews</i> , 2012, 38, 861-867.	3.4	19
758	Assessment of quality of life in advanced non-small-cell lung cancer: An overview of recent randomized trials. <i>Cancer Treatment Reviews</i> , 2012, 38, 807-814.	3.4	25
759	Cost-Effectiveness of Maintenance Pemetrexed in Patients with Advanced Nonsquamous-Cell Lung Cancer from the Perspective of the Swiss Health Care System. <i>Value in Health</i> , 2012, 15, 65-71.	0.1	27
760	Lung cancer associated venous thromboembolic disease: A comprehensive review. <i>Lung Cancer</i> , 2012, 75, 1-8.	0.9	54
761	Cytology-based treatment decision in primary lung cancer: Is it accurate enough?. <i>Lung Cancer</i> , 2012, 75, 293-299.	0.9	17
762	Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2012, 76, 78-83.	0.9	33
763	Is there a standard regimen for first-line treatment of advanced/metastatic Non-Small-Cell Lung Cancer? What has meta-analyses contributed to today's standard of care. <i>Lung Cancer</i> , 2012, 75, 269-274.	0.9	11
764	The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. <i>Lung Cancer</i> , 2012, 76, 1-18.	0.9	206
765	Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): A combined analysis of three phase 3 trials. <i>Lung Cancer</i> , 2012, 76, 222-227.	0.9	38
766	Pemetrexed as a possible cause of severe rhabdomyolysis in the treatment of lung cancer. <i>Lung Cancer</i> , 2012, 76, 491-492.	0.9	8
767	Retrospective study of erlotinib in patients with advanced squamous lung cancer. <i>Lung Cancer</i> , 2012, 77, 128-133.	0.9	35
768	Prognostic factors in patients with advanced non-small cell lung cancer: Data from the phase III FLEX study. <i>Lung Cancer</i> , 2012, 77, 376-382.	0.9	53
769	Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2012, 77, 346-352.	0.9	23
770	Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: A subanalysis of the phase III, randomized SATURN study. <i>Lung Cancer</i> , 2012, 77, 339-345.	0.9	34

#	ARTICLE	IF	CITATIONS
771	Impact of non-small cell lung cancer histology on survival predicted from the graded prognostic assessment for patients with brain metastases. <i>Lung Cancer</i> , 2012, 77, 389-393.	0.9	20
772	Chemotherapy for pulmonary large cell neuroendocrine carcinoma: Similar to that for small cell lung cancer or non-small cell lung cancer?. <i>Lung Cancer</i> , 2012, 77, 365-370.	0.9	130
773	Issues surrounding clinical trial endpoints in solid malignancies with a focus on metastatic non-small cell lung cancer. <i>Lung Cancer</i> , 2012, 77, 475-481.	0.9	13
774	Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed+carboplatin. <i>Lung Cancer</i> , 2012, 78, 92-99.	0.9	37
775	Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05). <i>Lung Cancer</i> , 2012, 78, 239-244.	0.9	33
776	Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma. <i>Targeted Oncology</i> , 2012, 7, 199-210.	1.7	28
777	Individualized chemotherapy in advanced NSCLC patients based on mRNA levels of BRCA1 and RRM1. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2012, 24, 226-231.	0.7	14
778	Advanced Non-Small Cell Lung Cancer (NSCLC): Maintenance Therapy for All?. <i>Current Treatment Options in Oncology</i> , 2012, 13, 478-490.	1.3	4
779	Bevacizumab as First-Line Therapy in Advanced Non-Small-Cell Lung Cancer. <i>Drugs in R and D</i> , 2012, 12, 207-216.	1.1	4
781	Fixed-dose rate infusion and standard rate infusion of gemcitabine in patients with advanced non-small-cell lung cancer: a meta-analysis of six trials. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 861-873.	1.1	9
782	Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 883-890.	1.1	22
783	A phase II study of docetaxel plus nedaplatin in patients with metastatic non-small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 531-537.	1.1	14
784	Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 271-276.	1.1	15
785	Personalized cancer therapy for stage IV non-small cell lung cancer: Combined use of active hexose correlated compound and genistein concentrated polysaccharide. <i>Personalized Medicine Universe</i> , 2012, 1, 39-44.	0.1	5
786	Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies. <i>British Journal of Cancer</i> , 2012, 107, 1107-1115.	2.9	54
787	Classification of the Four Main Types of Lung Cancer Using a MicroRNA-Based Diagnostic Assay. <i>Journal of Molecular Diagnostics</i> , 2012, 14, 510-517.	1.2	107
788	Molecular Pathology of Lung Cancer. <i>Molecular Pathology Library</i> , 2012, , .	0.1	6
789	Molecular Basis for the Current Lung Cancer Classification. <i>Molecular Pathology Library</i> , 2012, , 75-85.	0.1	0

#	ARTICLE	IF	CITATIONS
790	Personalizing Lung Cancer Prevention Through a Reverse Migration Strategy. Topics in Current Chemistry, 2012, 329, 221-240.	4.0	4
791	Association between Single Nucleotide Polymorphisms (SNPs) and Toxicity of Advanced Non-Small-Cell Lung Cancer Patients Treated with Chemotherapy. PLoS ONE, 2012, 7, e48350.	1.1	35
792	Challenges in Implementing Personalized Medicine for Lung Cancer within a National Healthcare System. Journal of Personalized Medicine, 2012, 2, 77-92.	1.1	2
793	The Role of Histology and Molecular Markers in NSCLE. Oncology Issues, 2012, 27, 38-40.	0.0	0
794	The Clinical Significance of the Serum Cross-Linked N-Telopeptide of Type I Collagen as a Prognostic Marker for Non-Small-Cell Lung Cancer. Annals of Oncology, 2012, 23, xi158.	0.6	0
795	Foot pain: uncommon presentation of lung cancer. BMJ Case Reports, 2012, 2012, bcr1220115360-bcr1220115360.	0.2	7
796	The place of TKI in the treatment of EGFR mutation-positive lung cancer. Journal of Solid Tumors, 2012, 2, .	0.1	0
797	Adjuvant Treatment of Older Patients with Lung Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 315-319.	1.8	0
798	A Minimal Immunohistochemical Panel for Subtyping Poorly Differentiated Non-Small Cell Lung Carcinoma: A Tissue Microarray Study Simulating Small Biopsy Conditions. Journal of Lung Cancer, 2012, 11, 21.	0.2	4
801	Maintenance therapy with oral etoposide following first-line docetaxel-cisplatin chemotherapy in metastatic non-small cell lung cancer patients. Bangladesh Journal of Pharmacology, 2012, 7, .	0.1	1
802	K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive Value. , 2012, 2012, 1-8.		23
803	Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: a cost minimization analysis. Lung Cancer: Targets and Therapy, 2012, 3, 43.	1.3	2
804	The Price We Pay for Progress: A Meta-Analysis of Harms of Newly Approved Anticancer Drugs. Journal of Clinical Oncology, 2012, 30, 3012-3019.	0.8	152
805	Combined double CK5/P63 stain: Useful adjunct test for diagnosing pulmonary squamous cell carcinoma. Diagnostic Cytopathology, 2012, 40, 943-948.	0.5	14
806	The application and diagnostic utility of immunocytochemistry on direct smears in the diagnosis of pulmonary adenocarcinoma and squamous cell carcinoma. Diagnostic Cytopathology, 2012, 40, 949-955.	0.5	27
807	Epidermal growth factor receptor tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials. International Journal of Cancer, 2012, 131, E822-9.	2.3	119
808	Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: Evidence from an individual patient analysis. Cancer, 2012, 118, 2525-2531.	2.0	45
809	Oncogene status predicts patterns of metastatic spread in treatment-naïve nonsmall cell lung cancer. Cancer, 2012, 118, 4502-4511.	2.0	247

#	ARTICLE	IF	CITATIONS
810	Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer. <i>Cancer</i> , 2012, 118, 4694-4705.	2.0	40
811	Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer. <i>Cancer</i> , 2012, 118, 5580-5587.	2.0	23
812	Association of <i>EGFR</i> mutation or <i>ALK</i> rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma. <i>Cancer</i> , 2012, 118, 5588-5594.	2.0	52
813	Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG01). <i>Cancer</i> , 2012, 118, 6234-6242.	2.0	89
814	Improvement of cellularity on cell block preparations using the so-called tissue coagulum clot method during endobronchial ultrasound-guided transbronchial fine-needle aspiration. <i>Cancer Cytopathology</i> , 2012, 120, 185-195.	1.4	89
815	Driver mutations as predictive biomarkers in lung cancer. <i>Current Respiratory Care Reports</i> , 2012, 1, 21-29.	0.6	0
816	Developmental antiangiogenic agents for the treatment of Non-Small Cell Lung Cancer (NSCLC). <i>Investigational New Drugs</i> , 2012, 30, 1802-1811.	1.2	12
817	Cost-Effectiveness of Gemcitabine + Cisplatin vs. Gemcitabine Monotherapy in Advanced Biliary Tract Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2012, 43, 215-223.	0.6	18
818	Phase II study of pemetrexed plus oxaliplatin for platinum-resistant advanced or metastatic non-small cell lung cancer patients. <i>Medical Oncology</i> , 2012, 29, 640-643.	1.2	2
819	Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 545-554.	1.2	6
820	Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 745-751.	1.2	13
822	Factors associated with long-term survival of patients with advanced non-small cell lung cancer. <i>Respirology</i> , 2012, 17, 134-142.	1.3	43
823	Pulmonary adenocarcinoma: A renewed entity in 2011. <i>Respirology</i> , 2012, 17, 50-65.	1.3	65
824	Personalized medicine for lung cancer: new challenges for pathology. <i>Histopathology</i> , 2012, 60, 531-546.	1.6	84
825	Brain Metastases as the Primary Site of Relapse in Two Randomized Phase III Pemetrexed Trials in Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2012, 13, 24-30.	1.1	30
826	Smoking History as a Predictive Factor of Treatment Response in Advanced Non-Small-Cell Lung Cancer: A Systematic Review. <i>Clinical Lung Cancer</i> , 2012, 13, 239-251.	1.1	27
827	Pemetrexed-induced Lung Toxicity: A Case Report. <i>Clinical Oncology</i> , 2012, 24, 76-77.	0.6	6
828	Challenges in the current antiangiogenic treatment paradigm for patients with non-small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 82, 200-212.	2.0	12

#	ARTICLE	IF	CITATIONS
829	Strategies for maintenance therapy in advanced non-small cell lung cancer: Current status, unanswered questions and future directions. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 82, 338-360.	2.0	13
830	Individualized therapy for patients with non-small cell lung cancer: Emerging trends and challenges. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 130-144.	2.0	24
831	Prognostic impact of cell type under the seventh TNM staging system in resected non-small cell lung cancer. <i>Thoracic Cancer</i> , 2012, 3, 249-254.	0.8	0
832	Management of lung cancer. <i>Medicine</i> , 2012, 40, 202-207.	0.2	0
833	Increase in circulating endothelial progenitor cells predicts response in patients with advanced non-small cell lung cancer. <i>Cancer Science</i> , 2012, 103, 1065-1070.	1.7	16
834	Second-line Treatment of Stage III/IV Non-Small-Cell Lung Cancer (NSCLC) with pemetrexed in routine clinical practice: Evaluation of performance status and health-related quality of life. <i>BMC Cancer</i> , 2012, 12, 14.	1.1	11
835	Acute small bowel obstruction: a rare initial presentation for the metastasis of the large-cell carcinoma of the lung. <i>World Journal of Surgical Oncology</i> , 2012, 10, 26.	0.8	13
836	Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapy. <i>Cancer</i> , 2012, 118, 164-172.	2.0	35
837	Molecular classification of nonsmall cell lung cancer using a 4-protein quantitative assay. <i>Cancer</i> , 2012, 118, 1607-1618.	2.0	23
838	Effect of Feitai Capsule (è,æ³èf¶âš) on quality of life and progression-free survival of patients with unresectable non-small cell lung cancer. <i>Chinese Journal of Integrative Medicine</i> , 2012, 18, 106-111.	0.7	2
839	A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 709-722.	1.1	12
842	Second-line epidermal growth factor receptor inhibitors followed by third-line pemetrexed or the reverse sequence: a retrospective analysis of 83 Chinese patients with advanced lung adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 285-291.	1.2	1
843	Pemertrexed combined with cisplatin in the treatment of advanced non-small cell lung cancer: a case report and literature review. <i>Chinese-German Journal of Clinical Oncology</i> , 2012, 11, 49-51.	0.1	0
844	Pemetrexed induces both intrinsic and extrinsic apoptosis through ataxia telangiectasia mutated/p53-dependent and -independent signaling pathways. <i>Molecular Carcinogenesis</i> , 2013, 52, 183-194.	1.3	30
845	Ancillary techniques on direct smear aspirate slides. <i>Cancer Cytopathology</i> , 2013, 121, 120-128.	1.4	117
846	Pemetrexed downregulates ERCC1 expression and enhances cytotoxicity effected by resveratrol in human nonsmall cell lung cancer cells. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2013, 386, 1047-1059.	1.4	12
847	The Impact of Genomic Changes on Treatment of Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 770-775.	2.5	91
848	EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2013, 9, 991-1003.	1.1	8

#	ARTICLE	IF	CITATIONS
849	Prognostic impact of serum CYFRA 211 in patients with advanced lung adenocarcinoma: a retrospective study. <i>BMC Cancer</i> , 2013, 13, 354.	1.1	42
850	Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. <i>The Cochrane Library</i> , 2013, , CD009256.	1.5	70
851	Histology as a Potential Clinical Predictor of Outcome in Advanced Non-Small-Cell Lung Cancer Treated with Vinorelbine and Mitomycin Combination Chemotherapy. <i>Lung</i> , 2013, 191, 271-280.	1.4	3
852	Lung adenocarcinoma in the era of targeted therapies: histological classification, sample prioritization, and predictive biomarkers. <i>Clinical and Translational Oncology</i> , 2013, 15, 503-508.	1.2	27
853	Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2013, 31, 927-936.	1.2	12
854	Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer. <i>Investigational New Drugs</i> , 2013, 31, 1275-1282.	1.2	38
855	Management of non-small-cell lung cancer: recent developments. <i>Lancet</i> , The, 2013, 382, 709-719.	6.3	658
856	Comparison of the efficacy and safety of single-agent erlotinib and doublet molecular targeted agents based on erlotinib in advanced non-small cell lung cancer (NSCLC): a systematic review and meta-analysis. <i>Targeted Oncology</i> , 2013, 8, 107-116.	1.7	7
857	Phase I/II study of amrubicin in combination with S-1 as second-line chemotherapy for non-small-cell lung cancer without EGFR mutation. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 705-711.	1.1	6
858	Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 307-319.	1.1	18
859	The Efficacy and Safety of Standardized Allergen-Removed <i>Rhus verniciflua</i> Extract as Maintenance Therapy after First-Line Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer. <i>The American Journal of Chinese Medicine</i> , 2013, 41, 773-787.	1.5	20
860	Re-examination of Maintenance Therapy in Non-Small Cell Lung Cancer with the Advent of New Anti-cancer Agents. <i>Drugs</i> , 2013, 73, 517-532.	4.9	5
861	First-Line Management of EGFR-Mutated Advanced Lung Adenocarcinoma: Recent Developments. <i>Drugs</i> , 2013, 73, 357-369.	4.9	12
862	Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: A Hellenic Oncology Research Group (HORG) randomized phase 3 study. <i>Cancer</i> , 2013, 119, 2754-2764.	2.0	106
863	<sup>125</sup> I-Who™, <sup>125</sup> I-when™ and <sup>125</sup> I-how™ in re-irradiation of recurrent painful bone metastases. <i>Journal of Bone Oncology</i> , 2013, 2, 33-37.	1.0	2
864	Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient setting. <i>Lung Cancer</i> , 2013, 82, 121-127.	0.9	11
865	A 75-Year-Old Man With Progressive Bronchioalveolar Carcinoma. <i>Seminars in Oncology</i> , 2013, 40, e1-e8.	0.8	1
866	Biologic Approaches to Drug Selection and Targeted Therapy. <i>Thoracic Surgery Clinics</i> , 2013, 23, 421-428.	0.4	3

#	ARTICLE	IF	CITATIONS
867	Pemetrexed as the first-line therapy for Chinese patients with advanced non-squamous non-small-cell lung cancer. <i>Biomedicine and Pharmacotherapy</i> , 2013, 67, 763-769.	2.5	3
868	Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck. <i>European Journal of Cancer</i> , 2013, 49, 2877-2883.	1.3	30
870	Pemetrexed in head and neck cancer: A systematic review. <i>Oral Oncology</i> , 2013, 49, 492-501.	0.8	12
871	Cost-Effectiveness of Continuation Maintenance Pemetrexed After Cisplatin and Pemetrexed Chemotherapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: Estimates From the Perspective of the Chinese Health Care System. <i>Clinical Therapeutics</i> , 2013, 35, 54-65.	1.1	30
872	Adjuvant treatment in resected non-small cell lung cancer: Current and future issues. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, 375-386.	2.0	14
873	Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2013, 82, 288-293.	0.9	32
874	Pemetrexed for the treatment of non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1545-1558.	0.9	24
875	Crizotinib in the Treatment of Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2013, 14, 473-480.	1.1	36
876	Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2013, 24, 2390-2396.	0.6	65
877	SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2013. <i>Clinical and Translational Oncology</i> , 2013, 15, 977-984.	1.2	18
878	A phase II study of irinotecan as a third- or fourth-line treatment for advanced non-small cell lung cancer: NJLCG0703. <i>Respiratory Investigation</i> , 2013, 51, 28-34.	0.9	10
879	KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung. <i>Lung Cancer</i> , 2013, 81, 377-381.	0.9	8
880	Lung Cancer Imaging. , 2013, , .		2
881	Role of the Pulmonologist in Ordering Post-Procedure Molecular Markers in Non-Small-Cell Lung Cancer: Implications for Personalized Medicine. <i>Clinical Lung Cancer</i> , 2013, 14, 609-626.	1.1	15
882	Chemotherapy Outcomes by Histologic Subtypes of Non-Small-Cell Lung Cancer: Analysis of the Southwest Oncology Group Database for Antimicrotubule-Platinum Therapy. <i>Clinical Lung Cancer</i> , 2013, 14, 627-635.	1.1	12
883	PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> . 2013. 31. 4349-4357.	0.8	326
884	PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 2895-2902.	0.8	558
885	Maintenance Therapy for Advanced Lung Cancer: Who, What, and When?. <i>Journal of Clinical Oncology</i> , 2013, 31, 2983-2990.	0.8	13

#	ARTICLE	IF	CITATIONS
886	Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non-“Small-Cell Lung Cancer: AVAPERL (MO22089). <i>Journal of Clinical Oncology</i> , 2013, 31, 3004-3011.	0.8	301
887	A Randomized Phase II Study of Pemetrexed in Combination With Cisplatin or Carboplatin as First-Line Therapy for Patients With Locally Advanced or Metastatic Non-“Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2013, 14, 215-223.	1.1	41
888	Home administration of maintenance pemetrexed for patients with advanced non-squamous non-small cell lung cancer: rationale, practicalities and phase II feasibility study design. <i>Health and Quality of Life Outcomes</i> , 2013, 11, 163.	1.0	9
889	Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer. <i>Investigational New Drugs</i> , 2013, 31, 1587-1591.	1.2	10
891	Overall survival and toxicities regarding thoracic three-dimensional radiotherapy with concurrent chemotherapy for stage IV non-small cell lung cancer: results of a prospective single-center study. <i>BMC Cancer</i> , 2013, 13, 474.	1.1	16
892	Treatment and outcome of patients with metastatic NSCLC: a retrospective institution analysis of 493 patients. <i>Respiratory Research</i> , 2013, 14, 139.	1.4	18
893	Leukocytes and systemic inflammatory response syndrome as prognostic factors in pulmonary embolism patients. <i>BMC Pulmonary Medicine</i> , 2013, 13, 74.	0.8	44
894	Paclitaxel plus platinum or gemcitabine plus platinum in first-line treatment of advanced non-small-cell lung cancer: results from 6 randomized controlled trials. <i>International Journal of Clinical Oncology</i> , 2013, 18, 1005-1013.	1.0	3
895	Safety and efficacy of sequential chemotherapy with carboplatin plus gemcitabine followed by weekly paclitaxel in advanced non-small cell lung cancer. <i>International Journal of Clinical Oncology</i> , 2013, 18, 988-996.	1.0	5
896	PEGylated liposomal Gemcitabine: insights into a potential breast cancer therapeutic. <i>Cellular Oncology (Dordrecht)</i> , 2013, 36, 449-457.	2.1	25
897	Targeted Therapies for Locally Advanced or Metastatic Squamous Cell Carcinoma of the Lung. <i>Current Treatment Options in Oncology</i> , 2013, 14, 568-579.	1.3	6
898	Comparative effectiveness of three platinum-“doublet chemotherapy regimens in elderly patients with advanced non-“small cell lung cancer. <i>Cancer</i> , 2013, 119, 2048-2060.	2.0	15
899	Regionale Therapie maligner Tumoren. , 2013, , .		1
900	Biomarkers in Oncology. , 2013, , .		1
901	Maintenance therapy and precision medicine in NSCLC. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 549-550.	12.5	46
902	An evaluation of the pharmacokinetics and clinical use of vinorelbine for NSCLC treatment. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 1037-1051.	1.5	10
903	Differential immunohistochemical localization of desmosomal plaque-“related proteins in non-“small-“cell lung cancer. <i>Histopathology</i> , 2013, 63, 103-113.	1.6	33
904	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-“Resistant Disease. <i>Journal of Clinical Oncology</i> , 2013, 31, 1070-1080.	0.8	425



#	ARTICLE	IF	CITATIONS
906	Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations. <i>Journal of Clinical Oncology</i> , 2013, 31, 3327-3334.	0.8	2,854
907	Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations. <i>Journal of Clinical Oncology</i> , 2013, 31, 3342-3350.	0.8	285
908	Systemic therapy of advanced non-small cell lung cancer: Major-developments of the last 5-years. <i>European Journal of Cancer</i> , 2013, 49, 1216-1225.	1.3	87
909	Pemetrexed in patients with refractory soft tissue sarcoma: A non-comparative multicenter phase II study of the German Sarcoma Group AIO-STS 005. <i>Investigational New Drugs</i> , 2013, 31, 167-174.	1.2	3
910	Validation of Interobserver Agreement in Lung Cancer Assessment: Hematoxylin-Eosin Diagnostic Reproducibility for Non-Small Cell Lung Cancer: The 2004 World Health Organization Classification and Therapeutically Relevant Subsets. <i>Archives of Pathology and Laboratory Medicine</i> , 2013, 137, 32-40.	1.2	54
911	Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. <i>Annals of Oncology</i> , 2013, 24, 59-66.	0.6	103
912	New Pathologic Classification of Lung Cancer: Relevance for Clinical Practice and Clinical Trials. <i>Journal of Clinical Oncology</i> , 2013, 31, 992-1001.	0.8	458
913	New Radiotherapy and Chemoradiotherapy Approaches for Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 1029-1038.	0.8	70
914	Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis. <i>Respirology</i> , 2013, 18, 131-139.	1.3	14
915	Role of thyroid transcription factor-1 and P63 immunocytochemistry in cytologic typing of non-small cell lung carcinomas. <i>Journal of the Egyptian National Cancer Institute</i> , 2013, 25, 209-218.	0.6	6
916	Cost-Effectiveness of Gene-Expression Profiling for Tumor-Site Origin. <i>Value in Health</i> , 2013, 16, 46-56.	0.1	6
917	The Evolution of Tumor Classification: A Role for Genomics?. <i>Cancer Cell</i> , 2013, 24, 693-694.	7.7	8
918	Factors Influencing a Specific Pathologic Diagnosis of Non-Small-Cell Lung Carcinoma. <i>Clinical Lung Cancer</i> , 2013, 14, 238-244.	1.1	7
919	Pemetrexed as second-line chemotherapy for castration-resistant prostate cancer after docetaxel failure: Results from a phase II study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 180-186.	0.8	5
920	Prospective Observational Comparison of Clinical Outcomes Between African-American and Caucasian Patients Receiving Second-Line Treatment With Pemetrexed for Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2013, 14, 726-735.	1.1	5
921	Prediction of Lung Cancer Histological Types by RT-qPCR Gene Expression in FFPE Specimens. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 485-497.	1.2	16
922	Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594. <i>Lung Cancer</i> , 2013, 81, 47-52.	0.9	15
923	Adequacy of endobronchial ultrasound transbronchial needle aspiration samples in the subtyping of non-small cell lung cancer. <i>Lung Cancer</i> , 2013, 80, 30-34.	0.9	63

#	ARTICLE	IF	CITATIONS
924	A Case Series of Lengthy Progression-Free Survival With Pemetrexed-Containing Therapy in Metastatic Non-Small-Cell Lung Cancer Patients Harboring ROS1 Gene Rearrangements. <i>Clinical Lung Cancer</i> , 2013, 14, 592-595.	1.1	33
925	A phase I/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2013, 81, 445-450.	0.9	75
926	Traitement des CBNPC au stade métastatique. Acquis et bonnes pratiques. <i>Revue Des Maladies Respiratoires Actualites</i> , 2013, 5, 427-435.	0.0	0
927	Vitamin supplementation in patients receiving pemetrexed for advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2013, 82, 511.	0.9	1
928	Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: A randomized, open-label study. <i>Lung Cancer</i> , 2013, 79, 143-150.	0.9	30
929	Continuous pemetrexed treatment for brain metastasis in non-small cell lung cancer—A report of two cases. <i>Lung Cancer</i> , 2013, 80, 111-113.	0.9	8
930	The optimal duration of vitamin supplementation prior to the first dose of pemetrexed in patients with non-small-cell lung cancer. <i>Lung Cancer</i> , 2013, 81, 231-235.	0.9	16
931	Impact of renal function on treatment options and outcomes in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2013, 80, 326-332.	0.9	24
932	Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with non-small cell lung cancer treated with first-line paclitaxel-cisplatin chemotherapy. <i>Lung Cancer</i> , 2013, 82, 330-339.	0.9	38
933	Excision Repair Cross Complementation Group 1 and Thymidylate Synthase Expression in Patients With Mesothelioma. <i>Clinical Lung Cancer</i> , 2013, 14, 164-171.	1.1	8
934	Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2013, 81, 97-101.	0.9	42
935	The role of molecular analyses in the diagnosis and treatment of non-small-cell lung carcinomas. <i>Seminars in Diagnostic Pathology</i> , 2013, 30, 298-312.	1.0	13
936	Suitability of Computed Tomography-Guided Biopsy Specimens for Subtyping and Genotyping of Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2013, 14, 719-725.	1.1	19
937	Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): A phase II trial. <i>Lung Cancer</i> , 2013, 80, 185-190.	0.9	28
938	Southwestern Oncology Group Phase II Trial (S0526) of Pemetrexed in Bronchioloalveolar Carcinoma Subtypes of Advanced Adenocarcinoma. <i>Clinical Lung Cancer</i> , 2013, 14, 351-355.	1.1	6
939	Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer. <i>Lung Cancer</i> , 2013, 81, 428-434.	0.9	9
940	Mistletoe as complementary treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based combinations: A randomised phase II study. <i>European Journal of Cancer</i> , 2013, 49, 1058-1064.	1.3	58
941	Other signalization targets. <i>Targeted Oncology</i> , 2013, 8, 69-77.	1.7	6

#	ARTICLE	IF	CITATIONS
942	Personalized therapy on the horizon for squamous cell carcinoma of the lung. <i>Lung Cancer</i> , 2013, 80, 249-255.	0.9	60
943	Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial. <i>Annals of Oncology</i> , 2013, 24, 309-314.	0.6	18
944	Surgery for NSCLC in the era of personalized medicine. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 235-244.	12.5	85
945	Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin. <i>Lung Cancer</i> , 2013, 81, 102-108.	0.9	39
947	The PARAMOUNT study and the re-challenge chemotherapy issue in advanced non-small cell lung cancer. <i>European Journal of Cancer</i> , 2013, 49, 2269-2270.	1.3	1
948	Identification of driver mutations in lung cancer: first step in personalized cancer. <i>Targeted Oncology</i> , 2013, 8, 3-14.	1.7	26
949	Axitinib for the treatment of advanced non-small-cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 765-773.	1.9	10
950	Primary Human Non-Small Cell Lung and Pancreatic Tumorgraft Models—Utility and Applications in Drug Discovery and Tumor Biology. <i>Current Protocols in Pharmacology</i> , 2013, 61, Unit 14.26.	4.0	21
951	Pemetrexed and cisplatin combination with concurrent whole brain radiotherapy in patients with brain metastases of lung adenocarcinoma: a single-arm phase II clinical trial. <i>Journal of Neuro-Oncology</i> , 2013, 112, 461-466.	1.4	56
952	Erlotinib in the first-line treatment of non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 523-533.	1.1	17
953	Targeted therapy for non-small-cell lung cancer: past, present and future. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 745-758.	1.1	100
954	Metronomic chemotherapy for cancer treatment: a decade of clinical studies. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 13-33.	1.1	81
955	Crizotinib: A New Treatment Option for ALK-Positive Non-Small Cell Lung Cancer. <i>Annals of Pharmacotherapy</i> , 2013, 47, 189-197.	0.9	45
956	Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors. <i>Cancer Treatment Reviews</i> , 2013, 39, 27-43.	3.4	14
957	Best immunohistochemical panel in distinguishing adenocarcinoma from squamous cell carcinoma of lung: tissue microarray assay in resected lung cancer specimens. <i>Annals of Diagnostic Pathology</i> , 2013, 17, 85-90.	0.6	75
958	Dose-Escalation Study of Thoracic Radiotherapy in Combination With Pemetrexed Plus Cisplatin Followed by Pemetrexed Consolidation Therapy in Japanese Patients With Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2013, 14, 62-69.	1.1	16
959	Clinical Significance of the Serum Crosslinked N-Telopeptide of Type I Collagen as a Prognostic Marker for Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2013, 14, 50-54.	1.1	14
960	Carboplatin and Paclitaxel Plus ASA404 as First-Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Multicenter Single Arm Phase II Trial (SAKK 15/08). <i>Clinical Lung Cancer</i> , 2013, 14, 34-39.	1.1	19

#	ARTICLE	IF	CITATIONS
961	Aggressive Treatment of Primary Tumor in Patients With Non-Small-Cell Lung Cancer and Exclusively Brain Metastases. <i>Clinical Lung Cancer</i> , 2013, 14, 6-13.	1.1	37
962	Clinical factors predictive of long-term survival in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2013, 79, 73-76.	0.9	21
963	Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2013, 79, 20-26.	0.9	39
964	Clinical impact of ki-67 labeling index in non-small cell lung cancer. <i>Lung Cancer</i> , 2013, 79, 1-7.	0.9	92
965	Elderly Subset Analysis of Randomized Phase III Study Comparing Pemetrexed Plus Carboplatin with Docetaxel Plus Carboplatin as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer. <i>Drugs in R and D</i> , 2013, 13, 289-296.	1.1	18
966	Association of thymidylate synthase gene 3'-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC. <i>Journal of Biomedical Science</i> , 2013, 20, 5.	2.6	16
967	KRAS Mutation in Patients with Lung Cancer: A Predictor for Poor Prognosis but Not for EGFR-TKIs or Chemotherapy. <i>Annals of Surgical Oncology</i> , 2013, 20, 1381-1388.	0.7	73
968	AERIO News in brief. <i>Oncologie</i> , 2013, 15, 61-64.	0.2	0
969	Aflibercept in lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 115-120.	1.4	6
970	Defining Risks of Taxane Neuropathy: Insights from Randomized Clinical Trials. <i>Clinical Cancer Research</i> , 2013, 19, 4570-4577.	3.2	47
971	Erlotinib versus Pemetrexed for Pretreated Non-Squamous Non-Small Cell Lung Cancer Patients in Clinical Practice. <i>Oncology</i> , 2013, 84, 255-264.	0.9	9
972	Phase II Study of Pemetrexed and Erlotinib in Pretreated Nonsquamous, Non-Small-Cell Lung Cancer Patients without an EGFR mutation. <i>Chemotherapy</i> , 2013, 59, 414-419.	0.8	7
974	Sunitinib malate in previously untreated, nonsquamous, non-small cell lung cancer patients over the age of 70 years: Results of a Phase II trial. <i>Investigational New Drugs</i> , 2013, 31, 1330-1338.	1.2	11
975	Peripheral CD8+ T cell proliferation is prognostic for patients with advanced thoracic malignancies. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 529-539.	2.0	21
976	Health-Related Quality of Life in Patients with Advanced Nonsquamous Non-Small-Cell Lung Cancer Receiving Bevacizumab or Bevacizumab-Plus-Pemetrexed Maintenance Therapy in AVAPERL (MO22089). <i>Journal of Thoracic Oncology</i> , 2013, 8, 1409-1416.	0.5	24
977	An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1529-1537.	0.5	33
978	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer. <i>Current Pharmaceutical Design</i> , 2013, 19, 818-832.	0.9	24
979	Associations between TS, TTF-1, FR- $\beta$ , FPGS, and Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Pemetrexed Plus Carboplatin or Gemcitabine Plus Carboplatin as First-Line Chemotherapy. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1255-1264.	0.5	41

#	ARTICLE	IF	CITATIONS
980	The Clinical Viewpoint: Definitions, Limitations of RECIST, Practical Considerations of Measurement. <i>Clinical Cancer Research</i> , 2013, 19, 2629-2636.	3.2	110
981	Advances in personalized therapy for lung cancer. <i>Expert Opinion on Medical Diagnostics</i> , 2013, 7, 475-485.	1.6	9
982	Modeling hard clinical end-point data in economic analyses. <i>Journal of Medical Economics</i> , 2013, 16, 1327-1343.	1.0	6
983	Afatinib in advanced non-small-cell lung cancer. <i>Lung Cancer Management</i> , 2013, 2, 493-504.	1.5	0
984	Thymidylate synthase expression and molecular alterations in adenosquamous carcinoma of the lung. <i>Modern Pathology</i> , 2013, 26, 239-246.	2.9	18
985	Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients. <i>Future Oncology</i> , 2013, 9, 327-345.	1.1	8
986	Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma. <i>Modern Pathology</i> , 2013, 26, 511-522.	2.9	95
987	Uracilâ€“DNA Glycosylase Expression Determines Human Lung Cancer Cell Sensitivity to Pemetrexed. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2248-2260.	1.9	42
988	Epigenetic Therapy of Non-Small Cell Lung Cancer Using Decitabine (5-Aza-2â€“Deoxycytidine). <i>Frontiers in Oncology</i> , 2013, 3, 188.	1.3	27
989	Bevacizumab treatment for advanced non-small cell lung cancer: A case report. <i>Oncology Letters</i> , 2013, 6, 1779-1783.	0.8	4
990	Efficacy and safety of metronomic administration of paclitaxel for advanced recurrent non-small-cell lung cancer. <i>Indian Journal of Cancer</i> , 2013, 50, 122.	0.2	14
991	Diagnosis of Lung Cancer in Small Biopsies and Cytology: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification. <i>Archives of Pathology and Laboratory Medicine</i> , 2013, 137, 668-684.	1.2	359
992	Tissue-Preserving Antibody Cocktails to Differentiate Primary Squamous Cell Carcinoma, Adenocarcinoma, and Small Cell Carcinoma of Lung. <i>Archives of Pathology and Laboratory Medicine</i> , 2013, 137, 1274-1281.	1.2	51
993	The current state of pemetrexed in ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1201-1210.	1.9	2
994	Is there still a role for mitomycin-based combination chemotherapy in treating patients with nonsmall cell lung cancer? A single institution experience. <i>Journal of Oncology Pharmacy Practice</i> , 2013, 19, 202-207.	0.5	2
995	Adjuvant Therapy for a 3.9â€“m Adenocarcinoma of the Lung. <i>Oncologist</i> , 2013, 18, 1258-1261.	1.9	0
996	Subtyping Nonâ€“Small Cell Lung Cancer. <i>International Journal of Surgical Pathology</i> , 2013, 21, 326-336.	0.4	35
997	Non-Small-Cell Lung Cancer: Treatment of Late Stage Disease: Chemotherapeutics and New Frontiers. <i>Seminars in Interventional Radiology</i> , 2013, 30, 191-198.	0.3	67

#	ARTICLE	IF	CITATIONS
998	Dose escalation study of carboplatin+/-pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer. <i>Annals of Oncology</i> , 2013, 24, 980-985.	0.6	26
999	Targeting the Epigenome in Lung Cancer: Expanding Approaches to Epigenetic Therapy. <i>Frontiers in Oncology</i> , 2013, 3, 261.	1.3	58
1000	Overall Survival Should Be the Primary Endpoint in Clinical Trials for Advanced Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2013, 20, 150-160.	0.9	36
1001	Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN). <i>Annals of Oncology</i> , 2013, 24, 1534-1542.	0.6	17
1002	The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , 2013, 25, 121-129.	1.1	10
1003	Histologic and Molecular Characterization of Lung Cancer With Tissue Obtained by Electromagnetic Navigation Bronchoscopy. <i>Journal of Bronchology and Interventional Pulmonology</i> , 2013, 20, 10-15.	0.8	18
1004	First assessment of whole-brain radiation therapy combined with pemetrexed-based chemotherapy in non-small-cell lung carcinoma. <i>Anti-Cancer Drugs</i> , 2013, 24, 736-742.	0.7	7
1005	Chemoradiation for Definitive, Preoperative, or Postoperative Therapy of Locally Advanced Non-Small Cell Lung Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2013, 19, 222-230.	1.0	9
1006	Phase II Trial of Pemetrexed Plus Gemcitabine in Patients With Locally Advanced and Metastatic Nonclear Cell Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 450-454.	0.6	7
1007	Personalized Treatment of Lung Adenocarcinoma. <i>Clinical Pulmonary Medicine</i> , 2013, 20, 309-314.	0.3	1
1008	The International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society grading system has limited prognostic significance in advanced resected pulmonary adenocarcinoma. <i>Pathology</i> , 2013, 45, 553-558.	0.3	37
1009	Afatinib, Erlotinib and Gefitinib in the First-Line Therapy of EGFR Mutation-Positive Lung Adenocarcinoma: A Review. <i>Onkologie</i> , 2013, 36, 5-5.	1.1	77
1010	Reply to F. Gelsomino et al. <i>Journal of Clinical Oncology</i> , 2013, 31, 3293-3294.	0.8	1
1011	Second-Line Therapy for Advanced NSCLC. <i>Oncologist</i> , 2013, 18, 947-953.	1.9	36
1012	Immunohistochemical Profiling of ALK Fusion Gene+/-Positive Adenocarcinomas of the Lung. <i>International Journal of Surgical Pathology</i> , 2013, 21, 476-482.	0.4	19
1013	Lack of Improvement in Overall Survival With Gemcitabine/ Erlotinib Maintenance and Its Relationship With Pemetrexed Use in the Second-Line Setting. <i>Journal of Clinical Oncology</i> , 2013, 31, 1250-1251.	0.8	4
1014	The Role of MET Receptor Tyrosine Kinase in Non-Small Cell Lung Cancer and Clinical Development of Targeted Anti-MET Agents. <i>Oncologist</i> , 2013, 18, 115-122.	1.9	62
1015	Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study. <i>Annals of Oncology</i> , 2013, 24, 986-992.	0.6	76

#	ARTICLE	IF	CITATIONS
1016	Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study. <i>Annals of Oncology</i> , 2013, 24, 1326-1331.	0.6	59
1017	Short Hydration in Chemotherapy Containing Cisplatin (>=75 mg/m <sup>2</sup> ) for Patients with Lung Cancer: A Prospective Study. <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 1105-1109.	0.6	50
1018	Current Therapeutic Strategies and Novel Approaches in Osteosarcoma. <i>Cancers</i> , 2013, 5, 591-616.	1.7	188
1019	Maintenance Chemotherapy for Advanced Non-Small-Cell Lung Cancer: New Life for an Old Idea. <i>Journal of Clinical Oncology</i> , 2013, 31, 1009-1020.	0.8	125
1020	Randomized Phase II Study of Ixabepilone or Paclitaxel Plus Carboplatin in Patients With Non-Small-Cell Lung Cancer Prospectively Stratified by Beta-3 Tubulin Status. <i>Journal of Clinical Oncology</i> , 2013, 31, 1990-1996.	0.8	25
1021	Epidermal Growth Factor Receptor Inhibition in Mutation-Positive Non-Small-Cell Lung Cancer: Is Afatinib Better or Simply Newer?. <i>Journal of Clinical Oncology</i> , 2013, 31, 3303-3306.	0.8	63
1022	Management of Elderly Patients with Advanced Non-Small Cell Lung Cancer: A Single-Center Experience. <i>Chemotherapy</i> , 2013, 59, 42-50.	0.8	8
1023	Efficacy and Safety of Platinum Combination Chemotherapy Re-Challenge for Relapsed Patients with Non-Small-Cell Lung Cancer after Postoperative Adjuvant Chemotherapy of Cisplatin plus Vinorelbine. <i>Chemotherapy</i> , 2013, 59, 307-313.	0.8	9
1024	Dose Escalation and Feasibility Study of Amrubicin Combined With Cisplatin in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 105-109.	0.6	1
1025	Is Immunohistochemistry Always Required to Diagnose Lung Cancer?. <i>Advances in Anatomic Pathology</i> , 2013, 20, 327-333.	2.4	11
1026	Basic Mechanisms of Therapeutic Resistance to Radiation and Chemotherapy in Lung Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 200-207.	1.0	160
1027	Nonsmall Cell Lung Cancer Therapy: Insight into Multitargeted Small-Molecule Growth Factor Receptor Inhibitors. <i>BioMed Research International</i> , 2013, 2013, 1-11.	0.9	18
1028	Retrospective analysis of the clinical and demographic variables on the outcomes after second-line treatment in advanced non-small cell lung cancer. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2013, 34, 274.	0.1	2
1029	Histo-cytological diagnostic accuracy in lung cancer. <i>Cytopathology</i> , 2014, 25, 404-411.	0.4	5
1030	Thymidylate Synthase as a Predictive Biomarker for Pemetrexed Response in NSCLC. <i>Lung Cancer International</i> , 2013, 2013, 1-7.	1.2	16
1031	Nanoparticle Albumin Bound Paclitaxel in the Treatment of Human Cancer: Nanodelivery Reaches Prime-Time?. <i>Journal of Drug Delivery</i> , 2013, 2013, 1-10.	2.5	62
1032	Novel medium-term carcinogenesis model for lung squamous cell carcinoma induced by N-nitrosochloroethylurea in mice. <i>Cancer Science</i> , 2013, 104, 1560-1566.	1.7	10
1033	A potential new enriching trial design for selecting non-small-cell lung cancer patients with no predictive biomarker for trials based on both histology and early tumor response: further analysis of a thalidomide trial. <i>Cancer Medicine</i> , 2013, 2, 360-366.	1.3	9

#	ARTICLE	IF	CITATIONS
1034	Pemetrexed in combination with cisplatin versus cisplatin monotherapy in Asian patients with recurrent or metastatic head and neck cancer: Results of an exploratory subgroup analysis of a phase III trial. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2013, 9, 331-341.	0.7	1
1035	Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non small cell lung cancer. <i>Journal of Cellular Physiology</i> , 2013, 229, n/a-n/a.	2.0	96
1036	Antiangiogenic agents and chemotherapy in advanced non-small cell lung cancer: a clinical perspective. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 1193-1206.	1.1	2
1037	Evidence-based role of bevacizumab in non-small cell lung cancer. <i>Annals of Oncology</i> , 2013, 24, 6-9.	0.6	50
1038	Model Pharmacoeconomic Study on Iressa® (Gefitinib) as a First Line Treatment of Non-Small Cell Lung Cancer at Stage IIIB/IV in EGFR Mutation Positive Bulgarian Patients. <i>Biotechnology and Biotechnological Equipment</i> , 2013, 27, 3586-3594.	0.5	0
1039	The place of pemetrexed in the management of non-small-cell lung cancer patients. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 257-266.	1.1	8
1040	Adherence to CONSORT Adverse Event Reporting Guidelines in Randomized Clinical Trials Evaluating Systemic Cancer Therapy: A Systematic Review. <i>Journal of Clinical Oncology</i> , 2013, 31, 3957-3963.	0.8	87
1041	A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 3068-3077.	3.2	212
1042	Clinical relevance of the new IASLC/ERS/ATS adenocarcinoma classification. <i>Journal of Clinical Pathology</i> , 2013, 66, 832-838.	1.0	18
1043	Estado actual del tratamiento del cáncer pulmonar. <i>Revista Médica Clínica Las Condes</i> , 2013, 24, 611-625.	0.2	0
1044	Inhibition of BRCA2 and Thymidylate Synthase Creates Multidrug Sensitive Tumor Cells via the Induction of Combined Complementary Lethality. <i>Molecular Therapy - Nucleic Acids</i> , 2013, 2, e78.	2.3	15
1045	Efficacy of third-generation chemotherapeutic agents combined with cisplatin or carboplatin in 3100 Chinese patients with advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2013, 4, 117-122.	0.8	2
1046	Phase Ib safety and pharmacokinetic study of volociximab, an anti- $\alpha 5 \beta 1$ integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2013, 24, 90-96.	0.6	63
1047	Cancer survival extension from drug treatments. <i>British Actuarial Journal</i> , 2013, 18, 467-485.	0.2	0
1048	Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. <i>Cancer Biology and Therapy</i> , 2013, 14, 469-475.	1.5	82
1050	Polymorphisms in thymidylate synthase and reduced folate carrier (SLC19A1) genes predict survival outcome in advanced non-small cell lung cancer patients treated with pemetrexed-based chemotherapy. <i>Oncology Letters</i> , 2013, 5, 1165-1170.	0.8	31
1051	Chemotherapy: still an essential player in non-small-cell lung cancer treatment?. <i>Lung Cancer Management</i> , 2013, 2, 381-390.	1.5	0
1052	Chemotherapy of advanced non-small-cell lung cancer: current landscape. <i>Clinical Investigation</i> , 2013, 3, 265-279.	0.0	0



#	ARTICLE	IF	CITATIONS
1053	Efficacy of Pemetrexed as Second-Line Therapy in Advanced NSCLC after Either Treatment-Free Interval or Maintenance Therapy with Gemcitabine or Erlotinib in IFCT-GFPC 05-02 Phase III Study. <i>Journal of Thoracic Oncology</i> , 2013, 8, 906-914.	0.5	12
1054	Challenges to Implementation of an Epidermal Growth Factor Receptor Testing Strategy for Non-Small-Cell Lung Cancer in a Publicly Funded Health Care System. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1136-1141.	0.5	42
1055	Phase 2 Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin with Concurrent Radiation Therapy Followed by Pemetrexed Consolidation in Patients with Favorable-Prognosis Inoperable Stage IIIA/B Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1308-1316.	0.5	32
1056	Cytokeratin 19 Fragment Predicts the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small-Cell Lung Cancer Harboring EGFR Mutation. <i>Journal of Thoracic Oncology</i> , 2013, 8, 892-898.	0.5	44
1057	Analysis of Subgroup Data of Clinical Trials. <i>Journal of Causal Inference</i> , 2013, 1, 193-207.	0.5	2
1058	A Patient With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer With Development of Leptomeningeal Carcinomatosis While on Targeted Treatment With Crizotinib. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 389-394.	2.3	14
1059	Treatment of Stage IV Non-small Cell Lung Cancer. <i>Chest</i> , 2013, 143, e341S-e368S.	0.4	180
1060	Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697. <i>International Journal of Oncology</i> , 2013, 42, 1088-1092.	1.4	3
1061	Impact of the new EGF receptor and ALK testing guideline on personalized lung cancer medicine. <i>Personalized Medicine</i> , 2013, 10, 415-417.	0.8	0
1062	Significance of Folate Receptor Alpha and Thymidylate Synthase Protein Expression in Patients with Non-Small-Cell Lung Cancer Treated with Pemetrexed. <i>Journal of Thoracic Oncology</i> , 2013, 8, 19-30.	0.5	79
1063	Epidemiology of Lung Cancer. <i>Chest</i> , 2013, 143, e1S-e29S.	0.4	559
1064	Establishing the Diagnosis of Lung Cancer. <i>Chest</i> , 2013, 143, e142S-e165S.	0.4	825
1065	Targeting angiogenesis in non-small-cell lung cancer: a focus on current approaches and future developments. <i>Clinical Practice (London, England)</i> , 2013, 10, 503-517.	0.1	0
1066	Identification of microRNAs differentially expressed between lung squamous cell carcinoma and lung adenocarcinoma. <i>Molecular Medicine Reports</i> , 2013, 8, 456-462.	1.1	59
1067	Prognostic Factors and the Significance of Treatment After Recurrence in Completely Resected Stage I Non-small Cell Lung Cancer. <i>Chest</i> , 2013, 143, 1626-1634.	0.4	65
1068	Predicting toxicity in advanced lung cancer patients treated with platinum-based chemotherapy. <i>Lung Cancer Management</i> , 2013, 2, 281-293.	1.5	0
1069	Conference Scene: Australia Lung Cancer Conference 2012: focus on systemic treatment of advanced non-small-cell lung cancer. <i>Lung Cancer Management</i> , 2013, 2, 27-30.	1.5	1
1070	Prognostic Value of the New International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Lung Adenocarcinoma Classification on Death and Recurrence in Completely Resected Stage I Lung Adenocarcinoma. <i>Annals of Surgery</i> , 2013, 258, 1079-1086.	2.1	175

#	ARTICLE	IF	CITATIONS
1071	Thymidylate Synthase Expression and Outcome of Patients Receiving Pemetrexed for Advanced Nonsquamous Non-Small-Cell Lung Cancer in a Prospective Blinded Assessment Phase II Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2013, 8, 930-939.	0.5	56
1072	Association between TYMS Expression and Efficacy of Pemetrexed-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis. <i>PLoS ONE</i> , 2013, 8, e74284.	1.1	36
1073	Thymidylate synthase inhibitors for thoracic tumors. <i>Pteridines</i> , 2013, 24, 57-67.	0.5	1
1074	Histology-Related Associations of ERCC1, RRM1, and TS Biomarkers in Patients with Non-Small-Cell Lung Cancer: Implications for Therapy. <i>Journal of Thoracic Oncology</i> , 2013, 8, 582-586.	0.5	26
1075	Clinical characteristics of brain metastases from lung cancer according to histological type: Pretreatment evaluation and survival following whole-brain radiotherapy. <i>Molecular and Clinical Oncology</i> , 2013, 1, 692-698.	0.4	12
1076	Phase II Trial of Neoadjuvant Bevacizumab Plus Chemotherapy and Adjuvant Bevacizumab in Patients with Resectable Nonsquamous Non-Small-Cell Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1084-1090.	0.5	111
1077	Histology and Smoking Status Predict Survival of Patients with Advanced Non-Small-Cell Lung Cancer: Results of West Japan Oncology Group (WJOG) Study 3906L. <i>Journal of Thoracic Oncology</i> , 2013, 8, 753-758.	0.5	42
1078	Genomewide DNA Methylation Analysis Identifies Novel Methylated Genes in Non-Small-Cell Lung Carcinomas. <i>Journal of Thoracic Oncology</i> , 2013, 8, 562-573.	0.5	31
1079	Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancer. <i>Cancer Management and Research</i> , 2013, 5, 15.	0.9	4
1080	Prognostic factors of tumor recurrence in completely resected non-small cell lung cancer. <i>Cancer Management and Research</i> , 2013, 5, 77.	0.9	11
1081	Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy. <i>Journal of Cancer</i> , 2013, 4, 736-754.	1.2	77
1082	Can MicroRNAs Improve the Management of Lung Cancer Patients? A Clinician's Perspective. <i>Theranostics</i> , 2013, 3, 953-963.	4.6	18
1083	Biopsy and Mutation Detection Strategies in Non-Small Cell Lung Cancer. <i>Tuberculosis and Respiratory Diseases</i> , 2013, 75, 181.	0.7	13
1084	Practical management of NSCLC patients with long-term bevacizumab treatment: a report of four cases. <i>Lung Cancer: Targets and Therapy</i> , 2013, 4, 55.	1.3	1
1085	Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy. <i>Lung Cancer: Targets and Therapy</i> , 2013, 4, 9.	1.3	8
1086	Role of the extracellular matrix in variations of invasive pathways in lung cancers. <i>Brazilian Journal of Medical and Biological Research</i> , 2013, 46, 21-31.	0.7	7
1087	A Trial-Based Cost-Effectiveness Analysis of Erlotinib Alone versus Platinum-Based Doublet Chemotherapy as First-Line Therapy for Eastern Asian Nonsquamous Non-Small-Cell Lung Cancer. <i>PLoS ONE</i> , 2013, 8, e55917.	1.1	46
1088	Simultaneous Multi-Antibody Staining in Non-Small Cell Lung Cancer Strengthens Diagnostic Accuracy Especially in Small Tissue Samples. <i>PLoS ONE</i> , 2013, 8, e56333.	1.1	20

#	ARTICLE	IF	CITATIONS
1089	Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel and cisplatin/pemetrexed in chemotherapy-naïve patients with advanced non-squamous bronchogenic carcinoma not harboring EGFR mutation. <i>OncoTargets and Therapy</i> , 2013, 6, 803.	1.0	3
1090	Pharmacogenomic Assessment of Outcomes of Pemetrexed-Treated Patients with Adenocarcinoma of the Lung. <i>Yonsei Medical Journal</i> , 2013, 54, 854.	0.9	14
1091	Difference in the emetic control among highly emetogenic chemotherapy regimens: Implementation for appropriate use of aprepitant. <i>Molecular and Clinical Oncology</i> , 2013, 1, 41-46.	0.4	5
1092	Conventional Cancer Treatment. , 2013, , .		6
1093	Squamous cell carcinoma of the lung. , 0, , 1093-1113.		0
1094	Lung Cancer Patients Benefit from Second Opinions by Improvement of Diagnosis and Therapy. <i>Cancer and Clinical Oncology</i> , 2014, 3, .	0.2	0
1095	Cytotoxic Chemotherapy for Non-small Cell Lung Cancer. <i>Hanyang Medical Reviews</i> , 2014, 34, 31.	0.4	2
1096	Identifying differentially expressed genes and pathways in two types of non-small cell lung cancer: adenocarcinoma and squamous cell carcinoma. <i>Genetics and Molecular Research</i> , 2014, 13, 95-102.	0.3	32
1097	Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemotherapy-naïve patients with EGFR-mutant lung adenocarcinoma. <i>OncoTargets and Therapy</i> , 2014, 7, 799.	1.0	14
1098	Correlation between EGFR mutation status and response to first-line platinum-based chemotherapy in patients with advanced non-small cell lung cancer. <i>OncoTargets and Therapy</i> , 2014, 7, 1185.	1.0	18
1099	Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations. <i>PLoS ONE</i> , 2014, 9, e85245.	1.1	125
1100	Alteration in Mir-21/PTEN Expression Modulates Gefitinib Resistance in Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2014, 9, e103305.	1.1	98
1101	Critical appraisal of pemetrexed in the treatment of NSCLC and metastatic pulmonary nodules. <i>OncoTargets and Therapy</i> , 2014, 7, 937.	1.0	8
1102	Non-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial Design. <i>Journal of Personalized Medicine</i> , 2014, 4, 386-401.	1.1	13
1103	Maintaining clarity: Review of maintenance therapy in non-small cell lung cancer. <i>World Journal of Clinical Oncology</i> , 2014, 5, 103.	0.9	22
1104	Survival and prognostic factors in patients with Non-Small Cell Lung Cancer treated in private health care. <i>Revista Brasileira De Epidemiologia</i> , 2014, 17, 1001-1014.	0.3	19
1105	Erlotinib in the treatment of advanced squamous cell NSCLC. <i>Neoplasma</i> , 2014, 60, 676-682.	0.7	2
1106	Update on Taxanes in the First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2014, 21, 691-703.	0.9	30

#	ARTICLE	IF	CITATIONS
1107	Individual-level data on the relationships of progression-free survival, post-progression survival, and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer. <i>Neoplasma</i> , 2014, 61, 233-240.	0.7	27
1108	The impact of both platinum-based chemotherapy and EGFR-TKIs on overall survival of patients with advanced non-small cell lung cancer. <i>Chinese Journal of Cancer</i> , 2014, 33, 105-114.	4.9	6
1109	Molecular Targeted Therapy in Lung Cancer. <i>Hanyang Medical Reviews</i> , 2014, 34, 37.	0.4	1
1110	Chemotherapy for Lung Cancers: Here to Stay. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e375-e380.	1.8	4
1111	50 Years of Progress in the Systemic Therapy of Non-Small Cell Lung Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , 177-189.	1.8	92
1112	MicroRNAs: a new key in lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 1105-1111.	1.1	77
1113	Development in the diagnostic lung cancer pathway: implication for treatment. <i>Lung Cancer Management</i> , 2014, 3, 417-428.	1.5	1
1114	Survivin as prognostic and predictive factor in patients treated with gemcitabine, dexamethasone, and cisplatin for relapsed or refractory aggressive NHL. <i>Medical Oncology</i> , 2014, 31, 244.	1.2	1
1115	Tumor Acquisition for Biomarker Research in Lung Cancer. <i>Cancer Investigation</i> , 2014, 32, 291-298.	0.6	6
1116	Performance of standard procedures in detection of EGFR mutations in daily practice in advanced NSCLC patients selected according to the ESMO guideline: a large Caucasian cohort study. <i>Translational Respiratory Medicine</i> , 2014, 2, 9.	3.8	12
1117	Long progression-free survival with first-line paclitaxel plus platinum is associated with improved response and progression-free survival with second-line docetaxel in advanced non-small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 681-690.	1.1	12
1118	Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNAActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. <i>BMC Cancer</i> , 2014, 14, 748.	1.1	101
1119	The Optimal Treatment Modality in Patients with T4N2M0 Non-Small Cell Lung Cancer: The Best Choice May Be Definitive Chemoradiotherapy Followed by Consolidation Chemotherapy. <i>Chemotherapy</i> , 2014, 60, 107-111.	0.8	4
1120	Clinical effectiveness and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced non-squamous non-small cell lung cancer in Chinese patients: a retrospective cohort study. <i>BMC Cancer</i> , 2014, 14, 940.	1.1	8
1121	Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in patients with non-small cell lung cancer. <i>Cancer Biology and Therapy</i> , 2014, 15, 1542-1551.	1.5	16
1122	Safety and efficacy evaluation of albumin-bound paclitaxel. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 511-520.	1.0	29
1123	A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer. <i>British Journal of Cancer</i> , 2014, 110, 602-608.	2.9	27
1124	Third- and further-line therapy in advanced non-small-cell lung cancer patients: an overview. <i>Future Oncology</i> , 2014, 10, 2081-2096.	1.1	16

#	ARTICLE	IF	CITATIONS
1125	Usp9x- and Noxa-mediated Mcl-1 downregulation contributes to pemetrexed-induced apoptosis in human non-small-cell lung cancer cells. <i>Cell Death and Disease</i> , 2014, 5, e1316-e1316.	2.7	58
1126	A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer. <i>Cancer Biology and Therapy</i> , 2014, 15, 832-839.	1.5	26
1127	Significance of thymidylate synthase expression for resistance to pemetrexed in pulmonary adenocarcinoma. <i>Oncology Letters</i> , 2014, 7, 227-232.	0.8	19
1128	Treatment Paradigms for Patients with Metastatic Non-Small Cell Lung Cancer, Squamous Lung Cancer: First, Second, and Third-Line. <i>Frontiers in Oncology</i> , 2014, 4, 157.	1.3	41
1129	Promising Targets and Current Clinical Trials in Metastatic Squamous Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2014, 4, 320.	1.3	5
1130	Pulmonary Large Cell Carcinoma Lacking Squamous Differentiation Is Clinicopathologically Indistinguishable From Solid-Subtype Adenocarcinoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 626-635.	1.2	39
1131	The changing landscape of phase II/III metastatic NSCLC clinical trials and the importance of biomarker selection criteria. <i>Cancer</i> , 2014, 120, 3853-3858.	2.0	9
1132	Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer. <i>Oncology Letters</i> , 2014, 8, 2453-2457.	0.8	12
1133	Hidden Treasures in "Ancient" Microarrays: Gene-Expression Portrays Biology and Potential Resistance Pathways of Major Lung Cancer Subtypes and Normal Tissue. <i>Frontiers in Oncology</i> , 2014, 4, 251.	1.3	15
1134	Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized Medicine. <i>Frontiers in Oncology</i> , 2014, 4, 258.	1.3	4
1135	Drug Resistance to Molecular Targeted Therapy and Its Consequences for Treatment Decisions in Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2014, 4, 190.	1.3	50
1136	Prognosis of recurrent non-small cell lung cancer following complete resection. <i>Oncology Letters</i> , 2014, 7, 1300-1304.	0.8	38
1137	Oncogenic mutations are associated with histological subtypes but do not have an independent prognostic value in lung adenocarcinoma. <i>OncoTargets and Therapy</i> , 2014, 7, 1423.	1.0	41
1138	Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS. <i>Frontiers in Oncology</i> , 2014, 4, 204.	1.3	137
1139	Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. <i>Molecular Medicine Reports</i> , 2014, 10, 931-938.	1.1	26
1140	Efficacy and safety of docetaxel plus oxaliplatin as a first-line chemotherapy in patients with advanced or metastatic non-small cell lung cancer. <i>Thoracic Cancer</i> , 2014, 5, 525-529.	0.8	5
1141	Melanoma-associated antigen-A3 vaccination in the treatment of non-small-cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 365-376.	1.4	8
1142	Updating the 2011 International Association for the Study of Lung Cancer classification of lung adenocarcinoma: main priorities and implications for clinicians. <i>Lung Cancer Management</i> , 2014, 3, 149-158.	1.5	0

#	ARTICLE	IF	CITATIONS
1143	Immunotherapy and lung cancer: current developments and novel targeted therapies. <i>Immunotherapy</i> , 2014, 6, 1221-1235.	1.0	44
1144	Year in review 2013: Lung cancer, respiratory infections, tuberculosis, cystic fibrosis, pleural diseases, bronchoscopic intervention and imaging. <i>Respirology</i> , 2014, 19, 448-460.	1.3	5
1145	Subtyping of nonsmall cell lung cancer on cytology specimens: Reproducibility of cytopathologic diagnoses on sparse material. <i>Diagnostic Cytopathology</i> , 2014, 42, 105-110.	0.5	4
1146	2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. <i>Annals of Oncology</i> , 2014, 25, 1475-1484.	0.6	210
1147	Maintenance bevacizumabâ€“pemetrexed after first-line cisplatinâ€“pemetrexedâ€“bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. <i>Annals of Oncology</i> , 2014, 25, 1044-1052.	0.6	152
1148	First-Line Crizotinib versus Chemotherapy in <i>ALK</i> -Positive Lung Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 2167-2177.	13.9	2,808
1149	CÃ¡ncer de pulmÃ³n. <i>Medicine</i> , 2014, 11, 3983-3994.	0.0	0
1150	A Personalized Treatment for Lung Cancer: Molecular Pathways, Targeted Therapies, and Genomic Characterization. <i>Advances in Experimental Medicine and Biology</i> , 2014, 799, 85-117.	0.8	98
1151	Preparing for tomorrow: Molecular diagnostics and the changing nonsmall cell lung cancer landscape. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, 2-10.	0.7	4
1152	A Prospective Study of Shortened Vitamin Supplementation Prior to Cisplatinâ€“Pemetrexed Therapy for Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2014, 19, 1194-1199.	1.9	16
1153	Alternating Electric Fields (Tumor-Treating Fields Therapy) Can Improve Chemotherapy Treatment Efficacy in Non-Small Cell Lung Cancer Both In Vitro and In Vivo. <i>Seminars in Oncology</i> , 2014, 41, S35-S41.	0.8	98
1154	Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014, 25, iii27-iii39.	0.6	600
1155	Phase I Study of Carboplatin Combined with Pemetrexed for Elderly Patients with Advanced Non-squamous Non-small Cell Lung Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 472-478.	0.6	4
1156	Advances in the Diagnosis and Treatment of Nonâ€“Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 557-564.	1.9	18
1157	Polymorphisms in <i>TS</i> , <i>MTHFR</i> and <i>ERCC1</i> genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 2047-2057.	1.2	28
1159	Acute and fatal thrombocytopenic thrombotic purpura after a single dose of pemetrexed. <i>International Journal of Clinical Pharmacy</i> , 2014, 36, 1141-1143.	1.0	4
1160	Maintenance strategies in stage IV non-small-cell lung cancer (NSCLC): in which patients, with which drugs?. <i>Annals of Oncology</i> , 2014, 25, 1283-1293.	0.6	19
1161	A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung. <i>BMC Cancer</i> , 2014, 14, 684.	1.1	13

#	ARTICLE	IF	CITATIONS
1162	Prospective genetic profiling of squamous cell lung cancer and adenosquamous carcinoma in Japanese patients by multitarget assays. <i>BMC Cancer</i> , 2014, 14, 786.	1.1	35
1163	Difference in prognostic values of maximal standardized uptake value on fluorodeoxyglucose-positron emission tomography and cyclooxygenase-2 expression between lung adenocarcinoma and squamous cell carcinoma. <i>World Journal of Surgical Oncology</i> , 2014, 12, 343.	0.8	12
1164	Histological comparison between preoperative and surgical specimens of non-small cell lung cancer for distinguishing between "squamous" and "non-squamous" cell carcinoma. <i>Diagnostic Pathology</i> , 2014, 9, 103.	0.9	6
1165	Final Efficacy and Safety Results of Pemetrexed Continuation Maintenance Therapy in the Elderly from the PARAMOUNT Phase III Study. <i>Journal of Thoracic Oncology</i> , 2014, 9, 991-997.	0.5	46
1166	New developments in the treatment of squamous cell lung cancer. <i>Current Opinion in Oncology</i> , 2014, 26, 152-158.	1.1	20
1167	Phase II Study of Perioperative Chemotherapy with Cisplatin and Pemetrexed in Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 222-230.	0.5	14
1168	NCCTG N0821 (Alliance): A Phase II First-Line Study of Pemetrexed, Carboplatin, and Bevacizumab in Elderly Patients with Advanced Nonsquamous Non-Small-Cell Lung Cancer With Good Performance Status. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1146-1153.	0.5	7
1169	Second-line treatment in advanced non-small-cell lung cancer in the epidermal growth factor receptor wild-type population. <i>Anti-Cancer Drugs</i> , 2014, 25, 368-374.	0.7	3
1170	The Clinical Relevance of Pathologic Subtypes in Metastatic Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2014, 9, 654-663.	0.5	20
1171	Vaccination therapy for non-small-cell lung cancer. <i>Current Opinion in Oncology</i> , 2014, 26, 165-170.	1.1	40
1172	Large-Scale Screening and Molecular Characterization of EML4-ALK Fusion Variants in Archival Non-Small-Cell Lung Cancer Tumor Specimens Using Quantitative Reverse Transcription Polymerase Chain Reaction Assays. <i>Journal of Thoracic Oncology</i> , 2014, 9, 18-25.	0.5	58
1173	Reproducibility of Histopathological Diagnosis in Poorly Differentiated NSCLC: An International Multiobserver Study. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1354-1362.	0.5	34
1174	Glucocorticoid Receptor Status Is a Principal Determinant of Variability in the Sensitivity of Non-Small-Cell Lung Cancer Cells to Pemetrexed. <i>Journal of Thoracic Oncology</i> , 2014, 9, 519-526.	0.5	27
1175	Validation of a Histology-Independent Prognostic Gene Signature for Early-Stage, Non-Small-Cell Lung Cancer Including Stage IA Patients. <i>Journal of Thoracic Oncology</i> , 2014, 9, 59-64.	0.5	243
1176	ALK inhibitors and advanced non-small cell lung cancer (Review). <i>International Journal of Oncology</i> , 2014, 45, 499-508.	1.4	37
1177	Maintenance treatment after induction therapy in non-small cell lung cancer: latest evidence and clinical implications. <i>Therapeutic Advances in Medical Oncology</i> , 2014, 6, 4-15.	1.4	20
1178	A comprehensive immunohistochemistry algorithm for the histological subtyping of small biopsies obtained from non-small cell lung cancers. <i>Histopathology</i> , 2014, 65, 868-878.	1.6	27
1179	Convex Probe Endobronchial Ultrasound. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2014, 35, 636-644.	0.8	5

#	ARTICLE	IF	CITATIONS
1180	Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. <i>Annals of Oncology</i> , 2014, 25, 1681-1690.	0.6	246
1182	Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2014, 140, 1225.	1.2	263
1183	Non—Small Cell Lung Cancer and Precision Medicine. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1975.	3.8	31
1184	Simple and Objective Prediction of Survival in Patients with Lung Cancer: Staging the Host Systemic Inflammatory Response. <i>Lung Cancer International</i> , 2014, 2014, 1-10.	1.2	5
1185	Serum biomarkers for assessing histology and outcomes in patients with metastatic lung cancer. <i>Cancer Biomarkers</i> , 2014, 14, 207-214.	0.8	18
1186	Chemotherapy in Metastatic NSCLC — New Regimens (Pemetrexed, Nab-Paclitaxel). <i>Frontiers in Oncology</i> , 2014, 4, 177.	1.3	6
1187	Rechallenge with pemetrexed-based chemotherapy improves the survival of patients with advanced non-squamous non-small-cell lung cancer. <i>Molecular and Clinical Oncology</i> , 2014, 2, 953-959.	0.4	9
1188	The Dose and Risk Factors for Radiation Exposure to Medical Staff during Endobronchial Ultrasonography with a Guide Sheath for Peripheral Pulmonary Lesions under X-ray Fluoroscopy. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 257-262.	0.6	12
1189	nab-paclitaxel for the management of patients with advanced non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2014, 14, 129-141.	1.1	14
1190	KRAS Mutation Status Is Associated with Enhanced Dependency on Folate Metabolism Pathways in Non—Small Cell Lung Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1611-1624.	1.9	51
1191	Response to Chemotherapy, Reexposure to Crizotinib and Treatment with a Novel ALK Inhibitor in a Patient with Acquired Crizotinib Resistance. <i>Respiration</i> , 2014, 88, 262-264.	1.2	10
1192	Chemotherapy and Targeted Therapeutics as Maintenance of Response in Advanced Non-Small Cell Lung Cancer. <i>Seminars in Oncology</i> , 2014, 41, 93-100.	0.8	12
1193	Invasive and Noninvasive Advances in the Staging of Lung Cancer. <i>Seminars in Oncology</i> , 2014, 41, 17-27.	0.8	2
1194	Targeted Therapies in Non-Small Cell Lung Cancer: Emerging Oncogene Targets Following the Success of Epidermal Growth Factor Receptor. <i>Seminars in Oncology</i> , 2014, 41, 110-125.	0.8	60
1195	Extending Survival of Stage IV Non-Small Cell Lung Cancer. <i>Seminars in Oncology</i> , 2014, 41, 69-92.	0.8	34
1196	Prognostic and predictive biomarkers in lung cancer. A review. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 464, 347-358.	1.4	77
1197	Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 464, 61-68.	1.4	88
1198	The effect of chemotherapy with cisplatin and pemetrexed for choroidal metastasis of non-squamous cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 199-205.	1.1	21



#	ARTICLE	IF	CITATIONS
1199	Systematic review of efficacy and safety of pemetrexed in non-small-cell-lung cancer. <i>International Journal of Clinical Pharmacy</i> , 2014, 36, 476-487.	1.0	12
1200	Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2014, 83, 211-218.	0.9	64
1201	Synergistic effects of pemetrexed and amrubicin in non-small cell lung cancer cell lines: Potential for combination therapy. <i>Cancer Letters</i> , 2014, 343, 74-79.	3.2	16
1202	Thymidylate synthase protein expression levels remain stable during paclitaxel and carboplatin treatment in non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 645-652.	1.2	1
1203	Pemetrexed-Carboplatin Adjuvant Chemotherapy With or Without Gefitinib in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Harboring EGFR Mutations: A Randomized, Phase II Study. <i>Annals of Surgical Oncology</i> , 2014, 21, 2091-2096.	0.7	83
1204	Immunotherapy for non-small-cell lung cancer: current approaches. <i>Current Respiratory Care Reports</i> , 2014, 3, 19-25.	0.6	2
1205	Reduced folate carrier (RFC) as a predictive marker for response to pemetrexed in advanced non-small cell lung cancer (NSCLC). <i>Investigational New Drugs</i> , 2014, 32, 377-381.	1.2	4
1206	Systems Analysis of Human Multigene Disorders. <i>Advances in Experimental Medicine and Biology</i> , 2014, 799, v - viii.	0.8	4
1207	Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 282-298.	12.5	312
1208	Rationale and Design of MILES-3 and MILES-4 Studies: Two Randomized Phase 3 Trials Comparing Single-Agent Chemotherapy Versus Cisplatin-Based Doublets in Elderly Patients With Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2014, 15, 166-170.	1.1	25
1209	Recent Clinical Advances in Lung Cancer Management. <i>Journal of Clinical Oncology</i> , 2014, 32, 973-982.	0.8	203
1210	Effects of exercise training programs on physical performance and quality of life in patients with metastatic lung cancer undergoing palliative chemotherapy—A study protocol. <i>Contemporary Clinical Trials</i> , 2014, 37, 120-128.	0.8	18
1211	Impact and Safety of Adjuvant Chemotherapy on Pulmonary Function in Early Stage Non-Small Cell Lung Cancer. <i>Respiration</i> , 2014, 87, 204-210.	1.2	6
1212	Survival and prognostic factors in non-small cell lung cancer patients with spinal bone metastases. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 59-63.	1.0	23
1213	The impact of personalized medicine on survival: Comparisons of results in metastatic breast, colorectal and non-small-cell lung cancers. <i>Cancer Treatment Reviews</i> , 2014, 40, 485-494.	3.4	21
1214	Carcinome bronchique non À petites cellules : quelle chimiothérapie de rattrapage ?. <i>Revue Des Maladies Respiratoires Actualites</i> , 2014, 6, 442-452.	0.0	0
1215	Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous non-small cell lung cancer, and correlation between the efficacy/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 1149-1157.	1.1	11
1216	Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: Comparison with histological assessment. <i>Cancer Cytopathology</i> , 2014, 122, 445-453.	1.4	40

#	ARTICLE	IF	CITATIONS
1217	A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer. <i>Annals of Oncology</i> , 2014, 25, 2156-2162.	0.6	26
1218	LUX-Lung 3: redundancy, toxicity or a major step forward? Afatinib as front-line therapy for patients with metastatic EGFR-mutated lung cancer. <i>Future Oncology</i> , 2014, 10, 533-540.	1.1	6
1219	Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1379-1388.	5.1	119
1220	Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer. <i>Lung Cancer</i> , 2014, 85, 401-407.	0.9	31
1221	A phase II trial evaluating the clinical and immunologic response of HLA-A2+ non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide. <i>Lung Cancer</i> , 2014, 86, 59-66.	0.9	50
1222	Kinetic and mechanistic studies of 1,3-bis(2-pyridylimino)isoindolate Pt( $\text{II}$ ) derivatives. Experimental and new computational approach. <i>Dalton Transactions</i> , 2014, 43, 2549-2558.	1.6	25
1223	Immune Checkpoint Inhibitors in NSCLC. <i>Current Treatment Options in Oncology</i> , 2014, 15, 658-669.	1.3	64
1224	Oral Anticancer Drugs: How Limited Dosing Options and Dose Reductions May Affect Outcomes in Comparative Trials and Efficacy in Patients. <i>Journal of Clinical Oncology</i> , 2014, 32, 1620-1629.	0.8	60
1225	Molecular Characterization May Be of PARAMOUNT Importance. <i>Journal of Clinical Oncology</i> , 2014, 32, 481-482.	0.8	2
1226	Risk of Incremental Toxicities and Associated Costs of New Anticancer Drugs: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2014, 32, 3634-3642.	0.8	64
1227	Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study. <i>Lung Cancer</i> , 2014, 85, 415-419.	0.9	18
1228	PARAMOUNT Trial: Reopening a Window to Maintenance Therapy. <i>Journal of Clinical Oncology</i> , 2014, 32, 480-481.	0.8	2
1229	A Novel of Biodegradable Implants Based on PLGA for Control Delivery of Cisplatin. <i>International Journal of Polymeric Materials and Polymeric Biomaterials</i> , 2014, 63, 368-373.	1.8	4
1230	Shifting Patterns in the Interpretation of Phase III Clinical Trial Outcomes in Advanced Non-Small-Cell Lung Cancer: The Bar Is Dropping. <i>Journal of Clinical Oncology</i> , 2014, 32, 1407-1411.	0.8	44
1231	Update on systemic therapy of advanced non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1189-1203.	1.1	31
1232	Reality Check for Pemetrexed and Maintenance Therapy in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 482-483.	0.8	10
1233	Bevacizumab combined with pemetrexed plus cisplatin followed by maintenance bevacizumab/pemetrexed as first-line treatment of advanced non-squamous non-small cell lung cancer: A single-arm Phase 2 study. <i>Lung Cancer</i> , 2014, 86, 47-53.	0.9	0
1234	Reply to S. Barni et al, K.R. Dearing et al, and N. Murray. <i>Journal of Clinical Oncology</i> , 2014, 32, 483-485.	0.8	1

#	ARTICLE	IF	CITATIONS
1235	American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes. <i>Journal of Clinical Oncology</i> , 2014, 32, 1277-1280.	0.8	354
1236	First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial. <i>European Journal of Cancer</i> , 2014, 50, 2219-2230.	1.3	44
1237	Progression-free survival as an end-point in solid tumours – Perspectives from clinical trials and clinical practice. <i>European Journal of Cancer</i> , 2014, 50, 2303-2308.	1.3	32
1238	Digital differentiation of non-small cell carcinomas of the lung by the fractal dimension of their epithelial architecture. <i>Micron</i> , 2014, 67, 125-131.	1.1	13
1239	Difficult Decisions in Thoracic Surgery. <i>Difficult Decisions in Surgery: an Evidence-based Approach</i> , 2014, , .	0.0	3
1240	Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials. <i>Lung Cancer</i> , 2014, 85, 408-414.	0.9	19
1241	Introduction. <i>Seminars in Oncology Nursing</i> , 2014, 30, 137-138.	0.7	0
1242	Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin. <i>Cell</i> , 2014, 158, 929-944.	13.5	1,242
1243	nab-Paclitaxel for the Treatment of Advanced Squamous Non-Small-Cell Lung Cancer: A Comprehensive Update. <i>Clinical Lung Cancer</i> , 2014, 15, 391-397.	1.1	11
1244	Resistance to Chemotherapy: Patient Variability and Cellular Heterogeneity. <i>Cancer Research</i> , 2014, 74, 4663-4670.	0.4	54
1245	Development and cross-validation of prognostic models to assess the treatment effect of cisplatin/pemetrexed chemotherapy in lung adenocarcinoma patients. <i>Medical Oncology</i> , 2014, 31, 59.	1.2	14
1246	Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy. <i>Medical Oncology</i> , 2014, 31, 88.	1.2	15
1247	LMO1 is a novel oncogene in lung cancer, and its overexpression is a new predictive marker for anti-EGFR therapy. <i>Medical Oncology</i> , 2014, 31, 99.	1.2	11
1248	Lung Cancer in Older Adults. <i>Current Geriatrics Reports</i> , 2014, 3, 166-174.	1.1	0
1249	Radiation dose and survival of patients with stage IV non-small cell lung cancer undergoing concurrent chemotherapy and thoracic three-dimensional radiotherapy: reanalysis of the findings of a single-center prospective study. <i>BMC Cancer</i> , 2014, 14, 491.	1.1	11
1250	Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease. <i>BMC Cancer</i> , 2014, 14, 508.	1.1	41
1251	Prognosis of non-small cell lung cancer patients with bone oligometastases treated concurrently with thoracic three-dimensional radiotherapy and chemotherapy. <i>Radiation Oncology</i> , 2014, 9, 147.	1.2	5
1252	Combination of stereotactic ablative body radiation with targeted therapies. <i>Lancet Oncology</i> , The, 2014, 15, e426-e434.	5.1	32

#	ARTICLE	IF	CITATIONS
1253	Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 1217-1225.	1.1	32
1254	Treatment of the postoperative recurrence of lung cancer in octogenarians. <i>Surgery Today</i> , 2014, 44, 1626-1632.	0.7	4
1255	Preclinical analyses and phase I evaluation of LY2603618 administered in combination with Pemetrexed and cisplatin in patients with advanced cancer. <i>Investigational New Drugs</i> , 2014, 32, 955-968.	1.2	55
1256	Immunotherapy for lung cancer: ongoing clinical trials. <i>Future Oncology</i> , 2014, 10, 91-105.	1.1	27
1257	Accuracy of fine needle aspiration and core lung biopsies to predict histology in patients with non-small cell lung cancer. <i>Medical Oncology</i> , 2014, 31, 967.	1.2	2
1258	Safety and efficacy of first-line bevacizumab combination therapy in Chinese population with advanced non-squamous NSCLC: data of subgroup analyses from MO19390 (SAIL) study. <i>Clinical and Translational Oncology</i> , 2014, 16, 463-468.	1.2	18
1259	Reevaluation of survival and prognostic factors in pathologic stage I lung adenocarcinoma by the new 2009 TNM classification. <i>Tumor Biology</i> , 2014, 35, 5905-5910.	0.8	13
1260	Valutazione economica in base allo studio NAVOTRIAL01 con riferimento al contesto sanitario italiano: Vinorelbine orale e Cisplatino o Pemetrexed e Cisplatino seguiti da mantenimento rispettivamente con Vinorelbine orale e Pemetrexed nel trattamento del Carcinoma Polmonare Non a Piccole Cellule Non Squamoso (NS-NSCLC) in stadio avanzato. <i>Pharmacoeconomics Italian Research Articles</i> , 2014, 16, 1.	0.2	2
1261	The pemetrexed-containing treatments in the non-small cell lung cancer, is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-analysis. <i>BMC Cancer</i> , 2014, 14, 205.	1.1	29
1262	Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer. <i>BMC Cancer</i> , 2014, 14, 290.	1.1	46
1263	Thymidylate synthase polymorphisms in genomic DNA as clinical outcome predictors in a European population of advanced non-small cell lung cancer patients receiving pemetrexed. <i>Journal of Translational Medicine</i> , 2014, 12, 98.	1.8	13
1264	Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients. <i>Respiratory Investigation</i> , 2014, 52, 101-106.	0.9	6
1265	Customized Adjuvant Phase II Trial in Patients With Non-Small-Cell Lung Cancer: IFCT-0801 TASTE. <i>Journal of Clinical Oncology</i> , 2014, 32, 1256-1261.	0.8	66
1266	Understanding lung cancer molecular subtypes. <i>Clinical Practice (London, England)</i> , 2014, 11, 441-453.	0.1	2
1267	Treatment algorithm in 2014 for advanced non-small cell lung cancer: Therapy selection by tumour histology and molecular biology. <i>Advances in Medical Sciences</i> , 2014, 59, 308-313.	0.9	21
1268	New Strategies in Lung Cancer: Epigenetic Therapy for Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 2244-2248.	3.2	54
1269	Prospective phase II study of cisplatin plus pemetrexed with maintenance of pemetrexed for advanced non-squamous cell non-small cell lung cancer in Japan. <i>Thoracic Cancer</i> , 2014, 5, 289-296.	0.8	2
1270	Pathology in drug discovery and development. <i>Journal of Pathology</i> , 2014, 232, 99-102.	2.1	12

#	ARTICLE	IF	CITATIONS
1272	Oral Vinorelbine Plus Cisplatin as First-Line Chemotherapy in Nonsquamous Non-“Small-Cell Lung Cancer: Final Results of an International Randomized Phase II Study (NAVotrial 01). <i>Clinical Lung Cancer</i> , 2014, 15, 258-265.	1.1	19
1273	Molecular testing in oncology: Problems, pitfalls and progress. <i>Lung Cancer</i> , 2014, 83, 309-315.	0.9	23
1274	Down-regulation of MSH2 expression by an Hsp90 inhibitor enhances pemetrexed-induced cytotoxicity in human non-small-cell lung cancer cells. <i>Experimental Cell Research</i> , 2014, 322, 345-354.	1.2	19
1275	Subtype-specific KRAS mutations in advanced lung adenocarcinoma: A retrospective study of patients treated with platinum-based chemotherapy. <i>European Journal of Cancer</i> , 2014, 50, 1819-1828.	1.3	68
1276	Treatment of Advanced Non-“Small-Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation or ALK Gene Rearrangement: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. <i>Clinical Lung Cancer</i> , 2014, 15, 173-181.	1.1	56
1277	Prolonged Survival of Patients With Non-“Small-Cell Lung Cancer With Leptomeningeal Carcinomatosis in the Modern Treatment Era. <i>Clinical Lung Cancer</i> , 2014, 15, 202-206.	1.1	68
1278	Self-assembled nanoscale coordination polymers with trigger release properties for effective anticancer therapy. <i>Nature Communications</i> , 2014, 5, 4182.	5.8	205
1279	Pharmacogenetics of pemetrexed combination therapy in lung cancer: pathway analysis reveals novel toxicity associations. <i>Pharmacogenomics Journal</i> , 2014, 14, 411-417.	0.9	16
1280	Bevacizumab in Non-small Cell Lung Cancer: An Overview of Practice in the Era of Molecular Testing. <i>Clinical Oncology</i> , 2014, 26, 468-472.	0.6	3
1281	Nuclear distribution of claudin-2 increases cell proliferation in human lung adenocarcinoma cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2014, 1843, 2079-2088.	1.9	70
1282	Afatinib in the treatment of EGFR mutation-positive NSCLC -“ A network meta-analysis. <i>Lung Cancer</i> , 2014, 85, 230-238.	0.9	47
1283	Assessment of Folate Receptor-1 and Epidermal Growth Factor Receptor Expression in Pemetrexed-Treated Non-“Small-Cell Lung Cancer Patients. <i>Clinical Lung Cancer</i> , 2014, 15, 320-330.e3.	1.1	14
1286	First-Line Chemotherapy Treatment of Advanced Non-“Small-Cell Lung Cancer: Does Cisplatin versus Carboplatin Make a Difference?. <i>Journal of Thoracic Oncology</i> , 2014, 9, e82.	0.5	4
1287	Assessment of DDR2, BRAF, EGFR and KRAS mutations as therapeutic targets in non-adenocarcinoma lung cancer patients. <i>Molecular and Clinical Oncology</i> , 2014, 2, 714-718.	0.4	10
1288	Chemotherapy for newly diagnosed inoperable brain metastases from non-small cell lung cancer. <i>The Cochrane Library</i> , 0, , .	1.5	0
1289	Advances in the Treatment of Non-Small Cell Lung Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 764-767.	2.3	13
1290	Systemic and Targeted Therapies for Early-Stage Lung Cancer. <i>Cancer Control</i> , 2014, 21, 21-31.	0.7	22
1291	Ramucirumab: a promising development in advanced non-small cell lung cancer. <i>Clinical Investigation</i> , 2014, 4, 969-977.	0.0	0

#	ARTICLE	IF	CITATIONS
1295	Learning curve for endobronchial ultrasound-guided transbronchial needle aspiration: Experience of a community-based teaching hospital. <i>Molecular Medicine Reports</i> , 2014, 10, 2441-2446.	1.1	2
1296	Pemetrexed in non-small-cell lung cancer. <i>Lung Cancer Management</i> , 2014, 3, 273-285.	1.5	1
1297	Enhanced apoptosis by pemetrexed and simvastatin in malignant mesothelioma and lung cancer cells by reactive oxygen species-dependent mitochondrial dysfunction and Bim induction. <i>International Journal of Oncology</i> , 2014, 45, 1769-1777.	1.4	20
1298	The role of autophagy induced by pemetrexed in lung adenocarcinoma cells. <i>Oncology Reports</i> , 2014, 31, 2365-2370.	1.2	9
1299	Circulating Endothelial Cells as a Biomarker in Non-Small Cell Lung Cancer Patients: Correlation with Clinical Outcome. <i>International Journal of Biological Markers</i> , 2014, 29, 337-344.	0.7	12
1300	A Prospective Phase I/II Study: Combination Chemotherapy with Docetaxel and Pemetrexed as Second-Line Treatment in Patients with Stage IIIB/IV Non-Small Cell Lung Cancer. <i>Case Reports in Oncology</i> , 2014, 7, 435-443.	0.3	5
1302	Quality of Care of Patients with Non-Small-Cell Lung Cancer: A Report of a Performance Improvement Initiative. <i>Cancer Control</i> , 2014, 21, 90-97.	0.7	6
1303	Early-stage non-small-cell lung cancer: overview of adjuvant chemotherapy and promising advances. <i>Lung Cancer Management</i> , 2014, 3, 85-99.	1.5	0
1304	Looking backwards to move forward: a review of randomized lung cancer treatment trials to inform future research. <i>Clinical Investigation</i> , 2014, 4, 415-428.	0.0	0
1305	Downregulation of both EGFR and ErbB3 improves the cellular response to pemetrexed in an established pemetrexed-resistant lung adenocarcinoma A549 cell line. <i>Oncology Reports</i> , 2014, 31, 1818-1824.	1.2	12
1306	The Pemetrexed-Containing Treatments in the Non-small Cell Lung Cancer, Is -/Low Thymidylate Synthase Expression Better than +/High Thymidylate Synthase Expression? A Meta-analysis. <i>Chest</i> , 2014, 145, 349A.	0.4	0
1307	Effect of nitric oxide synthase on multiple drug resistance is related to Wnt signaling in non-small cell lung cancer. <i>Oncology Reports</i> , 2014, 32, 1703-1708.	1.2	18
1308	Activity of pemetrexed-based regimen as first-line chemotherapy for advanced non-small cell lung cancer with asymptomatic inoperable brain metastasis: a retrospective study. <i>Journal of Chemotherapy</i> , 2015, 27, 221-226.	0.7	9
1309	Spontaneous regression of non-small cell lung cancer that progressed after multiple chemotherapies: A case report. <i>Thoracic Cancer</i> , 2015, 6, 805-807.	0.8	7
1310	Synergistic interaction between MEK inhibitor and gefitinib in EGFR-TKI-resistant human lung cancer cells. <i>Oncology Letters</i> , 2015, 10, 2652-2656.	0.8	16
1311	Prognostic significance of PIK3CA and SOX2 in Asian patients with lung squamous cell carcinoma. <i>International Journal of Oncology</i> , 2015, 46, 505-512.	1.4	12
1312	FAM83B is a novel biomarker for diagnosis and prognosis of lung squamous cell carcinoma. <i>International Journal of Oncology</i> , 2015, 46, 999-1006.	1.4	47
1313	Risk Factors for Predicting Severe Neutropenia Induced by Pemetrexed Plus Carboplatin Therapy in Patients with Advanced Non-small Cell Lung Cancer. <i>Biological and Pharmaceutical Bulletin</i> , 2015, 38, 1192-1198.	0.6	18

#	ARTICLE	IF	CITATIONS
1314	Pemetrexed-Induced Rash May Be Prevented by Supplementary Corticosteroids. <i>Biological and Pharmaceutical Bulletin</i> , 2015, 38, 1752-1756.	0.6	11
1315	Non-small-cell lung cancer. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15048.	18.1	11
1316	The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1523-1531.	0.5	15
1317	Evaluation of tumour vaccine immunotherapy for the treatment of advanced non-small cell lung cancer: a systematic meta-analysis. <i>BMJ Open</i> , 2015, 5, e006321-e006321.	0.8	6
1318	Feasibility of cisplatin/pemetrexed with 15 mg/kg bevacizumab for the treatment of patients with advanced non-squamous non-small cell lung cancer. <i>Oncology Letters</i> , 2015, 9, 2577-2582.	0.8	3
1319	Expressions of Thyroid Transcription Factor-1, Napsin A, p40, p63, CK5/6 and Desmocollin-3 in Non-Small Cell Lung Cancer, as Revealed by Imprint Cytology Using a Malinol-Based Cell-Transfer Technique. <i>Acta Cytologica</i> , 2015, 59, 457-464.	0.7	6
1320	Medical Oncology Principles for the Spine Oncology Surgeon. , 2015, , .		0
1321	SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015. <i>Clinical and Translational Oncology</i> , 2015, 17, 1020-1029.	1.2	43
1322	microRNA-30b inhibits cell invasion and migration through targeting collagen triple helix repeat containing 1 in non-small cell lung cancer. <i>Cancer Cell International</i> , 2015, 15, 85.	1.8	31
1324	Educational Outcomes in the Era of the Affordable Care Act: Impact of Personalized Education about Non-Small Cell Lung Cancer. <i>Journal of Continuing Education in the Health Professions</i> , 2015, 35, S5-S12.	0.4	2
1325	Erlotinib Plus Capecitabine as First-Line Treatment for Older Chinese Patients With Advanced Adenocarcinoma of the Lung (C-TONG0807). <i>Medicine (United States)</i> , 2015, 94, e249.	0.4	2
1326	Reevaluation and Reclassification of Resected Lung Carcinomas Originally Diagnosed as Squamous Cell Carcinoma Using Immunohistochemical Analysis. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1170-1180.	2.1	61
1327	Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer. <i>BMC Pulmonary Medicine</i> , 2015, 15, 132.	0.8	19
1328	Study on expression of lncRNA RCMB-AS1 and repulsive guidance molecule b in non-small cell lung cancer. <i>Diagnostic Pathology</i> , 2015, 10, 63.	0.9	23
1329	Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib. <i>Cancer</i> , 2015, 121, 3212-3220.	2.0	160
1330	Advances in EGFR as a Predictive Marker in Lung Adenocarcinoma. <i>Cancer Control</i> , 2015, 22, 193-199.	0.7	23
1331	Anterior Gradient 2 is Correlated with EGFR Mutation in Lung Adenocarcinoma Tissues. <i>International Journal of Biological Markers</i> , 2015, 30, 234-242.	0.7	4
1332	Lung cancer Presenting as a Metastasis to the Tibial Bones: A Case Report. <i>Tumori</i> , 2015, 101, e18-e20.	0.6	3

#	ARTICLE	IF	CITATIONS
1333	Management of cancer of the lung. , 0, , 413-426.		0
1334	Defining the issues in the treatment of elderly patients with advanced non-small-cell lung cancer. Lung Cancer Management, 2015, 4, 17-30.	1.5	0
1335	Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated?. Cancer, 2015, 121, 2562-2569.	2.0	71
1336	Chemotherapy for Advanced-Stage Non-small Cell Lung Cancer. Cancer Journal (Sudbury, Mass ), 2015, 21, 366-370.	1.0	47
1337	The Evolution of Therapies in Non-Small Cell Lung Cancer. Cancers, 2015, 7, 1815-1846.	1.7	107
1338	Widespread Renal Polycystosis Induced by Crizotinib. Tumori, 2015, 101, e128-e131.	0.6	5
1339	Advanced squamous lung carcinoma in a patient experiencing long-term survival following repeated responses to gemcitabine and cisplatin chemotherapy: A case report. Oncology Letters, 2015, 9, 2874-2878.	0.8	1
1340	TERT Polymorphism rs2853669 Influences on Lung Cancer Risk in the Korean Population. Journal of Korean Medical Science, 2015, 30, 1423.	1.1	23
1341	Kinase Inhibitors or Docetaxel in Second-Line Treatment of EGFR Wild-Type Non-small-Cell Lung Cancer: A Retrospective Real-World Practice Review at a Single Tertiary Care Centre. Current Oncology, 2015, 22, 157-163.	0.9	6
1342	Histologic Classification of Non-Small-Cell Lung Cancer over Time: Reducing the Rates of Not-Otherwise-Specified. Current Oncology, 2015, 22, 164-170.	0.9	28
1343	The distinctive nature of adenocarcinoma of the lung. OncoTargets and Therapy, 2015, 8, 2399.	1.0	16
1344	Clinical and biological significance of erlotinib therapy after pemetrexed in non-small cell lung cancer with wild-type EGFR. Neoplasma, 2015, 62, 996-1004.	0.7	2
1345	Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR. Pharmacogenomics and Personalized Medicine, 2015, 8, 63.	0.4	24
1346	Diagnosing Lung Cancer in the 21st Century: Are We Ready to Meet the Challenge of Individualized Care?. Current Oncology, 2015, 22, 272-278.	0.9	8
1347	A current review of folate receptor alpha as a potential tumor target in non-small-cell lung cancer. Drug Design, Development and Therapy, 2015, 9, 4989.	2.0	57
1348	Ready or Not? Lung Cancer Diagnosis in 2015. Current Oncology, 2015, 22, 239-242.	0.9	2
1349	Plasma homocysteine levels and hematological toxicity in NSCLC patients after the first cycle of pemetrexed under folate supplementation. Anti-Cancer Drugs, 2015, 26, 573-578.	0.7	5
1350	Squamous Non-small Cell Lung Cancer as a Distinct Clinical Entity. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 220-226.	0.6	25



#	ARTICLE	IF	CITATIONS
1351	Medical management of lung cancer: Experience in China. <i>Thoracic Cancer</i> , 2015, 6, 10-16.	0.8	37
1352	Current and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptors. <i>Future Oncology</i> , 2015, 11, 865-878.	1.1	15
1353	Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 763-774.	5.1	431
1354	Non-small-cell lung cancer. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15009.	18.1	653
1355	Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity. <i>Archives of Toxicology</i> , 2015, 89, 1227-1240.	1.9	42
1357	A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial. <i>Annals of Oncology</i> , 2015, 26, 1401-1408.	0.6	77
1358	Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non-Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses. <i>Journal of Clinical Oncology</i> , 2015, 33, 1008-1014.	0.8	179
1359	Comparisons of the clinicopathological features and survival outcomes between lung cancer patients with adenocarcinoma and squamous cell carcinoma. <i>General Thoracic and Cardiovascular Surgery</i> , 2015, 63, 507-513.	0.4	43
1360	Prognostic Value of Malic Enzyme and ATP-Citrate Lyase in Non-Small Cell Lung Cancer of the Young and the Elderly. <i>PLoS ONE</i> , 2015, 10, e0126357.	1.1	33
1361	Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung. <i>Future Oncology</i> , 2015, 11, 2175-2191.	1.1	5
1362	Necitumumab for non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1231-1239.	1.4	14
1363	Développement des adénocarcinomes bronchopulmonaires : le point de vue du pathologiste. <i>Revue Des Maladies Respiratoires Actualites</i> , 2015, 7, 290-305.	0.0	0
1364	Estimated Creatinine Clearance Rate Is Associated With the Treatment Effectiveness and Toxicity of Pemetrexed As Continuation Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2015, 16, e131-e140.	1.1	10
1365	Radiation therapy (RT) and chemotherapy (CHT) in stage II non-small cell lung cancer (NSCLC): Clinical entity neglected by radiation oncologists?. <i>Lung Cancer</i> , 2015, 90, 622-623.	0.9	0
1366	The Efficacy and Safety of Chemotherapy in Patients With Nonsmall Cell Lung Cancer and Interstitial Lung Disease. <i>Medicine (United States)</i> , 2015, 94, e1451.	0.4	23
1367	Use of pemetrexed for non-small cell lung cancer in the Andalusian public health system. <i>Journal of Chemotherapy</i> , 2015, 27, 371-377.	0.7	1
1368	Cost-effectiveness of first-line induction and maintenance treatment sequences in non-squamous non-small cell lung cancer (NSCLC) in the U.S.. <i>Lung Cancer</i> , 2015, 89, 294-300.	0.9	18
1370	Therapeutic options in advanced squamous cell lung carcinoma. <i>Lung Cancer Management</i> , 2015, 4, 75-86.	1.5	0

#	ARTICLE	IF	CITATIONS
1371	Traitement de 1re ligne des cancers bronchopulmonaires non Ā petites cellules de stade IV en l'absence d'addiction oncogĀ©nique. <i>Revue Des Maladies Respiratoires Actualites</i> , 2015, 7, 404-413.	0.0	0
1372	Curcumin-induced downregulation of Axl receptor tyrosine kinase inhibits cell proliferation and circumvents chemoresistance in non-small lung cancer cells. <i>International Journal of Oncology</i> , 2015, 47, 2296-2303.	1.4	37
1373	Maslinic acid potentiates the antitumor activities of gemcitabine in vitro and in vivo by inhibiting NF-ĀB-mediated survival signaling pathways in human gallbladder cancer cells. <i>Oncology Reports</i> , 2015, 33, 1683-1690.	1.2	17
1374	Pemetrexed induces apoptosis in malignant mesothelioma and lung cancer cells through activation of reactive oxygen species and inhibition of sirtuin 1. <i>Oncology Reports</i> , 2015, 33, 2411-2419.	1.2	21
1375	Second-line combination therapies in nonsmall cell lung cancer without known driver mutations. <i>European Respiratory Review</i> , 2015, 24, 582-593.	3.0	22
1376	Dose Escalation and Pharmacokinetic Study of Carboplatin plus Pemetrexed for Elderly Patients with Advanced Nonsquamous Non-Small-Cell Lung Cancer: Kumamoto Thoracic Oncology Study Group Trial 1002. <i>Oncology</i> , 2015, 88, 201-207.	0.9	9
1377	Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer. <i>Supportive Care in Cancer</i> , 2015, 23, 1699-1708.	1.0	129
1378	Developing biomarker-specific end points in lung cancer clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 135-146.	12.5	43
1379	Comparative Effectiveness of First-Line Platinum-Based Chemotherapy Regimens for Advanced Lung Squamous Cell Carcinoma. <i>Clinical Lung Cancer</i> , 2015, 16, 137-143.	1.1	14
1380	Emerging drugs for squamous cell lung cancer. <i>Expert Opinion on Emerging Drugs</i> , 2015, 20, 149-160.	1.0	18
1381	Microwave ablation plus chemotherapy improved progression-free survival of advanced non-small cell lung cancer compared to chemotherapy alone. <i>Medical Oncology</i> , 2015, 32, 464.	1.2	36
1382	Mechanisms of and strategies for overcoming resistance to anti-vascular endothelial growth factor therapy in non-small cell lung cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1855, 193-201.	3.3	11
1383	Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer. <i>Lung Cancer</i> , 2015, 87, 176-185.	0.9	51
1384	Longitudinal analysis of 2293 NSCLC patients: A comprehensive study from the TYROL registry. <i>Lung Cancer</i> , 2015, 87, 193-200.	0.9	115
1385	Phase 2, randomized, openĀlabel study of ramucirumab in combination with firstĀline pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic nonĀsmall cell lung cancer. <i>Cancer</i> , 2015, 121, 883-892.	2.0	58
1386	Downregulation of MTSS1 expression is an independent prognosticator in squamous cell carcinoma of the lung. <i>British Journal of Cancer</i> , 2015, 112, 866-873.	2.9	24
1387	Image-derived biomarkers and multimodal imaging strategies for lung cancer management. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 634-643.	3.3	20
1388	Predictive and prognostic value of circulating endothelial cells in non-small cell lung cancer patients treated with standard chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 119-125.	1.2	19

#	ARTICLE	IF	CITATIONS
1389	Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis. <i>Future Oncology</i> , 2015, 11, 409-420.	1.1	34
1390	Is fourth-line chemotherapy routine practice in advanced non-small cell lung cancer?. <i>Lung Cancer</i> , 2015, 87, 155-161.	0.9	8
1391	A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer. <i>Annals of Oncology</i> , 2015, 26, 762-768.	0.6	75
1392	A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer. <i>Thorax</i> , 2015, 70, 359-367.	2.7	104
1393	What is the best strategy for targeting EGF receptors in non-small-cell lung cancer?. <i>Future Oncology</i> , 2015, 11, 153-167.	1.1	22
1394	Postoperative Radiotherapy for Pathologic N2 Non-Small-Cell Lung Cancer Treated With Adjuvant Chemotherapy: A Review of the National Cancer Data Base. <i>Journal of Clinical Oncology</i> , 2015, 33, 870-876.	0.8	219
1395	Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: A systematic review of completed and ongoing studies. <i>Lung Cancer</i> , 2015, 87, 232-240.	0.9	23
1396	The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC). <i>Tumor Biology</i> , 2015, 36, 2491-2499.	0.8	7
1397	Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements. <i>Clinical Lung Cancer</i> , 2015, 16, e83-e89.	1.1	40
1398	Complex Decisions for First-Line and Maintenance Treatment of Advanced Wild-Type Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2015, 20, 299-306.	1.9	11
1399	Low immunogenicity in non-small cell lung cancer; do new developments and novel treatments have a role?. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 129-144.	2.7	11
1400	Concurrent paclitaxel-based chemo-radiotherapy for post-surgical microscopic residual tumor at the bronchial margin (R1 resection) in non-small-cell lung cancer. <i>BMC Cancer</i> , 2015, 15, 36.	1.1	7
1401	Phase II study of carboplatin, docetaxel and bevacizumab for chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer. <i>International Journal of Clinical Oncology</i> , 2015, 20, 659-667.	1.0	2
1402	A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2015, 26, 354-362.	0.6	132
1403	Cisplatin/Pemetrexed Followed by Maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab Followed by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 262-273.	1.9	54
1404	Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study. <i>Lung Cancer</i> , 2015, 88, 215-222.	0.9	58
1405	Cancer Stem Cells Sensitivity Assay (STELLA) in Patients with Advanced Lung and Colorectal Cancer: A Feasibility Study. <i>PLoS ONE</i> , 2015, 10, e0125037.	1.1	9
1406	Pemetrexed in maintenance treatment of advanced non-squamous non-small-cell lung cancer. <i>Lung Cancer: Targets and Therapy</i> , 2015, 6, 13.	1.3	8

#	ARTICLE	IF	CITATIONS
1407	The Treatment of Metastatic Non-Small Cell Lung Cancer in a New Era of Personalized Medicine. <i>Frontiers in Oncology</i> , 2015, 5, 20.	1.3	2
1408	Modern Treatments in Advanced Non-Small-Cell Lung Cancer: Temporal Trends and Effect on Survival. A French Population-Based Study. <i>Clinical Lung Cancer</i> , 2015, 16, 496-506.	1.1	3
1409	American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. <i>Journal of Clinical Oncology</i> , 2015, 33, 2563-2577.	0.8	783
1410	Evaluation of a "Watch and Wait" Approach for Chemotherapy in Patients with Newly Diagnosed Advanced Non-small Cell Lung Cancer from a Diverse Community Population. <i>Clinical Oncology</i> , 2015, 27, 505-513.	0.6	4
1411	Definitive dose thoracic radiation therapy in oligometastatic non-small cell lung cancer: A hypothesis-generating study. <i>Practical Radiation Oncology</i> , 2015, 5, e355-e363.	1.1	18
1412	Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR -mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer. <i>Lung Cancer</i> , 2015, 89, 301-305.	0.9	14
1413	CHAMP: A Phase II Study of Panitumumab With Pemetrexed and Cisplatin Versus Pemetrexed and Cisplatin in the Treatment of Patients With Advanced-Stage Primary Nonsquamous Non-Small-Cell Lung Cancer With Particular Regard to the KRAS Status. <i>Clinical Lung Cancer</i> , 2015, 16, 447-456.	1.1	12
1414	Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 213-227.	2.0	51
1415	Prevalence and risk factors of brain metastases in patients with newly diagnosed advanced non-small-cell lung cancer. <i>Cancer Treatment Communications</i> , 2015, 4, 106-112.	0.4	6
1416	Achieving a tissue diagnosis in PS3 patients with advanced lung cancer: What are the safety and diagnostic outcomes with EBUS?. <i>Lung Cancer</i> , 2015, 88, 236-237.	0.9	1
1417	Glucocorticoid Signaling. <i>Advances in Experimental Medicine and Biology</i> , 2015, , .	0.8	15
1418	Glucocorticoids and Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2015, 872, 315-333.	0.8	154
1419	Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 2450-2456.	0.8	61
1420	Epigenetic Therapy in Lung Cancer and Mesothelioma. , 2015, , 189-213.		4
1421	Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib, Erlotinib, Afatinib, Dacomitinib, and Icotinib in the Treatment of Non-Small-Cell Lung Cancer: A Systematic Review. <i>Current Oncology</i> , 2015, 22, 183-215.	0.9	59
1422	Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1245-1253.	0.9	45
1423	Carboplatin-Pemetrexed in Treatment of Patients with Recurrent/Metastatic Cancers of the Head and Neck; Superior Outcomes in Oropharyngeal Primaries. <i>Frontiers in Oncology</i> , 2014, 4, 362.	1.3	2
1424	Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients. <i>Lung Cancer</i> , 2015, 88, 319-324.	0.9	5

#	ARTICLE	IF	CITATIONS
1426	Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study (KCSG 10-17). <i>British Journal of Cancer</i> , 2015, 112, 260-265.	2.9	9
1427	Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer. <i>Molecular Aspects of Medicine</i> , 2015, 45, 55-66.	2.7	26
1428	Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2015, 88, 160-166.	0.9	12
1429	Systematic qualitative review of randomised trials conducted in nonsmall cell lung cancer with a noninferiority or equivalence design. <i>European Respiratory Journal</i> , 2015, 45, 511-524.	3.1	6
1430	5-Fluorouracil preferentially sensitizes mutant KRAS non-small cell lung carcinoma cells to TRAIL-induced apoptosis. <i>Molecular Oncology</i> , 2015, 9, 1815-1824.	2.1	20
1431	Best practice in the treatment of advanced squamous cell lung cancer. <i>Therapeutic Advances in Respiratory Disease</i> , 2015, 9, 224-235.	1.0	14
1432	Stereotactic Body Radiotherapy for Oligometastatic Disease. <i>Clinical Oncology</i> , 2015, 27, 290-297.	0.6	27
1433	Factors Influencing the Diagnostic Accuracy of Identifying the Histologic Type of Non-Small-Lung Cancer With Small Samples. <i>Clinical Lung Cancer</i> , 2015, 16, 374-378.	1.1	5
1434	Large cell carcinoma of the lung: A tumor in search of an author. A clinically oriented critical reappraisal. <i>Lung Cancer</i> , 2015, 87, 226-231.	0.9	39
1435	Maintenance chemotherapy in advanced NSCLC: A population-based assessment of eligibility. <i>Lung Cancer</i> , 2015, 87, 296-302.	0.9	2
1436	Prognostic Factors for Survival After Recurrence in Patients With Completely Resected Lung Adenocarcinoma: Important Roles of Epidermal Growth Factor Receptor Mutation Status and the Current Staging System. <i>Clinical Lung Cancer</i> , 2015, 16, e213-e221.	1.1	18
1438	Pemetrexed-based chemotherapy in advanced lung adenocarcinoma patients with different EGFR genotypes. <i>Tumor Biology</i> , 2015, 36, 861-869.	0.8	8
1439	Bevacizumab in combination with anticancer drugs for previously treated advanced non-small cell lung cancer. <i>Tumor Biology</i> , 2015, 36, 1323-1327.	0.8	8
1440	Effect of thymidylate synthase gene polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer patients. <i>Tumor Biology</i> , 2015, 36, 7151-7157.	0.8	3
1441	Addressing the unmet need in lung cancer: The potential of immuno-oncology. <i>Cancer Treatment Reviews</i> , 2015, 41, 465-475.	3.4	30
1442	Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. <i>Clinical Lung Cancer</i> , 2015, 16, 358-365.	1.1	14
1443	Refining the treatment of NSCLC according to histological and molecular subtypes. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 511-526.	12.5	247
1444	Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics. <i>Clinical Cancer Research</i> , 2015, 21, 2236-2243.	3.2	147

#	ARTICLE	IF	CITATIONS
1445	Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2015, 9, 255-268.	1.0	24
1447	Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. <i>Lancet Oncology</i> , The, 2015, 16, 328-337.	5.1	124
1448	Superiority of Concomitant Chemoradiation Over Sequential Chemoradiation in Inoperable, Locally Advanced Non-Small Cell Lung Cancer: Challenges in the Selection of Appropriate Chemotherapy. <i>Seminars in Radiation Oncology</i> , 2015, 25, 122-132.	1.0	7
1449	Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer. <i>European Respiratory Journal</i> , 2015, 46, 219-229.	3.1	14
1450	Targeting of MEK in lung cancer therapeutics. <i>Lancet Respiratory Medicine</i> , the, 2015, 3, 319-327.	5.2	40
1451	FGFR as potential target in the treatment of squamous non small cell lung cancer. <i>Cancer Treatment Reviews</i> , 2015, 41, 527-539.	3.4	55
1452	KRAS Mutation as the Biomarker of Response to Chemotherapy and EGFR-TKIs in Patients With Advanced Non-Small Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 33-40.	0.6	39
1453	Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. <i>Lancet Oncology</i> , The, 2015, 16, e165-e172.	5.1	685
1454	Cost-Effectiveness of Multiplexed Predictive Biomarker Screening in Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 586-594.	0.5	35
1455	Semiautomatic Determination of Arterial Input Functions for Quantitative Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Non-Small Cell Lung Cancer Patients. <i>Investigative Radiology</i> , 2015, 50, 129-134.	3.5	4
1456	Associations of Blood Pressure With Common Factors Among Left-Behind Farmers in Rural China. <i>Medicine (United States)</i> , 2015, 94, e142.	0.4	10
1457	PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients with Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 134-142.	0.5	145
1458	Full-dose pemetrexed plus cisplatin combined with concurrent thoracic radiotherapy for previously untreated advanced nonsquamous non-small cell lung cancer. <i>Anti-Cancer Drugs</i> , 2015, 26, 456-463.	0.7	6
1459	Management of Metastatic Cervical Cancer: Should We Ignore Lessons Learned From Treating Other Advanced Squamous Cell Cancers?. <i>Journal of Clinical Oncology</i> , 2015, 33, 965-966.	0.8	2
1460	Quality of Life Analyses from the Randomized, Open-Label, Phase III PointBreak Study of Pemetrexed-Carboplatin-Bevacizumab followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 353-359.	0.5	22
1461	Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , 2015, 27, 94-101.	1.1	126
1462	Improvement in Lung Cancer Outcomes With Targeted Therapies: An Update for Family Physicians. <i>Journal of the American Board of Family Medicine</i> , 2015, 28, 124-133.	0.8	28
1463	Determinants of the activities of antifolates delivered into cells by folate-receptor-mediated endocytosis. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 1163-1173.	1.1	7

#	ARTICLE	IF	CITATIONS
1464	Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (<sc>NSCLC</sc>). <i>Respirology</i> , 2015, 20, 370-378.	1.3	119
1465	Adjuvant Epidermal Growth Factor Receptor Inhibitors in Non-small Cell Lung Cancer. <i>Oncologist</i> , 2015, 20, 975-978.	1.9	4
1466	Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1630-1638.	5.1	75
1467	Nedaplatin: a new platinum for squamous lung cancer?. <i>Lancet Oncology</i> , The, 2015, 16, 1573-1574.	5.1	5
1468	Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations. <i>Oncologist</i> , 2015, 20, 1175-1181.	1.9	26
1469	<sc>miR</sc>â€138 inhibits proliferation by targeting 3â€phosphoinositideâ€dependent protein kinaseâ€1 in non-small cell lung cancer cells. <i>Clinical Respiratory Journal</i> , 2015, 9, 27-33.	0.6	63
1470	Pharmacogenomics in the treatment of lung cancer: an update. <i>Pharmacogenomics</i> , 2015, 16, 1751-1760.	0.6	6
1471	Take-home message in times of crisis: Is it really better to treat with cisplatin & pemetrexed than cisplatin & gemcitabine in first line NSCLC? The power of statistical considerations. <i>Lung Cancer</i> , 2015, 90, 620-622.	0.9	1
1472	Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis. <i>British Journal of Cancer</i> , 2015, 113, 1519-1528.	2.9	94
1473	A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). <i>Annals of Oncology</i> , 2015, 26, 1547-1573.	0.6	635
1474	Diagnostic challenges in non-small-cell lung cancer: an integrated medicine approach. <i>Future Oncology</i> , 2015, 11, 489-500.	1.1	20
1475	Necitumumab in Metastatic Squamous Cell Lung Cancer. <i>JAMA Oncology</i> , 2015, 1, 1293.	3.4	43
1476	Systemic Therapy for Stage IV Non-small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2015, 33, 3488-3515.	0.8	606
1477	Locally Advanced Non-Small Cell Lung Cancer: Optimal Chemotherapeutic Agents and Duration. <i>Current Treatment Options in Oncology</i> , 2015, 16, 47.	1.3	6
1478	Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer. <i>Lung Cancer</i> , 2015, 90, 71-77.	0.9	29
1479	Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs. <i>Lung Cancer</i> , 2015, 90, 261-266.	0.9	4
1480	The evolving role of radiotherapy in treatment of oligometastatic NSCLC. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1459-1471.	1.1	8
1481	Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non-small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2015, 16, 366-373.	1.1	23

#	ARTICLE	IF	CITATIONS
1482	Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-“Small-Cell Lung Cancers. <i>Clinical Lung Cancer</i> , 2015, 16, 514-522.	1.1	10
1483	Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance. <i>Drug Resistance Updates</i> , 2015, 23, 20-54.	6.5	57
1484	In Reply. <i>Oncologist</i> , 2015, 20, e22.	1.9	0
1485	Radiation therapy for oligometastatic non-small cell lung cancer. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 183-193.	2.7	12
1486	Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 121-128.	1.1	2
1487	Attenuation of the DNA Damage Response by Transforming Growth Factor-Beta Inhibitors Enhances Radiation Sensitivity of Non-“Small-Cell Lung Cancer Cells In-Vitro and In-Vivo. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 91-99.	0.4	40
1488	Meta-analysis of Epidermal Growth Factor Receptor and KRAS Gene Status between Primary and Corresponding Metastatic Tumours of Non-small Cell Lung Cancer. <i>Clinical Oncology</i> , 2015, 27, 30-39.	0.6	25
1489	Pemetrexed in patients with thymic malignancies previously treated with chemotherapy. <i>Lung Cancer</i> , 2015, 87, 34-38.	0.9	27
1490	Albumin nanocapsules containing fenretinide: pre-clinical evaluation of cytotoxic activity in experimental models of human non-small cell lung cancer. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 263-273.	1.7	23
1491	The prevalence of <scp>EGFR</scp> mutations in non-“small cell lung cancer in an unselected Caucasian population. <i>Apmis</i> , 2015, 123, 108-115.	0.9	55
1492	ATF2 contributes to cisplatin resistance in non-“small cell lung cancer and celastrol induces cisplatin resensitization through inhibition of JNK/ATF2 pathway. <i>International Journal of Cancer</i> , 2015, 136, 2598-2609.	2.3	45
1493	Combinatorial immunotherapy of sorafenib and blockade of programmed death-ligand 1 induces effective natural killer cell responses against hepatocellular carcinoma. <i>Tumor Biology</i> , 2015, 36, 1561-1566.	0.8	22
1495	Some considerations about the value based pricing in oncology: an analysis on metastatic first line medicinal products. <i>Global &amp; Regional Health Technology Assessment</i> , 2016, 3, 9-15.	0.2	1
1496	Immunotherapy for Non-Small Cell Lung Cancer - Finally a Hint of Hope. <i>Reviews on Recent Clinical Trials</i> , 2016, 11, 87-92.	0.4	3
1497	Prognostic significance of thymidylate synthase (TS) expression in cutaneous malignant melanoma. <i>Neoplasma</i> , 2016, 63, 282-7.	0.7	1
1498	Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives. <i>Lung Cancer: Targets and Therapy</i> , 2016, 7, 83.	1.3	6
1499	Cytotoxic Chemotherapy as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer in Taiwan: Daily Practice. <i>Journal of Cancer</i> , 2016, 7, 1515-1523.	1.2	9
1500	Efficacy of pemetrexed-based regimen in relapsed advanced thymic epithelial tumors and its association with thymidylate synthase level. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 4527-4531.	1.0	5



#	ARTICLE	IF	CITATIONS
1501	Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer. <i>OncoTargets and Therapy</i> , 2016, 9, 3187.	1.0	11
1502	New targeted treatments for non-small-cell lung cancer &ndash; role of nivolumab. <i>Biologics: Targets and Therapy</i> , 2016, Volume 10, 103-117.	3.0	23
1503	Efficacy of cisplatin/pemetrexed with bevacizumab to treat advanced lung adenocarcinoma with different drive genes: case report and literature review. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 4639-4644.	1.0	6
1504	Real-world hospital costs for nonchemotherapy drugs and nondrug care associated with platinum-based doublets in the first-line setting for advanced nonsquamous non-small-cell lung cancer in Chinese patients: a retrospective cohort study. <i>ClinicoEconomics and Outcomes Research</i> , 2016, 8, 97.	0.7	1
1505	Prognostic effect of liver metastasis in lung cancer patients with distant metastasis. <i>Oncotarget</i> , 2016, 7, 53245-53253.	0.8	120
1506	Dynamic Assessment of Value During High-Cost Cancer Treatment: A Response to American Society of Clinical Oncology and European Society of Medical Oncology. <i>Journal of Oncology Practice</i> , 2016, 12, 1215-1218.	2.5	2
1507	A potential new therapeutic option for patients with advanced EGFR mutation-positive non-small cell lung cancer in first-line setting. <i>Journal of Thoracic Disease</i> , 2016, 8, E1520-E1524.	0.6	0
1508	Pembrolizumab as first-line treatment for non-small cell lung cancer&rdquo;a game changer?. <i>Translational Lung Cancer Research</i> , 2016, 5, 538-542.	1.3	4
1509	State of the art of chemotherapy for the treatment of central nervous system metastases from non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2016, 5, 599-609.	1.3	20
1510	Metastatic lung cancer in the age of targeted therapy: improving long-term survival. <i>Translational Lung Cancer Research</i> , 2016, 5, 727-730.	1.3	14
1511	Current advances of endobronchial ultrasonography in the diagnosis and staging of lung cancer. <i>Journal of Thoracic Disease</i> , 2016, 8, S690-S696.	0.6	8
1512	A phase I trial of an oral subtype-selective histone deacetylase inhibitor, chidamide, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2016, 28, 444-451.	0.7	24
1513	An 8-gene signature for prediction of prognosis and chemoresponse in non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 86561-86572.	0.8	32
1514	Improving survival of patients with locally advanced non-small-cell cancer remains a challenge: comment to PROCLAIM. <i>Journal of Thoracic Disease</i> , 2016, 8, E607-E610.	0.6	2
1515	The role of surgical intervention in lung cancer with carcinomatous pleuritis. <i>Journal of Thoracic Disease</i> , 2016, 8, S901-S907.	0.6	10
1516	Synergistic effects of sorafenib in combination with gemcitabine or pemetrexed in lung cancer cell lines with K-ras mutations. <i>Wspolczesna Onkologia</i> , 2016, 1, 33-38.	0.7	8
1517	Lobaplatin for the treatment of SK-MES-1 lung squamous cell line in vitro and in vivo. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 4215-4224.	1.0	20
1518	Efficacy of pemetrexed plus platinum doublet chemotherapy as first-line treatment for advanced nonsquamous non-small-cell-lung cancer: a systematic review and meta-analysis. <i>OncoTargets and Therapy</i> , 2016, 9, 1471.	1.0	16

#	ARTICLE	IF	CITATIONS
1519	Exploratory Study to Identify Radiomics Classifiers for Lung Cancer Histology. <i>Frontiers in Oncology</i> , 2016, 6, 71.	1.3	306
1520	Recent Advances in Immunotherapy in Metastatic NSCLC. <i>Frontiers in Oncology</i> , 2016, 6, 239.	1.3	29
1521	Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression. <i>PLoS ONE</i> , 2016, 11, e0154293.	1.1	11
1522	Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based chemotherapy after developing resistance to the first-line gefitinib treatment. <i>OncoTargets and Therapy</i> , 2016, 9, 1579.	1.0	22
1523	Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far. <i>Therapeutics and Clinical Risk Management</i> , 2016, 12, 807.	0.9	10
1524	Cost-effectiveness analysis of pemetrexed and gemcitabine treatment for advanced nonsmall cell lung cancer in Turkey. <i>Turkish Journal of Medical Sciences</i> , 2016, 46, 152-158.	0.4	5
1525	Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting. <i>Annals of Translational Medicine</i> , 2016, 4, 268-268.	0.7	16
1526	Novel cytotoxic drugs in advanced nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , 2016, 28, 110-114.	1.1	11
1527	Dose-Escalation Study of Thoracic Radiotherapy in Combination With Pemetrexed Plus Cisplatin in Japanese Patients With Locally Advanced Nonsquamous Non-Small Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 132-135.	0.6	2
1528	Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with <i>FGFR1</i> amplification: A single-arm, phase 2 study. <i>Cancer</i> , 2016, 122, 3024-3031.	2.0	72
1529	Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2016, 99, 31-37.	0.9	31
1530	Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2969-2979.	0.8	397
1531	Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2980-2987.	0.8	444
1532	Napsin A/p40 antibody cocktail for subtyping non-small cell lung carcinoma on cytology and small biopsy specimens. <i>Cancer Cytopathology</i> , 2016, 124, 472-484.	1.4	11
1533	The Efficacy of Single-Agent Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Biologically Selected Patients with Non-Small-Cell Lung Cancer: A Meta-Analysis of 19 Randomized Controlled Trials. <i>Chemotherapy</i> , 2016, 61, 179-189.	0.8	5
1534	First-line treatment of nonsquamous NSCLC using gemcitabine: a retrospective study of real-life practice. <i>Lung Cancer Management</i> , 2016, 5, 123-130.	1.5	3
1535	A phase I study of nedaplatin, pemetrexed and thoracic intensity-modulated radiotherapy for inoperable stage III lung adenocarcinoma. <i>BMC Cancer</i> , 2016, 16, 775.	1.1	2
1536	Primary pulmonary adenocarcinoma in a 16-year-old boy – a five-year follow-up. <i>European Clinical Respiratory Journal</i> , 2016, 3, 32633.	0.7	3

#	ARTICLE	IF	CITATIONS
1537	Establishment of a first-line second-line treatment model for human pulmonary adenocarcinoma. <i>Oncology Letters</i> , 2016, 12, 4461-4466.	0.8	3
1538	Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed. <i>BMC Cancer</i> , 2016, 16, 417.	1.1	17
1539	First-Line Treatment with Bevacizumab and Platinum Doublet Combination in Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study in US Oncology Community Practices. <i>Drugs - Real World Outcomes</i> , 2016, 3, 333-343.	0.7	14
1540	Doublet chemotherapy with cisplatin and pemetrexed is associated with a favorable outcome in patients with advanced non-squamous non-small-cell lung cancer who are eligible for bevacizumab and maintenance therapy. <i>Molecular and Clinical Oncology</i> , 2016, 5, 575-578.	0.4	7
1541	MicroRNA-profiles in lung adenocarcinomas. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 469-474.	0.4	0
1542	<i>FGFR</i> gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib. <i>Cancer Science</i> , 2016, 107, 1667-1676.	1.7	31
1543	Feasibility study of first-line chemotherapy using Pemetrexed and Bevacizumab for advanced or recurrent nonsquamous non-small cell lung cancer in elderly patients: TORG1015. <i>BMC Cancer</i> , 2016, 16, 306.	1.1	6
1544	Les cancers bronchiques non À petites cellules de stade IV Hors addiction oncogÃ©nique : 1 re ligne et maintenance. <i>Revue Des Maladies Respiratoires Actualites</i> , 2016, 8, 351-360.	0.0	2
1545	SOX2 suppresses CDKN1A to sustain growth of lung squamous cell carcinoma. <i>Scientific Reports</i> , 2016, 6, 20113.	1.6	32
1546	Bevacizumab, pemetrexed and carboplatin in first-line treatment of non-small cell lung cancer patients: Focus on patients with brain metastases. <i>Oncology Letters</i> , 2016, 12, 4635-4642.	0.8	16
1547	Evaluation of plasma microRNA levels to predict insensitivity of patients with advanced lung adenocarcinomas to pemetrexed and platinum. <i>Oncology Letters</i> , 2016, 12, 4829-4837.	0.8	17
1548	Safety profiles of first-line therapies for metastatic non-squamous non-small-cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 837-851.	1.0	14
1549	Assessment of chemotherapy strategy using bevacizumab for non-squamous non-small cell lung cancer in a real-world setting: A multi-institutional observational study. <i>Cancer Treatment Communications</i> , 2016, 5, 1-10.	0.4	1
1550	Pemetrexed-Induced Nephrogenic Diabetes Insipidus. <i>American Journal of Kidney Diseases</i> , 2016, 68, 628-632.	2.1	6
1551	Relationship between efficacy outcomes and weight gain during treatment of advanced, non-squamous, non-small-cell lung cancer patients. <i>Annals of Oncology</i> , 2016, 27, 1612-1619.	0.6	30
1552	Epidermal Growth Factor Receptor Activating Mutations in Squamous Histology of Lung Cancer Patients of Southern Bulgaria. <i>Folia Medica</i> , 2016, 57, 191-199.	0.2	2
1553	Progression-Free Survival, Response Rate, and Disease Control Rate as Predictors of Overall Survival in Phase III Randomized Controlled Trials Evaluating the First-Line Chemotherapy for Advanced, Locally Advanced, and Recurrent Non-Small Cell Lung Carcinoma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1574-1585.	0.5	22
1554	Targeting PD-L1 for non-small-cell lung cancer. <i>Immunotherapy</i> , 2016, 8, 747-758.	1.0	12

#	ARTICLE	IF	CITATIONS
1555	Pneumothorax with prolonged chest tube requirement after CT-guided percutaneous lung biopsy: incidence and risk factors. <i>European Radiology</i> , 2016, 26, 3483-3491.	2.3	30
1556	Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence. <i>Therapeutic Advances in Respiratory Disease</i> , 2016, 10, 256-264.	1.0	17
1557	Impaired c-Met Receptor Degradation Mediated by <i>MET</i> Exon 14 Mutations in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 879-881.	0.8	48
1558	A phase II, open-label trial of bortezomib (VELCADE®) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 949-956.	1.1	14
1559	Management of lung cancer. <i>Medicine</i> , 2016, 44, 244-248.	0.2	2
1560	Depletion of BIS sensitizes A549 cells to treatment with cisplatin. <i>Molecular and Cellular Toxicology</i> , 2016, 12, 63-71.	0.8	17
1561	Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2016, 11, 890-899.	0.5	4
1562	Chemotherapy for Advanced Non-small Cell Lung Cancer. <i>Cancer Treatment and Research</i> , 2016, 170, 119-149.	0.2	18
1563	USP7 promotes cell proliferation through the stabilization of Ki-67 protein in non-small cell lung cancer cells. <i>International Journal of Biochemistry and Cell Biology</i> , 2016, 79, 209-221.	1.2	49
1564	YL4073 is a potent autophagy-stimulating antitumor agent in an in vivo model of Lewis lung carcinoma. <i>Oncology Reports</i> , 2016, 35, 2081-2088.	1.2	4
1565	Sumario ejecutivo de las recomendaciones SEPAR de diagnóstico y tratamiento del cáncer de pulmón de células no pequeñas. <i>Archivos De Bronconeumología</i> , 2016, 52, 378-388.	0.4	20
1566	Targeting Neovasculature with Multitargeted Antiangiogenesis Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer. <i>BioDrugs</i> , 2016, 30, 421-439.	2.2	9
1567	Transcriptomic response of yeast cells to ATX1 deletion under different copper levels. <i>BMC Genomics</i> , 2016, 17, 489.	1.2	12
1568	The role of docetaxel in the treatment of non-small cell lung cancer lung cancer: an update. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 1229-1241.	1.0	9
1569	The safety and efficacy of ramucirumab in combination with docetaxel in the treatment of lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 1119-1129.	1.1	2
1570	The predictive value of endobronchial ultrasonography with a guide sheath in the diagnosis of the histologic subtypes of lung cancer. <i>Respiratory Investigation</i> , 2016, 54, 473-478.	0.9	3
1571	Immunotherapy for Lung Cancer: No Longer an Abstract Concept. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2016, 37, 771-782.	0.8	12
1572	Predictive and Prognostic Biomarkers in Non-Small Cell Lung Cancer. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2016, 37, 760-770.	0.8	50

#	ARTICLE	IF	CITATIONS
1573	Bone-targeted therapy use in patients with bone metastases from lung cancer: A systematic review of randomized controlled trials. <i>Cancer Treatment Reviews</i> , 2016, 50, 183-193.	3.4	39
1574	Efficacy of platinum-based combination chemotherapy in advanced lung adenocarcinoma harboring sensitive epidermal growth factor receptor (EGFR) mutations with acquired resistance to first-line EGFR tyrosine kinase inhibitor (TKI). <i>Cancer Treatment and Research Communications</i> , 2016, 9, 48-55.	0.7	7
1575	Phase II study of a novel taxane (Cabazitaxel-XRP 6258) in previously treated advanced non-small cell lung cancer (NSCLC) patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 509-515.	1.1	2
1576	Overweight and obesity predict better overall survival rates in cancer patients with distant metastases. <i>Cancer Medicine</i> , 2016, 5, 665-675.	1.3	70
1577	Is there a progression-free survival benefit of first-line crizotinib versus standard chemotherapy and second-line crizotinib in <i>ALK</i> -positive advanced lung adenocarcinoma? A retrospective study of Chinese patients. <i>Cancer Medicine</i> , 2016, 5, 1013-1021.	1.3	20
1578	Chemotherapy with gemcitabine plus cisplatin in patients with advanced thymic squamous cell carcinoma: Evaluation of efficacy and toxicity. <i>Thoracic Cancer</i> , 2016, 7, 167-172.	0.8	7
1579	Clinical effect of pemetrexed as the first-line treatment in Chinese patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer. <i>Thoracic Cancer</i> , 2016, 7, 452-458.	0.8	8
1580	Sufficiency of Single-Arm Studies to Support Registration of Targeted Agents in Molecularly Selected Patients with Cancer: Lessons from the Clinical Development of Crizotinib. <i>Clinical and Translational Science</i> , 2016, 9, 63-73.	1.5	14
1581	Serum protein profiles of patients with lung cancer of different histological types. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 70-76.	0.7	3
1582	Health-related quality of life after first-line anti-cancer treatments for advanced non-small cell lung cancer in clinical practice. <i>Quality of Life Research</i> , 2016, 25, 1441-1449.	1.5	15
1583	Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape. <i>Annals of Oncology</i> , 2016, 27, 2004-2016.	0.6	93
1584	Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2066-2081.	0.5	49
1585	Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. <i>Lancet, The</i> , 2016, 388, 1002-1011.	6.3	132
1586	Patients with <i>ROS</i> 1 rearrangement-positive non-small-cell lung cancer benefit from pemetrexed-based chemotherapy. <i>Cancer Medicine</i> , 2016, 5, 2688-2693.	1.3	35
1587	Multimodality Therapy for NSCLC. <i>Cancer Treatment and Research</i> , 2016, 170, 151-163.	0.2	6
1588	Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery. <i>Clinical Lung Cancer</i> , 2016, 17, 550-557.	1.1	9
1589	Lansoprazole Exacerbates Pemetrexed-Mediated Hematologic Toxicity by Competitive Inhibition of Renal Basolateral Human Organic Anion Transporter 3. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1543-1549.	1.7	26
1590	Stratified Treatment in Lung Cancer. <i>Oncology Research and Treatment</i> , 2016, 39, 760-766.	0.8	13

#	ARTICLE	IF	CITATIONS
1591	The safety of afatinib for the treatment of non-small cell lung cancer. Expert Opinion on Drug Safety, 2016, 15, 1563-1572.	1.0	15
1592	Non-“Small Cell Lung Cancer. , 2016, , 809-842.e8.		0
1593	The impact of immunohistochemistry on the classification of lung tumors. Expert Review of Respiratory Medicine, 2016, 10, 1105-1121.	1.0	16
1594	Smoking History as a Predictor of Pemetrexed Monotherapy in Patients with Non-Squamous Non-Small Cell Lung Cancer. Oncology, 2016, 91, 41-47.	0.9	10
1595	Novel therapeutic targets on the horizon for lung cancer. Lancet Oncology, The, 2016, 17, e347-e362.	5.1	156
1596	Recomendaciones SEPAR de diagnóstico y tratamiento del cáncer de pulmón de células no pequeñas. Archivos De Bronconeumología, 2016, 52, 2-62.	0.4	12
1597	Biweekly Carboplatin Plus Gemcitabine as First-Line Treatment of Elderly Patients With Advanced Squamous Non-“Small-cell Lung Cancer: A Multicenter Phase III Trial by the Hellenic Oncology Research Group. Clinical Lung Cancer, 2016, 17, 543-549.	1.1	10
1598	Impact of the oncogenic status on the mode of recurrence in resected non-small cell lung cancer. Japanese Journal of Clinical Oncology, 2016, 46, 928-934.	0.6	10
1599	Recomendaciones SEPAR de diagnóstico y tratamiento del cáncer de pulmón de células no pequeñas. Archivos De Bronconeumología, 2016, 52, 2-62.	0.4	25
1600	Risk factors for serious adverse events due to cytotoxic chemotherapy for advanced non-small cell lung cancer. Cancer Treatment and Research Communications, 2016, 9, 106-110.	0.7	1
1601	Therapy for EGFR tyrosine kinase inhibitor-resistant NSCLC with a focus on the T790M-resistant mutation. Memo - Magazine of European Medical Oncology, 2016, 9, 187-190.	0.3	0
1602	The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna. ESMO Open, 2016, 1, e000066.	2.0	17
1603	FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer. World Journal of Surgical Oncology, 2016, 14, 238.	0.8	25
1604	Clinicopathologic characteristics, genetic variability and therapeutic options of RET rearrangements patients in lung adenocarcinoma. Lung Cancer, 2016, 101, 16-21.	0.9	32
1605	Targeting the KRAS Pathway in Non-Small Cell Lung Cancer. Oncologist, 2016, 21, 1450-1460.	1.9	101
1606	ZNF32 contributes to the induction of multidrug resistance by regulating TGF-β <sup>2</sup> receptor 2 signaling in lung adenocarcinoma. Cell Death and Disease, 2016, 7, e2428-e2428.	2.7	17
1607	A folylpoly-β <sup>3</sup> -glutamate synthase single nucleotide polymorphism associated with response to pemetrexed treatment combined with platinum for non-small cell lung cancer. Lung Cancer, 2016, 102, 15-20.	0.9	13
1608	Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study. Annals of Oncology, 2016, 27, 2242-2250.	0.6	84

#	ARTICLE	IF	CITATIONS
1609	Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial. Lung Cancer, 2016, 102, 65-73.	0.9	76
1610	Is the Chemotherapy Era in Advanced Non-Small Cell Lung Cancer Really Over? Maybe not Yet. Tumori, 2016, 102, 223-225.	0.6	7
1611	Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2016, 27, v1-v27.	0.6	1,351
1612	Thresholding of a Continuous Companion Diagnostic Test Confident of Efficacy in Targeted Population. Statistics in Biopharmaceutical Research, 2016, 8, 325-333.	0.6	4
1613	Metastatic non-small cell lung cancer. Nurse Practitioner, 2016, 41, 1-5.	0.2	0
1614	The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC). Medicine (United States), 2016, 95, 1-14.	0.7	14
1615	The role of Napsin-A and Desmocollin-3 in classifying poorly differentiating non-small cell lung carcinoma. Journal of the Egyptian National Cancer Institute, 2016, 28, 13-22.	0.6	5
1616	Clinicopathologic Features of Advanced Squamous NSCLC. Journal of Thoracic Oncology, 2016, 11, 1411-1422.	0.5	101
1617	Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG). Cancer Chemotherapy and Pharmacology, 2016, 78, 369-376.	1.1	8
1618	Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other Platinum-Based Doublet Regimens in Elderly East Asian Patients With Advanced Nonsquamous Non-small-Cell Lung Cancer. Clinical Lung Cancer, 2016, 17, e103-e112.	1.1	11
1619	Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes. Therapeutic Advances in Medical Oncology, 2016, 8, 198-208.	1.4	46
1620	Induction Chemotherapy. , 2016, , .		3
1621	Management of Resistance to Crizotinib in Anaplastic Lymphoma Kinase-Positive Non-small-Cell Lung Cancer. Clinical Lung Cancer, 2016, 17, 474-482.	1.1	19
1622	Palliative systemic therapy for advanced non-small cell lung cancer: Investigating disparities between patients who are treated versus those who are not. Lung Cancer, 2016, 97, 15-21.	0.9	39
1623	Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations. Journal of Thoracic Oncology, 2016, 11, 1140-1152.	0.5	64
1624	Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer. BMC Cancer, 2016, 16, 210.	1.1	26
1625	Executive Summary of the SEPAR Recommendations for the Diagnosis and Treatment of Non-small Cell Lung Cancer. Archivos De Bronconeumologia, 2016, 52, 378-388.	0.4	17
1626	Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers. Lung Cancer, 2016, 99, 53-56.	0.9	45

#	ARTICLE	IF	CITATIONS
1627	Continuation maintenance therapy with S-1 in chemotherapy-naïve patients with advanced squamous cell lung cancer. <i>Investigational New Drugs</i> , 2016, 34, 490-496.	1.2	8
1628	Adjuvant Therapy for Stage I and II Non-Small Cell Lung Cancer. <i>Surgical Oncology Clinics of North America</i> , 2016, 25, 585-599.	0.6	11
1629	Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium. <i>Cancer</i> , 2016, 122, 766-772.	2.0	92
1630	Cytomorphology is often insufficient to categorize non-small cell lung carcinoma on FNA specimens. <i>Diagnostic Cytopathology</i> , 2016, 44, 73-79.	0.5	4
1631	Changing trends in diagnosis, staging, treatment and survival in lung cancer: comparison of three consecutive cohorts in an Australian lung cancer centre. <i>Internal Medicine Journal</i> , 2016, 46, 946-954.	0.5	14
1632	Effect of renal function on pemetrexed-induced haematotoxicity. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 183-189.	1.1	9
1633	Evidence-based practice in times of drug shortage. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 566-570.	0.5	7
1634	Adjuvant therapy following surgery in non-small cell lung cancer (NSCLC). <i>Surgery Today</i> , 2016, 46, 25-37.	0.7	30
1636	Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review). <i>International Journal of Oncology</i> , 2016, 48, 13-27.	1.4	23
1637	Radiographic patterns and survival of patients with early and late brain metastases in EGFR wild type and mutant non small cell lung cancer. <i>Journal of Neuro-Oncology</i> , 2016, 127, 525-533.	1.4	11
1638	On the pharmacogenetics of non-small cell lung cancer treatment. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 307-317.	1.5	27
1639	Prevention of lung cancer recurrence using cisplatin-loaded superhydrophobic nanofiber meshes. <i>Biomaterials</i> , 2016, 76, 273-281.	5.7	105
1640	Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study). <i>Journal of Thoracic Oncology</i> , 2016, 11, 85-93.	0.5	26
1641	The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial. <i>Journal of Thoracic Oncology</i> , 2016, 11, 808-818.	0.5	20
1642	Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas. <i>Cancer Investigation</i> , 2016, 34, 57-63.	0.6	0
1643	Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung. <i>Oncologist</i> , 2016, 21, 205-213.	1.9	22
1644	Bronchoscopic Re-biopsy for Mutational Analysis of Non-small Cell Lung Cancer. <i>Lung</i> , 2016, 194, 371-378.	1.4	27
1645	Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. <i>Lancet Oncology</i> , The, 2016, 17, 452-463.	5.1	418



#	ARTICLE	IF	CITATIONS
1646	Pemetrexed and interstitial lung disease. <i>Acta Oncologica</i> , 2016, 55, 521-522.	0.8	3
1647	Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer. <i>Science China Life Sciences</i> , 2016, 59, 468-479.	2.3	222
1648	Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 102, 37-46.	2.0	219
1649	Adaptive Neoadjuvant Chemotherapy Guided by 18 F-FDG PET in Resectable Non-Small Cell Lung Cancers: The NEOSCAN Trial. <i>Journal of Thoracic Oncology</i> , 2016, 11, 537-544.	0.5	42
1650	Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer. <i>European Journal of Cancer</i> , 2016, 58, 30-37.	1.3	29
1651	Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis. <i>Chemotherapy</i> , 2016, 61, 41-50.	0.8	9
1652	Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes. <i>European Journal of Cancer</i> , 2016, 56, 162-171.	1.3	19
1653	Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer. <i>Cancer Treatment Reviews</i> , 2016, 44, 42-50.	3.4	296
1654	Traditional Chinese Medicine treatment as maintenance therapy in advanced non-small-cell lung cancer: A randomized controlled trial. <i>Complementary Therapies in Medicine</i> , 2016, 24, 55-62.	1.3	66
1655	Phase II Study of Concurrent Pemetrexed, Cisplatin, and Radiation Therapy for Stage IIIA/B Unresectable Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016, 17, 133-141.	1.1	10
1656	Rare cancers: a sea of opportunity. <i>Lancet Oncology</i> , The, 2016, 17, e52-e61.	5.1	76
1657	Minor Components of Micropapillary and Solid Subtypes in Lung Adenocarcinoma are Predictors of Lymph Node Metastasis and Poor Prognosis. <i>Annals of Surgical Oncology</i> , 2016, 23, 2099-2105.	0.7	108
1658	Personalized treatment of advanced non-small-cell lung cancer in routine clinical practice. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 141-150.	2.7	25
1659	Identification of haptoglobin peptide as a novel serum biomarker for lung squamous cell carcinoma by serum proteome and peptidome profiling. <i>International Journal of Oncology</i> , 2016, 48, 945-952.	1.4	26
1660	Tubulin inhibitors in non-small cell lung cancer: looking back and forward. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1113-1129.	0.9	20
1662	Claudin-18 inhibits cell proliferation and motility mediated by inhibition of phosphorylation of PDK1 and Akt in human lung adenocarcinoma A549 cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 1170-1178.	1.9	41
1663	The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 383-390.	1.1	58
1664	Long-Term Survival of a Patient With Non-Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene. <i>Clinical Lung Cancer</i> , 2016, 17, e17-e21.	1.1	11

#	ARTICLE	IF	CITATIONS
1665	Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. <i>Journal of Thoracic Oncology</i> , 2016, 11, 556-565.	0.5	268
1666	Chemotherapy Resistance in Lung Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2016, 893, 189-209.	0.8	116
1667	Gender, Sex Hormones and Respiratory Disease. <i>Respiratory Medicine</i> , 2016, , .	0.1	5
1668	A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer. <i>Medical Oncology</i> , 2016, 33, 2.	1.2	18
1669	Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development. <i>Advances in Experimental Medicine and Biology</i> , 2016, 890, 1-23.	0.8	7
1670	Results of a Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab for the Treatment of Never or Former/Light Smoking Patients With Stage IV Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016, 17, 128-132.	1.1	7
1671	Sex-Specific Differences in Lung Cancer. <i>Respiratory Medicine</i> , 2016, , 147-171.	0.1	2
1672	Personalized Therapy of Non-small Cell Lung Cancer (NSCLC). <i>Advances in Experimental Medicine and Biology</i> , 2016, 890, 203-222.	0.8	28
1673	A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 375-383.	1.1	10
1675	Overexpression of Gremlin promotes non-small cell lung cancer progression. <i>Tumor Biology</i> , 2016, 37, 2597-2602.	0.8	10
1676	The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients. <i>Pathology and Oncology Research</i> , 2016, 22, 49-56.	0.9	10
1677	Elevated expression of ASCL2 is an independent prognostic indicator in lung squamous cell carcinoma. <i>Journal of Clinical Pathology</i> , 2016, 69, 313-318.	1.0	20
1678	Pemetrexed With Platinum Combination as a Backbone for Targeted Therapy in Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016, 17, 1-9.	1.1	23
1679	Characterization of M1/M2 Tumour-Associated Macrophages (TAMs) and Th1/Th2 Cytokine Profiles in Patients with NSCLC. <i>Cancer Microenvironment</i> , 2016, 9, 1-11.	3.1	107
1680	Overexpression of Cathepsin L is associated with gefitinib resistance in non-small cell lung cancer. <i>Clinical and Translational Oncology</i> , 2016, 18, 722-727.	1.2	13
1681	Single-dose dexamethasone for the prevention of pemetrexed associated cutaneous adverse reactions. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 271-274.	0.5	9
1682	Clinical Aspects of Lung Cancer. , 2016, , 940-964.e22.		1
1683	Biology of Lung Cancer. , 2016, , 912-926.e6.		1

#	ARTICLE	IF	CITATIONS
1684	Extending the classification approach for comparing two active treatment arms to binary and time-to-event outcomes. <i>Journal of Biopharmaceutical Statistics</i> , 2017, 27, 584-594.	0.4	0
1685	Assessing the clinical outcome of nab-paclitaxel in Chinese patients with advanced non-small cell lung cancer. <i>Clinical Respiratory Journal</i> , 2017, 11, 632-639.	0.6	3
1686	Association of Graded Folic Acid Supplementation and Total Plasma Homocysteine Levels With Hematological Toxicity During First-line Treatment of Nonsquamous NSCLC Patients With Pemetrexed-based Chemotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 75-82.	0.6	26
1687	Frontline Systemic Therapy With Pemetrexed-Platinum in Nonsquamous Non-Small-Cell Lung Cancer With Asymptomatic Brain Metastases. <i>American Journal of Therapeutics</i> , 2017, 24, e111-e120.	0.5	5
1688	First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. <i>Lancet</i> , 2017, 389, 917-929.	6.3	919
1689	Developments in pharmacotherapy for treating metastatic non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 151-163.	0.9	10
1690	Randomized Phase III Study of Docetaxel Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-line Treatment of Nonsquamous Non-Small-cell Lung Cancer: A TRAIL Trial. <i>Clinical Lung Cancer</i> , 2017, 18, e289-e296.	1.1	21
1691	Pharmacological management of relapsed/refractory NSCLC with chemical drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 295-304.	0.9	12
1692	A comparison of the effects of medical Qigong and standard exercise therapy on symptoms and quality of life in patients with advanced cancer. <i>Supportive Care in Cancer</i> , 2017, 25, 1749-1758.	1.0	46
1693	Non-Small-cell Lung Cancer Patients With Adenocarcinoma Morphology Have a Better Outcome Compared With Patients Diagnosed With Non-Small-cell Lung Cancer Favor Adenocarcinoma. <i>Clinical Lung Cancer</i> , 2017, 18, 316-323.e1.	1.1	7
1694	Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. <i>Tumor Biology</i> , 2017, 39, 101042831769118.	0.8	12
1695	Percutaneous biopsy. , 2017, , 403-412.e2.		1
1696	Determination of 16 serum angiogenic factors in stage I non-small cell lung cancer using a bead-based multiplex immunoassay. <i>Biomedicine and Pharmacotherapy</i> , 2017, 88, 1031-1037.	2.5	4
1697	ERCC1 as Predictor of Platinum Benefit in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 384-386.	0.8	23
1698	Safety profiles of non-small cell lung cancer patients treated with pemetrexed plus carboplatin: a real-world retrospective, observational, cohort study. <i>Current Medical Research and Opinion</i> , 2017, 33, 931-936.	0.9	4
1699	Investigational therapies for squamous cell lung cancer: from animal studies to phase II trials. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 415-426.	1.9	5
1700	Looking back and to the future: Are we improving "cure"™ in non-small cell lung cancer?. <i>European Journal of Cancer</i> , 2017, 75, 192-194.	1.3	13
1701	Meta-analysis of pemetrexed plus carboplatin doublet safety profile in first-line non-squamous non-small cell lung cancer studies. <i>Current Medical Research and Opinion</i> , 2017, 33, 937-941.	0.9	4

#	ARTICLE	IF	CITATIONS
1702	Survival Gains from First-Line Systemic Therapy in Metastatic Non-Small Cell Lung Cancer in the U.S., 1990–2015: Progress and Opportunities. <i>Oncologist</i> , 2017, 22, 304-310.	1.9	8
1703	Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches. <i>Lung Cancer</i> , 2017, 106, 70-75.	0.9	30
1704	Long-term Outcomes of Induction Carboplatin and Gemcitabine Followed by Concurrent Radiotherapy With Low-dose Paclitaxel and Gemcitabine for Stage III Non–small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 565-571.	1.1	9
1705	Emerging challenges of advanced squamous cell lung cancer. <i>ESMO Open</i> , 2017, 2, e000129.	2.0	6
1706	Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer. <i>Targeted Oncology</i> , 2017, 12, 153-161.	1.7	31
1707	Surgical intervention for vertebral metastases may benefit lung cancer patients no less than other patients: a retrospective study. <i>Journal of Medical Case Reports</i> , 2017, 11, 4.	0.4	3
1708	Downregulation of miR-218 contributes to epithelial–mesenchymal transition and tumor metastasis in lung cancer by targeting Slug/ZEB2 signaling. <i>Oncogene</i> , 2017, 36, 2577-2588.	2.6	135
1709	Ramucirumab in the treatment of non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 637-644.	1.0	24
1712	Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy. <i>Chemotherapy</i> , 2017, 62, 205-213.	0.8	10
1713	Degradation of Mcl-1 through GSK-3 <sup>β</sup> Activation Regulates Apoptosis Induced by Bufalin in Non-Small Cell Lung Cancer H1975 Cells. <i>Cellular Physiology and Biochemistry</i> , 2017, 41, 2067-2076.	1.1	42
1714	Safety Analyses of Pemetrexed-cisplatin and Pemetrexed Maintenance Therapies in Patients With Advanced Non-squamous NSCLC: Retrospective Analyses From 2 Phase III Studies. <i>Clinical Lung Cancer</i> , 2017, 18, 489-496.	1.1	14
1715	MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1233-1246.	0.5	68
1716	Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma. <i>Scientific Reports</i> , 2017, 7, 1453.	1.6	3
1717	<i>AJRCCM</i> : 100-Year Anniversary. The Shifting Landscape for Lung Cancer: Past, Present, and Future. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1150-1160.	2.5	75
1718	Second-line therapy of squamous non-small cell lung cancer: an evolving landscape. <i>Expert Review of Respiratory Medicine</i> , 2017, 11, 469-479.	1.0	11
1719	Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma. <i>ESMO Open</i> , 2017, 2, e000168.	2.0	48
1720	Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy. <i>British Journal of Cancer</i> , 2017, 116, 36-43.	2.9	18
1721	Epidermal Growth Factor Receptor Mutated Advanced Non–Small Cell Lung Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 83-99.	0.9	10

#	ARTICLE	IF	CITATIONS
1722	First-Line Systemic Therapy for Non-Small Cell Lung Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 59-70.	0.9	9
1723	Second-Line Chemotherapy and Beyond for Non-Small Cell Lung Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 71-81.	0.9	9
1724	New Targets in Non-Small Cell Lung Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 113-129.	0.9	20
1725	Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET). <i>Journal of Clinical Oncology</i> , 2017, 35, 402-411.	0.8	54
1726	Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. <i>Lancet Oncology</i> , 2017, 18, 31-41.	5.1	845
1727	The Evolving Role of Biomarkers in Personalized Lung Cancer Therapy. <i>Respiration</i> , 2017, 93, 1-14.	1.2	7
1728	Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials. <i>JAMA Oncology</i> , 2017, 3, e171029.	3.4	70
1729	Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1499-1529.	1.2	43
1730	Prognostic value of pretreatment inflammatory biomarkers in advanced lung adenocarcinoma patients receiving first-line pemetrexed/platinum doublet. <i>Tumor Biology</i> , 2017, 39, 101042831770163.	0.8	8
1731	First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 2415-2426.	13.9	2,145
1732	Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer. <i>Oncolmmunology</i> , 2017, 6, e1339856.	2.1	8
1733	Cytoplasmic RAP1 mediates cisplatin resistance of non-small cell lung cancer. <i>Cell Death and Disease</i> , 2017, 8, e2803-e2803.	2.7	65
1734	Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors. <i>Cell Reports</i> , 2017, 19, 1669-1684.	2.9	82
1735	Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1376-1387.	0.5	39
1736	Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 504-535.	2.3	994
1737	Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy. <i>Medical Oncology</i> , 2017, 34, 121.	1.2	12
1738	Efficacy and tolerability of nanoparticle albumin-bound paclitaxel in combination with carboplatin as a late-phase chemotherapy for recurrent and advanced non-small-cell lung cancer: A multi-center study of the Fukushima lung cancer association group of surgeons. <i>Oncology Letters</i> , 2017, 13, 4315-4321.	0.8	13
1739	A Comparative Pharmacokinetic Study of 2 Pemetrexed Formulations in Indian Adult Chemonaive Patients With Adenocarcinoma Stage III/IV Non-Small Cell Lung Cancer. <i>Clinical Pharmacology in Drug Development</i> , 2017, 6, 234-239.	0.8	2

#	ARTICLE	IF	CITATIONS
1740	Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. <i>Drugs</i> , 2017, 77, 813-827.	4.9	42
1741	Immunotherapy in NSCLC: A Promising and Revolutionary Weapon. <i>Advances in Experimental Medicine and Biology</i> , 2017, 995, 97-125.	0.8	99
1742	Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?. <i>BMC Medicine</i> , 2017, 15, 55.	2.3	65
1743	Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer. <i>Handbook of Experimental Pharmacology</i> , 2017, 249, 63-89.	0.9	10
1744	Prospects and progress of atezolizumab in non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 781-789.	1.4	13
1745	Pemetrexed monotherapy for chemo-naïve elderly (aged ≥80) patients with non-squamous non-small cell lung cancer: results from combined analysis of two single arm phase II studies (HANSHIN002 and Tj ETQq1 1 01784314 regBT /Overlo	0.7	10
1746	Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas. <i>Lung Cancer</i> , 2017, 108, 205-211.	0.9	42
1747	Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2017, 35, 909-919.	1.7	5
1748	Crizotinib treatment for advanced non-small-cell lung cancer patients: a budget impact analysis based in Thailand. <i>Current Medical Research and Opinion</i> , 2017, 33, 955-961.	0.9	5
1750	Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. <i>Clinical Lung Cancer</i> , 2017, 18, 303-309.	1.1	13
1751	A Histologic Basis for the Efficacy of SBRT to the lung. <i>Journal of Thoracic Oncology</i> , 2017, 12, 510-519.	0.5	82
1752	Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 46-58.	1.4	27
1753	Karnofsky Award 2016: A Lung Cancer Journey, 1973 to 2016. <i>Journal of Clinical Oncology</i> , 2017, 35, 243-252.	0.8	19
1754	Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 104, 45-51.	0.9	9
1755	Correlation of clinicopathologic features and lung squamous cell carcinoma subtypes according to the 2015 WHO classification. <i>European Journal of Surgical Oncology</i> , 2017, 43, 2308-2314.	0.5	13
1756	Phase II study of nedaplatin and paclitaxel for patients with previously untreated advanced squamous cell lung cancer. <i>Cancer Treatment and Research Communications</i> , 2017, 13, 9-12.	0.7	1
1757	Metformin as a repurposed therapy in advanced non-small cell lung cancer (NSCLC): results of a phase II trial. <i>Investigational New Drugs</i> , 2017, 35, 813-819.	1.2	40
1758	Trends in prescribing systemic treatment and overall survival for non-small cell lung cancer stage IIIB/IV in the Netherlands: 2008-2012. <i>Cancer Epidemiology</i> , 2017, 51, 1-6.	0.8	16

#	ARTICLE	IF	CITATIONS
1759	<i>EGFR</i> -Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine: Importance of Germline <i>EGFR</i> T790M Testing. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1188-1192.	2.3	7
1760	Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer by downregulating PD-L1 and resuming immune. <i>Biomedicine and Pharmacotherapy</i> , 2017, 96, 378-383.	2.5	90
1762	Cancer: Towards a general theory of the target. <i>BioEssays</i> , 2017, 39, 1700059.	1.2	2
1763	SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting. <i>British Journal of Cancer</i> , 2017, 117, 938-946.	2.9	18
1764	First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. <i>Annals of Oncology</i> , 2017, 28, 2443-2450.	0.6	236
1765	Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence. <i>Therapeutic Advances in Respiratory Disease</i> , 2017, 11, 353-373.	1.0	28
1766	Genetic variants in ERCC1 and XPC predict survival outcome of non-small cell lung cancer patients treated with platinum-based therapy. <i>Scientific Reports</i> , 2017, 7, 10702.	1.6	12
1767	Non-small cell lung cancer PC-9 cells exhibit increased sensitivity to gemcitabine and vinorelbine upon acquiring resistance to EGFR-tyrosine kinase inhibitors. <i>Oncology Letters</i> , 2017, 14, 3559-3565.	0.8	10
1768	Expression of thymidylate synthase predicts clinical outcomes of S-1-based chemotherapy in squamous cell lung cancer. <i>Oncology Letters</i> , 2017, 14, 3319-3326.	0.8	1
1769	Metformin synergistic pemetrexed suppresses non-small cell lung cancer cell proliferation and invasion in vitro. <i>Cancer Medicine</i> , 2017, 6, 1965-1975.	1.3	19
1770	Assessment of interfering factors and clinical risk associated with discontinuation of pemetrexed maintenance therapy in advanced non-squamous non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 111, 43-50.	0.9	2
1772	MEDI 4736 (durvalumab) in non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1317-1323.	1.4	14
1773	Gemcitabine combined with cisplatin as adjuvant chemotherapy for non-small cell lung cancer: retrospective analysis. <i>Thoracic Cancer</i> , 2017, 8, 482-488.	0.8	7
1774	Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small cell lung cancer. <i>Cancer Science</i> , 2017, 108, 1843-1849.	1.7	40
1775	Significance of glucocorticoid receptor expression in patients with non-small cell lung cancer treated with pemetrexed-based chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 851-860.	1.1	2
1776	Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor ( EGFR ) mutations and anaplastic lymphoma kinase ( ALK ) translocations – Still a daily challenge. <i>European Journal of Cancer</i> , 2017, 83, 266-278.	1.3	22
1777	Genetic characterization drives personalized therapy for early-stage non-small-cell lung cancer (NSCLC) patients and survivors with metachronous second primary tumor (MST). <i>Medicine (United States)</i> , 2017, 96, 1070-1076.	0.8	10
1778	First-Line Carboplatin, Pemetrexed, and Panitumumab in Patients with Advanced Non-Squamous KRAS Wild Type (WT) Non-Small-Cell Lung Cancer (NSCLC). <i>Cancer Investigation</i> , 2017, 35, 541-546.	0.6	5

#	ARTICLE	IF	CITATIONS
1779	Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets. <i>ESMO Open</i> , 2017, 2, e000200.	2.0	31
1780	Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer. <i>Current Opinion in Oncology</i> , 2017, 29, 97-104.	1.1	37
1781	Single pemetrexed is noninferior to platinum-based pemetrexed doublet as first-line treatment on elderly Chinese patients with advanced nonsquamous nonsmall cell lung cancer. <i>Medicine (United States)</i> , 2017, 96, 107-114.	0.4	0
1782	Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial. <i>European Journal of Cancer</i> , 2017, 83, 302-312.	1.3	18
1783	Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer. <i>ESMO Open</i> , 2017, 2, e000102.	2.0	9
1784	Synthesis, characterization and molecular docking studies of thiouracil derivatives as potent thymidylate synthase inhibitors and potential anticancer agents. <i>Molecular Diversity</i> , 2017, 21, 967-983.	2.1	49
1785	Correlation between molecular analysis, diagnosis according to the 2015 WHO classification of unresected lung tumours and TTF1 expression in small biopsies and cytology specimens from 344 non-small cell lung carcinoma patients. <i>Pathology</i> , 2017, 49, 604-610.	0.3	11
1786	Impact of in vitro chemosensitivity test-guided platinum-based adjuvant chemotherapy on the surgical outcomes of patients with p-stage IIIA non-small cell lung cancer that underwent complete resection. <i>Molecular and Clinical Oncology</i> , 2017, 7, 327-335.	0.4	1
1787	Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients. <i>Lung Cancer</i> , 2017, 112, 10-15.	0.9	3
1788	Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer. <i>Lung Cancer</i> , 2017, 112, 181-187.	0.9	40
1789	Cholesterol derivative-based liposomes for gemcitabine delivery: preparation, <i>in vitro</i> , and <i>in vivo</i> characterization. <i>Drug Development and Industrial Pharmacy</i> , 2017, 43, 2016-2025.	0.9	10
1790	Personalised medicine for nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2017, 26, 170066.	3.0	37
1791	Severity and predictive factors of adverse events in pemetrexed-containing chemotherapy for non-small cell lung cancer. <i>Medical Oncology</i> , 2017, 34, 195.	1.2	7
1792	Suppression of the FA pathway combined with CHK1 inhibitor hypersensitize lung cancer cells to gemcitabine. <i>Scientific Reports</i> , 2017, 7, 15031.	1.6	10
1793	What's new in chemotherapy for non-small cell lung cancer?. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 123-126.	0.3	0
1794	Metformin in combination with cisplatin inhibits cell viability and induces apoptosis of human ovarian cancer cells by inactivating ERK 1/2. <i>Oncology Letters</i> , 2017, 14, 7557-7564.	0.8	25
1795	Application of Immunohistochemistry in the Diagnosis of Pulmonary and Pleural Neoplasms. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 1195-1213.	1.2	20
1796	Enzymes in the Base Excision Repair Pathway as Targets for Small Molecule Mediated Therapeutics. , 2017, , 663-729.		0



#	ARTICLE	IF	CITATIONS
1797	Weekly paclitaxel after first-line failure in patients with advanced non-small-cell lung cancer. <i>Anti-Cancer Drugs</i> , 2017, 28, 654-659.	0.7	2
1798	Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study. <i>Targeted Oncology</i> , 2017, 12, 475-485.	1.7	30
1799	Protein and mRNA expression of folic acid-associated enzymes as biomarkers for the cytotoxicity of the thymidylate synthase-targeted drugs, pemetrexed and S-1, in non-small cell lung cancer. <i>Molecular and Clinical Oncology</i> , 2017, 7, 15-23.	0.4	3
1800	Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens. <i>European Respiratory Review</i> , 2017, 26, 170007.	3.0	74
1801	Comprehensive treatment with Chinese medicine in patients with advanced non-small cell lung cancer: A multicenter, prospective, cohort study. <i>Chinese Journal of Integrative Medicine</i> , 2017, 23, 733-739.	0.7	17
1802	Emerging roles of <i>RAC1</i> in treating lung cancer patients. <i>Clinical Genetics</i> , 2017, 91, 520-528.	1.0	32
1803	Pretreatment Red Blood Cell Total Folate Concentration Is Associated With Response to Pemetrexed in Stage IV Nonsquamous Non-Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, e143-e149.	1.1	3
1804	Equilibrative nucleoside transporters: A review. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2017, 36, 7-30.	0.4	146
1805	Therapeutic Effects of CT-guided Radiofrequency Ablation with Concurrent Platinum-Doublet Chemotherapy in a Rabbit VX2 Lung Tumor Model. <i>Radiology</i> , 2017, 283, 391-398.	3.6	5
1806	Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG). <i>Clinical and Translational Oncology</i> , 2017, 19, 317-325.	1.2	7
1807	Treatment patterns and cost-effectiveness of first line treatment of advanced non-squamous non-small cell lung cancer in Medicare patients. <i>Journal of Medical Economics</i> , 2017, 20, 151-161.	1.0	13
1808	An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 383-389.	0.5	18
1809	Pre and post operative diagnosis of lung cancer patients: Is there a concordance?. <i>The Egyptian Journal of Chest Diseases and Tuberculosis</i> , 2017, 66, 465-469.	0.1	0
1810	Advanced non small cell lung cancer: response to microwave ablation and EGFR Status. <i>European Radiology</i> , 2017, 27, 1685-1694.	2.3	18
1811	A consensus statement on the gender perspective in lung cancer. <i>Clinical and Translational Oncology</i> , 2017, 19, 527-535.	1.2	26
1812	Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer. <i>Investigational New Drugs</i> , 2017, 35, 37-46.	1.2	26
1813	Targeting <i>EGFR</i> mutation in non-small-cell lung cancer: challenges and future perspectives. <i>Future Oncology</i> , 2017, 13, 201-204.	1.1	3
1814	Immune checkpoint inhibitors (anti PD-1 or anti PD-L1) versus chemotherapy for second- or third-line treatment of metastatic non-small cell lung cancer. <i>The Cochrane Library</i> , 2017, , .	1.5	0

#	ARTICLE	IF	CITATIONS
1815	Traitement de première ligne et de maintenance dans les CBNPC avancés en l'absence d'addiction oncogénique. <i>Revue Des Maladies Respiratoires Actualites</i> , 2017, 9, 234-247.	0.0	0
1818	Advanced squamous lung cancer: therapeutic options, future directions, unmet needs and results of a monocentric survey. <i>Lung Cancer Management</i> , 2017, 6, 93-107.	1.5	5
1819	Mandatory dexamethasone strictly monitored by pharmacists reduces the severity of pemetrexed-induced skin rash. <i>European Journal of Hospital Pharmacy</i> , 2017, 24, 283-285.	0.5	1
1820	Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma. <i>Experimental Hematology and Oncology</i> , 2017, 6, 29.	2.0	12
1821	Management of Dyspnea and Central Airway Obstruction in Patients With Malignancy. , 2017, , 101-118.		0
1822	Pathology Issues in Thoracic Oncology: Histologic Characterization and Tissue/Plasma Genotyping May Resolve Diagnostic Dilemmas. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 619-629.	1.8	4
1823	Treatment Patterns and Overall Survival Associated with First-Line Systemic Therapy for Patients with Advanced Non-Small Cell Lung Cancer. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2017, 23, 195-205.	0.5	11
1824	Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come. <i>Ecancermedicalscience</i> , 2017, 11, 787.	0.6	34
1825	Real-world usage and clinical outcomes of alectinib among post-crizotinib progression anaplastic lymphoma kinase positive non-small-cell lung cancer patients in the USA. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 75-82.	1.0	7
1826	Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) from morphology to molecular testing. <i>Journal of Thoracic Disease</i> , 2017, 9, S395-S404.	0.6	30
1827	Layer-by-layer nanoparticles co-loading gemcitabine and platinum (IV) prodrugs for synergistic combination therapy of lung cancer. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 2631-2642.	2.0	57
1828	Lung Cancer-Targeting Peptides with Multi-subtype Indication for Combinational Drug Delivery and Molecular Imaging. <i>Theranostics</i> , 2017, 7, 1612-1632.	4.6	38
1829	Licochalcone A Inhibits the Proliferation of Human Lung Cancer Cell Lines A549 and H460 by Inducing G2/M Cell Cycle Arrest and ER Stress. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1761.	1.8	69
1830	Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer. <i>Frontiers in Medicine</i> , 2017, 4, 4.	1.2	27
1831	Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib. <i>Frontiers in Medicine</i> , 2017, 4, 13.	1.2	13
1832	Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer. <i>Frontiers in Medicine</i> , 2017, 4, 39.	1.2	18
1833	The status of immunosuppression in patients with stage IIIB or IV non-small-cell lung cancer correlates with the clinical characteristics and response to chemotherapy. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3557-3566.	1.0	16
1834	65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer. <i>Lung Cancer: Targets and Therapy</i> , 2017, Volume 8, 217-229.	1.3	4

#	ARTICLE	IF	CITATIONS
1835	A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France. <i>ClinicoEconomics and Outcomes Research</i> , 2017, Volume 9, 505-518.	0.7	9
1836	Efficacy and safety of pemetrexed and nedaplatin followed by pemetrexed maintenance therapy in advanced lung adenocarcinoma. <i>Cancer Management and Research</i> , 2017, Volume 9, 671-677.	0.9	2
1837	Identification of Key Transcription Factors Associated with Lung Squamous Cell Carcinoma. <i>Medical Science Monitor</i> , 2017, 23, 172-206.	0.5	25
1838	Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3697-3708.	1.0	6
1839	Non-steroidal anti-inflammatory drugs induce severe hematologic toxicities in lung cancer patients receiving pemetrexed plus carboplatin: A retrospective cohort study. <i>PLoS ONE</i> , 2017, 12, e0171066.	1.1	16
1840	Mass spectrometry-based serum peptidome profiling accurately and reliably predicts outcomes of pemetrexed plus platinum chemotherapy in patients with advanced lung adenocarcinoma. <i>PLoS ONE</i> , 2017, 12, e0179000.	1.1	3
1841	A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506). <i>BMC Cancer</i> , 2017, 17, 462.	1.1	28
1842	Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC. <i>BMC Cancer</i> , 2017, 17, 884.	1.1	41
1843	Unusually prolonged pemetrexed cytotoxicity in a patient with a lung adenocarcinoma: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 262.	0.4	2
1844	A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer. , 2017, 5, 103.		8
1845	Renal failure during chemotherapy: renal biopsy for assessing subacute nephrotoxicity of pemetrexed. <i>BMC Cancer</i> , 2017, 17, 770.	1.1	17
1846	Risk factors of brain metastasis of lung squamous cell carcinoma: a retrospective analysis of 188 patients from single center. <i>Chinese Neurosurgical Journal</i> , 2017, 3, .	0.3	0
1847	Molecular binary classification of NSCLC: miR-375 is a potential biomarker to differentiate SQCC from ADCC in Indian NSCLC patients. <i>Applied Cancer Research</i> , 2017, 37, .	1.0	2
1848	Difference in Postsurgical Prognostic Factors between Lung Adenocarcinoma and Squamous Cell Carcinoma. <i>Annals of Thoracic and Cardiovascular Surgery</i> , 2017, 23, 291-297.	0.3	16
1849	Evaluating the Prognostic Value of ERCC1 and Thymidylate Synthase Expression and the Epidermal Growth Factor Receptor Mutation Status in Adenocarcinoma Non-Small-Cell Lung Cancer. <i>International Journal of Medical Sciences</i> , 2017, 14, 1410-1417.	1.1	5
1850	Comparative effectiveness and safety of nab-paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology setting. <i>Lung Cancer: Targets and Therapy</i> , 2017, Volume 8, 179-190.	1.3	6
1851	Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase Deficient Thoracic Cancers. <i>Journal of Clinical Oncology</i> , 2017, 35, 1778-1785.	0.8	96
1852	Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3449-3457.	0.8	311

#	ARTICLE	IF	CITATIONS
1853	Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1 "Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). <i>Journal of Clinical Oncology</i> , 2017, 35, 2781-2789.	0.8	348
1854	Dramatic response of CTNNB1 and VEGFR-2 mutant temporal bone squamous cell carcinoma to bevacizumab in combination with pemetrexed. <i>Oncotarget</i> , 2017, 8, 57898-57904.	0.8	2
1855	Downregulation of matrix metalloproteinase 14 by the antitumor miRNA, miR-150-5p, inhibits the aggressiveness of lung squamous cell carcinoma cells. <i>International Journal of Oncology</i> , 2018, 52, 913-924.	1.4	22
1856	Expression of thymidylate synthase (TS) and its prognostic significance in patients with cutaneous angiosarcoma. <i>Neoplasma</i> , 2017, 64, 916-921.	0.7	4
1857	Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexed. <i>Neoplasma</i> , 2017, 64, 605-610.	0.7	3
1858	Anti-cancer activity of dose-fractioned mPE +/∧ bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients. <i>Journal of Thoracic Disease</i> , 2017, 9, 3123-3131.	0.6	18
1859	Complete resection of the primary lesion improves survival of certain patients with stage IV non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, 5278-5287.	0.6	15
1860	Multicentric retrospective analysis of platinum+/-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A "snapshot" from clinical practice. <i>Thoracic Cancer</i> , 2018, 9, 241-252.	0.8	6
1862	Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. <i>Molecular Cancer</i> , 2018, 17, 38.	7.9	489
1863	Oral rehydration solution (OS-1) as a substitute of intravenous hydration after cisplatin administration in patients with lung cancer: a prospective multicenter trial. <i>ESMO Open</i> , 2018, 3, e000288.	2.0	10
1864	Treatment of Advanced Non-Small Cell Lung Cancer in 2018. <i>JAMA Oncology</i> , 2018, 4, 569.	3.4	82
1865	Using Radiolabeled 3-Deoxy- <sup>18</sup> F-Fluorothymidine with PET to Monitor the Effect of Dexamethasone on Non-Small Cell Lung Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1544-1550.	2.8	8
1866	Transcription factor PAX6 as a novel prognostic factor and putative tumour suppressor in non-small cell lung cancer. <i>Scientific Reports</i> , 2018, 8, 5059.	1.6	11
1867	Cost effectiveness vs. affordability in the age of immuno-oncology cancer drugs. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 351-357.	0.7	40
1869	Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591876209.	1.4	102
1870	NSCLC: State of the Art Diagnosis, Treatment, and Outcomes. <i>Current Pulmonology Reports</i> , 2018, 7, 29-41.	0.5	2
1871	Survival benefit from RetroNectin-activated cytokine-induced killer cells combined with chemotherapy in advanced EGFR wild-type lung adenocarcinoma. <i>Immunotherapy</i> , 2018, 10, 501-510.	1.0	6
1872	Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 1043-1050.	1.1	4

#	ARTICLE	IF	CITATIONS
1873	Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non-small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2. <i>Cancer</i> , 2018, 124, 1982-1991.	2.0	12
1874	Quantitative Proteomic Analysis Reveals Synaptic Dysfunction in the Amygdala of Rats Susceptible to Chronic Mild Stress. <i>Neuroscience</i> , 2018, 376, 24-39.	1.1	26
1876	Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation. <i>Radiotherapy and Oncology</i> , 2018, 126, 511-518.	0.3	18
1877	Combining chemotherapy with PD-1 blockade in NSCLC. , 2018, 186, 130-137.		97
1878	Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2018, 118, 6-12.	0.9	9
1879	Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas. <i>Cancer Cytopathology</i> , 2018, 126, 253-263.	1.4	70
1880	Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 123, 149-161.	2.0	50
1881	Is heterogeneity in stage 3 non-small cell lung cancer obscuring the potential benefits of dose-escalated concurrent chemo-radiotherapy in clinical trials?. <i>Lung Cancer</i> , 2018, 118, 139-147.	0.9	10
1882	Targeting minimal residual disease: a path to cure?. <i>Nature Reviews Cancer</i> , 2018, 18, 255-263.	12.8	106
1883	ALK-rearranged adenocarcinoma transformed to small-cell lung cancer: a new entity with specific prognosis and treatment?. <i>Personalized Medicine</i> , 2018, 15, 111-115.	0.8	21
1884	Prediction of Chemotherapeutic Efficacy in Non-small Cell Lung Cancer by Serum Metabolomic Profiling. <i>Clinical Cancer Research</i> , 2018, 24, 2100-2109.	3.2	53
1885	Metastatic Brain Disease from Non-small Cell Lung Cancer - Getting Back to the Drawing Board. <i>Clinical Oncology</i> , 2018, 30, 137-143.	0.6	1
1886	Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients. <i>Clinical and Translational Oncology</i> , 2018, 20, 1072-1079.	1.2	43
1887	The biology and management of non-small cell lung cancer. <i>Nature</i> , 2018, 553, 446-454.	13.7	2,877
1888	Chemotherapy Immunophenotypes in Non-small Cell Lung Cancer by Personalized Membrane Proteomics. <i>Proteomics - Clinical Applications</i> , 2018, 12, 1700040.	0.8	6
1889	What's happening next. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 1781-1782.	0.4	0
1890	Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 165-183.	0.5	134
1891	Changing health care costs for NSCLC, what does it mean?. <i>Lung Cancer</i> , 2018, 117, 62-63.	0.9	2

#	ARTICLE	IF	CITATIONS
1892	Influence of body mass index on the therapeutic efficacy of gemcitabine plus cisplatin and overall survival in lung squamous cell carcinoma. <i>Thoracic Cancer</i> , 2018, 9, 291-297.	0.8	5
1893	Tissue Acquisition in Patients with Suspected Lung Cancer: Techniques Available to the Pulmonologist. , 2018, , 299-312.		0
1894	Personalized Lung Cancer Treatment: A Teamwork. , 2018, , 333-348.		1
1895	A Kinetic Dearomatization Strategy for an Expedient Biomimetic Route to the Bielschowskysin Skeleton. <i>Angewandte Chemie</i> , 2018, 130, 1330-1335.	1.6	4
1896	Resolution of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) during Nivolumab therapy for non-small cell lung cancer: a case report.. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, e17-e20.	1.6	10
1897	Dynamic change of fatigue of pemetrexed maintenance treatment in the JMEN trial. <i>Lung Cancer</i> , 2018, 115, 121-126.	0.9	2
1898	Deep Convolutional Neural Networks Enable Discrimination of Heterogeneous Digital Pathology Images. <i>EBioMedicine</i> , 2018, 27, 317-328.	2.7	240
1899	CIMAvax-EGF: Toward long-term survival of advanced NSCLC. <i>Seminars in Oncology</i> , 2018, 45, 34-40.	0.8	19
1900	Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers. <i>BMC Cancer</i> , 2018, 18, 326.	1.1	42
1901	Population-based differences in the outcome and presentation of lung cancer patients based upon racial, histologic, and economic factors in all lung patients and those with metastatic disease. <i>Cancer Medicine</i> , 2018, 7, 1211-1220.	1.3	22
1902	Evaluation of calculating carboplatin dosage in carboplatin-pemetrexed therapy as the first-line therapy for Chinese patients with advanced lung adenocarcinoma. <i>Thoracic Cancer</i> , 2018, 9, 400-407.	0.8	3
1903	Recent advances in the management of lung cancer. <i>Clinical Medicine</i> , 2018, 18, s41-s46.	0.8	274
1904	Treatment Satisfaction of Patients With Advanced Non-Small-cell Lung Cancer Receiving Platinum-based Chemotherapy: Results From a Prospective Cohort Study (PERSONAL). <i>Clinical Lung Cancer</i> , 2018, 19, e503-e516.	1.1	8
1905	Pharmacokinetic/pharmacodynamic modeling of combination-chemotherapy for lung cancer. <i>Journal of Theoretical Biology</i> , 2018, 448, 38-52.	0.8	11
1906	A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3). <i>Lung Cancer</i> , 2018, 120, 27-33.	0.9	18
1907	Phase Ib Study of Baviximab With Carboplatin and Pemetrexed in Chemotherapy-Naive Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, e481-e487.	1.1	12
1908	Response to Costantini et al. - Comments on Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, e56-e57.	0.5	1
1910	A phase I/II trial of pemetrexed plus radiotherapy in elderly patients with locally advanced non-small cell lung cancer. <i>Investigational New Drugs</i> , 2018, 36, 667-673.	1.2	2

#	ARTICLE	IF	CITATIONS
1911	Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 310-320.	2.3	476
1912	Randomized Phase III Study of Cisplatin With Pemetrexed and Cisplatin With Vinorelbine for Completely Resected Nonsquamous Nonâ€“Small-Cell Lung Cancer: The JIPANG Study Protocol. Clinical Lung Cancer, 2018, 19, e1-e3.	1.1	16
1913	Pemetrexed in Nonsquamous Nonâ€“Small Cell Lung Cancer. JAMA Oncology, 2018, 4, 17.	3.4	11
1914	A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2018, 19, 27-34.	1.1	21
1915	Downregulation of DNMT3A by miR-708-5p Inhibits Lung Cancer Stem Cellâ€“like Phenotypes through Repressing Wnt/ $\beta$ -catenin Signaling. Clinical Cancer Research, 2018, 24, 1748-1760.	3.2	96
1916	Phase I study of the combination of quinacrine and erlotinib in patients with locally advanced or metastatic non small cell lung cancer. Investigational New Drugs, 2018, 36, 435-441.	1.2	15
1917	Gender-Related Differences in Lung Cancer. , 2018, , 30-45.e5.		0
1918	Frontline Systemic Therapy Options in Non-small Cell Lung Cancer. , 2018, , 418-433.e6.		0
1919	Systemic Options for Second-Line Therapy and Beyond. , 2018, , 434-447.e5.		0
1920	Maintenance Chemotherapy for Non-small Cell Lung Cancer. , 2018, , 448-465.e4.		0
1921	Pharmacogenomics in Lung Cancer. , 2018, , 466-478.e3.		0
1922	Adjuvant and Neoadjuvant Chemotherapy for Early-Stage Non-small Cell Lung Cancer. , 2018, , 512-524.e4.		0
1923	Clinical Trial Methodology in Lung Cancer. , 2018, , 620-627.e2.		1
1924	Lung cancer epigenetics: From knowledge to applications. Seminars in Cancer Biology, 2018, 51, 116-128.	4.3	202
1925	Bevacizumab in combination with different platinumâ€“based doublets in the firstâ€“line treatment for advanced nonsquamous nonâ€“smallâ€“cell lung cancer: A network metaâ€“analysis. International Journal of Cancer, 2018, 142, 1676-1688.	2.3	8
1926	Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer. Immunotherapy, 2018, 10, 93-105.	1.0	86
1927	Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC. Targeted Oncology, 2018, 13, 89-98.	1.7	63
1928	A Kinetic Dearomatization Strategy for an Expedient Biomimetic Route to the Bielschowskysin Skeleton. Angewandte Chemie - International Edition, 2018, 57, 1316-1321.	7.2	17

#	ARTICLE	IF	CITATIONS
1929	Exposure to genotoxic compounds alters <i>in vitro</i> cellular VOC excretion. <i>Journal of Breath Research</i> , 2018, 12, 027101.	1.5	1
1930	Recent strategies in spray drying for the enhanced bioavailability of poorly water-soluble drugs. <i>Journal of Controlled Release</i> , 2018, 269, 110-127.	4.8	115
1931	A phase II study of biweekly gemcitabine and carboplatin in completely resected stage IB-IIIa non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 103-109.	1.1	7
1932	TGF $\beta$ 2 pathway inhibition in the treatment of non-small cell lung cancer. , 2018, 184, 112-130.		85
1933	Loss of Uracil DNA Glycosylase Selectively Resensitizes p53-Mutant and -Deficient Cells to 5-FdU. <i>Molecular Cancer Research</i> , 2018, 16, 212-221.	1.5	21
1934	An <i>ERCC4</i> regulatory variant predicts grade $\beta$ or $\gamma$ toxicities in patients with advanced non-small cell lung cancer treated by platinum-based therapy. <i>International Journal of Cancer</i> , 2018, 142, 1218-1229.	2.3	7
1935	“My Patient Was Diagnosed With Nontargetable Advanced Non-Small Cell Lung Cancer. What Now?” Diagnosis and Initial Treatment Options for Newly Diagnosed Patients With Advanced NSCLC. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 696-707.	1.8	5
1936	Precision Medicine in Non-Small Cell Lung Cancer: Current Standards in Pathology and Biomarker Interpretation. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 708-715.	1.8	30
1937	CNS Metastases in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: Impact on Health Resource Utilization. <i>Journal of Oncology Practice</i> , 2018, 14, e612-e620.	2.5	8
1938	Immunotherapy in treatment naïve advanced non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S412-S421.	0.6	13
1939	BRAF inhibitors in metastatic non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 589-592.	0.6	27
1940	Knockdown of SNHG12 suppresses tumor metastasis and epithelial-mesenchymal transition via the Slug/ZEB2 signaling pathway by targeting miR-218 in NSCLC. <i>Oncology Letters</i> , 2018, 17, 2356-2364.	0.8	25
1941	Immunotherapy in the Asiatic population: any differences from Caucasian population?. <i>Journal of Thoracic Disease</i> , 2018, 10, S1482-S1493.	0.6	42
1942	Adjuvant bevacizumab for resected non-small cell lung cancer: the end of an era?. <i>Translational Lung Cancer Research</i> , 2018, 7, S179-S182.	1.3	0
1943	Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2251-2258.	0.8	308
1944	Current outcomes of postrecurrence survival in patients after resection of non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 1788-1796.	0.6	13
1945	Learning from the past to design better trials in second-line treatment for mesothelioma patients. <i>Ecanermedicalscience</i> , 2018, 12, 881.	0.6	0
1946	Management of Advanced Non-Small Cell Lung Cancer. , 2018, , 99-115.		1



#	ARTICLE	IF	CITATIONS
1947	Do toxicity patterns vary between programmed death-1 and programmed death ligand-1 inhibitors?. <i>Journal of Thoracic Disease</i> , 2018, 10, S4069-S4072.	0.6	3
1948	Influence of different drug delivery methods for Endostar combined with a gemcitabine/cisplatin regimen in locally advanced or metastatic lung squamous cell carcinoma. <i>Medicine (United States)</i> , 2018, 97, e11822.	0.4	7
1949	SOX30 specially prevents Wnt-signaling to suppress metastasis and improve prognosis of lung adenocarcinoma patients. <i>Respiratory Research</i> , 2018, 19, 241.	1.4	16
1950	Elevated IL6/IL1Ra ratio as a prognostic biomarker of poor chemotherapy efficacy in Chinese patients with metastatic NSCLC, validated in a Caucasian patient cohort. <i>Molecular and Clinical Oncology</i> , 2018, 10, 309-317.	0.4	3
1951	Cancer Diagnosis: From Tumor to Liquid Biopsy and Beyond. <i>Lab on A Chip</i> , 2018, 19, 11-34.	3.1	123
1952	First-Line Therapies for Metastatic Lung Adenocarcinoma Without a Driver Mutation. <i>Journal of Oncology Practice</i> , 2018, 14, 529-535.	2.5	41
1953	Immunotherapy and new frontiers in the treatment of lung cancer. <i>Shanghai Chest</i> , 0, 2, 77-77.	0.3	0
1956	Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study. <i>British Journal of Cancer</i> , 2018, 119, 1326-1331.	2.9	15
1957	Research progress of the clinicopathologic features of lung adenosquamous carcinoma. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7011-7017.	1.0	12
1959	High UDG and BRCA1 expression is associated with adverse outcome in patients with pemetrexed treated non-small cell lung Cancer. <i>Lung Cancer</i> , 2018, 126, 48-54.	0.9	4
1960	Lung cancer biopsy: Can diagnosis be changed after immunohistochemistry when the H&E-Based morphology corresponds to a specific tumor subtype?. <i>Clinics</i> , 2018, 73, e361.	0.6	7
1961	Hospitalization and Survival of Medicare Patients Treated With Carboplatin Plus Paclitaxel or Pemetrexed for Metastatic, Nonsquamous, Non-Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2018, 1, e183023.	2.8	5
1962	What is Currently the Best for Adenocarcinoma without Driver Mutation?. <i>Tuberculosis and Respiratory Diseases</i> , 2018, 81, 258.	0.7	3
1963	Effects of proton pump inhibitors on severe haematotoxicity induced after first course of pemetrexed/carboplatin combination chemotherapy. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2019, 44, 276-284.	0.7	3
1964	Impact of chemotherapy in the prognosis of non-small-cell lung cancer patients with severe to very severe COPD. <i>International Journal of COPD</i> , 2018, Volume 13, 3805-3812.	0.9	6
1965	Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study. <i>BMC Cancer</i> , 2018, 18, 1231.	1.1	10
1966	Immunotherapy in Lung Cancer: A New Age in Cancer Treatment. <i>Advances in Experimental Medicine and Biology</i> , 2018, 995, 65-95.	0.8	49
1967	Quelles stratégies thérapeutiques pour les CBNPC de stade IIIB (T4N2/T1-T3N3) ?. <i>Revue Des Maladies Respiratoires Actualites</i> , 2018, 10, 319-325.	0.0	0

#	ARTICLE	IF	CITATIONS
1970	Systematic evaluation of the efficacy“effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer. <i>European Respiratory Journal</i> , 2018, 52, 1801100.	3.1	34
1971	Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv192-iv237.	0.6	1,571
1972	Novel platinum agents and mesenchymal stromal cells for thoracic malignancies: state of the art and future perspectives. <i>Expert Opinion on Therapeutic Patents</i> , 2018, 28, 813-821.	2.4	5
1973	Comparison of efficacy and toxicity of bevacizumab, endostar and apatinib in transgenic and human lung cancer xenograftzebrafish model. <i>Scientific Reports</i> , 2018, 8, 15837.	1.6	28
1974	The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1969-1976.	0.9	24
1975	Recent advances in gold and silver nanoparticle based therapies for lung and breast cancers. <i>International Journal of Pharmaceutics</i> , 2018, 553, 483-509.	2.6	54
1976	Should chemotherapy plus immune checkpoint inhibition be the standard front“line therapy for patients with metastatic non“small cell lung cancer?. <i>Cancer</i> , 2018, 124, 4592-4596.	2.0	7
1977	Biomarker Clinical Trials in Lung Cancer: Design, Logistics, Challenges, and Practical Considerations. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1625-1637.	0.5	10
1978	RET fusions observed in lung and colorectal cancers are sensitive to ponatinib. <i>Oncotarget</i> , 2018, 9, 29654-29664.	0.8	20
1979	Metabolic Characterization of Antifolate Responsiveness and Non-responsiveness in Malignant Pleural Mesothelioma Cells. <i>Frontiers in Pharmacology</i> , 2018, 9, 1129.	1.6	7
1980	Chronic p27Kip1 Induction by Dexamethasone Causes Senescence Phenotype and Permanent Cell Cycle Blockade in Lung Adenocarcinoma Cells Over-expressing Glucocorticoid Receptor. <i>Scientific Reports</i> , 2018, 8, 16006.	1.6	8
1981	Programmed death-ligand 1 expression and CD8+ tumor-infiltrating lymphocytes in advanced non-small cell lung cancer treated with microwave ablation and chemotherapy. <i>International Journal of Hyperthermia</i> , 2018, 35, 591-598.	1.1	4
1982	Light-stimulus Dual-drug Responsive Nanoparticles for Photoactivated Therapy Using Mesoporous Silica Nanospheres. <i>Chemical Research in Chinese Universities</i> , 2018, 34, 676-683.	1.3	6
1983	The potential to treat lung cancer via inhalation of repurposed drugs. <i>Advanced Drug Delivery Reviews</i> , 2018, 133, 107-130.	6.6	57
1984	Nedaplatin Plus Docetaxel Versus Cisplatin Plus Docetaxel as First-Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung “A Multicenter, Open-label, Randomized, Phase III Trial. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1743-1749.	0.5	13
1986	Long-Term Outcomes of a Phase 2 Trial of Chemotherapy With Consolidative Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 527-535.	0.4	47
1987	Pembrolizumab plus Chemotherapy in Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 379, e18.	13.9	64
1988	In Vivo Anticancer Activity of a Nontoxic Inert Phenolato Titanium Complex: High Efficacy on Solid Tumors Alone and Combined with Platinum Drugs. <i>ChemMedChem</i> , 2018, 13, 2290-2296.	1.6	24

#	ARTICLE	IF	CITATIONS
1989	Efficacy and safety of rhâ€ndostatin (Endostar) combined with pemetrexed/cisplatin followed by rhâ€ndostatin plus pemetrexed maintenance in nonâ€small cell lung cancer: A retrospective comparison with standard chemotherapy. <i>Thoracic Cancer</i> , 2018, 9, 1354-1360.	0.8	14
1990	Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis. <i>Journal of Thoracic Disease</i> , 2018, 10, 6636-6652.	0.6	33
1991	Real world study of regimen containing bevacizumab as firstâ€line therapy in Chinese patients with advanced nonâ€small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 805-813.	0.8	10
1992	Immunotherapy in non-metastatic non-small cell lung cancer: Can the benefits of stage IV therapy be translated into earlier stages?. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591877281.	1.4	18
1993	Reduction in nephrotoxicities using short hydration for chemotherapy containing cisplatin: a consecutive analysis of 467 patients with thoracic malignancies. <i>ESMO Open</i> , 2018, 3, e000342.	2.0	8
1994	Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Nonâ€Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care. <i>Clinical Lung Cancer</i> , 2018, 19, e823-e830.	1.1	10
1995	Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy. <i>Lung Cancer</i> , 2018, 122, 234-242.	0.9	22
1996	The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 130, 1-12.	2.0	16
1997	Microtubule-Associated Protein 4 Is a Prognostic Factor and Promotes Tumor Progression in Lung Adenocarcinoma. <i>Disease Markers</i> , 2018, 2018, 1-8.	0.6	18
1998	Nano-selenium and its nanomedicine applications: a critical review. <i>International Journal of Nanomedicine</i> , 2018, Volume 13, 2107-2128.	3.3	394
1999	Management of Leptomeningeal Metastases in Non-oncogene Addicted Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 278.	1.3	15
2000	Perioperative chemotherapy with pemetrexed and cisplatin for pulmonary large-cell neuroendocrine carcinoma: a case report and literature review. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 2557-2563.	1.0	4
2001	Pemetrexed Continuation Maintenance versus Conventional Platinum-Based Doublet Chemotherapy in EGFR-Negative Lung Adenocarcinoma: Retrospective Analysis. <i>Tuberculosis and Respiratory Diseases</i> , 2018, 81, 148.	0.7	4
2002	Overexpression of PEAK1 contributes to epithelialâ€mesenchymal transition and tumor metastasis in lung cancer through modulating ERK1/2 and JAK2 signaling. <i>Cell Death and Disease</i> , 2018, 9, 802.	2.7	40
2003	Chemotherapy with or without pemetrexed as second-line regimens for advanced non-small-cell lung cancer patients who have progressed after first-line EGFR TKIs: a systematic review and meta-analysis. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 3697-3703.	1.0	5
2004	Tripartite motifâ€containing 37 (TRIM37) promotes the aggressiveness of nonâ€smallâ€cell lung cancer cells by activating the NFâ€B pathway. <i>Journal of Pathology</i> , 2018, 246, 366-378.	2.1	45
2005	Efficacy of pemetrexed-based regimens in advanced non&ndash;small cell lung cancer patients with activating epidermal growth factor receptor mutations after tyrosine kinase inhibitor failure: a systematic review. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 2121-2129.	1.0	15
2006	Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer. <i>Yonsei Medical Journal</i> , 2018, 59, 202.	0.9	7

#	ARTICLE	IF	CITATIONS
2007	Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial. <i>BMC Cancer</i> , 2018, 18, 598.	1.1	11
2008	Factors associated with gene aberration test status and treatment decision in patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer: A multicenter survey in China (CTONG 1506). <i>Lung Cancer</i> , 2018, 123, 7-13.	0.9	2
2009	NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 807-821.	2.3	394
2010	Comparison of chemotherapy plus bevacizumab vs. chemotherapy alone as third-line treatment or beyond for advanced non-small cell lung cancer: A propensity score-matched analysis. <i>Oncology Letters</i> , 2018, 15, 5671-5679.	0.8	4
2011	Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immunotherapy for first-line treatment of advanced non-small cell lung cancer: a generic protocol. <i>The Cochrane Library</i> , 0, , .	1.5	6
2012	Evaluation of pemetrexed and etoposide as therapeutic regimens for human papillomavirus-positive oral and oropharyngeal cancer. <i>PLoS ONE</i> , 2018, 13, e0200509.	1.1	6
2013	A Review of Recent Advances in the Treatment of Elderly and Poor Performance NSCLC. <i>Cancers</i> , 2018, 10, 236.	1.7	31
2014	Risk factors and treatments for brain metastasis in patients with adenocarcinoma of the lung: a retrospective analysis of 373 patients. <i>Chinese Neurosurgical Journal</i> , 2018, 4, 9.	0.3	2
2015	Phase II trial of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for untreated non-squamous non-small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 111-117.	1.1	2
2016	Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report. <i>BMC Pulmonary Medicine</i> , 2018, 18, 13.	0.8	5
2017	KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target. <i>Molecular Cancer</i> , 2018, 17, 33.	7.9	237
2018	Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer. <i>BMC Cancer</i> , 2018, 18, 6.	1.1	7
2019	Ammonium Bisphosphonate Polymeric Magnetic Nanocomplexes for Platinum Anticancer Drug Delivery and Imaging with Potential Hyperthermia and Temperature-Dependent Drug Release. <i>Journal of Nanomaterials</i> , 2018, 2018, 1-14.	1.5	1
2020	Pemetrexed, Vitamin B12, and Thoracic Tumors: The Times, They Are A-Changin'™. <i>Clinical Lung Cancer</i> , 2018, 19, 461-463.	1.1	2
2021	Current Smoking has a Detrimental Effect on Survival for Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) negative Advanced non-squamous Non-small Cell Lung Cancer (NSCLC) Patients Treated with Pemetrexed Continuation Maintenance. <i>Journal of Cancer</i> , 2018, 9, 2140-2146.	1.2	6
2022	Algorithm for the Treatment of Advanced or Metastatic Squamous Non-Small-Cell Lung Cancer: An Evidence-Based Overview. <i>Current Oncology</i> , 2018, 25, 77-85.	0.9	9
2023	Association between EGFR mutation and expression of BRCA1 and RAP80 in non-small cell lung cancer. <i>Oncology Letters</i> , 2018, 16, 2201-2206.	0.8	7
2024	Treatment and outcomes of non-small-cell lung cancer patients with high comorbidity. <i>Cancer Management and Research</i> , 2018, Volume 10, 167-175.	0.9	12

#	ARTICLE	IF	CITATIONS
2025	Surgical significance and efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in patients with primary lung adenosquamous carcinoma. <i>Cancer Management and Research</i> , 2018, Volume 10, 2401-2407.	0.9	10
2026	Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer. <i>Annals of Oncology</i> , 2018, 29, 1701-1709.	0.6	24
2027	Overexpression of dihydrofolate reductase is a factor of poor survival in acute lymphoblastic leukemia. <i>Oncology Letters</i> , 2018, 15, 8405-8411.	0.8	8
2028	Oral pemetrexed facilitates low-dose metronomic therapy and enhances antitumor efficacy in lung cancer. <i>Journal of Controlled Release</i> , 2018, 284, 160-170.	4.8	14
2029	The Influence of Histologic Subtype in Predicting Survival of Lung Cancer Patients With Spinal Metastases. <i>Clinical Spine Surgery</i> , 2018, 31, E1-E7.	0.7	4
2030	Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer. <i>BMJ Open</i> , 2018, 8, e020690.	0.8	56
2031	Nimotuzumab combined with chemotherapy as first-line treatment for advanced lung squamous cell carcinoma. <i>Thoracic Cancer</i> , 2018, 9, 1056-1061.	0.8	7
2032	Deciphering Clinicoradiologic Phenotype for Thymidylate Synthase Expression Status in Patients with Advanced Lung Adenocarcinoma Using a Radiomics Approach. <i>Scientific Reports</i> , 2018, 8, 8968.	1.6	13
2033	Comparing first-line treatment patterns and clinical outcomes of patients with pan-negative advanced non-squamous non-small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 1005-1011.	0.8	2
2034	Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer. <i>Clinical Pharmacokinetics</i> , 2019, 58, 403-420.	1.6	31
2035	Safety of dose-reduced pemetrexed in patients with renal insufficiency. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1125-1129.	0.5	5
2036	Absence of thyroid transcription factor-1 expression is associated with poor survival in patients with advanced pulmonary adenocarcinoma treated with pemetrexed-based chemotherapy. <i>Irish Journal of Medical Science</i> , 2019, 188, 69-74.	0.8	5
2037	<p>Relative value assessment: characterizing the benefit of oncology therapies through diverse survival metrics from a US perspective</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 199-219.	0.7	1
2038	Lung adenocarcinoma metastasis to pancreas after the absence of primary tumour for almost two years. <i>JRSM Open</i> , 2019, 10, 205427041985049.	0.2	0
2040	A Phase II Study of Cisplatin Plus Gemcitabine followed by Maintenance Gemcitabine for Advanced Squamous Non-Small-Cell Lung Cancer: Kyoto Thoracic Oncology Research Group 1302. <i>Oncology</i> , 2019, 97, 327-333.	0.9	5
2041	Compliance to regional recommendations for molecular analyses and management of advanced lung cancer patients. <i>Future Oncology</i> , 2019, 15, 2139-2149.	1.1	2
2042	Nivolumab in disadvantaged subgroups of metastatic non-small-cell lung cancer patients: a single-institution experience. <i>Immunotherapy</i> , 2019, 11, 945-952.	1.0	2
2043	Phase II study of nedaplatin and amrubicin as first-line treatment for advanced squamous cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 1764-1769.	0.8	3

#	ARTICLE	IF	CITATIONS
2044	Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-“Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2019, 5, 1283.	3.4	220
2045	Positive PD-“L1 expression is predictive for patients with advanced EGFR wild-“type non-“small cell lung cancer treated with gemcitabine and cisplatin. <i>Oncology Letters</i> , 2019, 18, 161-168.	0.8	2
2046	Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade. <i>Journal of Clinical Medicine</i> , 2019, 8, 1014.	1.0	41
2047	Differential Relapse Patterns for Non-small Cell Lung Cancer Subtypes Adenocarcinoma and Squamous Cell Carcinoma: Implications for Radiation Oncology. <i>Clinical Oncology</i> , 2019, 31, 711-719.	0.6	14
2048	Synchronous Oligometastatic Non-small Cell Lung Cancer Managed With Curative-Intent Chemoradiation Therapy: Long-term Outcomes From a Single Institution. <i>Advances in Radiation Oncology</i> , 2019, 4, 541-550.	0.6	6
2049	Microwave ablation combined with chemotherapy improved progression free survival of IV stage lung adenocarcinoma patients compared with chemotherapy alone. <i>Thoracic Cancer</i> , 2019, 10, 1628-1635.	0.8	12
2050	Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM). <i>Tumori</i> , 2019, 105, 3-14.	0.6	9
2051	Chemotherapy for Lung Cancer in the Era of Personalized Medicine. <i>Tuberculosis and Respiratory Diseases</i> , 2019, 82, 179.	0.7	48
2053	Pemetrexed exposure predicts toxicity in advanced non-“small-cell lung cancer: A prospective cohort study. <i>European Journal of Cancer</i> , 2019, 121, 64-73.	1.3	16
2054	Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis. <i>BMJ: British Medical Journal</i> , 2019, 367, l5460.	2.4	108
2055	Associations of cytosine deaminase gene polymorphisms with effectiveness of gemcitabine/cisplatin chemotherapy in patients of Xinjiang Uyghur and Han nationality with non-small cell lung cancer. <i>International Journal of Biological Markers</i> , 2019, 34, 389-397.	0.7	2
2056	Integrated transcriptomics reveals master regulators of lung adenocarcinoma and novel repositioning of drug candidates. <i>Cancer Medicine</i> , 2019, 8, 6717-6729.	1.3	16
2057	Metabolic vulnerability in tumours illuminated. <i>Nature</i> , 2019, 575, 296-297.	13.7	3
2058	Pemetrexed Plus Platinum for Patients With Advanced Non-small Cell Lung Cancer and Interstitial Lung Disease. <i>In Vivo</i> , 2019, 33, 2059-2064.	0.6	13
2059	A Review on Curability of Cancers: More Efforts for Novel Therapeutic Options Are Needed. <i>Cancers</i> , 2019, 11, 1782.	1.7	53
2060	In silico identification of thiostrepton as an inhibitor of cancer stem cell growth and an enhancer for chemotherapy in non-“small-“cell lung cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 8184-8195.	1.6	28
2061	Discovery of Novel Biomarkers of Therapeutic Responses in Han Chinese Pemetrexed-Based Treated Advanced NSCLC Patients. <i>Frontiers in Pharmacology</i> , 2019, 10, 944.	1.6	9
2062	Systemic Therapy for Locally Advanced and Metastatic Non-“Small Cell Lung Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 764.	3.8	720

#	ARTICLE	IF	CITATIONS
2063	Assessing the Justification, Funding, Success, and Survival Outcomes of Randomized Noninferiority Trials of Cancer Drugs. <i>JAMA Network Open</i> , 2019, 2, e199570.	2.8	13
2064	Predictive and Prognostic Value of 18F-fluorodeoxyglucose Uptake Combined with Thymidylate Synthase Expression in Patients with Advanced Non-Small Cell Lung Cancer. <i>Scientific Reports</i> , 2019, 9, 12215.	1.6	3
2065	A phase II trial of induction of erlotinib followed by cytotoxic chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 1065-1071.	1.1	1
2066	Validity of using immunohistochemistry to predict treatment outcome in patients with non-small cell lung cancer not otherwise specified. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2495-2506.	1.2	5
2067	Homologous recombination in lung cancer, germline and somatic mutations, clinical and phenotype characterization. <i>Lung Cancer</i> , 2019, 137, 48-51.	0.9	22
2068	New options for combination therapy for advanced non-squamous NSCLC. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 1095-1107.	1.0	15
2069	Histological Transformation to Small Cell Carcinoma of an Adenosquamous Carcinoma of the Lung With Epidermal Growth Factor Receptor Mutation in Exons 20 and 21 After Treatment With Erlotinib: Case Report. <i>Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine</i> , 2019, 13, 117954841987299.	0.5	1
2070	First-line immune-chemotherapy combination: the right strategy to fight squamous non-small cell lung cancer?. <i>Translational Lung Cancer Research</i> , 2019, 8, 546-549.	1.3	3
2071	Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 2121-2137.	0.9	7
2072	High-grade non-small cell lung carcinoma: a comparative analysis of the phenotypic profile in small biopsies with the corresponding postoperative material. <i>Polish Journal of Pathology</i> , 2019, 70, 100-108.	0.1	5
2073	A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer. <i>Scientific Reports</i> , 2019, 9, 648.	1.6	21
2074	Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysis. <i>Immunotherapy</i> , 2019, 11, 407-428.	1.0	53
2076	MicroRNAs associated with lung squamous cell carcinoma: New prognostic biomarkers and therapeutic targets. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 18956-18966.	1.2	33
2077	First-Line Systemic Treatments for Stage IV Non-Small Cell Lung Cancer in California: Patterns of Care and Outcomes in a Real-World Setting. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz020.	1.4	12
2078	Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 513-523.	1.9	21
2079	The role of combination chemo-immunotherapy in advanced non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 561-568.	1.1	58
2080	Thyroid transcription factor-1 as a prognostic indicator for stage IV lung adenocarcinoma with and without EGFR-sensitizing mutations. <i>BMC Cancer</i> , 2019, 19, 574.	1.1	12
2081	Metabolic reprogramming and Notch activity distinguish between non-small cell lung cancer subtypes. <i>British Journal of Cancer</i> , 2019, 121, 51-64.	2.9	33

#	ARTICLE	IF	CITATIONS
2082	Nivolumab plus ipilimumab in non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 2287-2302.	1.1	42
2083	Integrative Omics Analysis Revealed that Metabolic Intervention Combined with Metronomic Chemotherapy Selectively Kills Cancer Cells. <i>Journal of Proteome Research</i> , 2019, 18, 2643-2653.	1.8	8
2084	In Situ Hybridization. , 2019, , 93-109.		1
2085	Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: A randomized controlled study. <i>Lung Cancer</i> , 2019, 133, 23-31.	0.9	23
2086	Focus on Recommendations for the Management of Non-small Cell Lung Cancer. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 1230-1239.	0.9	2
2087	The promise and challenges of deep learning models for automated histopathologic classification and mutation prediction in lung cancer. <i>Journal of Thoracic Disease</i> , 2019, 11, 369-372.	0.6	9
2088	Prediction of response to pemetrexed in non-small-cell lung cancer with immunohistochemical phenotyping based on gene expression profiles. <i>BMC Cancer</i> , 2019, 19, 440.	1.1	7
2089	Landmark Trials in Oncology. , 2019, , .		0
2090	The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. <i>International Journal of Clinical Oncology</i> , 2019, 24, 731-770.	1.0	100
2091	The vertebral 3 <sup>â€²</sup> -deoxy-3 <sup>â€²</sup> -18F-fluorothymidine uptake predicts the hematological toxicity after systemic chemotherapy in patients with lung cancer. <i>European Radiology</i> , 2019, 29, 3908-3917.	2.3	6
2092	First-line pemetrexed/carboplatin or cisplatin/bevacizumab compared with paclitaxel/carboplatin/bevacizumab in patients with advanced non-squamous non-small cell lung cancer with wild-type driver genes: A real-world study in China. <i>Thoracic Cancer</i> , 2019, 10, 1043-1050.	0.8	2
2093	Profiling of apoptosis- and autophagy-associated molecules in human lung cancer A549 cells in response to cisplatin treatment using stable isotope labeling with amino acids in cell culture. <i>International Journal of Oncology</i> , 2019, 54, 1071-1085.	1.4	12
2094	First-Line Therapy for Wild-Type Patients. , 2019, , 87-102.		1
2095	Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. , 2019, , 115-131.		0
2096	Carboplatin Plus Nab-paclitaxel in Performance Status 2 Patients With Advanced Non-small-cell Lung Cancer. <i>Anticancer Research</i> , 2019, 39, 1463-1468.	0.5	5
2097	Recent treatment strategy for advanced squamous cell carcinoma of the lung in Japan. <i>International Journal of Clinical Oncology</i> , 2019, 24, 461-467.	1.0	7
2098	Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naïve Patients With Advanced Nonsquamous Non-small-cell Lung Cancer in China. <i>Clinical Therapeutics</i> , 2019, 41, 518-529.	1.1	12
2099	First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors. <i>BioDrugs</i> , 2019, 33, 159-171.	2.2	40



#	ARTICLE	IF	CITATIONS
2100	How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer. <i>Annals of Oncology</i> , 2019, 30, 884-896.	0.6	78
2101	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 547-559.	1.1	22
2102	Predictive factors for long-term responders of pemetrexed maintenance treatment in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 942-949.	0.8	5
2103	The role of immune checkpoint inhibitors in advanced non-small cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 435-447.	1.0	7
2104	Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score. <i>Journal of Clinical Oncology</i> , 2019, 37, 336-349.	0.8	101
2105	Observational Prospective Study to Determine the Evolution of the Symptomatic Profile of Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients and Its Relation to the Control of the Disease. <i>Advances in Therapy</i> , 2019, 36, 1497-1508.	1.3	4
2106	Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, e442-e451.	1.1	15
2107	Role of Targeted Therapy and Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A Review. <i>Oncologist</i> , 2019, 24, 1270-1284.	1.9	21
2108	Complete and Durable Response to Combined Chemo/Radiation Therapy in EGFR Wild-Type Lung Adenocarcinoma with Diffuse Brain Metastases. <i>Diagnostics</i> , 2019, 9, 42.	1.3	0
2109	Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer. <i>EClinicalMedicine</i> , 2019, 9, 19-25.	3.2	6
2110	Comparative efficacy and safety for different chemotherapy regimens used concurrently with thoracic radiation for locally advanced non-small cell lung cancer: a systematic review and network meta-analysis. <i>Radiation Oncology</i> , 2019, 14, 55.	1.2	16
2111	Re-irradiation in locally recurrent lung cancer patients. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 725-733.	1.0	17
2112	Clinical analysis of patients with skeletal metastasis of lung cancer. <i>BMC Cancer</i> , 2019, 19, 303.	1.1	42
2113	Sequence-dependent synergistic cytotoxicity of icotinib and pemetrexed in human lung cancer cell lines in vitro and in vivo. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 148.	3.5	8
2114	Effect of pemetrexed on brain metastases from nonsmall cell lung cancer with wild-type and unknown EGFR status. <i>Medicine (United States)</i> , 2019, 98, e14110.	0.4	9
2115	Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma. <i>Investigational New Drugs</i> , 2019, 37, 531-537.	1.2	3
2116	Simultaneous presence of lung adenocarcinoma and malignant pleural mesothelioma: A case report. <i>Respiratory Medicine Case Reports</i> , 2019, 26, 45-49.	0.2	0
2117	Osimertinib Regresses an EGFR-Mutant Cisplatin-Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice. <i>Translational Oncology</i> , 2019, 12, 640-645.	1.7	10

#	ARTICLE	IF	CITATIONS
2118	Timing of folic acid/vitamin B12 supplementation and hematologic toxicity during first-line treatment of patients with nonsquamous non-small cell lung cancer using pemetrexed-based chemotherapy: The PEMVITASTART randomized trial. <i>Cancer</i> , 2019, 125, 2203-2212.	2.0	9
2119	Treatment of Pulmonary Adenocarcinoma With Immune Checkpoint Inhibitors. , 2019, , 151-171.		0
2120	Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?. <i>Future Oncology</i> , 2019, 15, 1363-1383.	1.1	10
2121	The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer. <i>Cancers</i> , 2019, 11, 201.	1.7	49
2122	Real-world outcomes of various regimens of recombinant human endostatin combined with chemotherapy in non-driver gene mutation advanced non-small cell lung cancer. <i>Cancer Medicine</i> , 2019, 8, 1434-1441.	1.3	12
2123	Cancer medicines in Asia and Asia-Pacific: What is available, and is it effective enough?. <i>ESMO Open</i> , 2019, 4, e000483.	2.0	31
2124	Traitements de première ligne dans les CBNPC avancés, en l'absence d'addiction oncogénique (incluant) Tj ETQq0 0 0 rgBT 2019, 11, 342-354.	0.0	0
2125	Mechanisms of resistance to pemetrexed in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 1107-1118.	1.3	34
2126	Addition of atezolizumab to nab-paclitaxel plus carboplatin is a new standard option for the first-line treatment for non-squamous non-small cell lung cancer. <i>Translational Cancer Research</i> , 2019, 8, E11-E14.	0.4	0
2127	Cancers bronchiques de stade III: rôle de l'onco-radiothérapie. <i>Revue Des Maladies Respiratoires Actualites</i> , 2019, 11, 278-289.	0.0	0
2128	Retrospective Evaluation of Lung Adenocarcinoma Patients Progressing on 1st Line Chemotherapy. <i>Medicina (Lithuania)</i> , 2019, 55, 743.	0.8	1
2129	KEYNOTE-042: is lowering the PD-L1 threshold for first-line pembrolizumab monotherapy a good idea?. <i>Translational Lung Cancer Research</i> , 2019, 8, 723-727.	1.3	4
2130	Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status. <i>The Cochrane Library</i> , 0, , .	1.5	1
2131	Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer. <i>The Cochrane Library</i> , 0, , .	1.5	2
2132	Pemetrexed plus cisplatin versus docetaxel plus cisplatin for stage IV lung adenocarcinoma based on propensity score matching. <i>Anti-Cancer Drugs</i> , 2019, 30, 295-301.	0.7	2
2133	Risk factors of grade ≥ 2 radiation pneumonitis after gemcitabine induction chemotherapy for patients with non-small cell lung cancer. <i>Radiation Oncology</i> , 2019, 14, 229.	1.2	13
2134	The effect of PD-L1/PD-1 immunotherapy in the treatment of squamous non-small-cell lung cancer: a meta-analysis of randomized controlled clinical trials. <i>Journal of Thoracic Disease</i> , 2019, 11, 4453-4463.	0.6	5
2135	Cisplatin-resistant A549 non-small cell lung cancer cells can be identified by increased mitochondrial mass and are sensitive to pemetrexed treatment. <i>Cancer Cell International</i> , 2019, 19, 317.	1.8	19

#	ARTICLE	IF	CITATIONS
2136	<p>Bevacizumab in Combination with Pemetrexed and Platinum Significantly Improved the Clinical Outcome of Patients with Advanced Adenocarcinoma NSCLC and Brain Metastases</p>. Cancer Management and Research, 2019, Volume 11, 10083-10092.	0.9	9
2137	A phase II study of concurrent nab-paclitaxel/carboplatin combined with thoracic radiotherapy in locally advanced squamous cell lung cancer. Journal of Thoracic Disease, 2019, 11, 4529-4537.	0.6	8
2138	Creating a Synthetic Clinical Trial: Comparative Effectiveness Analyses Using an Electronic Medical Record. JCO Clinical Cancer Informatics, 2019, 3, 1-10.	1.0	4
2139	Safety outcomes in advanced non-small-cell lung cancer patients treated with first-line platinum-based regimens in the United States. Journal of Thoracic Disease, 2019, 11, 4474-4483.	0.6	3
2140	Modulation of lung cancer cell plasticity and heterogeneity with the restoration of cisplatin sensitivity by neurotensin antibody. Cancer Letters, 2019, 444, 147-161.	3.2	13
2141	Design and Application of Cisplatin-Loaded Magnetic Nanoparticle Clusters for Smart Chemotherapy. ACS Applied Materials & Interfaces, 2019, 11, 1864-1875.	4.0	49
2142	Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO&#x201c;ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. Annals of Oncology, 2019, 30, 171-210.	0.6	214
2144	Lung squamous cell carcinoma: A postoperative recurrence analysis of keratinizing and nonkeratinizing subtypes. European Journal of Surgical Oncology, 2019, 45, 838-844.	0.5	6
2145	Gene Fusion in NSCLC. , 2019, , 443-464.		1
2146	Correct and logical inference on efficacy in subgroups and their mixture for binary outcomes. Biometrical Journal, 2019, 61, 8-26.	0.6	13
2147	SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018). Clinical and Translational Oncology, 2019, 21, 3-17.	1.2	110
2148	Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens. Investigational New Drugs, 2019, 37, 498-506.	1.2	7
2149	Demographics, Safety and Quality, and Prognostic Information in Both the Seventh and Eighth Editions of the TNM Classification in 18,973 Surgical Cases of the Japanese Joint Committee of Lung Cancer Registry Database in 2010. Journal of Thoracic Oncology, 2019, 14, 212-222.	0.5	136
2150	Metal-based antitumor compounds: beyond cisplatin. Future Medicinal Chemistry, 2019, 11, 119-135.	1.1	84
2151	Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. Lung Cancer, 2019, 129, 35-40.	0.9	122
2152	Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of outcome. BMC Cancer, 2019, 19, 70.	1.1	6
2153	miR&#x201c;210 promotes lung adenocarcinoma proliferation, migration, and invasion by targeting <b>lysyl oxidase&#x201c;like 4</b>. Journal of Cellular Physiology, 2019, 234, 14050-14057.	2.0	29
2154	LUBAC determines chemotherapy resistance in squamous cell lung cancer. Journal of Experimental Medicine, 2019, 216, 450-465.	4.2	57

#	ARTICLE	IF	CITATIONS
2155	ZWINT is the next potential target for lung cancer therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 661-673.	1.2	23
2156	Development and validation of a UPLC-MS/MS method for determination of motesanib in plasma: Application to metabolic stability and pharmacokinetic studies in rats. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 166, 244-251.	1.4	6
2157	A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2019, 37, 658-665.	1.2	8
2158	Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer. <i>Journal of Medical Economics</i> , 2019, 22, 140-150.	1.0	17
2159	Pemetrexed-induced severe rhabdomyolysis in lung cancer: A case report. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 2007-2009.	0.5	1
2160	Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC). <i>Clinical Lung Cancer</i> , 2019, 20, 43-47.	1.1	45
2161	Computational Drug Repositioning with Random Walk on a Heterogeneous Network. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2019, 16, 1890-1900.	1.9	47
2162	Internal Medicine Residents' Perception of Cancer Prognosis. <i>Journal of Cancer Education</i> , 2020, 35, 983-987.	0.6	1
2163	An advanced c-MET-amplified NSCLC patient that was treated with crizotinib. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 474-477.	0.5	1
2164	Cancers in Taiwan: Practical insight from epidemiology, treatments, biomarkers, and cost. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1731-1741.	0.8	60
2165	Accumulated cytotoxicity of CDK inhibitor dinaciclib with first-line chemotherapy drugs in salivary adenoid cystic carcinoma cells. <i>Odontology / the Society of the Nippon Dental University</i> , 2020, 108, 300-311.	0.9	4
2166	Classification and Imaging Findings of Lung Neoplasms. <i>Seminars in Roentgenology</i> , 2020, 55, 41-50.	0.2	2
2167	Organic anion transporters and PI3K-AKT-mTOR pathway mediate the synergistic anticancer effect of pemetrexed and rhein. <i>Journal of Cellular Physiology</i> , 2020, 235, 3309-3319.	2.0	25
2168	Durable response after discontinuation of nivolumab therapy in the absence of disease progression or toxicity with two advanced NSCLC patients. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 761-767.	0.5	12
2169	Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer. <i>Clinical and Translational Oncology</i> , 2020, 22, 708-716.	1.2	6
2170	Cancer of the Lung. , 2020, , 1108-1158.e16.		11
2171	Using Electronic Health Records to Derive Control Arms for Early Phase Single-Arm Lung Cancer Trials: Proof of Concept in Randomized Controlled Trials. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 369-377.	2.3	73
2172	Factors correlating with shorter survival after treatment: aiding oncologists to choose who (not) to receive palliative systemic therapy. <i>Annals of Palliative Medicine</i> , 2020, 9, 4430-4445.	0.5	0

#	ARTICLE	IF	CITATIONS
2173	Synergistic anticancer effect of combined use of <i>Trichosanthes kirilowii</i> with cisplatin and pemetrexed enhances apoptosis of H1299 non-small-cell lung cancer cells via modulation of ErbB3. <i>Phytomedicine</i> , 2020, 66, 153109.	2.3	14
2174	Impact of histology on patterns of failure and clinical outcomes in patients treated with definitive chemoradiotherapy for locally advanced non-small cell lung cancer. <i>International Journal of Clinical Oncology</i> , 2020, 25, 274-281.	1.0	7
2175	Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand. <i>Value in Health Regional Issues</i> , 2020, 21, 9-16.	0.5	5
2176	Assessing the efficacy-effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and population-based, real-world data for contemporary parenteral cancer therapeutics. <i>Cancer</i> , 2020, 126, 1717-1726.	2.0	35
2177	Non-small Cell Lung Cancer as a Chronic Disease – A Prospective Study from the Czech TULLUNG Registry. <i>In Vivo</i> , 2020, 34, 369-379.	0.6	9
2178	Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical) Tj ETQq1 1 0.784314 rgBT/Overloca	2.0	39
2179	Platinum-based combination chemotherapy triggers cancer cell death through induction of BNIP3 and ROS, but not autophagy. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 1993-2003.	1.6	23
2180	Twenty-five years of <i>Respirology</i> : Advances in lung cancer. <i>Respirology</i> , 2020, 25, 26-31.	1.3	2
2181	Precision Medicine in Lung Cancer Treatment. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 15-21.	0.6	23
2182	The value of desmosomal plaque-related markers to distinguish squamous cell carcinoma and adenocarcinoma of the lung. <i>Upsala Journal of Medical Sciences</i> , 2020, 125, 19-29.	0.4	11
2183	Sâ€ plus cisplatin as first-line treatment of patients with advanced non-small cell lung cancer in Taiwan. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, e68-e73.	0.7	1
2184	Therapeutic efficacy and imaging assessment of the HER2-targeting chemotherapy drug ZHER2:V2-pemetrexed in lung adenocarcinoma Xenografts. <i>Investigational New Drugs</i> , 2020, 38, 1031-1043.	1.2	3
2185	Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L). <i>Journal of Clinical Oncology</i> , 2020, 38, 793-803.	0.8	28
2186	Regulation of MicroRNA-497-Targeting AKT2 Influences Tumor Growth and Chemoresistance to Cisplatin in Lung Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 840.	1.8	9
2187	The Role of Surgery in Lung Cancer Treatment. <i>Cancers</i> , 2020, 12, 2777.	1.7	0
2188	Does Pemetrexed Work in Targetable, Nonsquamous Non-Small-Cell Lung Cancer? A Narrative Review. <i>Cancers</i> , 2020, 12, 2658.	1.7	10
2189	First-line cytotoxic chemotherapy regimen for non-small cell lung cancer in the elderly population: plus cïsa change. <i>Translational Lung Cancer Research</i> , 2020, 9, 1591-1594.	1.3	0
2190	Efficacy and safety of bevacizumab in advanced lung adenocarcinoma patients with stable disease after two cycles of first-line chemotherapy: A multicenter prospective cohort study. <i>Thoracic Cancer</i> , 2020, 11, 3641-3644.	0.8	4

#	ARTICLE	IF	CITATIONS
2191	Real-life effectiveness of first-line anticancer treatments in stage III/IV NSCLC patients: Data from the Czech TULUNG Registry. <i>Thoracic Cancer</i> , 2020, 11, 3346-3356.	0.8	8
2192	Utility of immune checkpoint inhibitors in non-small cell lung cancer patients with poor performance status. <i>Cancer Science</i> , 2020, 111, 3739-3746.	1.7	20
2193	KRAS oncogene may be another target conquered in non-small cell lung cancer (NSCLC). <i>Thoracic Cancer</i> , 2020, 11, 3425-3435.	0.8	10
2194	Homeopathic Treatment as an Add-On Therapy May Improve Quality of Life and Prolong Survival in Patients with Non-Small Cell Lung Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Three-Arm, Multicenter Study. <i>Oncologist</i> , 2020, 25, e1930-e1955.	1.9	20
2196	Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell lung cancer who have progressed after platinum-based chemotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093688.	1.4	17
2197	Predictors of Acquired T790M Mutation in Patients Failing First- or Second-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors. <i>Cancer Management and Research</i> , 2020, Volume 12, 5439-5450.	0.9	8
2198	Disparities in survival following surgery among patients with different histological types of N2-III non-small cell lung cancer: a Surveillance, Epidemiology and End Results (SEER) database analysis. <i>Annals of Translational Medicine</i> , 2020, 8, 1288-1288.	0.7	4
2199	Clinical observation of Pemetrexed first-line treatment in advanced non-squamous lung cancer or non-small cell lung cancer without driver-mutations: a phase 2, single-arm trial. <i>Annals of Translational Medicine</i> , 2020, 8, 1315-1315.	0.7	0
2200	Real-World Outcomes and Value of First-Line Therapy for Metastatic Non-Small Cell Lung Cancer. <i>Cancer Investigation</i> , 2020, 38, 608-617.	0.6	1
2201	Diagnostic Patterns of Non-Small-Cell Lung Cancer at Princess Margaret Cancer Centre. <i>Current Oncology</i> , 2020, 27, 244-249.	0.9	3
2202	First line Immunotherapy for Non-Small Cell Lung Cancer. <i>Pharmaceuticals</i> , 2020, 13, 373.	1.7	49
2203	A comparison of the efficacy of antiangiogenic agents combined with chemotherapy for the treatment of non-small cell lung cancer: a network meta-analysis. <i>Cancer Cell International</i> , 2020, 20, 548.	1.8	3
2204	Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology). <i>Journal of Thoracic Oncology</i> , 2020, 15, 1000-1010.	0.5	10
2205	Changes and Influential Factors of Chemotherapy Usage for Non-Small Cell Lung Cancer Patients in China: A Multicenter 10-Year (2005-2014) Retrospective Study. <i>Cancer Management and Research</i> , 2020, Volume 12, 6033-6044.	0.9	0
2206	The Importance of Dose Intensity When Administering Cytotoxic Chemotherapy in NSCLC: A Matter as Actual Now as in the Past. <i>Processes</i> , 2020, 8, 936.	1.3	0
2207	Methylation Patterns and Chromatin Accessibility in Neuroendocrine Lung Cancer. <i>Cancers</i> , 2020, 12, 2003.	1.7	5
2208	Enhancement of Antitumor Efficacy of Paclitaxel-Loaded PEGylated Liposomes by N,N-Dimethyl Tertiary Amino Moiety in Pancreatic Cancer. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 2945-2957.	2.0	6
2209	Vinorelbine in Non-Small Cell Lung Cancer: Real-World Data From a Single-Institution Experience. <i>Oncology Research</i> , 2020, 28, 237-248.	0.6	8

#	ARTICLE	IF	CITATIONS
2210	Lung cancer and intraocular metastasis in gestation: Clinical experiences of a rare case. <i>Thoracic Cancer</i> , 2020, 11, 2723-2726.	0.8	2
2211	HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib. <i>Frontiers in Oncology</i> , 2020, 10, 1162.	1.3	8
2212	BMI1-Mediated Pemetrexed Resistance in Non-Small Cell Lung Cancer Cells Is Associated with Increased SP1 Activation and Cancer Stemness. <i>Cancers</i> , 2020, 12, 2069.	1.7	20
2213	Apatinib in combination with pemetrexed-platinum chemotherapy for chemo-naïve non-squamous non-small cell lung cancer: a phase II clinical study. <i>Lung Cancer</i> , 2020, 147, 229-236.	0.9	9
2214	Phase III study of adjuvant chemotherapy with pemetrexed and cisplatin with a short hydration method for completely resected nonsquamous non-small cell lung cancer. <i>Thoracic Cancer</i> , 2020, 11, 2536-2541.	0.8	7
2215	Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver. <i>Lung Cancer Management</i> , 2020, 9, LMT36.	1.5	19
2216	Management of cisplatin-associated toxicities in bladder cancer patients. <i>Current Opinion in Supportive and Palliative Care</i> , 2020, 14, 286-292.	0.5	9
2217	Network meta-analyses for EGFR mutation-positive non-small-cell lung cancer: systematic review and overview of methods and shortcomings. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 1179-1194.	0.6	1
2218	Tambulin Targets Histone Deacetylase 1 Inhibiting Cell Growth and Inducing Apoptosis in Human Lung Squamous Cell Carcinoma. <i>Frontiers in Pharmacology</i> , 2020, 11, 1188.	1.6	7
2219	Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 944-957.	13.9	542
2220	Novel Multitarget Therapies for Lung Cancer and Respiratory Disease. <i>Molecules</i> , 2020, 25, 3987.	1.7	14
2221	Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 1568.	1.3	2
2222	Prognostic value of log odds of positive lymph nodes in node-positive lung squamous cell carcinoma patients after surgery: a SEER population-based study. <i>Translational Lung Cancer Research</i> , 2020, 9, 1285-1301.	1.3	27
2223	Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients. <i>BMC Cancer</i> , 2020, 20, 875.	1.1	32
2224	Another Brick in the Wall: Sintilimab Plus Chemotherapy in Advanced Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1556-1558.	0.5	5
2225	The Efficacy and Safety of First-Line Chemotherapy in Patients With Non-small Cell Lung Cancer and Interstitial Lung Disease: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 1636.	1.3	8
2226	Past, present and future use of cytotoxic agents in oncology practice: A systematic review of Pubmed and ClinicalTrials.gov databases. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 2069-2072.	0.5	1
2227	An Activatable Nano-Prodrug for Treating Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer and for Optoacoustic and Fluorescent Imaging. <i>Small</i> , 2020, 16, e2003451.	5.2	24

#	ARTICLE	IF	CITATIONS
2228	Variants of SLC22A16 Predict the Efficacy of Platinum Combination Chemotherapy in Advanced Non-small-cell Lung Cancer. <i>Anticancer Research</i> , 2020, 40, 4245-4251.	0.5	4
2229	Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients. <i>Cancer Cell International</i> , 2020, 20, 590.	1.8	0
2230	Changing paradigm in advanced and metastatic non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 6992-7001.	0.6	3
2231	Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi® 1/4, AstraZeneca UK) Tj ETQq1 1207843143gBT /Ove		
2232	Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2020, 26, 517-524.	1.0	18
2233	Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. <i>The Cochrane Library</i> , 2020, 12, CD013257.	1.5	30
2234	Long-term exposure to pemetrexed induces chronic renal dysfunction in patients with advanced and recurrent non-squamous cell lung cancer: a retrospective study. <i>Renal Replacement Therapy</i> , 2020, 6, .	0.3	1
2235	Using the Systemic Immune-Inflammation Index (SII) as a Mid-Treatment Marker for Survival among Patients with Stage-III Locally Advanced Non-Small Cell Lung Cancer (NSCLC). <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 7995.	1.2	14
2236	Hematologic adverse drug reactions leading to hospitalization among cancer patients: A retrospective case-control study. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 784-790.	0.6	1
2237	Timing of Severe Toxicity from Chemotherapy in Patients With Lung Cancer. <i>Anticancer Research</i> , 2020, 40, 6399-6406.	0.5	4
2238	&lt;p&gt;Desmoglein 3 and Keratin 14 for Distinguishing Between Lung Adenocarcinoma and Lung Squamous Cell Carcinoma&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 11111-11124.	1.0	10
2239	Classifying non-small cell lung cancer types and transcriptomic subtypes using convolutional neural networks. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2020, 27, 757-769.	2.2	69
2240	Hedgehog Pathway Activation Might Mediate Pemetrexed Resistance in NSCLC Cells. <i>Anticancer Research</i> , 2020, 40, 1451-1458.	0.5	7
2241	Drug repurposing of pyrimidine analogs as potent antiviral compounds against human enterovirus A71 infection with potential clinical applications. <i>Scientific Reports</i> , 2020, 10, 8159.	1.6	18
2242	GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4901-4910.	3.2	191
2243	A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2020, 40, 2981-2987.	0.5	4
2244	LINC00173.v1 promotes angiogenesis and progression of lung squamous cell carcinoma by sponging miR-511-5p to regulate VEGFA expression. <i>Molecular Cancer</i> , 2020, 19, 98.	7.9	95
2245	Pemetrexed-Based Chemotherapy Is Inferior to Pemetrexed-Free Regimens in Thyroid Transcription Factor 1 (TTF-1)-Negative, EGFR/ALK-Negative Lung Adenocarcinoma: A Propensity Score Matched Pairs Analysis. <i>Clinical Lung Cancer</i> , 2020, 21, e607-e621.	1.1	32



#	ARTICLE	IF	CITATIONS
2246	PNO1, which is negatively regulated by miR-340-5p, promotes lung adenocarcinoma progression through Notch signaling pathway. <i>Oncogenesis</i> , 2020, 9, 58.	2.1	20
2247	Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 2187-2196.	0.8	78
2248	Systemic treatment of brain metastases in non-small cell lung cancer. <i>European Journal of Cancer</i> , 2020, 132, 187-198.	1.3	61
2249	Adjuvant Chemotherapy. <i>Thoracic Surgery Clinics</i> , 2020, 30, 179-185.	0.4	1
2250	Better survival in impaired renal function patients with metastatic non-small cell lung cancer treated by cisplatin-pemetrexed. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1573-1580.	0.8	3
2251	Molecular Diagnostics in Non-Small Cell Lung Carcinoma. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 386-399.	0.8	3
2252	Lung cancer histology-driven strategic therapeutic approaches. <i>Shanghai Chest</i> , 0, 4, 29-29.	0.3	4
2253	The top 100 cited articles in lung cancer – a bibliometric analysis. <i>Wspolczesna Onkologia</i> , 2020, 24, 17-28.	0.7	7
2254	Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors. <i>Journal of Thoracic Disease</i> , 2020, 12, 2859-2876.	0.6	11
2255	Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non-small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, e196828.	3.4	48
2256	Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1505-1517.	0.8	710
2257	Low-Dose Gemcitabine Treatment Enhances Immunogenicity and Natural Killer Cell-Driven Tumor Immunity in Lung Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 331.	2.2	41
2258	Subtyping and EGFR mutation testing from blocks of cytological materials, based on liquid-based cytology for lung cancer at bronchoscopic examinations. <i>Diagnostic Cytopathology</i> , 2020, 48, 516-523.	0.5	11
2259	First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer. <i>Cancer Medicine</i> , 2020, 9, 3310-3318.	1.3	24
2260	The Functional Effects of Key Driver KRAS Mutations on Gene Expression in Lung Cancer. <i>Frontiers in Genetics</i> , 2020, 11, 17.	1.1	7
2261	First-iGAP: A Randomized Placebo-Controlled Phase II Study of First-line Intercalated Gefitinib and Pemetrexed-Cisplatin Chemotherapy for Never-Smoker Lung Adenocarcinoma Patients. <i>Clinical Lung Cancer</i> , 2020, 21, e572-e582.	1.1	0
2262	Rechallenge Strategy in Cancer Therapy. <i>Oncology</i> , 2020, 98, 669-679.	0.9	9
2263	Development and validation of a novel immune-related prognostic model in lung squamous cell carcinoma. <i>International Journal of Medical Sciences</i> , 2020, 17, 1393-1405.	1.1	7

#	ARTICLE	IF	CITATIONS
2264	Effect of anlotinib as a third- or further- line therapy in advanced non-small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial. <i>Cancer Medicine</i> , 2020, 9, 2621-2630.	1.3	19
2265	A novel, more reliable approach to use of progression-free survival as a predictor of gain in overall survival: The Ottawa PFS Predictive Model. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 148, 102896.	2.0	10
2266	ADP ribose polymerase inhibitors for treating non-small cell lung cancer: new additions to the pharmacotherapeutic armamentarium. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 679-686.	0.9	3
2267	Efficacy and Safety of Nivolumab in Previously Treated Patients With Non-small-cell Lung Cancer: Real World Experience in Argentina. <i>Clinical Lung Cancer</i> , 2020, 21, e380-e387.	1.1	19
2268	The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patients. <i>Respiratory Investigation</i> , 2020, 58, 269-274.	0.9	5
2269	Elevated SRC3 expression predicts pemetrexed resistance in lung adenocarcinoma. <i>Biomedicine and Pharmacotherapy</i> , 2020, 125, 109958.	2.5	5
2270	Association Between RET Fusions and Efficacy of Pemetrexed-based Chemotherapy for Patients With Advanced NSCLC in China: A Multicenter Retrospective Study. <i>Clinical Lung Cancer</i> , 2020, 21, e349-e354.	1.1	23
2271	Clinical factors associated with treatment toxicity of pemetrexed plus platinum in elderly patients with non-small cell lung cancer. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1506-1513.	0.8	4
2272	Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. <i>Nature Medicine</i> , 2020, 26, 47-51.	15.2	255
2273	A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 1796-1802.	3.2	8
2274	Precision Management of Advanced Non-small Cell Lung Cancer. <i>Annual Review of Medicine</i> , 2020, 71, 117-136.	5.0	101
2275	Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. <i>The Cochrane Library</i> , 2020, 2020, CD009256.	1.5	28
2276	Randomized phase II study of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for locally advanced non-squamous non-small cell lung cancer: SPECTRA study. <i>Lung Cancer</i> , 2020, 141, 64-71.	0.9	14
2277	The novel proautophagy anticancer drug ABTL0812 potentiates chemotherapy in adenocarcinoma and squamous nonsmall cell lung cancer. <i>International Journal of Cancer</i> , 2020, 147, 1163-1179.	2.3	16
2278	Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. <i>Lancet Oncology</i> , 2020, 21, 373-386.	5.1	300
2279	Pulmonary artery coil embolisation prevented tumour progression in a patient with advanced squamous cell lung carcinoma. <i>Upsala Journal of Medical Sciences</i> , 2020, 125, 257-261.	0.4	0
2280	Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, 661.	3.4	446
2281	Is tissue still the issue in detecting molecular alterations in lung cancer?. <i>Respirology</i> , 2020, 25, 933-943.	1.3	31

#	ARTICLE	IF	CITATIONS
2282	Drug Selection for Formulary Inclusion: An Exploratory Case Study of Oncology Medicines in Jordan. Value in Health Regional Issues, 2020, 21, 211-221.	0.5	2
2283	Shallow whole-genome sequencing of plasma cell-free DNA accurately differentiates small from non-small cell lung carcinoma. Genome Medicine, 2020, 12, 35.	3.6	28
2284	Reweighting Randomized Controlled Trial Evidence to Better Reflect Real Life – A Case Study of the Innovative Medicines Initiative. Clinical Pharmacology and Therapeutics, 2020, 108, 817-825.	2.3	12
2285	Aberrant static and dynamic functional connectivity of the executive control network in lung cancer patients after chemotherapy: a longitudinal fMRI study. Brain Imaging and Behavior, 2020, 14, 927-940.	1.1	11
2286	Pemetrexed sensitizes human lung cancer cells to cytotoxic immune cells. Cancer Science, 2020, 111, 1910-1920.	1.7	21
2287	Long-term safety of icotinib in patients with non-small cell lung cancer: a retrospective, real-world study. Journal of Thoracic Disease, 2020, 12, 639-650.	0.6	6
2288	Therapeutic Landscape of Metastatic Non-Small-Cell Lung Cancer in Canada in 2020. Current Oncology, 2020, 27, 52-60.	0.9	13
2289	Acetyl-11-keto- $\beta$ -boswellic acid enhances the cisplatin sensitivity of non-small cell lung cancer cells through cell cycle arrest, apoptosis induction, and autophagy suppression via p21-dependent signaling pathway. Cell Biology and Toxicology, 2021, 37, 209-228.	2.4	31
2290	Advances in Small-Cell Lung Cancer (SCLC) Translational Research. Cold Spring Harbor Perspectives in Medicine, 2021, 11, a038240.	2.9	34
2291	Histogram Analysis of ADC Maps for Differentiating Brain Metastases From Different Histological Types of Lung Cancers. Canadian Association of Radiologists Journal, 2021, 72, 271-278.	1.1	12
2292	Development, internal validation and calibration of a risk score to predict survival in patients with <i>EGFR</i> -mutant non-small cell lung cancer. Journal of Clinical Pathology, 2021, 74, 116-122.	1.0	5
2293	Phase II study of the combination of S-1 with bevacizumab for patients with previously treated advanced non-squamous non-small-cell lung cancer. International Journal of Clinical Oncology, 2021, 26, 507-514.	1.0	1
2294	From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm. Trends in Cancer, 2021, 7, 15-28.	3.8	61
2295	Targeted drug therapy in nonsmall cell lung cancer: clinical significance and possible solutions-part II (role of nanocarriers). Expert Opinion on Drug Delivery, 2021, 18, 103-118.	2.4	13
2296	Thymidylate synthase drives the phenotypes of epithelial-to-mesenchymal transition in non-small cell lung cancer. British Journal of Cancer, 2021, 124, 281-289.	2.9	22
2297	Clinical Characteristics, Treatments, and Concurrent Mutations in Non-Small Cell Lung Cancer Patients With NF1 Mutations. Clinical Lung Cancer, 2021, 22, 32-41.e1.	1.1	6
2298	Randomized phase II trial of carboplatin + nab-paclitaxel versus cisplatin + gemcitabine for chemotherapy-naïve squamous cell carcinoma: North Japan lung cancer study group 1302. International Journal of Clinical Oncology, 2021, 26, 515-522.	1.0	3
2299	2020 Innovation-Based Optimism for Lung Cancer Outcomes. Oncologist, 2021, 26, e454-e472.	1.9	17

#	ARTICLE	IF	CITATIONS
2300	Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 653-664.	0.5	251
2301	Treatment sequencing for the care of patients with advanced or metastatic non-small cell lung cancer in the United States. <i>Current Medical Research and Opinion</i> , 2021, 37, 469-476.	0.9	1
2302	Recent advances in early stage lung cancer. <i>Journal of Clinical and Translational Research</i> , 0, , .	0.3	4
2303	Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110185.	1.4	12
2304	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Patients with Non-small Cell Lung Cancer of Squamous Histology: Focus on Afatinib. <i>Touch Reviews in Oncology &amp; Haematology</i> , 2021, 17, 36.	0.1	0
2305	Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110229.	1.4	2
2306	The Clinical Impact of Capmatinib in the Treatment of Advanced Non-“Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification. <i>Cancer Research and Treatment</i> , 2021, 53, 1024-1032.	1.3	8
2307	A case of remarkable response to atezolizumab in ALK-translocated metastatic lung adenocarcinoma. <i>Respiratory Medicine Case Reports</i> , 2021, 34, 101478.	0.2	5
2308	Pemetrexed-based first-line chemotherapy had particularly prominent objective response rate for advanced NSCLC: A network meta-analysis. <i>Open Medicine (Poland)</i> , 2021, 16, 183-191.	0.6	2
2309	An integrated epigenomic-transcriptomic landscape of lung cancer reveals novel methylation driver genes of diagnostic and therapeutic relevance. <i>Theranostics</i> , 2021, 11, 5346-5364.	4.6	23
2310	Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome. <i>Translational Lung Cancer Research</i> , 2021, 10, 202-220.	1.3	29
2311	Analysis of bevacizumab treatments and metastatic sites of lung cancer. <i>Cancer Treatment and Research Communications</i> , 2021, 26, 100290.	0.7	5
2312	Survival prediction for non-small cell lung cancer patients treated with CT-guided microwave ablation: development of a prognostic nomogram. <i>International Journal of Hyperthermia</i> , 2021, 38, 640-649.	1.1	9
2313	A Phase II study of nab-Paclitaxel (nab-P) in patients with advanced non-small cell lung cancer with EGFR mutations after frontline tyrosine kinase inhibitor therapy. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100416.	0.7	0
2314	Effects of SLC31A1 and ATP7B polymorphisms on platinum resistance in patients with esophageal squamous cell carcinoma receiving neoadjuvant chemoradiotherapy. <i>Medical Oncology</i> , 2021, 38, 6.	1.2	11
2315	Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 563-580.	1.3	14
2316	An Open-Label Randomized Controlled Trial Comparing the Efficacy and Safety of Pemetrexed-Carboplatin versus (Weekly) Paclitaxel-Carboplatin as First-Line Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer. <i>Oncology</i> , 2021, 99, 389-396.	0.9	4
2317	Detecting TYMS Tandem Repeat Polymorphism by the PSSD Method Based on Next-generation Sequencing. <i>Current Bioinformatics</i> , 2021, 15, 1153-1159.	0.7	1

#	ARTICLE	IF	CITATIONS
2318	miR-31 Displays Subtype Specificity in Lung Cancer. <i>Cancer Research</i> , 2021, 81, 1942-1953.	0.4	11
2319	Carcinoma de pulmão não microcítico. <i>Medicine</i> , 2021, 13, 1377-1387.	0.0	2
2320	Uncovering the Pharmacological Mechanism of 2-Dodecyl-6-Methoxycyclohexa-2,5 -Diene-1,4-Dione Against Lung Cancer Based on Network Pharmacology and Experimental Evaluation. <i>Frontiers in Pharmacology</i> , 2021, 12, 617555.	1.6	5
2321	Analysis of metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. <i>Annals of Translational Medicine</i> , 2021, 9, 206-206.	0.7	4
2322	Second-line therapy improves overall survival in primary refractory non-small cell lung cancer (NSCLC) patients. <i>ESMO Open</i> , 2021, 6, 100013.	2.0	2
2323	Efficacy and safety of carboplatin and pemetrexed followed by maintenance with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer: A single-arm, open-label, multicenter, phase II study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 486-494.	0.7	1
2324	High lymphocyte population-related predictive factors for a long-term response in non-small cell lung cancer patients treated with pemetrexed: a retrospective observational study. <i>Journal of Translational Medicine</i> , 2021, 19, 92.	1.8	5
2325	Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100131.	0.6	4
2326	The Gustave Roussy Immune (GRIIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab. <i>Journal of Clinical Medicine</i> , 2021, 10, 1005.	1.0	23
2327	Efficacy and safety of pemetrexed maintenance chemotherapy for advanced non-small cell lung cancer in a real-world setting. <i>Journal of Thoracic Disease</i> , 2021, 13, 1813-1821.	0.6	3
2328	Bioinformatics-Based Identification of HDAC Inhibitors as Potential Drugs to Target EGFR Wild-Type Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 620154.	1.3	0
2329	Analysis of Chronic Mild Stress-Induced Hypothalamic Proteome: Identification of Protein Dysregulations Associated With Vulnerability and Resiliency to Depression or Anxiety. <i>Frontiers in Molecular Neuroscience</i> , 2021, 14, 633398.	1.4	10
2330	Lung cancer chemotherapy using nanoparticles: Enhanced target ability of redox-responsive and pH-sensitive cisplatin prodrug and paclitaxel. <i>Biomedicine and Pharmacotherapy</i> , 2021, 136, 111249.	2.5	27
2331	Overcoming therapy resistance in EGFR-mutant lung cancer. <i>Nature Cancer</i> , 2021, 2, 377-391.	5.7	198
2332	Malignant Pleural Mesothelioma Interactome with 364 Novel Protein-Protein Interactions. <i>Cancers</i> , 2021, 13, 1660.	1.7	8
2333	PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the best strategy. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 160, 103302.	2.0	18
2334	Vascular Acrosyndromes Associated With Prolonged Tumor Response in Advanced Lung Cancer Patients During Treatment With Antimetabolites: A Report of Two Cases. <i>Frontiers in Oncology</i> , 2021, 11, 644282.	1.3	3
2335	Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. <i>The Cochrane Library</i> , 2021, 2021, CD013257.	1.5	35

#	ARTICLE	IF	CITATIONS
2336	Challenges and Novel Opportunities of Radiation Therapy for Brain Metastases in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 2141.	1.7	11
2337	Overexpression of PVR and PD-L1 and its association with prognosis in surgically resected squamous cell lung carcinoma. <i>Scientific Reports</i> , 2021, 11, 8551.	1.6	13
2338	Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, 709.	3.4	185
2339	Gemcitabine maintenance therapy after gemcitabine and platinum drug chemotherapy for naive stage IIIB/IV squamous cell lung cancer. <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, 767-772.	0.7	2
2340	Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2021, 125, 510-519.	2.9	59
2342	Current advances in the treatment of lung cancer with immune checkpoint inhibitors. <i>Journal of the Korean Medical Association</i> , 2021, 64, 333-341.	0.1	0
2343	The expression of Nanog protein and fibroblast growth factor-inducible molecule 14 in patients with non-small cell lung cancer and their relationship with pathological characteristics and prognosis. <i>Translational Cancer Research</i> , 2021, 10, 2470-2477.	0.4	4
2344	Improving the Subtype Classification of Non-small Cell Lung Cancer by Elastic Deformation Based Machine Learning. <i>Journal of Digital Imaging</i> , 2021, 34, 605-617.	1.6	8
2345	Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2021, 4, e2111113.	2.8	17
2346	The Optimal Adjuvant Strategy of Aidi Injection With Gemcitabine and Cisplatin in Advanced Non-Small Cell Lung Cancer: A Meta-analysis of 70 Randomized Controlled Trials. <i>Frontiers in Pharmacology</i> , 2021, 12, 582447.	1.6	10
2347	The future in the instant: The lung adenocarcinoma classification as a predictor of future adverse events. <i>Lung Cancer</i> , 2021, 155, 191-192.	0.9	0
2348	circCCND1 Regulates Oxidative Stress and FGF9 to Enhance Chemoresistance of Non-Small Cell Lung Cancer via Sponging miR-187-3p. <i>DNA and Cell Biology</i> , 2021, 40, 675-682.	0.9	7
2349	Long-Term Survival Effect of the Interval between Postoperative Chemotherapy and Radiotherapy in Patients with Completely Resected Pathological N2 Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 2494.	1.7	2
2350	Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report. <i>BMC Nephrology</i> , 2021, 22, 175.	0.8	6
2351	Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment. <i>Anticancer Research</i> , 2021, 41, 2597-2603.	0.5	0
2352	ERCC1 Is a Predictive Biomarker for Non-small Cell Lung Cancer But Is Antibody-dependent. <i>Anticancer Research</i> , 2021, 41, 2653-2660.	0.5	3
2353	Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189. <i>Lung Cancer</i> , 2021, 155, 53-60.	0.9	8
2354	Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia. <i>Expert Review of Hematology</i> , 2021, 14, 437-448.	1.0	29

#	ARTICLE	IF	CITATIONS
2355	Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations. <i>BMC Cancer</i> , 2021, 21, 495.	1.1	8
2356	Additive Antiproliferative and Antiangiogenic Effects of Metformin and Pemetrexed in a Non-Small-Cell Lung Cancer Xenograft Model. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 688062.	1.8	12
2357	Knowledge and Practice Patterns Among Pulmonologists for Molecular Biomarker Testing in Advanced Non-small Cell Lung Cancer. <i>Chest</i> , 2021, 160, 2293-2303.	0.4	11
2358	Randomized, Double-Blind Trial on the Impact of Word Count in Cancer Clinical Trial Consent Forms. <i>JCO Oncology Practice</i> , 2021, 17, e1460-e1472.	1.4	3
2359	Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 156, 41-49.	0.9	66
2360	One carbon metabolism in human lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2523-2538.	1.3	14
2361	Evaluation of Computer-Aided Nodule Assessment and Risk Yield (CANARY) in Korean patients for prediction of invasiveness of ground-glass opacity nodule. <i>PLoS ONE</i> , 2021, 16, e0253204.	1.1	1
2362	Anlotinib, a novel TKI, as a third-line or further-line treatment in patients with advanced non-small cell lung cancer in China. <i>Medicine (United States)</i> , 2021, 100, e25709.	0.4	2
2363	Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2021, 22, 72.	1.3	9
2364	Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial. <i>Lung Cancer</i> , 2021, 156, 91-99.	0.9	11
2365	Predictive Radiomic Models for the Chemotherapy Response in Non-Small-Cell Lung Cancer based on Computerized-Tomography Images. <i>Frontiers in Oncology</i> , 2021, 11, 646190.	1.3	12
2366	A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 157, 21-29.	0.9	8
2367	Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer (<scp>SCC</scp>): A post hoc analysis of the <scp>ALTER0303</scp> trial. <i>Thoracic Cancer</i> , 2021, 12, 2345-2351.	0.8	5
2368	Bevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open-label phase 2 study (CLEAR). <i>Translational Lung Cancer Research</i> , 2021, 10, 3059-3070.	1.3	2
2369	Survival Trends of Metastatic Lung Cancer in California by Age at Diagnosis, Gender, Race/Ethnicity, and Histology, 1990-2014. <i>Clinical Lung Cancer</i> , 2021, 22, e602-e611.	1.1	5
2370	The efficacy and safety of combination therapy with immune checkpoint inhibitors in non-small cell lung cancer: A meta-analysis. <i>International Immunopharmacology</i> , 2021, 96, 107594.	1.7	11
2371	Efficacy of Sâ€ after pemetrexed in patients with nonâ€small cell lung cancer: A retrospective multiâ€institutional analysis. <i>Thoracic Cancer</i> , 2021, 12, 2300-2306.	0.8	1
2372	Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1952-1958.	0.5	32

#	ARTICLE	IF	CITATIONS
2373	Update on recent key publications in lung oncology: picking up speed. <i>European Respiratory Review</i> , 2021, 30, 200300.	3.0	1
2374	Benefits of Metformin Combined with Pemetrexed-Based Platinum Doublets as a First-Line Therapy for Advanced Lung Adenocarcinoma Patients with Diabetes. <i>Biomolecules</i> , 2021, 11, 1252.	1.8	5
2375	Cancer-associated fibroblast-derived CCL5 contributes to cisplatin resistance in A549 NSCLC cells partially through upregulation of lncRNA HOTAIR expression. <i>Oncology Letters</i> , 2021, 22, 696.	0.8	17
2376	Treatment patterns in patients with metastatic non-small-cell lung cancer in the era of immunotherapy. <i>Future Oncology</i> , 2021, 17, 2940-2949.	1.1	11
2377	Toward personalized treatment approaches for non-small-cell lung cancer. <i>Nature Medicine</i> , 2021, 27, 1345-1356.	15.2	338
2378	Phase 1, pharmacogenomic, dose-expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancer. <i>Cancer Medicine</i> , 2021, 10, 6642-6652.	1.3	11
2379	Inferior outcome of bone metastasis in non-small-cell-lung-cancer patients treated with epidermal growth factor receptor inhibitors. <i>Journal of Bone Oncology</i> , 2021, 29, 100369.	1.0	5
2380	The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1721-1735.	1.2	3
2381	PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis. <i>Future Oncology</i> , 2021, 17, 4415-4424.	1.1	6
2382	Global effects of RAB3GAP1 dysexpression on the proteome of mouse cortical neurons. <i>Amino Acids</i> , 2021, 53, 1339-1350.	1.2	4
2383	Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients With Metastatic NSCLC. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100208.	0.6	0
2384	Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway. <i>Cell Death and Disease</i> , 2021, 12, 772.	2.7	11
2385	A phase I study of the anaplastic lymphoma kinase inhibitor ceritinib in combination with gemcitabine-based chemotherapy in patients with advanced solid tumors. <i>International Journal of Cancer</i> , 2021, 149, 2063-2074.	2.3	8
2386	Palm Pustules Induced by Pemetrexed. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1589-1591.	0.5	1
2387	Post-chemotherapy and targeted therapy imaging of the chest in lung cancer. <i>Clinical Radiology</i> , 2022, 77, e1-e10.	0.5	5
2388	The Effects of WISP1 Polymorphisms on the Prognosis of Lung Cancer Patients with Platinum-Based Chemotherapy. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 1193-1203.	0.4	1
2389	Nitrate increases cisplatin chemosensitivity of oral squamous cell carcinoma via REDD1/AKT signaling pathway. <i>Science China Life Sciences</i> , 2021, 64, 1814-1828.	2.3	6
2390	A Comprehensive Review of Current Perspectives on Novel Drug Delivery Systems and Approaches for Lung Cancer Management. <i>Journal of Pharmaceutical Innovation</i> , 2022, 17, 1530-1553.	1.1	4



#	ARTICLE	IF	CITATIONS
2391	Upregulation of Thymidylate Synthase Induces Pemetrexed Resistance in Malignant Pleural Mesothelioma. <i>Frontiers in Pharmacology</i> , 2021, 12, 718675.	1.6	8
2392	Long-Term Progression-Free Survival in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Patient Treated With Crizotinib. <i>Journal of Medical Cases</i> , 2021, 12, 366-368.	0.4	1
2393	Novel Mitochondria-Based Targeting Restores Responsiveness in Therapeutically Resistant Human Lung Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2527-2538.	1.9	6
2394	Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12). <i>Journal of Thoracic Oncology</i> , 2021, 16, 1501-1511.	0.5	158
2395	Pemetrexed plus cisplatin in patients with previously treated advanced sarcoma: a multicenter, single-arm, phase II trial. <i>ESMO Open</i> , 2021, 6, 100249.	2.0	3
2396	Comparative Proteomics of Rat Olfactory Bulb Reveal Insights into Susceptibility and Resiliency to Chronic-stress-induced Depression or Anxiety. <i>Neuroscience</i> , 2021, 473, 29-43.	1.1	6
2397	Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation study. <i>Lung Cancer</i> , 2021, 161, 180-188.	0.9	14
2398	Efficacy and Safety of Lipegfilgrastim in Lung Cancer Patients Receiving Myelosuppressive Chemotherapy in a Real-World Setting: Results of an Analysis of Pooled Data from Two Non-Interventional European Studies. <i>Oncology Research and Treatment</i> , 2021, 44, 1-9.	0.8	1
2399	Assessing efficacy and safety of stereotactic body radiation therapy for oligometastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) wild type. <i>Translational Cancer Research</i> , 2021, 10, 184-194.	0.4	0
2400	A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592199650.	1.4	1
2401	Detection of Non-Small Lung Cell Carcinoma-Associated Genetic Alterations Using a NanoString Gene Expression Platform Approach. <i>Methods in Molecular Biology</i> , 2021, 2279, 91-107.	0.4	0
2403	Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort. <i>Frontiers in Oncology</i> , 2020, 10, 590356.	1.3	4
2404	Phase II Study of Pemetrexed as a Salvage Chemotherapy for Thymidylate Synthase-“Low Squamous Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2021, 53, 87-92.	1.3	0
2405	Roles of ARF tumour suppressor protein in lung cancer: time to hit the nail on the head!. <i>Molecular and Cellular Biochemistry</i> , 2021, 476, 1365-1375.	1.4	2
2406	Long-Term Survival of Patients with Metastatic Non-Small-Cell Lung Cancer over Five Decades. <i>Journal of Oncology</i> , 2021, 2021, 1-10.	0.6	16
2407	Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV <i>EGFR</i> Variant-“Positive Non-“Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2020, 3, e2030442.	2.8	42
2410	Mutational Profile Evaluates Response and Survival to First-Line Chemotherapy in Lung Cancer. <i>Advanced Science</i> , 2021, 8, 2003263.	5.6	14
2411	Circular RNA hsa_circ_0085131 is involved in cisplatin-resistance of non-small cell lung cancer cells by regulating autophagy. <i>Cell Biology International</i> , 2020, 44, 1945-1956.	1.4	37



#	ARTICLE	IF	CITATIONS
2436	The Cost of Treating Advanced Non-Small Cell Lung Cancer: Estimates from the Chinese Experience. PLoS ONE, 2012, 7, e48323.	1.1	36
2437	The Impact of Bevacizumab (Avastin) on Survival in Metastatic Solid Tumors - A Meta-Analysis and Systematic Review. PLoS ONE, 2013, 8, e51780.	1.1	72
2438	Eligibility for Bevacizumab as an Independent Prognostic Factor for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study. PLoS ONE, 2013, 8, e59700.	1.1	12
2439	The Association between COX-2 Polymorphisms and Hematologic Toxicity in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Platinum-Based Chemotherapy. PLoS ONE, 2013, 8, e61585.	1.1	8
2440	Efficacy and Safety Profile of Combining Vandetanib with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer: A Meta-Analysis. PLoS ONE, 2013, 8, e67929.	1.1	6
2441	EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer. PLoS ONE, 2013, 8, e72966.	1.1	11
2442	Association between Gene Expression Profiles and Clinical Outcome of Pemetrexed-Based Treatment in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: Exploratory Results from a Phase II Study. PLoS ONE, 2014, 9, e107455.	1.1	10
2443	The Response, Outcome and Toxicity of Aggressive Palliative Thoracic Radiotherapy for Metastatic Non-Small Cell Lung Cancer Patients with Controlled Extrathoracic Diseases. PLoS ONE, 2015, 10, e0145936.	1.1	15
2444	Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIET). PLoS ONE, 2016, 11, e0147599.	1.1	17
2445	Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting. PLoS ONE, 2017, 12, e0178420.	1.1	73
2446	Pemetrexed-Induced Interstitial Pneumonitis: A Case Study and Literature Review. World Journal of Oncology, 2014, 5, 232-236.	0.6	7
2447	Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines. Oncotarget, 2016, 7, 76577-76589.	0.8	13
2448	Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC. Oncotarget, 2017, 8, 43555-43570.	0.8	10
2449	Astrocyte-elevated gene-1 confers resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase expression. Oncotarget, 2017, 8, 61901-61916.	0.8	10
2450	Identification of microRNA differentially expressed in three subtypes of non-small cell lung cancer and in silico functional analysis. Oncotarget, 2017, 8, 74554-74566.	0.8	20
2451	Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev). Oncotarget, 2017, 8, 75904-75913.	0.8	23
2452	Ex vivo evaluation of tumor cell specific drug responses in malignant pleural effusions. Oncotarget, 2017, 8, 82885-82896.	0.8	4
2453	Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2. Oncotarget, 2014, 5, 4529-4542.	0.8	41

#	ARTICLE	IF	CITATIONS
2454	Effect of postoperative systemic therapy on pulmonary adenocarcinoma with unexpected pleural spread detected during thoracotomy or thoracoscopy. <i>Oncotarget</i> , 2018, 9, 5435-5444.	0.8	6
2455	Cav3.1 overexpression is associated with negative characteristics and prognosis in non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 8573-8583.	0.8	10
2456	Novel drug-resistance mechanisms of pemetrexed-treated non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 16807-16821.	0.8	24
2457	Targeted therapies for advanced non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 37589-37607.	0.8	52
2458	A multicenter, single-arm, basket design, phase II study of NC-6004 plus gemcitabine in patients with advanced unresectable lung, biliary tract, or bladder cancer. <i>Oncotarget</i> , 2020, 11, 3105-3117.	0.8	15
2459	A retrospective analysis of cisplatin, pemetrexed, and bevacizumab in previously treated non-small-cell lung cancer. <i>Oncotarget</i> , 2015, 6, 22750-22757.	0.8	7
2460	Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance. <i>Oncotarget</i> , 2012, 3, 414-25.	0.8	129
2461	Inhibition of autophagy potentiates pemetrexed and simvastatin-induced apoptotic cell death in malignant mesothelioma and non-small cell lung cancer cells. <i>Oncotarget</i> , 2015, 6, 29482-29496.	0.8	41
2462	Folate Receptor Alpha Expression in Lung Cancer: Diagnostic and Prognostic Significance. <i>Oncotarget</i> , 2012, 3, 414-425.	0.8	175
2463	Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology. <i>Oncotarget</i> , 2015, 6, 32602-32609.	0.8	15
2464	Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the treatment of lung squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 2496-2507.	0.8	31
2465	Folic-acid metabolism and DNA-repair phenotypes differ between neuroendocrine lung tumors and associate with aggressive subtypes, therapy resistance and outcome. <i>Oncotarget</i> , 2016, 7, 20166-20179.	0.8	11
2466	Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies. <i>Oncotarget</i> , 2016, 7, 40781-40791.	0.8	10
2467	Clinical significance of the preoperative platelet count and platelet-to-lymphocyte ratio (PLT-PLR) in patients with surgically resected non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 36198-36206.	0.8	30
2468	Clinical-pathological and molecular characterization of long-term survivors with advanced non-small cell lung cancer. <i>Cancer Biology and Medicine</i> , 2020, 17, 444-457.	1.4	9
2469	Weight gain as a surrogate marker of longer survival in advanced non-small cell lung cancer patients. <i>Annals of Translational Medicine</i> , 2016, 4, 381-381.	0.7	9
2470	The emerging treatment landscape of advanced non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2018, 6, 138-138.	0.7	29
2471	Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?. <i>Annals of Translational Medicine</i> , 2018, 6, 143-143.	0.7	13

#	ARTICLE	IF	CITATIONS
2472	Novel chemotherapy regimens for advanced lung cancer: have we reached a plateau?. <i>Annals of Translational Medicine</i> , 2018, 6, 139-139.	0.7	44
2473	Is there an optimal time to initiate adjuvant chemotherapy to predict benefit of survival in non-small cell lung cancer?. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2017, 29, 263-271.	0.7	6
2474	Weekly albumin-bound paclitaxel/cisplatin versus gemcitabine/cisplatin as first-line therapy for patients with advanced non-small-cell lung cancer: A phase II open-label clinical study. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2019, 31, 339-348.	0.7	6
2475	First-line pemetrexed-platinum doublet chemotherapy with or without bevacizumab in non-squamous non-small cell lung cancer: A real-world propensity score-matched study in China. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2019, 31, 749-758.	0.7	5
2476	Cancer chemotherapy: targeting folic acid synthesis. <i>Cancer Management and Research</i> , 2010, 2, 293-301.	0.9	122
2477	Novel compounds in the treatment of lung cancer: current and developing therapeutic agents. <i>Journal of Experimental Pharmacology</i> , 2011, 3, 21.	1.5	4
2478	Establishment and Characterization of Pemetrexed-resistant NCI-H460/PMT Cells. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2019, 19, 731-739.	0.9	5
2479	Molecular Factors Associated with Pemetrexed Sensitivity According to Histological Type in Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2016, 36, 6319-6326.	0.5	11
2480	CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy. <i>Anticancer Research</i> , 2017, 37, 935-940.	0.5	20
2481	Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer. <i>Anticancer Research</i> , 2017, 37, 2501-2507.	0.5	14
2482	Olanzapine, an Atypical Antipsychotic, Inhibits Survivin Expression and Sensitizes Cancer Cells to Chemotherapeutic Agents. <i>Anticancer Research</i> , 2017, 37, 6177-6188.	0.5	27
2483	Expression of Estrogen Receptor- $\beta$ and Survival in Advanced-stage Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2018, 38, 2261-2269.	0.5	11
2484	Treatment of performance status 2 patients with advanced non-small-cell lung cancer: what we know and what we don't know. <i>Future Oncology</i> , 2009, 5, 837-841.	1.1	8
2485	Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. <i>Health Technology Assessment</i> , 2010, 14, 47-53.	1.3	6
2486	Post-operative chemotherapy with pemetrexed alone for elder patients with non-small cell lung cancer. <i>Academic Journal of Second Military Medical University</i> , 2010, 29, 1432-1434.	0.0	1
2492	CDKN1A upregulation and cisplatin-pemetrexed resistance in non-small cell lung cancer cells. <i>International Journal of Oncology</i> , 2020, 56, 1574-1584.	1.4	19
2493	Comparing cryoablation and microwave ablation for the treatment of patients with stage I-IIIB/IV non-small cell lung cancer. <i>Oncology Letters</i> , 2020, 19, 1031-1041.	0.8	14
2494	Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab. <i>Oncology Letters</i> , 2020, 19, 1559-1566.	0.8	46

#	ARTICLE	IF	CITATIONS
2495	Predictive value of tumor genetic alteration profiling for chemotherapy and EGFR TKI treatment in advanced NSCLC. <i>Oncology Letters</i> , 2020, 19, 3859-3870.	0.8	1
2496	Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 50-59.	0.7	14
2497	Selection of chemotherapy for patients with advanced non-small cell lung cancer. <i>Cleveland Clinic Journal of Medicine</i> , 2012, 79, S46-S50.	0.6	10
2498	Comparative outcomes of squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of ASA404 (DMXAA) - retrospective analysis of pooled data. <i>Journal of Thoracic Disease</i> , 2010, 2, 199-204.	0.6	30
2499	Update on anti-angiogenic therapy in non-small cell lung cancer: Are we making progress?. <i>Journal of Thoracic Disease</i> , 2011, 3, 19-29.	0.6	31
2500	Treatment of advanced non small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2011, 3, 122-33.	0.6	99
2501	Hydration with magnesium and mannitol without furosemide prevents the nephrotoxicity induced by cisplatin and pemetrexed in patients with advanced non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2012, 4, 562-8.	0.6	51
2502	Treatment of non-small cell lung cancer (NSCLC). <i>Journal of Thoracic Disease</i> , 2013, 5 Suppl 4, S389-96.	0.6	147
2503	Chemotherapy advances in small-cell lung cancer. <i>Journal of Thoracic Disease</i> , 2013, 5 Suppl 5, S565-78.	0.6	75
2504	The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era. <i>Journal of Thoracic Disease</i> , 2013, 5 Suppl 5, S556-64.	0.6	17
2505	Combining targeted agents and hypo- and hyper-fractionated radiotherapy in NSCLC. <i>Journal of Thoracic Disease</i> , 2014, 6, 356-68.	0.6	1
2506	The new IASLC/ATS/ERS lung adenocarcinoma classification from a clinical perspective: current concepts and future prospects. <i>Journal of Thoracic Disease</i> , 2014, 6, S526-36.	0.6	46
2507	Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification. <i>Journal of Thoracic Disease</i> , 2014, 6, S502-25.	0.6	13
2508	Sequential treatment of icotinib after first-line pemetrexed in advanced lung adenocarcinoma with unknown EGFR gene status. <i>Journal of Thoracic Disease</i> , 2014, 6, 958-64.	0.6	9
2509	Maintenance therapy in non-small-cell lung cancer. <i>Translational Lung Cancer Research</i> , 2012, 1, 105-10.	1.3	3
2510	Predictive models for customizing chemotherapy in advanced non-small cell lung cancer (NSCLC). <i>Translational Lung Cancer Research</i> , 2013, 2, 160-71.	1.3	11
2511	Adjuvant chemotherapy of completely resected early stage non-small cell lung cancer (NSCLC). <i>Translational Lung Cancer Research</i> , 2013, 2, 403-10.	1.3	36
2512	Clinical trials for lung cancer in China. <i>Translational Lung Cancer Research</i> , 2014, 3, 311-6.	1.3	2

#	ARTICLE	IF	CITATIONS
2513	Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer-the Holy Grail in cancer treatment?. <i>Translational Lung Cancer Research</i> , 2015, 4, 223-7.	1.3	18
2514	PROFILE 1014: lessons for the new era of lung cancer clinical research. <i>Translational Lung Cancer Research</i> , 2015, 4, 642-8.	1.3	9
2515	Treatment of advanced squamous cell carcinoma of the lung: a review. <i>Translational Lung Cancer Research</i> , 2015, 4, 524-32.	1.3	74
2516	Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysis. <i>Translational Lung Cancer Research</i> , 2015, 4, 392-403.	1.3	24
2517	Overall survival in non-small cell lung cancer-what is clinically meaningful?. <i>Translational Lung Cancer Research</i> , 2016, 5, 115-9.	1.3	23
2518	Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future. <i>Annals of Cardiothoracic Surgery</i> , 2012, 1, 508-15.	0.6	42
2519	Pemetrexed Induced Pneumonitis. <i>Clinics and Practice</i> , 2011, 1, e106.	0.6	8
2520	Chemotherapy regimens for metastatic nonsmall cell lung cancer: Generating good quality data is important before challenging evidence. <i>Lung India</i> , 2016, 33, 470.	0.3	1
2521	Role of FNAC, fluid specimens, and cell blocks for cytological diagnosis of lung cancer in the present era. <i>Journal of Cytology</i> , 2015, 32, 217.	0.2	11
2522	Role of Crizotinib in previously treated non-small-cell lung cancer. <i>South Asian Journal of Cancer</i> , 2014, 03, 138-140.	0.2	4
2523	Lung cancer in India: Current status and promising strategies. <i>South Asian Journal of Cancer</i> , 2016, 05, 093-095.	0.2	25
2524	Lung cancer in the Indian subcontinent. <i>South Asian Journal of Cancer</i> , 2016, 05, 095-103.	0.2	63
2525	Efficacy and toxicity profile of maintenance pemetrexed in patients with stage IV adenocarcinoma lung in Indian population. <i>South Asian Journal of Cancer</i> , 2016, 05, 196-203.	0.2	3
2526	Prevalence of the epidermal growth factor receptor mutations in lung adenocarcinoma patients from the Middle East region. <i>Annals of Thoracic Medicine</i> , 2019, 14, 173.	0.7	8
2527	Saudi lung cancer management guidelines 2017. <i>Annals of Thoracic Medicine</i> , 2017, 12, 221.	0.7	16
2528	Indian consensus statement for treatment of advanced non small cell lung cancer: First line, maintenance, and second line. <i>Indian Journal of Cancer</i> , 2017, 54, 89.	0.2	5
2529	Radical radiotherapy or chemoradiotherapy for inoperable, locally advanced, non-small cell lung cancer: Analysis of patient profile, treatment approaches, and outcomes for 213 patients at a tertiary cancer center. <i>Indian Journal of Cancer</i> , 2018, 55, 125.	0.2	6
2530	Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line – Indian consensus statement update. <i>South Asian Journal of Cancer</i> , 2019, 08, 01-17.	0.2	8

#	ARTICLE	IF	CITATIONS
2531	First-line management of metastatic non-small cell lung cancer: An Indian perspective. South Asian Journal of Cancer, 2019, 08, 073-079.	0.2	4
2532	Phase II Clinical Trial of Genexol(R) (Paclitaxel) and Carboplatin for Patients with Advanced Non-small Cell Lung Cancer. Cancer Research and Treatment, 2011, 43, 19-23.	1.3	12
2533	Pemetrexed Continuation Maintenance in Patients with Nonsquamous Non-small Cell Lung Cancer: Review of Two East Asian Trials in Reference to PARAMOUNT. Cancer Research and Treatment, 2015, 47, 424-435.	1.3	5
2534	Interstitial Pneumonitis after Treatment with Pemetrexed for Non-small Cell Lung Cancer. Cancer Research and Treatment, 2013, 45, 74-77.	1.3	14
2535	Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase II Trial. Cancer Research and Treatment, 2015, 47, 616-629.	1.3	10
2536	Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations. Cancer Research and Treatment, 2015, 47, 630-637.	1.3	21
2537	Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer. Cancer Research and Treatment, 2016, 48, 80-87.	1.3	14
2538	Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea. Cancer Research and Treatment, 2020, 52, 292-300.	1.3	17
2539	Recent Advances in Molecular Targeted Therapy for advanced Colorectal Cancer and Non-Small Cell Lung Cancer. , 2012, 02, .		1
2540	Safety and efficacy of pemetrexed in gynecologic cancers: A systematic literature review. Modern Chemotherapy, 2013, 02, 19-32.	0.5	6
2541	Molecular predictors of gemcitabine response in pancreatic cancer. World Journal of Gastrointestinal Oncology, 2011, 3, 153.	0.8	64
2542	Targeted treatments for metastatic esophageal squamous cell cancer. World Journal of Gastrointestinal Oncology, 2013, 5, 88.	0.8	8
2543	Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies. World Journal of Clinical Oncology, 2011, 2, 367.	0.9	39
2544	Review of the treatment of metastatic non small cell lung carcinoma: A practical approach. World Journal of Clinical Oncology, 2011, 2, 262.	0.9	9
2545	Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma. World Journal of Clinical Oncology, 2013, 4, 29.	0.9	11
2546	Apoptosis block as a barrier to effective therapy in non small cell lung cancer. World Journal of Clinical Oncology, 2014, 5, 588.	0.9	21
2547	Advances in adjuvant systemic therapy for non-small-cell lung cancer. World Journal of Clinical Oncology, 2014, 5, 633.	0.9	19
2548	Emerging role of thymidylate synthase for the pharmacogenomic selection of patients with thoracic cancer. International Journal of Clinical Pharmacology and Therapeutics, 2010, 48, 481-482.	0.3	4



#	ARTICLE	IF	CITATIONS
2549	Individualized Systemic Treatment of Lung Cancer. <i>Disease and Molecular Medicine</i> , 2013, 1, 15.	0.1	1
2550	The role of BRCA1 in non-small cell lung cancer. <i>Biomedical Papers of the Medical Faculty of the University Palacky&amp;#x0301;, Olomouc, Czechoslovakia</i> , 2012, 156, 200-203.	0.2	8
2551	Association of CYP3A4*1B and CYP3A5*3 genetic polymorphisms with lung cancer and its impact on taxane metabolism in Indian population. <i>Acta Medica International</i> , 2015, 2, 19.	0.2	1
2552	Application of Cancer Genomics to Solve Unmet Clinical Needs. <i>Genomics and Informatics</i> , 2013, 11, 174.	0.4	9
2553	Mixed Adenocarcinomas of the Lung: Place in New Proposals in Classification, Mandatory for Target Therapy. <i>Archives of Pathology and Laboratory Medicine</i> , 2010, 134, 55-65.	1.2	28
2554	Nonâ€“Small Cell Lung Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2008, 6, 228.	2.3	343
2555	Comparative Effectiveness of Carboplatin/Pemetrexed With Versus Without Bevacizumab for Advanced Nonsquamous Nonâ€“Small Cell Lung Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 469-477.	2.3	16
2556	Clinical Observation and Prognostic Analysis of Pemetrexed plus Platinum as First-line Treatment in Patients with Advanced Non-small Cell Lung Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 6267-6271.	0.5	10
2557	Clinical Investigation of Efficacy of Albumin Bound Paclitaxel plus Platinum Compounds as First-line Chemotherapy for Stage III/IV Squamous Non-small Cell Lung Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 7453-7457.	0.5	20
2558	Randomized Control Study of Nedaplatin or Cisplatin Concomitant with Other Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 731-736.	0.5	16
2559	Efficacy and Survival-associated Factors with Gefitinib Combined with Cisplatin and Gemcitabine for Advanced Non-small Cell Lung Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 15, 10967-10970.	0.5	5
2560	Effectiveness and Safety of Pemetrexed Versus Docetaxel as a Treatment for Advanced Non-small Cell Lung Cancer: a Systematic Review and Meta-analysis. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 3419-3424.	0.5	12
2561	Roles of Immunohistochemical Staining in Diagnosing Pulmonary Squamous Cell Carcinoma. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 551-557.	0.5	4
2562	Assays for predicting and monitoring responses to lung cancer immunotherapy. <i>Cancer Biology and Medicine</i> , 2015, 12, 87-95.	1.4	35
2563	Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies. <i>Drugs in Context</i> , 2015, 4, 1-7.	1.0	32
2565	Cancers bronchiques de stade III : rÃ¢le de lâ€™onco-radiothÃ©rapeute. <i>Revue Des Maladies Respiratoires Actualites</i> , 2021, 13, 2S97-2S108.	0.0	0
2566	Infections virales chroniques (hÃ©patites, VIH) et impact sur le choix thÃ©rapeutique. <i>Revue Des Maladies Respiratoires Actualites</i> , 2021, 13, 2S272-2S279.	0.0	0
2567	Proteomic Insights Into Susceptibility and Resistance to Chronic-Stress-Induced Depression or Anxiety in the Rat Striatum. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 730473.	1.6	4

#	ARTICLE	IF	CITATIONS
2568	Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer: A Network Meta-Analysis of Randomized Clinical Trials. <i>Frontiers in Pharmacology</i> , 2021, 12, 686876.	1.6	9
2569	Brigatinib treated <scp>ALK</scp> positive lung squamous cell carcinoma after failed chemotherapy: A case report. <i>Thoracic Cancer</i> , 2021, 12, 3273-3276.	0.8	3
2570	International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIa non-small-cell lung cancer. <i>Annals of Oncology</i> , 2022, 33, 57-66.	0.6	9
2571	Risk stratification and adjuvant chemotherapy after radical resection based on the clinical risk scores of patients with stage IB-IIA non-small cell lung cancer. <i>European Journal of Surgical Oncology</i> , 2022, 48, 752-760.	0.5	4
2572	First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update. <i>ESMO Open</i> , 2021, 6, 100273.	2.0	91
2573	USP28 deletion and small-molecule inhibition destabilizes c-MYC and elicits regression of squamous cell lung carcinoma. <i>ELife</i> , 2021, 10, .	2.8	25
2574	Budget Impact Analysis of Comprehensive Genomic Profiling in Patients With Advanced Nonâ€“Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 1611-1624.	1.5	7
2575	Systemic Therapy in Nonsmall Cell Lung Cancer and the Role of Biomarkers in Selection of Treatment. <i>Thoracic Surgery Clinics</i> , 2021, 31, 399-406.	0.4	1
2576	Long-term Pemetrexed Administration in 22 Patients with Non-small Cell Lung Cancer in a Japanese Phase II Randomized Study. <i>Japanese Journal of Lung Cancer</i> , 2009, 49, 1019-1026.	0.0	0
2577	Individualization of treatment in non-small cell lung cancer. <i>F1000 Medicine Reports</i> , 2009, 1, .	2.9	1
2578	Chemotherapy in advanced nonsmall cell lung cancer. , 2009, , 271-283.		0
2579	Rational use of cetuximab in the treatment of advanced non-small cell lung cancer. <i>OncoTargets and Therapy</i> , 2009, 2, 251.	1.0	1
2581	Lung Cancer Resistance to Chemotherapy. , 2010, , 331-393.		1
2582	Management of Advanced Non-small Cell Lung Cancer: Front Line Treatment. , 2010, , 177-194.		0
2583	Maintenance Chemotherapy for Advanced Non-small-cell Lung Cancer. <i>European Oncology and Haematology</i> , 2010, 06, 47.	0.0	0
2584	Tumors of the Lung, Pleura, and Mediastinum. , 2010, , 737-771.		2
2585	Maintenance Therapy of Patients with Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer&mdash;Role of Pemetrexed. <i>Clinical Medicine Reviews in Oncology</i> , 0, 2, 263-271.	0.0	0
2586	Abstract PL2-2: The genomic landscape in lung cancer. , 2010, , .		0

#	ARTICLE	IF	CITATIONS
2588	Lobectomy After Induction Therapy for Stage IIIA NSCLC in the Presence of Persistent N2 Disease. , 2011, , 111-117.		1
2589	The Clinical Investigation of Pemetrexed Plus Carboplatin as an Active and Tolerable Treatment Plan in Chinese Elderly Patients with Advanced Lung Adenocarcinoma. Journal of Cancer Therapy, 2011, 02, 311-316.	0.1	0
2590	Evaluation of the Safety Profiles of Pemetrexed in Combination with Cisplatin for Malignant Pleural Mesothelioma in an Outpatient Clinic. Japanese Journal of Lung Cancer, 2011, 51, 109-112.	0.0	0
2591	Adjuvant Therapy for Lung Cancer in the Elderly. , 2011, , 497-503.		0
2592	Facteurs prédictifs pour un traitement personnalisé des cancers bronchiques non à petites cellules. , 2011, , 103-125.		0
2593	Stratégie thérapeutique initiale dans les cancers bronchiques non à petites cellules. , 2011, , 93-101.		0
2594	Advanced Lung Cancer "Reaching a Survival Ceiling with Chemotherapy, the Nibs, and the Mabs. Journal of Cancer Therapy, 2011, 02, 157-160.	0.1	1
2595	A Retrospective Study of Feasibility of Third-line or Higher Chemotherapy Using Pemetrexed in Non-squamous, Non-small Cell Lung Cancer Patients. Japanese Journal of Lung Cancer, 2011, 51, 227-232.	0.0	0
2597	Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.. Journal of Clinical Oncology, 2011, 29, 7579-7579.	0.8	1
2598	HIV and Lung Cancer. , 0, , .		0
2599	Diagnostic, Prognostic, and Therapeutic Value of Gene Signatures in Non-Small Cell Lung Cancer. , 2012, , 81-94.		0
2600	Literaturhinweise und Internetadressen. , 2012, , e1-e61.		0
2601	Targeted Therapies for Non-small-Cell Lung Cancer. , 2012, , 93-114.		0
2602	A Case of Adenocarcinoma of the Lung Successfully Treated with Pemetrexed as Fourth-line Chemotherapy for Multiple Liver Metastases After Acquired Resistance to Crizotinib. Japanese Journal of Lung Cancer, 2012, 52, 242-247.	0.0	0
2603	Unexpected Dramatic Response of Pretreated Invasive Thymic Malignancies on Pemetrexed-Case Report and Review of Current Treatment Modalities. Open Journal of Respiratory Diseases, 2012, 02, 107-115.	0.1	0
2604	Phase II study of perioperative chemotherapy with cisplatin (C) and pemetrexed (P) in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2012, 30, e17535-e17535.	0.8	0
2605	First-line therapy of advanced non-small cell lung cancer not harboring an activating EGFR mutation. , 2012, , 59-74.		0
2607	Second-line therapy of non-small cell lung cancer. , 2012, , 85-92.		0

#	ARTICLE	IF	CITATIONS
2608	Treatment of small cell lung cancer. , 2012, , 129-140.		0
2609	Predictive Markers in Lung Cancer. , 2013, , 43-68.		0
2610	Markers in Lung Cancer. , 2013, , 163-187.		1
2612	Tissue Acquisition in Patients with Suspected Lung Cancer: Techniques Available to the Pulmonologist. , 2013, , 261-270.		0
2613	A Case of Squamous Cell Carcinoma of the Lung Diagnosed During Long Term Pemetrexed Chemotherapy for Recurrent Large Cell Carcinoma of the Lung. Japanese Journal of Lung Cancer, 2013, 53, 29-34.	0.0	0
2614	Histological Typing Accuracy Rate of Preoperative Bronchoscopic Cytology in Patients with Surgically Resected Lung Carcinoma. Japanese Journal of Lung Cancer, 2013, 53, 220-226.	0.0	1
2615	Bone Therapy. , 2013, , 643-652.		0
2616	Lung cancer and molecular targeted drugs. Okayama Igakkai Zasshi, 2013, 125, 57-66.	0.0	1
2617	The Case of a Patient with Non-small Cell Lung Cancer in Whom Periodic Testing for D-dimer Led to Early Detection of Pulmonary Embolus Caused by Bevacizumab and Early Initiation of Anticoagulation Therapy. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2013, 39, 552-557.	0.0	3
2618	A case of complete resection of adenocarcinoma of the lung after chemotherapy using Carboplatin, Pemetrexed, and Bevacizumab. The Journal of the Japanese Association for Chest Surgery, 2013, 27, 826-831.	0.0	0
2619	Assessment of Diagnostic Accuracy of Bronchoalveolar Lavage Cytology in the Diagnosis of Lung Tumors and Contribution to the Classification of Non-Small Cell Lung Cancer Entities: A Retrospective Clinicopathological Study. Open Journal of Pathology, 2013, 03, 107-112.	0.0	1
2620	Evaluation of Irinotecan as a Third- or Fourth-line Treatment for Advanced Non-small Cell Lung Cancer. UC Merced Undergraduate Research Journal, 2013, 5, .	0.1	0
2621	Isolierte Thoraxperfusion mit Chemofiltration (ITP-F) beim fortgeschrittenen und vorbehandelten nicht kleinzelligen Bronchialkarzinom. , 2013, , 403-411.		0
2622	Chemotherapy for the Lungs. , 2013, , 607-616.		0
2623	Systemic Therapy for Lung Cancer. , 2013, , 125-135.		0
2626	The Role of Phase III Trials in Modern Drug Development. Cancer Drug Discovery and Development, 2014, , 763-783.	0.2	0
2627	OUR EXPERIENCE WITH PEMETREXED/ CISPLATIN AS FIRST LINE CHEMOTHERAPY IN PATIENTS WITH ADVANCED NON- SQUAMOUS NON- SMALL CELL LUNG CANCER. Journal of IMAB, 2013, 19, 481-485.	0.1	0
2628	Crizotinib in non-small cell lung cancer. Modern Chemotherapy, 2014, 03, 5-9.	0.5	0

#	ARTICLE	IF	CITATIONS
2629	A Retrospective Study of Combination Chemotherapy with Cisplatin Plus Pemetrexed as a First-line Therapy for Advanced Non-squamous Non-small Cell Lung Cancer. Japanese Journal of Lung Cancer, 2014, 54, 128-134.	0.0	0
2630	Investigation of Combining Serum Tumor Biomarkers and Clinical Features for Elderly Lung Cancer Diagnosis and Classification. Journal of Cancer Therapy, 2014, 05, 133-140.	0.1	0
2631	Maintenance Chemotherapy for Advanced Non-small Cell Lung Cancer. Japanese Journal of Lung Cancer, 2014, 54, 887-891.	0.0	1
2632	Neoadjuvant use of Tyrosine Kinase Inhibitors. Chemotherapy, 2014, 03, .	0.0	0
2633	Frequency of Epidermal Growth Factor Mutation Status and Its Effect on Outcome of Patients with Adenocarcinoma of the Lung. Journal of Cancer Therapy, 2014, 05, 1012-1020.	0.1	1
2634	A Case of Left Axillary Lymph Node Metastasis Resected 25 Years after the Diagnosis of Stage IV Lung Cancer. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2014, 75, 922-927.	0.0	0
2636	Rola systemowych metod leczenia u chorych na niedrobnokomórkowego raka płuca i złośliwego międzybłonniaka opłucnej: uaktualnione zalecenia ekspertów. Nowotwory, 2014, 64, 61-75.	0.1	0
2638	A Predictive Model for Evaluating Responsiveness to Pemetrexed Treatment in Patients with Advanced Colorectal Cancer. Asian Pacific Journal of Cancer Prevention, 2014, 15, 5941-5944.	0.5	10
2639	Advances in Radiotherapy for Locally Advanced NSCLC. , 2015, , 69-94.		0
2640	Adequacy and Tissue Preservation of Small Biopsy and Cytology Specimens. , 2015, , 39-59.		1
2641	Current Status and Future Perspective on Cytotoxic Agents for Squamous Cell Carcinoma of the Lung. Japanese Journal of Lung Cancer, 2015, 55, 973-981.	0.0	0
2642	Serum Protein Pattern Could Predict the Therapeutic Effect of First-Line Pemetrexed/Cisplatin Chemotherapy in Patients With Lung Adenocarcinoma. World Journal of Oncology, 2015, 6, 292-296.	0.6	1
2644	Lung Cancer: Diagnosis and Treatment Approach. , 2015, , 97-144.		2
2645	Phase II Study of Carboplatin and Pemetrexed Followed by Gefitinib for Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive EGFR Mutation. Journal of Cancer Therapy, 2015, 06, 1214-1222.	0.1	0
2646	Therapy options for advanced NSCLC. , 2015, , 5-25.		0
2647	Targeted Therapies for Non-Small Cell Lung Cancer. Current Clinical Pathology, 2015, , 89-101.	0.0	1
2648	Pharmacology and Clinical Development of New Molecularly Targeted Agents. Current Clinical Pathology, 2015, , 9-29.	0.0	0
2649	E28 Literaturhinweise und Internetadressen. , 2015, , e1-e79.		0

#	ARTICLE	IF	CITATIONS
2650	Non-small cell lung cancer and superior vena cava obstruction. , 2015, , 11-24.		0
2651	Expectations in the Care of Lung Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e420-e424.	1.8	0
2652	Study of Pemetrexed-based Chemotherapy for Patients with Locally Advanced or Metastatic Cancers. Asian Pacific Journal of Cancer Prevention, 2015, 16, 4791-4795.	0.5	5
2653	Systematic Analysis of Icotinib Treatment for Patients with Non-Small Cell Lung Cancer. Asian Pacific Journal of Cancer Prevention, 2015, 16, 5521-5524.	0.5	6
2654	A Pooled Study on Combination of Gemcitabine and Nedaplatin for Treating Patients with Non-small Cell Lung Cancer. Asian Pacific Journal of Cancer Prevention, 2015, 16, 5963-5966.	0.5	3
2656	Histologic Distribution of Pulmonary Tumors in Lebanon: A 5-Year Single Institution Experience. Asian Pacific Journal of Cancer Prevention, 2015, 16, 5899-5902.	0.5	2
2657	Final Results of a Phase II Study of Bevacizumab, Cisplatin and Pemetrexed as First-Line Therapy for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer. Journal of Cancer Therapy, 2016, 07, 455-463.	0.1	0
2658	Isolated Thoracic Perfusion with Chemofiltration (ITP-F) for Advanced and Pretreated Non-small-cell Lung Cancer. , 2016, , 487-495.		0
2659	Successful Pemetrexed Rechallenge Chemotherapy in Advanced Pulmonary Adenocarcinoma. Japanese Journal of Lung Cancer, 2016, 56, 273-277.	0.0	0
2660	Identification of the Risk Factors for Severe Neutropenia Induced by Pemetrexed Plus Carboplatin Chemotherapy. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2016, 42, 278-285.	0.0	0
2661	Clinicopathological Characteristics of Primary Lung Cancer Patients at King Hussein Medical Center. Journal of the Royal Medical Services, 2016, 23, 75-82.	0.0	0
2662	Treatment of Advanced and Metastatic Squamous Non-small Cell Lung Cancer. Korean Journal of Medicine, 2016, 90, 1-6.	0.1	1
2663	Clinicopathological features and outcomes in advanced nonsmall cell lung cancer with tailored therapy. Indian Journal of Medical and Paediatric Oncology, 2016, 37, 242-250.	0.1	3
2664	Prospective Analysis of Patients Treated with Chemotherapy in Metastatic Adenocarcinoma of Lung Single Centre Experience. Journal of Cancer Therapy, 2017, 08, 838-844.	0.1	0
2665	Clinical profile and outcomes of patients with Stage IV adenocarcinoma of lung: A tertiary cancer center experience. Indian Journal of Cancer, 2017, 54, 197.	0.2	4
2666	Predictive Factors of Severe Toxicities of Pemetrexed-Containing Chemotherapy in Patients with Non-Squamous Non-Small Cell Lung Cancer. Journal of Cancer Therapy, 2017, 08, 1030-1039.	0.1	1
2667	Clinical profile of nonsmall cell lung carcinoma patients treated in a single unit at a tertiary cancer care center. Indian Journal of Cancer, 2017, 54, 193.	0.2	4
2668	First-line therapy outcomes in patients with advanced stage nonsmall cell lung cancer treated at nongovernment tertiary care center in India: Experience from a real world practice. Indian Journal of Cancer, 2017, 54, 182.	0.2	1

#	ARTICLE	IF	CITATIONS
2669	Metronomic chemotherapy with vinorelbine as the optimal treatment option in real clinical practice. <i>Onkologiya Zhurnal Imeni P A Gertsena</i> , 2017, 6, 64.	0.0	1
2670	Moving the mountain in advanced non-small-cell lung cancer: evolving immunotherapies for a dire disease. <i>Translational Cancer Research</i> , 2017, 6, S151-S157.	0.4	2
2671	PD-1/PD-L1 inhibitor therapy: transitioning from a second-line to a first-line therapy for non-small cell lung cancer. <i>Precision and Future Medicine</i> , 2017, 1, 3-9.	0.5	0
2672	Multimodale und palliative Therapie des Lungenkarzinoms. , 2018, , 205-211.		0
2674	Osimertinib - a new treatment option for patients with EGFR mutation T790M. <i>Onkologie (Czech) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50</i>	0.6	0
2675	1. Treatment for Lung Cancer with Cytotoxic Agents -2017 Update-. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2017, 106, 1089-1095.	0.0	0
2677	Clinicopathological and genetic characteristics of pulmonary large cell carcinoma under 2015 WHO classification: a pilot study. <i>Oncotarget</i> , 2017, 8, 100754-100763.	0.8	5
2678	A Retrospective Evaluation of Chemotherapy Regimens in Unselected Patients with Metastatic Non-Small Cell Lung Cancer. <i>Journal of Cancer Therapy</i> , 2018, 09, 314-322.	0.1	1
2679	Pathology of Lung Cancer. , 2018, , 9-22.		0
2681	Present Situation and Progress of Lung Cancer Therapy. <i>Advances in Clinical Medicine</i> , 2018, 08, 837-843.	0.0	0
2682	Respiratory Organ Aging and Cancer. , 2018, , 1-30.		0
2683	Superiority and Non-inferiority Phase III Oncology Trials. , 2018, , 203-216.		0
2684	Non-Small Cell Lung Cancer: Therapeutic and Evolutionary Aspects in Cote d'Ivoire. <i>Advances in Lung Cancer (Irvine)</i> , 2018, 07, 1-8.	0.2	0
2685	Management of Lung cancer. , 2018, , 23-33.		0
2686	Tyrosine kinase inhibitor versus physician choice chemotherapy in second-line epidermal growth factor receptor mutation non-small cell lung cancer: Post hoc analysis of randomized control trial. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2018, 39, 493.	0.1	0
2687	Feasibility Study of Sequentially Alternating EGFR-TKIs and Chemotherapy for Patients with Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2018, 38, 2385-2390.	0.5	1
2689	A clinical case of 3-year highly efficient pembrolizumab therapy of metastatic lung adenocarcinoma. <i>Meditsinskiy Sovet</i> , 2018, , 9-10.	0.1	1
2690	Strategies for Progress. , 2019, , 3-43.		0

#	ARTICLE	IF	CITATIONS
2691	Treatment for Advanced Squamous Cell Carcinoma of the Lung. Japanese Journal of Lung Cancer, 2018, 58, 325-330.	0.0	0
2692	Clinical case of long-term pemetrexed-based chemotherapy treatment for pulmonary adenocarcinoma (ALA +). Meditsinskiy Sovet, 2018, , 68-72.	0.1	0
2693	Recent Progress and Prospects of Medical Therapy for Lung Cancer. Journal of the Nihon University Medical Association, 2018, 77, 375-378.	0.0	0
2694	Non-small Cell Lung Cancer. , 2019, , 143-192.		0
2695	New Insights into the Discovery of Novel Drugs to Treat Human Pulmonary Adenocarcinoma. Journal of Cancer Therapy, 2019, 10, 178-187.	0.1	1
2696	Histopathological spectrum and immunohistochemical profile of lung carcinomas: A 9-year study from a tertiary hospital in North India. International Journal of Applied & Basic Medical Research, 2019, 9, 169.	0.2	3
2697	Landmark Trials in Lung Cancer. , 2019, , 41-74.		0
2698	Automated classification of histological subtypes of NSCLC using support vector machines with radiomic features. , 2019, , .		0
2699	Extended follow-up on KEYNOTE-024 suggests significant survival benefit for pembrolizumab in patients with PD-L1 ≥50%, but unanswered questions remain. Annals of Translational Medicine, 2019, 7, S127-S127.	0.7	7
2700	Sequential Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours. Asian Pacific Journal of Cancer Prevention, 2019, 20, 2415-2420.	0.5	1
2701	The influence of pemetrexed-based continuous maintenance therapy on survival of locally advanced and metastatic lung adenocarcinoma. Annals of Translational Medicine, 2019, 7, 524-524.	0.7	2
2702	Cáncer de pulmón de célula no pequeña metastásico. Acta Medica Colombiana: AMC: Organo De La Asociacion Colombiana De Medicina Interna, 2010, 35, 53-81.	0.0	1
2703	Advances in Nanotechnology and Effects of Nanoparticles on Oxidative Stress Parameters. Nanomedicine and Nanotoxicology, 2020, , 451-519.	0.1	0
2705	Malignant Epithelial Tumors of the Lung. , 2020, , 317-400.		0
2706	Nanotechnological modifications of nanoparticles on reactive oxygen and nitrogen species. , 2020, , 449-488.		0
2707	Druggable driver gene alterations in redefined large cell carcinoma in Chinese patients: an observational study. Translational Cancer Research, 2020, 9, 7562-7571.	0.4	0
2708	Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer. Oncotarget, 2019, 10, 6297-6307.	0.8	1
2709	Advances in the Treatment of Advanced Non-Small Cell Lung Cancer. Advances in Lung Cancer (Irvine), 2020, 09, 30-40.	0.2	0



#	ARTICLE	IF	CITATIONS
2710	Respiratory Organ Aging and Cancer. , 2020, , 215-244.		0
2711	A Case of Pulmonary Adenocarcinoma with Amylase Production. Japanese Journal of Lung Cancer, 2020, 60, 48-53.	0.0	0
2712	Real-World Treatment Patterns of Lung Cancer in a Resource-Restricted Country: the Experience of Georgia. Health Services Insights, 2021, 14, 117863292110552.	0.6	0
2713	Adding Base-Excision Repair Inhibitor TRC102 to Standard Pemetrexedâ€“Platinumâ€“Radiation in Patients with Advanced Nonsquamous Nonâ€“Small Cell Lung Cancer: Results of a Phase I Trial. Clinical Cancer Research, 2022, 28, 646-652.	3.2	3
2714	The Macrophage Reprogramming Ability of Antifolates Reveals Soluble CD14 as a Potential Biomarker for Methotrexate Response in Rheumatoid Arthritis. Frontiers in Immunology, 2021, 12, 776879.	2.2	7
2715	MTHFR polymorphism as a predictive biomarker for gastrointestinal and hematological toxicity in North Indian adenocarcinoma patients. Journal of Chemotherapy, 2021, , 1-15.	0.7	1
2716	Mechanisms, Management and Prevention of Pemetrexed-Related Toxicity. Drug Safety, 2021, 44, 1271-1281.	1.4	10
2717	Intratumoral hyperthermic chemotherapy injection in peripheral non-small cell lung cancer. Egyptian Journal of Bronchology, 2020, 14, .	0.3	1
2718	Molecular pathology. , 0, , 95-118.		2
2719	Can we expect progress from targeted therapy of SCLC?. , 0, , 234-246.		0
2721	The incidence of lung cancer in the Moscow region from 1998 to 2018. Pulmonologiya, 2020, 30, 401-407.	0.2	0
2722	Morphological and molecular genetic diagnosis of lung cancer: methods and problems. IssledovaniĀc I Praktika V Medicine, 2020, 7, 51-62.	0.1	3
2723	Real world efficacy of immunotherapy in nonsmall cell lung cancer. Malignant Tumours, 2020, 10, 5-20.	0.1	1
2724	New Strategies in the Treatment of Advanced Squamous Non-Small Cell Lung Cancer. Japanese Journal of Lung Cancer, 2020, 60, 379-384.	0.0	0
2725	Roles of EGFR and KRAS Mutations in the Treatment Of Patients With Non-Small-Cell Lung Cancer. P and T, 2011, 36, 263-79.	1.0	21
2726	Targeting the tumor vascular supply with vascular disrupting agents. Journal of Thoracic Disease, 2010, 2, 192-3.	0.6	0
2727	Patient selection in non-small cell lung cancer: Histologic versus molecular subtypes?. Journal of Thoracic Disease, 2010, 2, 189-91.	0.6	2
2728	Post-study therapy as a source of confounding in survival analysis of first-line studies in patients with advanced non-small-cell lung cancer. Journal of Thoracic Disease, 2011, 3, 88-98.	0.6	17

#	ARTICLE	IF	CITATIONS
2729	Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis. Ontario Health Technology Assessment Series, 2010, 10, 1-48.	3.0	23
2730	Predicting survival of patients with resectable non-small cell lung cancer: Beyond TNM. Journal of Thoracic Disease, 2012, 4, 214-6.	0.6	18
2732	Steatocystoma multiplex as initial impression of non-small cell lung cancer with complete response to gefitinib. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2014, 26, E5-9.	0.7	0
2733	Retreatment with pemetrexed chemotherapy in advanced non-small cell lung cancer patient. Journal of Thoracic Disease, 2014, 6, 856-60.	0.6	4
2734	Selection of chemotherapy for non-small cell lung cancer is facilitated by new therapeutic strategies. International Journal of Clinical and Experimental Medicine, 2014, 7, 3833-42.	1.3	4
2735	Efficacy of third-line pemetrexed monotherapy versus pemetrexed combination with bevacizumab in patients with advanced EGFR mutation-positive lung adenocarcinoma. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2014, 26, 705-10.	0.7	2
2736	Buyer beware: understanding the assumptions behind health economic assessments in personalized cancer care. Journal of Thoracic Disease, 2014, 6, 1888-91.	0.6	0
2737	Clinical perspective on PROSE: does VeriStrat testing improve selection of second-line treatment for patients with non-small cell lung cancer?. Annals of Translational Medicine, 2015, 3, 31.	0.7	1
2738	A strong step forward in maintenance therapy for non-small cell lung cancer treatment. Translational Lung Cancer Research, 2012, 1, 99-101.	1.3	0
2739	Personalized maintenance therapy in advanced non-small cell lung cancer. Translational Lung Cancer Research, 2013, 2, 452-6.	1.3	0
2740	The challenge of using biomarkers and molecularly targeted drugs to improve cure rate in early stage non-small cell lung cancer. Journal of Thoracic Disease, 2015, 7, 230-4.	0.6	2
2741	Disparate survival trends in histologic subtypes of metastatic non-small cell lung cancer: a population-based analysis. American Journal of Cancer Research, 2015, 5, 2229-40.	1.4	9
2742	Efficacies and adverse reactions of modified vitamin supplement programs before pemetrexed chemotherapy as a second-line treatment against epidermal growth factor receptor (EGFR) mutant wild-type lung adenocarcinoma. International Journal of Clinical and Experimental Medicine, 2015, 8, 13716-23.	1.3	0
2743	Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer. Translational Lung Cancer Research, 2015, 4, 704-12.	1.3	8
2758	Prospective analysis on survival outcomes of nonsmall cell lung cancer stages over IIIb treated with HangAm-Dan. Chinese Journal of Lung Cancer, 2010, 13, 1009-15.	0.7	3
2759	Diagnosis and Treatment of Adenocarcinomas and Squamous Cell Carcinomas of the Lung. Journal of the Advanced Practitioner in Oncology, 2017, 8, 267-272.	0.2	0
2764	A Phase IV Efficacy Study of Formeta Plus Carboplatin as First-Line Treatment of Advanced Non-Squamous, Non-Small Cell Lung Cancer in Iran: An Affordable Price with Clinical Benefit. Asian Pacific Journal of Cancer Prevention, 2018, 19, 2973-2978.	0.5	0
2768	Randomized phase II study of pemetrexed-cisplatin or docetaxel-cisplatin plus thoracic intensity-modulated radiation therapy in patients with stage IV lung adenocarcinoma. American Journal of Cancer Research, 2019, 9, 1235-1245.	1.4	3

#	ARTICLE	IF	CITATIONS
2771	UBE2T silencing inhibited non-small cell lung cancer cell proliferation and invasion by suppressing the wnt/ $\beta^2$ -catenin signaling pathway. <i>International Journal of Clinical and Experimental Pathology</i> , 2017, 10, 9482-9488.	0.5	11
2774	Recent advances in early stage lung cancer. <i>Journal of Clinical and Translational Research</i> , 2021, 7, 163-174.	0.3	4
2776	Circulating Levels of Monocytic Myeloid-Derived Suppressor Cells (M-MDSC) and CXCL-8 in Non-Small Cell Lung Cancer (NSCLC). <i>Tanaffos</i> , 2021, 20, 15-21.	0.5	2
2777	Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110396.	0.8	4
2778	Pyrotinib in Patients with HER2-Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial. <i>Clinical Cancer Research</i> , 2022, 28, 461-467.	3.2	24
2779	Malignant neoplasm of the bronchi and lung: Russian clinical guidelines. <i>Journal of Modern Oncology</i> , 2021, 23, 369-402.	0.1	5
2780	Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: results of the IFCT-GFPC-1101 multicenter randomized phase III trial. <i>Lung Cancer</i> , 2021, 164, 84-90.	0.9	0
2781	Under the Magnifying Glass: Searching for The Evidence of Pemetrexed in Nonsquamous Nonsmall Cell Lung Cancer. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2021, 42, 579-581.	0.1	0
2782	Clinical Outcomes of Chemotherapeutic Molecules as Single and Multiple Agents in Advanced Non-Small-Cell Lung Carcinoma (NSCLC) Patients. <i>Medicina (Lithuania)</i> , 2021, 57, 1252.	0.8	5
2783	Efficacy and Safety of Different Doses of Bevacizumab Combined With Pemetrexed and Platinum in First-Line Treatment of Advanced NSCLC: A Retrospective-Real World Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 727102.	1.6	0
2784	Identification of Clinical and Tumor Microenvironment Characteristics of Hypoxia-Related Risk Signature in Lung Adenocarcinoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 757421.	1.6	5
2785	Nicht-kleinzelliges Lungenkarzinom: Wandel und Möglichkeiten der molekularen Diagnostik. , 0, , .		0
2786	Epidemiological, clinical profile, and treatment outcome of stage iv nonsquamous nonsmall cell lung cancer patients presenting to tertiary care hospital in North India. <i>Oncology Journal of India</i> , 2021, 5, 104.	0.1	0
2787	Prevalence and Clinicopathologic Risk Factors for Epidermal Growth Factor Receptor, Anaplastic Lymphoma Kinase, and ROS-1 Fusion in Metastatic Non-small Cell Lung Carcinoma. <i>Journal of Radiation and Cancer Research</i> , 2022, 13, 48.	0.0	0
2788	Cancer Immunotherapy with Immune Checkpoint Inhibitors-Biomarkers of Response and Toxicity; Current Limitations and Future Promise. <i>Diagnostics</i> , 2022, 12, 124.	1.3	12
2789	OUP accepted manuscript. <i>Oncologist</i> , 2022, , .	1.9	1
2790	Case Report: Significant Clinical Benefit From Pemetrexed-Based Therapy in ROS1- and ALK-rearranged Lung Cancer With Adenosquamous Histology. <i>Frontiers in Oncology</i> , 2021, 11, 788245.	1.3	3
2791	Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005). <i>JTO Clinical and Research Reports</i> , 2022, 3, 100261.	0.6	9

#	ARTICLE	IF	CITATIONS
2792	Lungenkarzinom: Mehr Optionen für Patienten im fortgeschrittenen Stadium. , 0, , .		0
2793	The anti-programmed cell death 1 antibody immunotherapy: A paradigm shift in the treatment of non-small-cell lung cancer. Nigerian Journal of Cardiovascular & Thoracic Surgery, 2020, 5, 29.	0.1	0
2794	Ability of the Glasgow Prognostic Score to predict the tolerability and efficacy of platinum-combination chemotherapy among elderly patients with advanced non-small cell lung cancer. Journal of Medical Investigation, 2021, 68, 260-264.	0.2	2
2795	Prognostic Implications of Pyroptosis-Related Gene Signatures in Lung Squamous Cell Carcinoma. Frontiers in Pharmacology, 2022, 13, 806995.	1.6	6
2796	Targeted therapy for advanced anaplastic lymphoma kinase ( <i>ALK</i> )-rearranged non-small cell lung cancer. The Cochrane Library, 2022, 2022, CD013453.	1.5	18
2797	Comparative efficacy of 10 Chinese herbal injections combined with GP regimen chemotherapy for patients with advanced NSCLC a systematic review and network meta-analysis. Journal of Cancer, 2022, 13, 465-480.	1.2	3
2798	Immunohistochemical markers to diagnose primary squamous cell carcinoma of the lung: a meta-analysis of diagnostic test accuracy. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592110651.	1.4	2
2799	Clinical Features, Treatments, and Prognosis of Intramedullary Spinal Cord Metastases From Lung Cancer: A Case Series and Systematic Review. Neurospine, 2022, 19, 65-76.	1.1	7
2800	Targeting un-MET needs in advanced non-small cell lung cancer. Lung Cancer, 2022, 164, 56-68.	0.9	15
2801	Terelizumab Combined with Hypofractionated Radiation Therapy and GM-CSF as Dyspnea with Stage IV Lung Squamous Cell Carcinoma: A Case Report. SSRN Electronic Journal, 0, , .	0.4	0
2802	Global trends of researches on bone metastasis. Medicine (United States), 2022, 101, e28761.	0.4	4
2803	Severe immune-related adverse events of immune checkpoint inhibitors for advanced non-small cell lung cancer: a network meta-analysis of randomized clinical trials. Cancer Immunology, Immunotherapy, 2022, 71, 2239-2254.	2.0	11
2806	A Single-Arm Phase II Study to Evaluate Efficacy and Safety of First-Line Treatment With DCVAC/LuCa, Standard of Care Chemotherapy and Shenqi Fuzheng Injection in Advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer Patients. Integrative Cancer Therapies, 2022, 21, 153473542210839.	0.8	8
2807	A Retrospective Study of Intrathecal Pemetrexed Combined With Systemic Therapy for Leptomeningeal Metastasis of Lung Cancer. Technology in Cancer Research and Treatment, 2022, 21, 153303382210784.	0.8	8
2808	Neurological complications of lung cancer. , 2022, , 243-276.		0
2809	Challenges in the Use of Targeted Therapies in Non-Small Cell Lung Cancer. Cancer Research and Treatment, 2022, 54, 315-329.	1.3	17
2810	The Class I HDAC Inhibitor Valproic Acid Strongly Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Immune System Activation. Biomedicines, 2022, 10, 517.	1.4	7
2811	Pancreatic head vs pancreatic body/tail cancer: Are they different?. World Journal of Gastrointestinal Oncology, 2022, 14, 716-723.	0.8	4

#	ARTICLE	IF	CITATIONS
2812	Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity. <i>Frontiers in Oncology</i> , 2022, 12, 821391.	1.3	6
2814	Comparative survival analysis of platinum-based adjuvant chemotherapy for early-stage squamous cell carcinoma and adenocarcinoma of the lung. <i>Cancer Medicine</i> , 2022, 11, 2067-2078.	1.3	9
2815	Oligometastatic Disease in Non-Small-Cell Lung Cancer: An Update. <i>Cancers</i> , 2022, 14, 1350.	1.7	3
2816	Overall Survival Benefits of First-Line Treatments for Asian Patients With Advanced EGFR-Mutated NSCLC Harboring L858R Mutation: A Systematic Review and Network Meta-Analysis. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100322.	0.6	3
2817	Association between proton pump inhibitors and severe hematological toxicity in patients receiving pemetrexed-based anticancer treatment: The prospective IPPEM study. <i>Lung Cancer</i> , 2022, 166, 114-121.	0.9	4
2818	Anti-cancer peptide-based therapeutic strategies in solid tumors. <i>Cellular and Molecular Biology Letters</i> , 2022, 27, 33.	2.7	49
2819	A molecular approach integrating genomic and DNA methylation profiling for tissue of origin identification in lung-specific cancer of unknown primary. <i>Journal of Translational Medicine</i> , 2022, 20, 158.	1.8	6
2820	Anti-EGFR monoclonal antibody plus chemotherapy for treating advanced non-small cell lung cancer. <i>Medicine (United States)</i> , 2021, 100, e27954.	0.4	1
2821	Systematic review and meta-analysis of the predictive power of <i>MTHFR</i> polymorphisms for pemetrexed drug efficacy and toxicity in non-small cell lung cancer patients. <i>Journal of Chemotherapy</i> , 2022, 34, 472-482.	0.7	3
2854	Volumetric PET Parameters Predict Prognosis after Definitive Chemoradiotherapy with Cisplatin/Docetaxel for Stage III Non-Small Cell Lung Cancer. <i>Acta Medica Okayama</i> , 2021, 75, 15-23.	0.1	0
2890	The PARAMOUNT trial in NSCLC: is the amount of benefit clinically meaningful?. <i>Annals of Palliative Medicine</i> , 2013, 2, 161-3.	0.5	0
2892	Predictive significance of inflammatory indexes in metastatic nonsmall cell lung cancer patients treated with platinum-doublet chemotherapy. <i>Journal of Cancer Research and Therapeutics</i> , 2022, 18, 220.	0.3	2
2894	Safety and efficacy of pemetrexed for the treatment of lung adenocarcinoma in patients with various stages of chronic kidney disease. <i>Journal of Medicine and Life Science</i> , 2022, 19, 14-19.	0.1	0
2895	Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 497-530.	2.3	530
2896	Clinical-molecular prospective cohort study in Non-Small Cell Lung Cancer (PROMOLE study): a comprehensive approach to identify new predictive markers of pharmacological response. <i>Clinical Lung Cancer</i> , 2022, , .	1.1	5
2897	A randomized phase II study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with non-small cell lung cancer harboring EGFR mutations (JMTO LC12-01). <i>Thoracic Cancer</i> , 2022, 13, 1827-1836.	0.8	2
2898	Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies. <i>Haematologica</i> , 2022, 107, 1243-1263.	1.7	28
2899	Treatment of drug-induced immune thrombocytopenias. <i>Haematologica</i> , 2022, 107, 1264-1277.	1.7	17

#	ARTICLE	IF	CITATIONS
2900	The efficacy and safety of selumetinib as secondary therapy for late-stage and metastatic non-small cell lung cancer: results from a systematic review and meta-analysis. <i>Annals of Translational Medicine</i> , 2022, 10, 593-593.	0.7	1
2901	Hospital case-volume and mortality after lung cancer surgery: A population-based retrospective cohort study. <i>Lung Cancer</i> , 2022, 169, 61-66.	0.9	1
2902	LncRNA HARI1A Suppresses the Development of Non-Small Cell Lung Cancer by Inactivating the STAT3 Pathway. <i>Cancers</i> , 2022, 14, 2845.	1.7	6
2903	Survival benefit of using pemetrexed for EGFR mutation-positive advanced non-small-cell lung cancer in a randomized phase III study comparing gefitinib to cisplatin plus docetaxel (WJTOG3405). <i>International Journal of Clinical Oncology</i> , 2022, 27, 1404-1412.	1.0	1
2904	Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present. <i>Biomolecules</i> , 2022, 12, 815.	1.8	15
2905	ROS1-positive non-small cell lung cancer (NSCLC): biology, diagnostics, therapeutics and resistance. <i>Journal of Drug Targeting</i> , 2022, 30, 845-857.	2.1	8
2906	Investigation of the optimal platinum-based regimen in the postoperative adjuvant chemotherapy setting for early-stage resected non-small lung cancer: a Bayesian network meta-analysis. <i>BMJ Open</i> , 2022, 12, e057098.	0.8	2
2907	Correlations between Objective Response Rate and Survival-based Endpoints in First-line Advanced Non-Small Cell Lung Cancer: a Systematic Review and Meta-analysis. <i>Lung Cancer</i> , 2022, , .	0.9	5
2908	Chemotherapy for patients with advanced lung cancer with interstitial lung disease: a prospective observational study. <i>Therapeutic Advances in Chronic Disease</i> , 2022, 13, 204062232211083.	1.1	2
2909	Overall Survival Benefits of First-Line Treatments for Asian Patients with Advanced Epidermal Growth Factor Receptor-Mutated NSCLC Harboring Exon 19 Deletion: A Systematic Review and Network Meta-Analysis. <i>Cancers</i> , 2022, 14, 3362.	1.7	1
2910	Clinically-meaningful improvements in therapy for unresectable NSCLC. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 927-937.	1.1	6
2911	Updated recommendations on systemic treatment of non-small cell lung cancer and malignant pleural mesothelioma. <i>Pneumonologia I Alergologia Polska</i> , 2010, 78, 418-431.	0.6	3
2912	Gefitinib in patients with advanced non-small-cell lung cancer. <i>Pneumonologia I Alergologia Polska</i> , 2012, 80, 439-449.	0.6	1
2913	Singapore Cancer Network (SCAN) Guidelines for the Use of Systemic Therapy in Advanced Non-Small Cell Lung Cancer. <i>Annals of the Academy of Medicine, Singapore</i> , 2015, 44, 449-462.	0.2	2
2914	Advanced non-small cell lung cancer treated with palliative systemic therapy complicated by calvarial metastasis: a case report. <i>Translational Cancer Research</i> , 2021, .	0.4	1
2915	Molecular docking analysis of VEGF with compounds from tomato. <i>Bioinformatics</i> , 2022, 18, 478-481.	0.2	2
2916	Immune checkpoint inhibitors in extensiv-stage small-cell lung cancer. <i>Journal of the National Cancer Center</i> , 2022, , .	3.0	2
2917	PEGâ€™hGâ€™CSF for prophylaxis of neutropenia after chemotherapy in patients with nonâ€™small cell lung cancer: A multicenter, prospective, randomized study. <i>Thoracic Cancer</i> , 0, , .	0.8	2

#	ARTICLE	IF	CITATIONS
2918	Cuproptosis predicts the risk and clinical outcomes of lung adenocarcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	24
2919	Pemetrexed and platinum plus pembrolizumab in patients with metastatic non-squamous non-small cell lung cancer by tumor burden at baseline: a post hoc efficacy analysis of KEYNOTE-189. <i>JTO Clinical and Research Reports</i> , 2022, , 100389.	0.6	0
2920	Tumor mutational burden and efficacy of chemotherapy in lung cancer. <i>Clinical and Translational Oncology</i> , 2023, 25, 173-184.	1.2	3
2921	Safety and efficacy of pralsetinib in RET fusion- positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial. <i>Annals of Oncology</i> , 2022, 33, 1168-1178.	0.6	56
2922	Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment. <i>Lung Cancer</i> , 2022, 172, 19-28.	0.9	9
2923	Diagnostic work-up and systemic treatment for advanced non-squamous non-small-cell lung cancer in four Southeast Asian countries. <i>ESMO Open</i> , 2022, 7, 100560.	2.0	1
2924	Bench to bedside: recent advances in lung cancer pathological research with implications for diagnostic clinical practice. <i>Diagnostic Histopathology</i> , 2022, 28, 493-500.	0.2	0
2925	Polypharmacology in Clinical Applications- Anticancer Polypharmacology. , 2022, , 73-132.		0
2926	Chemotherapy for Lung Cancer. <i>Medical Radiology</i> , 2022, , .	0.0	0
2927	Open-label, multi-center, phase II study of adjuvant pemetrexed plus cisplatin for completely resected stage IB to IIIA adenocarcinoma of the lung: APICAL trial. <i>Translational Lung Cancer Research</i> , 2022, 11, 1606-1618.	1.3	3
2928	Protective roles of cytoplasmic p21 <sup>Cip1</sup> and Waf1 <sup>Cip1</sup> in senolysis and ferroptosis of lung cancer cells. <i>Cell Proliferation</i> , 2022, 55, .	2.4	5
2929	Non-small cell lung cancer in China. <i>Cancer Communications</i> , 2022, 42, 937-970.	3.7	129
2930	Immunohistochemistry with 3 different clones in anaplastic lymphoma kinase fluorescence in situ hybridization positive non-small-cell lung cancer with thymidylate synthase expression analysis: a multicentre, retrospective, Italian study. <i>Pathologica</i> , 2022, 114, 278-287.	1.3	0
2931	Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 4481.	1.7	3
2932	Identifying optimal PD-1/PD-L1 inhibitors in first-line treatment of patients with advanced squamous non-small cell lung cancer in China: Updated systematic review and network meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
2933	The Management of Oligometastases in Non-small Cell Lung Cancer - is Stereotactic Ablative Radiotherapy now Standard of Care?. <i>Clinical Oncology</i> , 2022, , .	0.6	2
2934	Chemotherapeutic Protocols for the Treatment of Lung Cancer. , 2022, , 291-305.		0
2935	Phase I trial of the TNF- inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas. <i>Nature Communications</i> , 2022, 13, .	5.8	6

#	ARTICLE	IF	CITATIONS
2936	Phase I/II study of nedaplatin and nab-paclitaxel for patients with previously untreated advanced squamous cell lung cancer: Kanto Respiratory Disease Study Group (KRSG) 1302. <i>International Journal of Clinical Oncology</i> , 0, , .	1.0	0
2937	Amivantamab in the Treatment of Metastatic NSCLC: Patient Selection and Special Considerations. <i>OncoTargets and Therapy</i> , 0, Volume 15, 1197-1210.	1.0	4
2938	Genetic Variants in Histone Modification Regions Predict Clinical Outcomes of Pemetrexed Chemotherapy in Lung Adenocarcinoma. <i>Oncology</i> , 2023, 101, 96-104.	0.9	0
2942	Fusion gene recurrence in non-small cell lung cancers and its association with cigarette smoke exposure. <i>Translational Lung Cancer Research</i> , 2022, 11, 2022-2039.	1.3	1
2943	Drug Resistance in Lung Cancer. , 2022, , .		0
2944	Immunocytochemical evaluation of TTF-1, Napsin-A, and p-63 for Subtyping of Non-Small Cell Lung Carcinoma and Clinicopathological Correlation. <i>Journal of Cytology</i> , 2022, 39, 180.	0.2	1
2945	Improved Survival of Advanced Lung Cancer in Singapore Over the Past Decade. <i>Annals of the Academy of Medicine, Singapore</i> , 2017, 46, 333-338.	0.2	4
2946	Folate Receptor as a Biomarker and Therapeutic Target in Solid Tumors. <i>Current Problems in Cancer</i> , 2023, 47, 100917.	1.0	13
2947	Biomarkers in the management of lung cancer: changing the practice of thoracic oncology. <i>Clinical Chemistry and Laboratory Medicine</i> , 2023, 61, 906-920.	1.4	4
2948	A Bayesian network analysis of immunotherapy and taxane chemotherapy as second- or later-line treatments in non-small cell lung cancer. <i>Medicine (United States)</i> , 2022, 101, e31751.	0.4	1
2950	Malignant neoplasm of the bronchi and lung: Russian clinical guidelines. <i>Journal of Modern Oncology</i> , 2022, 24, 269-304.	0.1	2
2951	The Safety and Efficacy of Preoperative Immunotherapy Combined with Chemotherapy in Patients with Stage IIIA-III B Lung Squamous Cell Carcinoma. <i>Thoracic and Cardiovascular Surgeon</i> , 0, , .	0.4	0
2952	Next-generation sequencing of homologous recombination genes could predict efficacy of platinum-based chemotherapy in non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
2953	Metabolic reprogramming of cancer as a therapeutic target. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2023, 1867, 130301.	1.1	2
2954	Neurogenic orthostatic hypotension after treatment with sorafenib. <i>BMJ Case Reports</i> , 2022, 15, e247140.	0.2	1
2956	Tumour Genetics and Genomics to Personalise Cancer Treatment. <i>Annals of the Academy of Medicine, Singapore</i> , 2011, 40, 362-368.	0.2	14
2957	CircRNA B cell linker regulates cisplatin sensitivity in nonsmall cell lung cancer via microRNA-25-3p/BarHâ€like homeobox 2 axis. <i>Anti-Cancer Drugs</i> , 2023, 34, 640-651.	0.7	1
2958	Impact of Results of TTF-1 Immunostaining on Efficacy of Platinum-Doublet Chemotherapy in Japanese Patients with Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2023, 12, 137.	1.0	0



#	ARTICLE	IF	CITATIONS
2959	Circ_0110498 facilitates the cisplatin resistance of non-small cell lung cancer by mediating the miR-1287-5p/RBBP4 axis. <i>Thoracic Cancer</i> , 2023, 14, 662-672.	0.8	2
2960	Alvopem® (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance. <i>Journal of Pharmaceutical Policy and Practice</i> , 2023, 16, .	1.1	0
2961	Unveiling the gemcitabine drug complexation with cucurbit[n]urils (n=6-8): a computational analysis. <i>Structural Chemistry</i> , 2023, 34, 1869-1882.	1.0	0
2962	Multicenter, single-arm phase II study of modified carboplatin/nab-paclitaxel in untreated performance status 2 patients with advanced non-small cell lung cancer: TORG1426. <i>Translational Cancer Research</i> , 2023, .	0.4	0
2963	Immune checkpoint inhibitors modulate the cytotoxic effect of chemotherapy in lung adenocarcinoma cells. <i>Oncology Letters</i> , 2023, 25, .	0.8	3
2964	Multiple cardiotoxicities during osimertinib therapy. <i>Journal of Oncology Pharmacy Practice</i> , 0, , 107815522311643.	0.5	1
2965	Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs. <i>Drug Resistance Updates</i> , 2023, 68, 100960.	6.5	36
2966	The pharmacological and biological importance of EZH2 signaling in lung cancer. <i>Biomedicine and Pharmacotherapy</i> , 2023, 160, 114313.	2.5	3
2967	Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model. <i>Frontiers in Public Health</i> , 0, 11, .	1.3	4
2968	Cytological characteristics of histological types of lung cancer by cytomorphometric and flow cytometric analyses using liquid-based cytology materials. <i>Diagnostic Cytopathology</i> , 0, , .	0.5	0
2969	Lung cancer in the emergency department. , 2023, 2, .		4
2970	Trends in Survival Rates of Non-Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020. <i>JAMA Network Open</i> , 2023, 6, e232002.	2.8	7
2971	NSCLC in the Era of Targeted and Immunotherapy: What Every Pulmonologist Must Know. <i>Diagnostics</i> , 2023, 13, 1117.	1.3	1
2972	Using an In-Sample Addition of Medronic Acid for the Analysis of Purine- and Pyrimidine-Related Derivatives and Its Application in the Study of Lung Adenocarcinoma A549 Cell Lines by LC-MS/MS. <i>Journal of Proteome Research</i> , 0, , .	1.8	1
2973	Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: A prospective real-world study. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	3
2974	Rigid Bronchoscopy with Y Stent Insertion at Left Secondary Carina. , 2012, , 291-298.		0
2975	HER2 exon 20 insertion mutations and myelosuppression in lung adenocarcinoma patient: a case report and response to trastuzumab deruxtecan. <i>Journal of Cardiothoracic Surgery</i> , 2023, 18, .	0.4	0
2976	Randomized Clinical Trials: Pitfalls in Design, Analysis, Presentation, and Interpretation. <i>Medical Radiology</i> , 2023, , .	0.0	0

#	ARTICLE	IF	CITATIONS
2977	Concomitant TP53 mutation in early-stage resected EGFR-mutated non-small cell lung cancer: a narrative approach in a genetically admixed Brazilian cohort. <i>Brazilian Journal of Medical and Biological Research</i> , 0, 56, .	0.7	1
2978	Budget impact analysis of comprehensive genomic profiling for untreated advanced or recurrent solid cancers in Japan. <i>Journal of Medical Economics</i> , 2023, 26, 614-626.	1.0	0
2980	Tissue Acquisition in Patients with Suspected Lung Cancer: Techniques Available and Sampling Adequacy for Molecular Testing. , 2023, , 307-325.		0
2994	Advancing oncology drug therapies for sub-Saharan Africa. <i>PLOS Global Public Health</i> , 2023, 3, e0001653.	0.5	0
3007	The Revolution of Lung Cancer Therapeutics. , 2023, , 235-249.		0
3011	Non-Small Cell Lung Cancer. , 2023, , 1-19.		0
3013	First-line therapy. , 2024, , 175-194.		0
3014	Treatment of Stage IV Non-small Cell Lung Cancer. <i>Respiratory Medicine</i> , 2023, , 165-186.	0.1	0